Datasets:
bio-datasets
/
bigbio-ner-merged

Dataset card Data Studio Files
xet
Community
answer
stringlengths
1
16.1k
id
stringlengths
7
56
instruction
stringlengths
106
72.6k
ner_tags
list
text
stringlengths
5
72.4k
tokens
list
types
list
Female, between 16 and 40 years, women, older than 40 years, cessation of ovarian function, before the age of 40 years, increased, levels of FSH, Primary or secondary, amenorrhea, for more than three months, LH and FSH, > 30mUI / ml, No, fragile X syndrome in the family or blepharophimosis syndrome, At least two, Caucasian, presence of cycles, until the age of 40 years, Amenorrhea, FSH, > 30mUI / ml, Women, Caucasian origin, Women, who had regular cycles until at least age 40, autoimmune, no, history, thyroid disease or diabetes type 1
NCT01177891_inc_task2
Sentence: Patients of familial cases of POF : Female subjects between 16 and 40 years or women older than 40 years with a cessation of ovarian function before the age of 40 years with increased levels of FSH Primary or secondary amenorrhea for more than three months with LH and FSH> 30mUI/ml No cases of fragile X syndrome in the family or blepharophimosis syndrome At least two cases in the family Origin Caucasian Patient signing the consent form for at least the blood sample Patient with Social Security Population Index related topics : The presence of cycles until the age of 40 years with proven fertility, at least one child Amenorrhea and FSH> 30mUI/ml according to the criteria of the index subject Men of the family of index case Population control : Women of Caucasian origin Women who had regular cycles until at least age 40 and at least one child Lack of land autoimmune (no history of thyroid disease or diabetes type 1) Woman signing the consent form for at least the blood sample Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Value", "B-Measurement", "I-Measurement", "I-Measurement", "O", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Negation", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Person", "O", "B-Condition", "I-Condition", "O", "B-Person", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "B-Negation", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Patients of familial cases of POF : Female subjects between 16 and 40 years or women older than 40 years with a cessation of ovarian function before the age of 40 years with increased levels of FSH Primary or secondary amenorrhea for more than three months with LH and FSH> 30mUI/ml No cases of fragile X syndrome in the family or blepharophimosis syndrome At least two cases in the family Origin Caucasian Patient signing the consent form for at least the blood sample Patient with Social Security Population Index related topics : The presence of cycles until the age of 40 years with proven fertility, at least one child Amenorrhea and FSH> 30mUI/ml according to the criteria of the index subject Men of the family of index case Population control : Women of Caucasian origin Women who had regular cycles until at least age 40 and at least one child Lack of land autoimmune (no history of thyroid disease or diabetes type 1) Woman signing the consent form for at least the blood sample
[ "Patients", "of", "familial", "cases", "of", "POF", ":", "\n", "Female", "subjects", "between", "16", "and", "40", "years", "or", "women", "older", "than", "40", "years", "with", "a", "cessation", "of", "ovarian", "function", "before", "the", "age", "of", "40", "years", "with", "increased", "levels", "of", "FSH", "\n", "Primary", "or", "secondary", "amenorrhea", "for", "more", "than", "three", "months", "with", "LH", "and", "FSH", ">", "30mUI", "/", "ml", "\n", "No", "cases", "of", "fragile", "X", "syndrome", "in", "the", "family", "or", "blepharophimosis", "syndrome", "\n", "At", "least", "two", "cases", "in", "the", "family", "\n", "Origin", "Caucasian", "\n", "Patient", "signing", "the", "consent", "form", "for", "at", "least", "the", "blood", "sample", "\n", "Patient", "with", "Social", "Security", "\n", "Population", "Index", "related", "topics", ":", "\n", "The", "presence", "of", "cycles", "until", "the", "age", "of", "40", "years", "with", "proven", "fertility", ",", "at", "least", "one", "child", "\n", "Amenorrhea", "and", "FSH", ">", "30mUI", "/", "ml", "according", "to", "the", "criteria", "of", "the", "index", "subject", "\n", "Men", "of", "the", "family", "of", "index", "case", "\n", "Population", "control", ":", "\n", "Women", "of", "Caucasian", "origin", "\n", "Women", "who", "had", "regular", "cycles", "until", "at", "least", "age", "40", "and", "at", "least", "one", "child", "\n", "Lack", "of", "land", "autoimmune", "(", "no", "history", "of", "thyroid", "disease", "or", "diabetes", "type", "1", ")", "\n", "Woman", "signing", "the", "consent", "form", "for", "at", "least", "the", "blood", "sample", "\n" ]
[ "Scope", "Condition", "Value", "Temporal", "Measurement", "Observation", "Multiplier", "Qualifier", "Person", "Reference_point", "Negation" ]
Adverse events is an outcome
504_task0
Sentence: Adverse events did not significantly differ in the 2 groups . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: outcome
[ "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Adverse events did not significantly differ in the 2 groups .
[ "Adverse", "events", "did", "not", "significantly", "differ", "in", "the", "2", "groups", "." ]
[ "outcome" ]
Adverse events is an outcome
504_task1
Sentence: Adverse events did not significantly differ in the 2 groups . Instructions: please typing these entity words according to sentence: Adverse events Options: outcome
[ "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Adverse events did not significantly differ in the 2 groups .
[ "Adverse", "events", "did", "not", "significantly", "differ", "in", "the", "2", "groups", "." ]
[ "outcome" ]
Adverse events
504_task2
Sentence: Adverse events did not significantly differ in the 2 groups . Instructions: please extract entity words from the input sentence
[ "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Adverse events did not significantly differ in the 2 groups .
[ "Adverse", "events", "did", "not", "significantly", "differ", "in", "the", "2", "groups", "." ]
[ "outcome" ]
Alpha-2 adrenoceptor is a GENE-N, nitric oxide is a CHEMICAL, alpha-2 adrenoceptor is a GENE-N, NG - nitro - L - arginine is a CHEMICAL, UK14,304 is a CHEMICAL, nitric oxide is a CHEMICAL, guanabenz is a CHEMICAL, UK14,304 is a CHEMICAL, clonidine is a CHEMICAL, epinephrine is a CHEMICAL, norepinephrine is a CHEMICAL, alpha-2 adrenoceptor is a GENE-N, alpha-2A adrenoceptor is a GENE-Y, rauwolscine is a CHEMICAL, WB-4101 is a CHEMICAL, SKF-104078 is a CHEMICAL, spiroxatrine is a CHEMICAL, prazosin is a CHEMICAL, alpha-2D adrenoceptor is a GENE-Y, rauwolscine is a CHEMICAL, WB-4101 is a CHEMICAL, alpha-2A adrenoceptor is a GENE-Y, alpha-2D adrenoceptor is a GENE-Y, NO is a CHEMICAL, forskolin is a CHEMICAL, alpha-2 adrenoceptor is a GENE-N, cAMP is a CHEMICAL, cAMP is a CHEMICAL, Forskolin is a CHEMICAL, UK14,304 is a CHEMICAL, cAMP is a CHEMICAL, alpha-2 adrenoceptors is a GENE-N, nitric oxide is a CHEMICAL
11864_task0
Sentence: Alpha-2 adrenoceptor subtype causing nitric oxide-mediated vascular relaxation in rats. The alpha-2 adrenoceptor subtype and its signal transduction pathway mediating vascular relaxation in rats were studied in vitro using rings of superior mesenteric arteries. Removal of endothelium or incubation with NG-nitro-L-arginine completely blocked relaxant responses to UK14,304, suggesting endothelium-derived nitric oxide mediates relaxation. The order of potency for full (F) or partial (P) agonists causing relaxation was guanabenz (P) > UK14,304 (F) > clonidine (P) > epinephrine (F) > norepinephrine (F). Affinities (Ka) of alpha-2 adrenoceptor subtype-selective drugs for blocking relaxation were obtained in side-by-side experiments comparing rat mesenteric arteries with pig coronary arteries. Relaxation of pig coronary arteries is known to be mediated by the alpha-2A adrenoceptor subtype. Ka values in nM for rauwolscine (19), WB-4101 (265), SKF-104078 (197), spiroxatrine (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the alpha-2D adrenoceptor subtype. Ka values for rauwolscine and WB-4101, drugs distinguishing the alpha-2D from the alpha-2A adrenoceptor subtype, were significantly higher in blocking relaxation of rat arteries compared with pig arteries, suggesting the alpha-2D adrenoceptor subtype mediates NO-induced relaxation in rat arteries. We used forskolin to oppose alpha-2 adrenoceptor-mediated inhibition of cAMP formation by directly stimulating cAMP formation in endothelium. Forskolin did not affect the relaxant response to UK14,304, suggesting that cAMP is not involved in the coupling of alpha-2 adrenoceptors to nitric oxide-induced vascular relaxation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL
[ "B-GENE-N", "I-GENE-N", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O" ]
Alpha-2 adrenoceptor subtype causing nitric oxide-mediated vascular relaxation in rats. The alpha-2 adrenoceptor subtype and its signal transduction pathway mediating vascular relaxation in rats were studied in vitro using rings of superior mesenteric arteries. Removal of endothelium or incubation with NG-nitro-L-arginine completely blocked relaxant responses to UK14,304, suggesting endothelium-derived nitric oxide mediates relaxation. The order of potency for full (F) or partial (P) agonists causing relaxation was guanabenz (P) > UK14,304 (F) > clonidine (P) > epinephrine (F) > norepinephrine (F). Affinities (Ka) of alpha-2 adrenoceptor subtype-selective drugs for blocking relaxation were obtained in side-by-side experiments comparing rat mesenteric arteries with pig coronary arteries. Relaxation of pig coronary arteries is known to be mediated by the alpha-2A adrenoceptor subtype. Ka values in nM for rauwolscine (19), WB-4101 (265), SKF-104078 (197), spiroxatrine (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the alpha-2D adrenoceptor subtype. Ka values for rauwolscine and WB-4101, drugs distinguishing the alpha-2D from the alpha-2A adrenoceptor subtype, were significantly higher in blocking relaxation of rat arteries compared with pig arteries, suggesting the alpha-2D adrenoceptor subtype mediates NO-induced relaxation in rat arteries. We used forskolin to oppose alpha-2 adrenoceptor-mediated inhibition of cAMP formation by directly stimulating cAMP formation in endothelium. Forskolin did not affect the relaxant response to UK14,304, suggesting that cAMP is not involved in the coupling of alpha-2 adrenoceptors to nitric oxide-induced vascular relaxation.
[ "Alpha-2", "adrenoceptor", "subtype", "causing", "nitric", "oxide", "-", "mediated", "vascular", "relaxation", "in", "rats", ".", "\n", "The", "alpha-2", "adrenoceptor", "subtype", "and", "its", "signal", "transduction", "pathway", "mediating", "vascular", "relaxation", "in", "rats", "were", "studied", "in", "vitro", "using", "rings", "of", "superior", "mesenteric", "arteries", ".", "Removal", "of", "endothelium", "or", "incubation", "with", "NG", "-", "nitro", "-", "L", "-", "arginine", "completely", "blocked", "relaxant", "responses", "to", "UK14,304", ",", "suggesting", "endothelium", "-", "derived", "nitric", "oxide", "mediates", "relaxation", ".", "The", "order", "of", "potency", "for", "full", "(", "F", ")", "or", "partial", "(", "P", ")", "agonists", "causing", "relaxation", "was", "guanabenz", "(", "P", ")", ">", "UK14,304", "(", "F", ")", ">", "clonidine", "(", "P", ")", ">", "epinephrine", "(", "F", ")", ">", "norepinephrine", "(", "F", ")", ".", "Affinities", "(", "Ka", ")", "of", "alpha-2", "adrenoceptor", "subtype", "-", "selective", "drugs", "for", "blocking", "relaxation", "were", "obtained", "in", "side", "-", "by", "-", "side", "experiments", "comparing", "rat", "mesenteric", "arteries", "with", "pig", "coronary", "arteries", ".", "Relaxation", "of", "pig", "coronary", "arteries", "is", "known", "to", "be", "mediated", "by", "the", "alpha-2A", "adrenoceptor", "subtype", ".", "Ka", "values", "in", "nM", "for", "rauwolscine", "(", "19", ")", ",", "WB-4101", "(", "265", ")", ",", "SKF-104078", "(", "197", ")", ",", "spiroxatrine", "(", "128", ")", ",", "and", "prazosin", "(", "1531", ")", "for", "blocking", "relaxation", "in", "rat", "arteries", "were", "consistent", "with", "their", "affinities", "for", "binding", "at", "the", "alpha-2D", "adrenoceptor", "subtype", ".", "Ka", "values", "for", "rauwolscine", "and", "WB-4101", ",", "drugs", "distinguishing", "the", "alpha-2D", "from", "the", "alpha-2A", "adrenoceptor", "subtype", ",", "were", "significantly", "higher", "in", "blocking", "relaxation", "of", "rat", "arteries", "compared", "with", "pig", "arteries", ",", "suggesting", "the", "alpha-2D", "adrenoceptor", "subtype", "mediates", "NO", "-", "induced", "relaxation", "in", "rat", "arteries", ".", "We", "used", "forskolin", "to", "oppose", "alpha-2", "adrenoceptor", "-", "mediated", "inhibition", "of", "cAMP", "formation", "by", "directly", "stimulating", "cAMP", "formation", "in", "endothelium", ".", "Forskolin", "did", "not", "affect", "the", "relaxant", "response", "to", "UK14,304", ",", "suggesting", "that", "cAMP", "is", "not", "involved", "in", "the", "coupling", "of", "alpha-2", "adrenoceptors", "to", "nitric", "oxide", "-", "induced", "vascular", "relaxation", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Alpha-2 adrenoceptor is a GENE-N, nitric oxide is a CHEMICAL, alpha-2 adrenoceptor is a GENE-N, NG - nitro - L - arginine is a CHEMICAL, UK14,304 is a CHEMICAL, nitric oxide is a CHEMICAL, guanabenz is a CHEMICAL, UK14,304 is a CHEMICAL, clonidine is a CHEMICAL, epinephrine is a CHEMICAL, norepinephrine is a CHEMICAL, alpha-2 adrenoceptor is a GENE-N, alpha-2A adrenoceptor is a GENE-Y, rauwolscine is a CHEMICAL, WB-4101 is a CHEMICAL, SKF-104078 is a CHEMICAL, spiroxatrine is a CHEMICAL, prazosin is a CHEMICAL, alpha-2D adrenoceptor is a GENE-Y, rauwolscine is a CHEMICAL, WB-4101 is a CHEMICAL, alpha-2A adrenoceptor is a GENE-Y, alpha-2D adrenoceptor is a GENE-Y, NO is a CHEMICAL, forskolin is a CHEMICAL, alpha-2 adrenoceptor is a GENE-N, cAMP is a CHEMICAL, cAMP is a CHEMICAL, Forskolin is a CHEMICAL, UK14,304 is a CHEMICAL, cAMP is a CHEMICAL, alpha-2 adrenoceptors is a GENE-N, nitric oxide is a CHEMICAL
11864_task1
Sentence: Alpha-2 adrenoceptor subtype causing nitric oxide-mediated vascular relaxation in rats. The alpha-2 adrenoceptor subtype and its signal transduction pathway mediating vascular relaxation in rats were studied in vitro using rings of superior mesenteric arteries. Removal of endothelium or incubation with NG-nitro-L-arginine completely blocked relaxant responses to UK14,304, suggesting endothelium-derived nitric oxide mediates relaxation. The order of potency for full (F) or partial (P) agonists causing relaxation was guanabenz (P) > UK14,304 (F) > clonidine (P) > epinephrine (F) > norepinephrine (F). Affinities (Ka) of alpha-2 adrenoceptor subtype-selective drugs for blocking relaxation were obtained in side-by-side experiments comparing rat mesenteric arteries with pig coronary arteries. Relaxation of pig coronary arteries is known to be mediated by the alpha-2A adrenoceptor subtype. Ka values in nM for rauwolscine (19), WB-4101 (265), SKF-104078 (197), spiroxatrine (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the alpha-2D adrenoceptor subtype. Ka values for rauwolscine and WB-4101, drugs distinguishing the alpha-2D from the alpha-2A adrenoceptor subtype, were significantly higher in blocking relaxation of rat arteries compared with pig arteries, suggesting the alpha-2D adrenoceptor subtype mediates NO-induced relaxation in rat arteries. We used forskolin to oppose alpha-2 adrenoceptor-mediated inhibition of cAMP formation by directly stimulating cAMP formation in endothelium. Forskolin did not affect the relaxant response to UK14,304, suggesting that cAMP is not involved in the coupling of alpha-2 adrenoceptors to nitric oxide-induced vascular relaxation. Instructions: please typing these entity words according to sentence: Alpha-2 adrenoceptor, nitric oxide, alpha-2 adrenoceptor, NG - nitro - L - arginine, UK14,304, nitric oxide, guanabenz, UK14,304, clonidine, epinephrine, norepinephrine, alpha-2 adrenoceptor, alpha-2A adrenoceptor, rauwolscine, WB-4101, SKF-104078, spiroxatrine, prazosin, alpha-2D adrenoceptor, rauwolscine, WB-4101, alpha-2A adrenoceptor, alpha-2D adrenoceptor, NO, forskolin, alpha-2 adrenoceptor, cAMP, cAMP, Forskolin, UK14,304, cAMP, alpha-2 adrenoceptors, nitric oxide Options: GENE-Y, GENE-N, CHEMICAL
[ "B-GENE-N", "I-GENE-N", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O" ]
Alpha-2 adrenoceptor subtype causing nitric oxide-mediated vascular relaxation in rats. The alpha-2 adrenoceptor subtype and its signal transduction pathway mediating vascular relaxation in rats were studied in vitro using rings of superior mesenteric arteries. Removal of endothelium or incubation with NG-nitro-L-arginine completely blocked relaxant responses to UK14,304, suggesting endothelium-derived nitric oxide mediates relaxation. The order of potency for full (F) or partial (P) agonists causing relaxation was guanabenz (P) > UK14,304 (F) > clonidine (P) > epinephrine (F) > norepinephrine (F). Affinities (Ka) of alpha-2 adrenoceptor subtype-selective drugs for blocking relaxation were obtained in side-by-side experiments comparing rat mesenteric arteries with pig coronary arteries. Relaxation of pig coronary arteries is known to be mediated by the alpha-2A adrenoceptor subtype. Ka values in nM for rauwolscine (19), WB-4101 (265), SKF-104078 (197), spiroxatrine (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the alpha-2D adrenoceptor subtype. Ka values for rauwolscine and WB-4101, drugs distinguishing the alpha-2D from the alpha-2A adrenoceptor subtype, were significantly higher in blocking relaxation of rat arteries compared with pig arteries, suggesting the alpha-2D adrenoceptor subtype mediates NO-induced relaxation in rat arteries. We used forskolin to oppose alpha-2 adrenoceptor-mediated inhibition of cAMP formation by directly stimulating cAMP formation in endothelium. Forskolin did not affect the relaxant response to UK14,304, suggesting that cAMP is not involved in the coupling of alpha-2 adrenoceptors to nitric oxide-induced vascular relaxation.
[ "Alpha-2", "adrenoceptor", "subtype", "causing", "nitric", "oxide", "-", "mediated", "vascular", "relaxation", "in", "rats", ".", "\n", "The", "alpha-2", "adrenoceptor", "subtype", "and", "its", "signal", "transduction", "pathway", "mediating", "vascular", "relaxation", "in", "rats", "were", "studied", "in", "vitro", "using", "rings", "of", "superior", "mesenteric", "arteries", ".", "Removal", "of", "endothelium", "or", "incubation", "with", "NG", "-", "nitro", "-", "L", "-", "arginine", "completely", "blocked", "relaxant", "responses", "to", "UK14,304", ",", "suggesting", "endothelium", "-", "derived", "nitric", "oxide", "mediates", "relaxation", ".", "The", "order", "of", "potency", "for", "full", "(", "F", ")", "or", "partial", "(", "P", ")", "agonists", "causing", "relaxation", "was", "guanabenz", "(", "P", ")", ">", "UK14,304", "(", "F", ")", ">", "clonidine", "(", "P", ")", ">", "epinephrine", "(", "F", ")", ">", "norepinephrine", "(", "F", ")", ".", "Affinities", "(", "Ka", ")", "of", "alpha-2", "adrenoceptor", "subtype", "-", "selective", "drugs", "for", "blocking", "relaxation", "were", "obtained", "in", "side", "-", "by", "-", "side", "experiments", "comparing", "rat", "mesenteric", "arteries", "with", "pig", "coronary", "arteries", ".", "Relaxation", "of", "pig", "coronary", "arteries", "is", "known", "to", "be", "mediated", "by", "the", "alpha-2A", "adrenoceptor", "subtype", ".", "Ka", "values", "in", "nM", "for", "rauwolscine", "(", "19", ")", ",", "WB-4101", "(", "265", ")", ",", "SKF-104078", "(", "197", ")", ",", "spiroxatrine", "(", "128", ")", ",", "and", "prazosin", "(", "1531", ")", "for", "blocking", "relaxation", "in", "rat", "arteries", "were", "consistent", "with", "their", "affinities", "for", "binding", "at", "the", "alpha-2D", "adrenoceptor", "subtype", ".", "Ka", "values", "for", "rauwolscine", "and", "WB-4101", ",", "drugs", "distinguishing", "the", "alpha-2D", "from", "the", "alpha-2A", "adrenoceptor", "subtype", ",", "were", "significantly", "higher", "in", "blocking", "relaxation", "of", "rat", "arteries", "compared", "with", "pig", "arteries", ",", "suggesting", "the", "alpha-2D", "adrenoceptor", "subtype", "mediates", "NO", "-", "induced", "relaxation", "in", "rat", "arteries", ".", "We", "used", "forskolin", "to", "oppose", "alpha-2", "adrenoceptor", "-", "mediated", "inhibition", "of", "cAMP", "formation", "by", "directly", "stimulating", "cAMP", "formation", "in", "endothelium", ".", "Forskolin", "did", "not", "affect", "the", "relaxant", "response", "to", "UK14,304", ",", "suggesting", "that", "cAMP", "is", "not", "involved", "in", "the", "coupling", "of", "alpha-2", "adrenoceptors", "to", "nitric", "oxide", "-", "induced", "vascular", "relaxation", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Alpha-2 adrenoceptor, nitric oxide, alpha-2 adrenoceptor, NG - nitro - L - arginine, UK14,304, nitric oxide, guanabenz, UK14,304, clonidine, epinephrine, norepinephrine, alpha-2 adrenoceptor, alpha-2A adrenoceptor, rauwolscine, WB-4101, SKF-104078, spiroxatrine, prazosin, alpha-2D adrenoceptor, rauwolscine, WB-4101, alpha-2A adrenoceptor, alpha-2D adrenoceptor, NO, forskolin, alpha-2 adrenoceptor, cAMP, cAMP, Forskolin, UK14,304, cAMP, alpha-2 adrenoceptors, nitric oxide
11864_task2
Sentence: Alpha-2 adrenoceptor subtype causing nitric oxide-mediated vascular relaxation in rats. The alpha-2 adrenoceptor subtype and its signal transduction pathway mediating vascular relaxation in rats were studied in vitro using rings of superior mesenteric arteries. Removal of endothelium or incubation with NG-nitro-L-arginine completely blocked relaxant responses to UK14,304, suggesting endothelium-derived nitric oxide mediates relaxation. The order of potency for full (F) or partial (P) agonists causing relaxation was guanabenz (P) > UK14,304 (F) > clonidine (P) > epinephrine (F) > norepinephrine (F). Affinities (Ka) of alpha-2 adrenoceptor subtype-selective drugs for blocking relaxation were obtained in side-by-side experiments comparing rat mesenteric arteries with pig coronary arteries. Relaxation of pig coronary arteries is known to be mediated by the alpha-2A adrenoceptor subtype. Ka values in nM for rauwolscine (19), WB-4101 (265), SKF-104078 (197), spiroxatrine (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the alpha-2D adrenoceptor subtype. Ka values for rauwolscine and WB-4101, drugs distinguishing the alpha-2D from the alpha-2A adrenoceptor subtype, were significantly higher in blocking relaxation of rat arteries compared with pig arteries, suggesting the alpha-2D adrenoceptor subtype mediates NO-induced relaxation in rat arteries. We used forskolin to oppose alpha-2 adrenoceptor-mediated inhibition of cAMP formation by directly stimulating cAMP formation in endothelium. Forskolin did not affect the relaxant response to UK14,304, suggesting that cAMP is not involved in the coupling of alpha-2 adrenoceptors to nitric oxide-induced vascular relaxation. Instructions: please extract entity words from the input sentence
[ "B-GENE-N", "I-GENE-N", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O" ]
Alpha-2 adrenoceptor subtype causing nitric oxide-mediated vascular relaxation in rats. The alpha-2 adrenoceptor subtype and its signal transduction pathway mediating vascular relaxation in rats were studied in vitro using rings of superior mesenteric arteries. Removal of endothelium or incubation with NG-nitro-L-arginine completely blocked relaxant responses to UK14,304, suggesting endothelium-derived nitric oxide mediates relaxation. The order of potency for full (F) or partial (P) agonists causing relaxation was guanabenz (P) > UK14,304 (F) > clonidine (P) > epinephrine (F) > norepinephrine (F). Affinities (Ka) of alpha-2 adrenoceptor subtype-selective drugs for blocking relaxation were obtained in side-by-side experiments comparing rat mesenteric arteries with pig coronary arteries. Relaxation of pig coronary arteries is known to be mediated by the alpha-2A adrenoceptor subtype. Ka values in nM for rauwolscine (19), WB-4101 (265), SKF-104078 (197), spiroxatrine (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the alpha-2D adrenoceptor subtype. Ka values for rauwolscine and WB-4101, drugs distinguishing the alpha-2D from the alpha-2A adrenoceptor subtype, were significantly higher in blocking relaxation of rat arteries compared with pig arteries, suggesting the alpha-2D adrenoceptor subtype mediates NO-induced relaxation in rat arteries. We used forskolin to oppose alpha-2 adrenoceptor-mediated inhibition of cAMP formation by directly stimulating cAMP formation in endothelium. Forskolin did not affect the relaxant response to UK14,304, suggesting that cAMP is not involved in the coupling of alpha-2 adrenoceptors to nitric oxide-induced vascular relaxation.
[ "Alpha-2", "adrenoceptor", "subtype", "causing", "nitric", "oxide", "-", "mediated", "vascular", "relaxation", "in", "rats", ".", "\n", "The", "alpha-2", "adrenoceptor", "subtype", "and", "its", "signal", "transduction", "pathway", "mediating", "vascular", "relaxation", "in", "rats", "were", "studied", "in", "vitro", "using", "rings", "of", "superior", "mesenteric", "arteries", ".", "Removal", "of", "endothelium", "or", "incubation", "with", "NG", "-", "nitro", "-", "L", "-", "arginine", "completely", "blocked", "relaxant", "responses", "to", "UK14,304", ",", "suggesting", "endothelium", "-", "derived", "nitric", "oxide", "mediates", "relaxation", ".", "The", "order", "of", "potency", "for", "full", "(", "F", ")", "or", "partial", "(", "P", ")", "agonists", "causing", "relaxation", "was", "guanabenz", "(", "P", ")", ">", "UK14,304", "(", "F", ")", ">", "clonidine", "(", "P", ")", ">", "epinephrine", "(", "F", ")", ">", "norepinephrine", "(", "F", ")", ".", "Affinities", "(", "Ka", ")", "of", "alpha-2", "adrenoceptor", "subtype", "-", "selective", "drugs", "for", "blocking", "relaxation", "were", "obtained", "in", "side", "-", "by", "-", "side", "experiments", "comparing", "rat", "mesenteric", "arteries", "with", "pig", "coronary", "arteries", ".", "Relaxation", "of", "pig", "coronary", "arteries", "is", "known", "to", "be", "mediated", "by", "the", "alpha-2A", "adrenoceptor", "subtype", ".", "Ka", "values", "in", "nM", "for", "rauwolscine", "(", "19", ")", ",", "WB-4101", "(", "265", ")", ",", "SKF-104078", "(", "197", ")", ",", "spiroxatrine", "(", "128", ")", ",", "and", "prazosin", "(", "1531", ")", "for", "blocking", "relaxation", "in", "rat", "arteries", "were", "consistent", "with", "their", "affinities", "for", "binding", "at", "the", "alpha-2D", "adrenoceptor", "subtype", ".", "Ka", "values", "for", "rauwolscine", "and", "WB-4101", ",", "drugs", "distinguishing", "the", "alpha-2D", "from", "the", "alpha-2A", "adrenoceptor", "subtype", ",", "were", "significantly", "higher", "in", "blocking", "relaxation", "of", "rat", "arteries", "compared", "with", "pig", "arteries", ",", "suggesting", "the", "alpha-2D", "adrenoceptor", "subtype", "mediates", "NO", "-", "induced", "relaxation", "in", "rat", "arteries", ".", "We", "used", "forskolin", "to", "oppose", "alpha-2", "adrenoceptor", "-", "mediated", "inhibition", "of", "cAMP", "formation", "by", "directly", "stimulating", "cAMP", "formation", "in", "endothelium", ".", "Forskolin", "did", "not", "affect", "the", "relaxant", "response", "to", "UK14,304", ",", "suggesting", "that", "cAMP", "is", "not", "involved", "in", "the", "coupling", "of", "alpha-2", "adrenoceptors", "to", "nitric", "oxide", "-", "induced", "vascular", "relaxation", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
electro - acupuncture is a Intervention_Physical, autism spectrum disorder . is a Participant_Condition, children is a Participant_Age, autism spectrum disorder ( ASD ) is a Participant_Condition, Children is a Participant_Age, electro - acupuncture ( EA ) is a Intervention_Physical, n=30 is a Participant_Sample-size, sham electro - acupuncture is a Intervention_Control, n=25 is a Participant_Sample-size, age is a Participant_Age, Primary outcome measures is a Outcome_Mental, Functional Independence Measure for Children ( WeeFIM ) is a Outcome_Mental, Pediatric Evaluation of Disability Inventory ( PEDI ) is a Outcome_Mental, Leiter International Performance Scale - Revised ( Leiter - R ) is a Outcome_Mental, Clinical Global Impression - Improvement ( CGI - I ) scale is a Outcome_Mental, Aberrant Behavior Checklist ( ABC ) is a Outcome_Mental, Ritvo - Freeman Real Life Scale ( RFRLS ) is a Outcome_Mental, Reynell Developmental Language Scale ( RDLS ) is a Outcome_Mental, standardized parental report is a Outcome_Mental, improvements in the language comprehension domain of WeeFIM ( p=0.02 ) is a Outcome_Physical, self - care caregiver assistant domain of PEDI ( p=0.028 ) is a Outcome_Physical, better is a Outcome_Physical, social initiation is a Outcome_Mental, ( p=0.01 ) is a Outcome_Physical, receptive language is a Outcome_Mental, ( p=0.006 ) is a Outcome_Physical, motor skills ( p=0.034 ) , is a Outcome_Physical, coordination is a Outcome_Mental, ( p=0.07 ) is a Outcome_Physical, attention span is a Outcome_Mental, adapted to acupuncture easily is a Outcome_Mental, poor acupuncture compliance is a Outcome_Mental, Mild side effects of minor superficial bleeding is a Outcome_Adverse-effects, irritability during acupuncture is a Outcome_Adverse-effects
47270_task0
Sentence: Randomized controlled trial of electro-acupuncture for autism spectrum disorder . OBJECTIVE To study the efficacy , safety , and compliance of short-term electro-acupuncture for children with autism spectrum disorder ( ASD ) . DESIGN Randomized , double-blind , sham-controlled , clinical trial . SUBJECTS AND METHODS Children with ASD were randomly assigned to an electro-acupuncture ( EA ) group ( n=30 ) or a sham electro-acupuncture ( SEA ) group ( n=25 ) matched by age and severity of autism . The EA group received electro-acupuncture for selected acupoints while the SEA group received sham electro-acupuncture to sham acupoints . A total of 12 EA and SEA sessions over four weeks were given . Primary outcome measures included Functional Independence Measure for Children ( WeeFIM ) , Pediatric Evaluation of Disability Inventory ( PEDI ) , Leiter International Performance Scale-Revised ( Leiter-R ) , and Clinical Global Impression-Improvement ( CGI-I ) scale . Secondary outcome measures consisted of Aberrant Behavior Checklist ( ABC ) , Ritvo-Freeman Real Life Scale ( RFRLS ) , Reynell Developmental Language Scale ( RDLS ) , and a standardized parental report . Data were analyzed by the Mann-Whitney test . RESULTS There were significant improvements in the language comprehension domain of WeeFIM ( p=0.02 ) , self-care caregiver assistant domain of PEDI ( p=0.028 ) , and CGI-I ( p=0.003 ) in the EA group compared to the SEA group . As for the parental report , the EA group also showed significantly better social initiation ( p=0.01 ) , receptive language ( p=0.006 ) , motor skills ( p=0.034 ) , coordination ( p=0.07 ) , and attention span ( p=0.003 ) . More than 70 percent of children with ASD adapted to acupuncture easily , while eight percent had poor acupuncture compliance . Mild side effects of minor superficial bleeding or irritability during acupuncture were observed . CONCLUSION A short , four-week ( 12 sessions ) course of electro-acupuncture is useful to improve specific functions in children with ASD , especially for language comprehension and self-care ability . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Adverse-effects, Intervention_Physical, Intervention_Control, Participant_Condition, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Mental
[ "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "B-Outcome_Mental", "I-Outcome_Mental", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Mental", "I-Outcome_Mental", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Mental", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Randomized controlled trial of electro-acupuncture for autism spectrum disorder . OBJECTIVE To study the efficacy , safety , and compliance of short-term electro-acupuncture for children with autism spectrum disorder ( ASD ) . DESIGN Randomized , double-blind , sham-controlled , clinical trial . SUBJECTS AND METHODS Children with ASD were randomly assigned to an electro-acupuncture ( EA ) group ( n=30 ) or a sham electro-acupuncture ( SEA ) group ( n=25 ) matched by age and severity of autism . The EA group received electro-acupuncture for selected acupoints while the SEA group received sham electro-acupuncture to sham acupoints . A total of 12 EA and SEA sessions over four weeks were given . Primary outcome measures included Functional Independence Measure for Children ( WeeFIM ) , Pediatric Evaluation of Disability Inventory ( PEDI ) , Leiter International Performance Scale-Revised ( Leiter-R ) , and Clinical Global Impression-Improvement ( CGI-I ) scale . Secondary outcome measures consisted of Aberrant Behavior Checklist ( ABC ) , Ritvo-Freeman Real Life Scale ( RFRLS ) , Reynell Developmental Language Scale ( RDLS ) , and a standardized parental report . Data were analyzed by the Mann-Whitney test . RESULTS There were significant improvements in the language comprehension domain of WeeFIM ( p=0.02 ) , self-care caregiver assistant domain of PEDI ( p=0.028 ) , and CGI-I ( p=0.003 ) in the EA group compared to the SEA group . As for the parental report , the EA group also showed significantly better social initiation ( p=0.01 ) , receptive language ( p=0.006 ) , motor skills ( p=0.034 ) , coordination ( p=0.07 ) , and attention span ( p=0.003 ) . More than 70 percent of children with ASD adapted to acupuncture easily , while eight percent had poor acupuncture compliance . Mild side effects of minor superficial bleeding or irritability during acupuncture were observed . CONCLUSION A short , four-week ( 12 sessions ) course of electro-acupuncture is useful to improve specific functions in children with ASD , especially for language comprehension and self-care ability .
[ "Randomized", "controlled", "trial", "of", "electro", "-", "acupuncture", "for", "autism", "spectrum", "disorder", ".", "OBJECTIVE", "To", "study", "the", "efficacy", ",", "safety", ",", "and", "compliance", "of", "short", "-", "term", "electro", "-", "acupuncture", "for", "children", "with", "autism", "spectrum", "disorder", "(", "ASD", ")", ".", "DESIGN", "Randomized", ",", "double", "-", "blind", ",", "sham", "-", "controlled", ",", "clinical", "trial", ".", "SUBJECTS", "AND", "METHODS", "Children", "with", "ASD", "were", "randomly", "assigned", "to", "an", "electro", "-", "acupuncture", "(", "EA", ")", "group", "(", "n=30", ")", "or", "a", "sham", "electro", "-", "acupuncture", "(", "SEA", ")", "group", "(", "n=25", ")", "matched", "by", "age", "and", "severity", "of", "autism", ".", "The", "EA", "group", "received", "electro", "-", "acupuncture", "for", "selected", "acupoints", "while", "the", "SEA", "group", "received", "sham", "electro", "-", "acupuncture", "to", "sham", "acupoints", ".", "A", "total", "of", "12", "EA", "and", "SEA", "sessions", "over", "four", "weeks", "were", "given", ".", "Primary", "outcome", "measures", "included", "Functional", "Independence", "Measure", "for", "Children", "(", "WeeFIM", ")", ",", "Pediatric", "Evaluation", "of", "Disability", "Inventory", "(", "PEDI", ")", ",", "Leiter", "International", "Performance", "Scale", "-", "Revised", "(", "Leiter", "-", "R", ")", ",", "and", "Clinical", "Global", "Impression", "-", "Improvement", "(", "CGI", "-", "I", ")", "scale", ".", "Secondary", "outcome", "measures", "consisted", "of", "Aberrant", "Behavior", "Checklist", "(", "ABC", ")", ",", "Ritvo", "-", "Freeman", "Real", "Life", "Scale", "(", "RFRLS", ")", ",", "Reynell", "Developmental", "Language", "Scale", "(", "RDLS", ")", ",", "and", "a", "standardized", "parental", "report", ".", "Data", "were", "analyzed", "by", "the", "Mann", "-", "Whitney", "test", ".", "RESULTS", "There", "were", "significant", "improvements", "in", "the", "language", "comprehension", "domain", "of", "WeeFIM", "(", "p=0.02", ")", ",", "self", "-", "care", "caregiver", "assistant", "domain", "of", "PEDI", "(", "p=0.028", ")", ",", "and", "CGI", "-", "I", "(", "p=0.003", ")", "in", "the", "EA", "group", "compared", "to", "the", "SEA", "group", ".", "As", "for", "the", "parental", "report", ",", "the", "EA", "group", "also", "showed", "significantly", "better", "social", "initiation", "(", "p=0.01", ")", ",", "receptive", "language", "(", "p=0.006", ")", ",", "motor", "skills", "(", "p=0.034", ")", ",", "coordination", "(", "p=0.07", ")", ",", "and", "attention", "span", "(", "p=0.003", ")", ".", "More", "than", "70", "percent", "of", "children", "with", "ASD", "adapted", "to", "acupuncture", "easily", ",", "while", "eight", "percent", "had", "poor", "acupuncture", "compliance", ".", "Mild", "side", "effects", "of", "minor", "superficial", "bleeding", "or", "irritability", "during", "acupuncture", "were", "observed", ".", "CONCLUSION", "A", "short", ",", "four", "-", "week", "(", "12", "sessions", ")", "course", "of", "electro", "-", "acupuncture", "is", "useful", "to", "improve", "specific", "functions", "in", "children", "with", "ASD", ",", "especially", "for", "language", "comprehension", "and", "self", "-", "care", "ability", "." ]
[ "Outcome_Physical", "Outcome_Mental", "Outcome_Adverse-effects", "Participant_Condition", "Intervention_Physical", "Intervention_Control", "Participant_Age", "Participant_Sample-size" ]
electro - acupuncture is a Intervention_Physical, autism spectrum disorder . is a Participant_Condition, children is a Participant_Age, autism spectrum disorder ( ASD ) is a Participant_Condition, Children is a Participant_Age, electro - acupuncture ( EA ) is a Intervention_Physical, n=30 is a Participant_Sample-size, sham electro - acupuncture is a Intervention_Control, n=25 is a Participant_Sample-size, age is a Participant_Age, Primary outcome measures is a Outcome_Mental, Functional Independence Measure for Children ( WeeFIM ) is a Outcome_Mental, Pediatric Evaluation of Disability Inventory ( PEDI ) is a Outcome_Mental, Leiter International Performance Scale - Revised ( Leiter - R ) is a Outcome_Mental, Clinical Global Impression - Improvement ( CGI - I ) scale is a Outcome_Mental, Aberrant Behavior Checklist ( ABC ) is a Outcome_Mental, Ritvo - Freeman Real Life Scale ( RFRLS ) is a Outcome_Mental, Reynell Developmental Language Scale ( RDLS ) is a Outcome_Mental, standardized parental report is a Outcome_Mental, improvements in the language comprehension domain of WeeFIM ( p=0.02 ) is a Outcome_Physical, self - care caregiver assistant domain of PEDI ( p=0.028 ) is a Outcome_Physical, better is a Outcome_Physical, social initiation is a Outcome_Mental, ( p=0.01 ) is a Outcome_Physical, receptive language is a Outcome_Mental, ( p=0.006 ) is a Outcome_Physical, motor skills ( p=0.034 ) , is a Outcome_Physical, coordination is a Outcome_Mental, ( p=0.07 ) is a Outcome_Physical, attention span is a Outcome_Mental, adapted to acupuncture easily is a Outcome_Mental, poor acupuncture compliance is a Outcome_Mental, Mild side effects of minor superficial bleeding is a Outcome_Adverse-effects, irritability during acupuncture is a Outcome_Adverse-effects
47270_task1
Sentence: Randomized controlled trial of electro-acupuncture for autism spectrum disorder . OBJECTIVE To study the efficacy , safety , and compliance of short-term electro-acupuncture for children with autism spectrum disorder ( ASD ) . DESIGN Randomized , double-blind , sham-controlled , clinical trial . SUBJECTS AND METHODS Children with ASD were randomly assigned to an electro-acupuncture ( EA ) group ( n=30 ) or a sham electro-acupuncture ( SEA ) group ( n=25 ) matched by age and severity of autism . The EA group received electro-acupuncture for selected acupoints while the SEA group received sham electro-acupuncture to sham acupoints . A total of 12 EA and SEA sessions over four weeks were given . Primary outcome measures included Functional Independence Measure for Children ( WeeFIM ) , Pediatric Evaluation of Disability Inventory ( PEDI ) , Leiter International Performance Scale-Revised ( Leiter-R ) , and Clinical Global Impression-Improvement ( CGI-I ) scale . Secondary outcome measures consisted of Aberrant Behavior Checklist ( ABC ) , Ritvo-Freeman Real Life Scale ( RFRLS ) , Reynell Developmental Language Scale ( RDLS ) , and a standardized parental report . Data were analyzed by the Mann-Whitney test . RESULTS There were significant improvements in the language comprehension domain of WeeFIM ( p=0.02 ) , self-care caregiver assistant domain of PEDI ( p=0.028 ) , and CGI-I ( p=0.003 ) in the EA group compared to the SEA group . As for the parental report , the EA group also showed significantly better social initiation ( p=0.01 ) , receptive language ( p=0.006 ) , motor skills ( p=0.034 ) , coordination ( p=0.07 ) , and attention span ( p=0.003 ) . More than 70 percent of children with ASD adapted to acupuncture easily , while eight percent had poor acupuncture compliance . Mild side effects of minor superficial bleeding or irritability during acupuncture were observed . CONCLUSION A short , four-week ( 12 sessions ) course of electro-acupuncture is useful to improve specific functions in children with ASD , especially for language comprehension and self-care ability . Instructions: please typing these entity words according to sentence: electro - acupuncture, autism spectrum disorder ., children, autism spectrum disorder ( ASD ), Children, electro - acupuncture ( EA ), n=30, sham electro - acupuncture, n=25, age, Primary outcome measures, Functional Independence Measure for Children ( WeeFIM ), Pediatric Evaluation of Disability Inventory ( PEDI ), Leiter International Performance Scale - Revised ( Leiter - R ), Clinical Global Impression - Improvement ( CGI - I ) scale, Aberrant Behavior Checklist ( ABC ), Ritvo - Freeman Real Life Scale ( RFRLS ), Reynell Developmental Language Scale ( RDLS ), standardized parental report, improvements in the language comprehension domain of WeeFIM ( p=0.02 ), self - care caregiver assistant domain of PEDI ( p=0.028 ), better, social initiation, ( p=0.01 ), receptive language, ( p=0.006 ), motor skills ( p=0.034 ) ,, coordination, ( p=0.07 ), attention span, adapted to acupuncture easily, poor acupuncture compliance, Mild side effects of minor superficial bleeding, irritability during acupuncture Options: Outcome_Adverse-effects, Intervention_Physical, Intervention_Control, Participant_Condition, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Mental
[ "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "B-Outcome_Mental", "I-Outcome_Mental", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Mental", "I-Outcome_Mental", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Mental", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Randomized controlled trial of electro-acupuncture for autism spectrum disorder . OBJECTIVE To study the efficacy , safety , and compliance of short-term electro-acupuncture for children with autism spectrum disorder ( ASD ) . DESIGN Randomized , double-blind , sham-controlled , clinical trial . SUBJECTS AND METHODS Children with ASD were randomly assigned to an electro-acupuncture ( EA ) group ( n=30 ) or a sham electro-acupuncture ( SEA ) group ( n=25 ) matched by age and severity of autism . The EA group received electro-acupuncture for selected acupoints while the SEA group received sham electro-acupuncture to sham acupoints . A total of 12 EA and SEA sessions over four weeks were given . Primary outcome measures included Functional Independence Measure for Children ( WeeFIM ) , Pediatric Evaluation of Disability Inventory ( PEDI ) , Leiter International Performance Scale-Revised ( Leiter-R ) , and Clinical Global Impression-Improvement ( CGI-I ) scale . Secondary outcome measures consisted of Aberrant Behavior Checklist ( ABC ) , Ritvo-Freeman Real Life Scale ( RFRLS ) , Reynell Developmental Language Scale ( RDLS ) , and a standardized parental report . Data were analyzed by the Mann-Whitney test . RESULTS There were significant improvements in the language comprehension domain of WeeFIM ( p=0.02 ) , self-care caregiver assistant domain of PEDI ( p=0.028 ) , and CGI-I ( p=0.003 ) in the EA group compared to the SEA group . As for the parental report , the EA group also showed significantly better social initiation ( p=0.01 ) , receptive language ( p=0.006 ) , motor skills ( p=0.034 ) , coordination ( p=0.07 ) , and attention span ( p=0.003 ) . More than 70 percent of children with ASD adapted to acupuncture easily , while eight percent had poor acupuncture compliance . Mild side effects of minor superficial bleeding or irritability during acupuncture were observed . CONCLUSION A short , four-week ( 12 sessions ) course of electro-acupuncture is useful to improve specific functions in children with ASD , especially for language comprehension and self-care ability .
[ "Randomized", "controlled", "trial", "of", "electro", "-", "acupuncture", "for", "autism", "spectrum", "disorder", ".", "OBJECTIVE", "To", "study", "the", "efficacy", ",", "safety", ",", "and", "compliance", "of", "short", "-", "term", "electro", "-", "acupuncture", "for", "children", "with", "autism", "spectrum", "disorder", "(", "ASD", ")", ".", "DESIGN", "Randomized", ",", "double", "-", "blind", ",", "sham", "-", "controlled", ",", "clinical", "trial", ".", "SUBJECTS", "AND", "METHODS", "Children", "with", "ASD", "were", "randomly", "assigned", "to", "an", "electro", "-", "acupuncture", "(", "EA", ")", "group", "(", "n=30", ")", "or", "a", "sham", "electro", "-", "acupuncture", "(", "SEA", ")", "group", "(", "n=25", ")", "matched", "by", "age", "and", "severity", "of", "autism", ".", "The", "EA", "group", "received", "electro", "-", "acupuncture", "for", "selected", "acupoints", "while", "the", "SEA", "group", "received", "sham", "electro", "-", "acupuncture", "to", "sham", "acupoints", ".", "A", "total", "of", "12", "EA", "and", "SEA", "sessions", "over", "four", "weeks", "were", "given", ".", "Primary", "outcome", "measures", "included", "Functional", "Independence", "Measure", "for", "Children", "(", "WeeFIM", ")", ",", "Pediatric", "Evaluation", "of", "Disability", "Inventory", "(", "PEDI", ")", ",", "Leiter", "International", "Performance", "Scale", "-", "Revised", "(", "Leiter", "-", "R", ")", ",", "and", "Clinical", "Global", "Impression", "-", "Improvement", "(", "CGI", "-", "I", ")", "scale", ".", "Secondary", "outcome", "measures", "consisted", "of", "Aberrant", "Behavior", "Checklist", "(", "ABC", ")", ",", "Ritvo", "-", "Freeman", "Real", "Life", "Scale", "(", "RFRLS", ")", ",", "Reynell", "Developmental", "Language", "Scale", "(", "RDLS", ")", ",", "and", "a", "standardized", "parental", "report", ".", "Data", "were", "analyzed", "by", "the", "Mann", "-", "Whitney", "test", ".", "RESULTS", "There", "were", "significant", "improvements", "in", "the", "language", "comprehension", "domain", "of", "WeeFIM", "(", "p=0.02", ")", ",", "self", "-", "care", "caregiver", "assistant", "domain", "of", "PEDI", "(", "p=0.028", ")", ",", "and", "CGI", "-", "I", "(", "p=0.003", ")", "in", "the", "EA", "group", "compared", "to", "the", "SEA", "group", ".", "As", "for", "the", "parental", "report", ",", "the", "EA", "group", "also", "showed", "significantly", "better", "social", "initiation", "(", "p=0.01", ")", ",", "receptive", "language", "(", "p=0.006", ")", ",", "motor", "skills", "(", "p=0.034", ")", ",", "coordination", "(", "p=0.07", ")", ",", "and", "attention", "span", "(", "p=0.003", ")", ".", "More", "than", "70", "percent", "of", "children", "with", "ASD", "adapted", "to", "acupuncture", "easily", ",", "while", "eight", "percent", "had", "poor", "acupuncture", "compliance", ".", "Mild", "side", "effects", "of", "minor", "superficial", "bleeding", "or", "irritability", "during", "acupuncture", "were", "observed", ".", "CONCLUSION", "A", "short", ",", "four", "-", "week", "(", "12", "sessions", ")", "course", "of", "electro", "-", "acupuncture", "is", "useful", "to", "improve", "specific", "functions", "in", "children", "with", "ASD", ",", "especially", "for", "language", "comprehension", "and", "self", "-", "care", "ability", "." ]
[ "Outcome_Physical", "Outcome_Mental", "Outcome_Adverse-effects", "Participant_Condition", "Intervention_Physical", "Intervention_Control", "Participant_Age", "Participant_Sample-size" ]
electro - acupuncture, autism spectrum disorder ., children, autism spectrum disorder ( ASD ), Children, electro - acupuncture ( EA ), n=30, sham electro - acupuncture, n=25, age, Primary outcome measures, Functional Independence Measure for Children ( WeeFIM ), Pediatric Evaluation of Disability Inventory ( PEDI ), Leiter International Performance Scale - Revised ( Leiter - R ), Clinical Global Impression - Improvement ( CGI - I ) scale, Aberrant Behavior Checklist ( ABC ), Ritvo - Freeman Real Life Scale ( RFRLS ), Reynell Developmental Language Scale ( RDLS ), standardized parental report, improvements in the language comprehension domain of WeeFIM ( p=0.02 ), self - care caregiver assistant domain of PEDI ( p=0.028 ), better, social initiation, ( p=0.01 ), receptive language, ( p=0.006 ), motor skills ( p=0.034 ) ,, coordination, ( p=0.07 ), attention span, adapted to acupuncture easily, poor acupuncture compliance, Mild side effects of minor superficial bleeding, irritability during acupuncture
47270_task2
Sentence: Randomized controlled trial of electro-acupuncture for autism spectrum disorder . OBJECTIVE To study the efficacy , safety , and compliance of short-term electro-acupuncture for children with autism spectrum disorder ( ASD ) . DESIGN Randomized , double-blind , sham-controlled , clinical trial . SUBJECTS AND METHODS Children with ASD were randomly assigned to an electro-acupuncture ( EA ) group ( n=30 ) or a sham electro-acupuncture ( SEA ) group ( n=25 ) matched by age and severity of autism . The EA group received electro-acupuncture for selected acupoints while the SEA group received sham electro-acupuncture to sham acupoints . A total of 12 EA and SEA sessions over four weeks were given . Primary outcome measures included Functional Independence Measure for Children ( WeeFIM ) , Pediatric Evaluation of Disability Inventory ( PEDI ) , Leiter International Performance Scale-Revised ( Leiter-R ) , and Clinical Global Impression-Improvement ( CGI-I ) scale . Secondary outcome measures consisted of Aberrant Behavior Checklist ( ABC ) , Ritvo-Freeman Real Life Scale ( RFRLS ) , Reynell Developmental Language Scale ( RDLS ) , and a standardized parental report . Data were analyzed by the Mann-Whitney test . RESULTS There were significant improvements in the language comprehension domain of WeeFIM ( p=0.02 ) , self-care caregiver assistant domain of PEDI ( p=0.028 ) , and CGI-I ( p=0.003 ) in the EA group compared to the SEA group . As for the parental report , the EA group also showed significantly better social initiation ( p=0.01 ) , receptive language ( p=0.006 ) , motor skills ( p=0.034 ) , coordination ( p=0.07 ) , and attention span ( p=0.003 ) . More than 70 percent of children with ASD adapted to acupuncture easily , while eight percent had poor acupuncture compliance . Mild side effects of minor superficial bleeding or irritability during acupuncture were observed . CONCLUSION A short , four-week ( 12 sessions ) course of electro-acupuncture is useful to improve specific functions in children with ASD , especially for language comprehension and self-care ability . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "B-Outcome_Mental", "I-Outcome_Mental", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Mental", "I-Outcome_Mental", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Mental", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Randomized controlled trial of electro-acupuncture for autism spectrum disorder . OBJECTIVE To study the efficacy , safety , and compliance of short-term electro-acupuncture for children with autism spectrum disorder ( ASD ) . DESIGN Randomized , double-blind , sham-controlled , clinical trial . SUBJECTS AND METHODS Children with ASD were randomly assigned to an electro-acupuncture ( EA ) group ( n=30 ) or a sham electro-acupuncture ( SEA ) group ( n=25 ) matched by age and severity of autism . The EA group received electro-acupuncture for selected acupoints while the SEA group received sham electro-acupuncture to sham acupoints . A total of 12 EA and SEA sessions over four weeks were given . Primary outcome measures included Functional Independence Measure for Children ( WeeFIM ) , Pediatric Evaluation of Disability Inventory ( PEDI ) , Leiter International Performance Scale-Revised ( Leiter-R ) , and Clinical Global Impression-Improvement ( CGI-I ) scale . Secondary outcome measures consisted of Aberrant Behavior Checklist ( ABC ) , Ritvo-Freeman Real Life Scale ( RFRLS ) , Reynell Developmental Language Scale ( RDLS ) , and a standardized parental report . Data were analyzed by the Mann-Whitney test . RESULTS There were significant improvements in the language comprehension domain of WeeFIM ( p=0.02 ) , self-care caregiver assistant domain of PEDI ( p=0.028 ) , and CGI-I ( p=0.003 ) in the EA group compared to the SEA group . As for the parental report , the EA group also showed significantly better social initiation ( p=0.01 ) , receptive language ( p=0.006 ) , motor skills ( p=0.034 ) , coordination ( p=0.07 ) , and attention span ( p=0.003 ) . More than 70 percent of children with ASD adapted to acupuncture easily , while eight percent had poor acupuncture compliance . Mild side effects of minor superficial bleeding or irritability during acupuncture were observed . CONCLUSION A short , four-week ( 12 sessions ) course of electro-acupuncture is useful to improve specific functions in children with ASD , especially for language comprehension and self-care ability .
[ "Randomized", "controlled", "trial", "of", "electro", "-", "acupuncture", "for", "autism", "spectrum", "disorder", ".", "OBJECTIVE", "To", "study", "the", "efficacy", ",", "safety", ",", "and", "compliance", "of", "short", "-", "term", "electro", "-", "acupuncture", "for", "children", "with", "autism", "spectrum", "disorder", "(", "ASD", ")", ".", "DESIGN", "Randomized", ",", "double", "-", "blind", ",", "sham", "-", "controlled", ",", "clinical", "trial", ".", "SUBJECTS", "AND", "METHODS", "Children", "with", "ASD", "were", "randomly", "assigned", "to", "an", "electro", "-", "acupuncture", "(", "EA", ")", "group", "(", "n=30", ")", "or", "a", "sham", "electro", "-", "acupuncture", "(", "SEA", ")", "group", "(", "n=25", ")", "matched", "by", "age", "and", "severity", "of", "autism", ".", "The", "EA", "group", "received", "electro", "-", "acupuncture", "for", "selected", "acupoints", "while", "the", "SEA", "group", "received", "sham", "electro", "-", "acupuncture", "to", "sham", "acupoints", ".", "A", "total", "of", "12", "EA", "and", "SEA", "sessions", "over", "four", "weeks", "were", "given", ".", "Primary", "outcome", "measures", "included", "Functional", "Independence", "Measure", "for", "Children", "(", "WeeFIM", ")", ",", "Pediatric", "Evaluation", "of", "Disability", "Inventory", "(", "PEDI", ")", ",", "Leiter", "International", "Performance", "Scale", "-", "Revised", "(", "Leiter", "-", "R", ")", ",", "and", "Clinical", "Global", "Impression", "-", "Improvement", "(", "CGI", "-", "I", ")", "scale", ".", "Secondary", "outcome", "measures", "consisted", "of", "Aberrant", "Behavior", "Checklist", "(", "ABC", ")", ",", "Ritvo", "-", "Freeman", "Real", "Life", "Scale", "(", "RFRLS", ")", ",", "Reynell", "Developmental", "Language", "Scale", "(", "RDLS", ")", ",", "and", "a", "standardized", "parental", "report", ".", "Data", "were", "analyzed", "by", "the", "Mann", "-", "Whitney", "test", ".", "RESULTS", "There", "were", "significant", "improvements", "in", "the", "language", "comprehension", "domain", "of", "WeeFIM", "(", "p=0.02", ")", ",", "self", "-", "care", "caregiver", "assistant", "domain", "of", "PEDI", "(", "p=0.028", ")", ",", "and", "CGI", "-", "I", "(", "p=0.003", ")", "in", "the", "EA", "group", "compared", "to", "the", "SEA", "group", ".", "As", "for", "the", "parental", "report", ",", "the", "EA", "group", "also", "showed", "significantly", "better", "social", "initiation", "(", "p=0.01", ")", ",", "receptive", "language", "(", "p=0.006", ")", ",", "motor", "skills", "(", "p=0.034", ")", ",", "coordination", "(", "p=0.07", ")", ",", "and", "attention", "span", "(", "p=0.003", ")", ".", "More", "than", "70", "percent", "of", "children", "with", "ASD", "adapted", "to", "acupuncture", "easily", ",", "while", "eight", "percent", "had", "poor", "acupuncture", "compliance", ".", "Mild", "side", "effects", "of", "minor", "superficial", "bleeding", "or", "irritability", "during", "acupuncture", "were", "observed", ".", "CONCLUSION", "A", "short", ",", "four", "-", "week", "(", "12", "sessions", ")", "course", "of", "electro", "-", "acupuncture", "is", "useful", "to", "improve", "specific", "functions", "in", "children", "with", "ASD", ",", "especially", "for", "language", "comprehension", "and", "self", "-", "care", "ability", "." ]
[ "Outcome_Physical", "Outcome_Mental", "Outcome_Adverse-effects", "Participant_Condition", "Intervention_Physical", "Intervention_Control", "Participant_Age", "Participant_Sample-size" ]
maennliche is an umlsterm, Grad - Gesichtsfeld is an umlsterm, Farbtafel is an umlsterm
DerOpthalmologe.70940222.ger.abstr_task0
Sentence: Mit Hilfe eines 3-Farben-Messgeraets nach Guild-Bechstein wurden fuer eine maennliche deuteranopische Versuchsperson in einem fovealen , d . h . 2 Grad-Gesichtsfeld ( 1 ) nach dem Wahrnehmungskriterium " ununterscheidbar gleich " die deuteranopische Fehlfarbe , ( 2 ) nach dem Wahrnehmungskriterium " weder blau noch gelb " die neutrale Zone , ( 3 ) nach dem Wahrnehmungskriterium " heterochrom gleich hell " die Alychne bestimmt . Die Auswertung ergab in der Farbtafel 2 Geraden eines dichromatischen Geradenbueschels , mit der deuteranopischen Fehlfarbe als Traegerpunkt . Diese beiden Geraden stellen die Referenzfarbarten eines deuteranopischen Gegenfarbensystems dar . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Mit Hilfe eines 3-Farben-Messgeraets nach Guild-Bechstein wurden fuer eine maennliche deuteranopische Versuchsperson in einem fovealen , d . h . 2 Grad-Gesichtsfeld ( 1 ) nach dem Wahrnehmungskriterium " ununterscheidbar gleich " die deuteranopische Fehlfarbe , ( 2 ) nach dem Wahrnehmungskriterium " weder blau noch gelb " die neutrale Zone , ( 3 ) nach dem Wahrnehmungskriterium " heterochrom gleich hell " die Alychne bestimmt . Die Auswertung ergab in der Farbtafel 2 Geraden eines dichromatischen Geradenbueschels , mit der deuteranopischen Fehlfarbe als Traegerpunkt . Diese beiden Geraden stellen die Referenzfarbarten eines deuteranopischen Gegenfarbensystems dar .
[ "Mit", "Hilfe", "eines", "3-Farben", "-", "Messgeraets", "nach", "Guild", "-", "Bechstein", "wurden", "fuer", "eine", "maennliche", "deuteranopische", "Versuchsperson", "in", "einem", "fovealen", ",", "d", ".", "h", ".", "2", "Grad", "-", "Gesichtsfeld", "(", "1", ")", "nach", "dem", "Wahrnehmungskriterium", "\"", "ununterscheidbar", "gleich", "\"", "die", "deuteranopische", "Fehlfarbe", ",", "(", "2", ")", "nach", "dem", "Wahrnehmungskriterium", "\"", "weder", "blau", "noch", "gelb", "\"", "die", "neutrale", "Zone", ",", "(", "3", ")", "nach", "dem", "Wahrnehmungskriterium", "\"", "heterochrom", "gleich", "hell", "\"", "die", "Alychne", "bestimmt", ".", "Die", "Auswertung", "ergab", "in", "der", "Farbtafel", "2", "Geraden", "eines", "dichromatischen", "Geradenbueschels", ",", "mit", "der", "deuteranopischen", "Fehlfarbe", "als", "Traegerpunkt", ".", "Diese", "beiden", "Geraden", "stellen", "die", "Referenzfarbarten", "eines", "deuteranopischen", "Gegenfarbensystems", "dar", "." ]
[ "umlsterm" ]
maennliche is an umlsterm, Grad - Gesichtsfeld is an umlsterm, Farbtafel is an umlsterm
DerOpthalmologe.70940222.ger.abstr_task1
Sentence: Mit Hilfe eines 3-Farben-Messgeraets nach Guild-Bechstein wurden fuer eine maennliche deuteranopische Versuchsperson in einem fovealen , d . h . 2 Grad-Gesichtsfeld ( 1 ) nach dem Wahrnehmungskriterium " ununterscheidbar gleich " die deuteranopische Fehlfarbe , ( 2 ) nach dem Wahrnehmungskriterium " weder blau noch gelb " die neutrale Zone , ( 3 ) nach dem Wahrnehmungskriterium " heterochrom gleich hell " die Alychne bestimmt . Die Auswertung ergab in der Farbtafel 2 Geraden eines dichromatischen Geradenbueschels , mit der deuteranopischen Fehlfarbe als Traegerpunkt . Diese beiden Geraden stellen die Referenzfarbarten eines deuteranopischen Gegenfarbensystems dar . Instructions: please typing these entity words according to sentence: maennliche, Grad - Gesichtsfeld, Farbtafel Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Mit Hilfe eines 3-Farben-Messgeraets nach Guild-Bechstein wurden fuer eine maennliche deuteranopische Versuchsperson in einem fovealen , d . h . 2 Grad-Gesichtsfeld ( 1 ) nach dem Wahrnehmungskriterium " ununterscheidbar gleich " die deuteranopische Fehlfarbe , ( 2 ) nach dem Wahrnehmungskriterium " weder blau noch gelb " die neutrale Zone , ( 3 ) nach dem Wahrnehmungskriterium " heterochrom gleich hell " die Alychne bestimmt . Die Auswertung ergab in der Farbtafel 2 Geraden eines dichromatischen Geradenbueschels , mit der deuteranopischen Fehlfarbe als Traegerpunkt . Diese beiden Geraden stellen die Referenzfarbarten eines deuteranopischen Gegenfarbensystems dar .
[ "Mit", "Hilfe", "eines", "3-Farben", "-", "Messgeraets", "nach", "Guild", "-", "Bechstein", "wurden", "fuer", "eine", "maennliche", "deuteranopische", "Versuchsperson", "in", "einem", "fovealen", ",", "d", ".", "h", ".", "2", "Grad", "-", "Gesichtsfeld", "(", "1", ")", "nach", "dem", "Wahrnehmungskriterium", "\"", "ununterscheidbar", "gleich", "\"", "die", "deuteranopische", "Fehlfarbe", ",", "(", "2", ")", "nach", "dem", "Wahrnehmungskriterium", "\"", "weder", "blau", "noch", "gelb", "\"", "die", "neutrale", "Zone", ",", "(", "3", ")", "nach", "dem", "Wahrnehmungskriterium", "\"", "heterochrom", "gleich", "hell", "\"", "die", "Alychne", "bestimmt", ".", "Die", "Auswertung", "ergab", "in", "der", "Farbtafel", "2", "Geraden", "eines", "dichromatischen", "Geradenbueschels", ",", "mit", "der", "deuteranopischen", "Fehlfarbe", "als", "Traegerpunkt", ".", "Diese", "beiden", "Geraden", "stellen", "die", "Referenzfarbarten", "eines", "deuteranopischen", "Gegenfarbensystems", "dar", "." ]
[ "umlsterm" ]
maennliche, Grad - Gesichtsfeld, Farbtafel
DerOpthalmologe.70940222.ger.abstr_task2
Sentence: Mit Hilfe eines 3-Farben-Messgeraets nach Guild-Bechstein wurden fuer eine maennliche deuteranopische Versuchsperson in einem fovealen , d . h . 2 Grad-Gesichtsfeld ( 1 ) nach dem Wahrnehmungskriterium " ununterscheidbar gleich " die deuteranopische Fehlfarbe , ( 2 ) nach dem Wahrnehmungskriterium " weder blau noch gelb " die neutrale Zone , ( 3 ) nach dem Wahrnehmungskriterium " heterochrom gleich hell " die Alychne bestimmt . Die Auswertung ergab in der Farbtafel 2 Geraden eines dichromatischen Geradenbueschels , mit der deuteranopischen Fehlfarbe als Traegerpunkt . Diese beiden Geraden stellen die Referenzfarbarten eines deuteranopischen Gegenfarbensystems dar . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Mit Hilfe eines 3-Farben-Messgeraets nach Guild-Bechstein wurden fuer eine maennliche deuteranopische Versuchsperson in einem fovealen , d . h . 2 Grad-Gesichtsfeld ( 1 ) nach dem Wahrnehmungskriterium " ununterscheidbar gleich " die deuteranopische Fehlfarbe , ( 2 ) nach dem Wahrnehmungskriterium " weder blau noch gelb " die neutrale Zone , ( 3 ) nach dem Wahrnehmungskriterium " heterochrom gleich hell " die Alychne bestimmt . Die Auswertung ergab in der Farbtafel 2 Geraden eines dichromatischen Geradenbueschels , mit der deuteranopischen Fehlfarbe als Traegerpunkt . Diese beiden Geraden stellen die Referenzfarbarten eines deuteranopischen Gegenfarbensystems dar .
[ "Mit", "Hilfe", "eines", "3-Farben", "-", "Messgeraets", "nach", "Guild", "-", "Bechstein", "wurden", "fuer", "eine", "maennliche", "deuteranopische", "Versuchsperson", "in", "einem", "fovealen", ",", "d", ".", "h", ".", "2", "Grad", "-", "Gesichtsfeld", "(", "1", ")", "nach", "dem", "Wahrnehmungskriterium", "\"", "ununterscheidbar", "gleich", "\"", "die", "deuteranopische", "Fehlfarbe", ",", "(", "2", ")", "nach", "dem", "Wahrnehmungskriterium", "\"", "weder", "blau", "noch", "gelb", "\"", "die", "neutrale", "Zone", ",", "(", "3", ")", "nach", "dem", "Wahrnehmungskriterium", "\"", "heterochrom", "gleich", "hell", "\"", "die", "Alychne", "bestimmt", ".", "Die", "Auswertung", "ergab", "in", "der", "Farbtafel", "2", "Geraden", "eines", "dichromatischen", "Geradenbueschels", ",", "mit", "der", "deuteranopischen", "Fehlfarbe", "als", "Traegerpunkt", ".", "Diese", "beiden", "Geraden", "stellen", "die", "Referenzfarbarten", "eines", "deuteranopischen", "Gegenfarbensystems", "dar", "." ]
[ "umlsterm" ]
Cucurbitacin I is a CHEMICAL, rac1 is a GENE-Y, oxygen is a CHEMICAL, janus tyrosine kinase 2 is a GENE-Y, p - rex1 is a GENE-Y, GTPase is a GENE-N, Rac1 is a GENE-Y, ErbB is a GENE-Y, Rac1 is a GENE-Y, Rac - guanine nucleotide exchange factor is a GENE-N, P - Rex1 is a GENE-Y, Janus tyrosine kinase 2 is a GENE-Y, Stat3 is a GENE-Y, ErbB is a GENE-Y, P - Rex1 is a GENE-Y, Rac1 is a GENE-Y, ErbB is a GENE-Y, cucurbitacin I is a CHEMICAL, Jak2 is a GENE-N, Rac1 is a GENE-Y, ErbB3 is a GENE-Y, heregulin is a GENE-Y, Rac1 is a GENE-Y, Jak2 is a GENE-Y, Stat3 is a GENE-Y, cucurbitacin I is a CHEMICAL, Cucurbitacin I is a CHEMICAL, P - Rex1 is a GENE-Y, heregulin is a GENE-Y, cucurbitacin I is a CHEMICAL, RhoA is a GENE-N, Rho is a GENE-N, Rho kinase is a GENE-N, ROCK is a GENE-N, RhoA is a GENE-N, ROCK is a GENE-N, cucurbitacin I is a CHEMICAL, Rac1 is a GENE-Y, heregulin is a GENE-Y, RhoA is a GENE-N, cucurbitacin I is a CHEMICAL, oxygen is a CHEMICAL, N - acetyl l - cysteine is a CHEMICAL, cucurbitacin I is a CHEMICAL, Rac1 is a GENE-Y, ErbB is a GENE-Y, Rac1 is a GENE-Y, Jak2 is a GENE-N, cucurbitacin I is a CHEMICAL, Rac1 is a GENE-Y, Rho is a GENE-N, Rac is a GENE-N
24521_task0
Sentence: Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1. The small GTPase Rac1 has been widely implicated in mammary tumorigenesis and metastasis. Previous studies established that stimulation of ErbB receptors in breast cancer cells activates Rac1 and enhances motility via the Rac-guanine nucleotide exchange factor P-Rex1. As the Janus tyrosine kinase 2 (Jak2)/signal transducer and activator of transcription 3 (Stat3) pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate P-Rex1/Rac1 activation in response to ErbB ligands. Here we found that the anticancer agent cucurbitacin I, a Jak2 inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells. However, Rac1 activation was not affected by Jak2 or Stat3 RNA interference, suggesting that the effect of cucurbitacin I occurs through a Jak2-independent mechanism. Cucurbitacin I also failed to affect the activation of P-Rex1 by heregulin. Subsequent analysis revealed that cucurbitacin I strongly activates RhoA and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers. Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of cucurbitacin I on Rac1 activation by heregulin. Lastly, we found that RhoA activation by cucurbitacin I is mediated by reactive oxygen species (ROS). The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on Rac1 activation. In conclusion, these results indicate that ErbB-driven Rac1 activation in breast cancer cells proceeds independently of the Jak2 pathway. Moreover, they established that the inhibitory effect of cucurbitacin I on Rac1 activity involves the alteration of the balance between Rho and Rac. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL
[ "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-N", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "B-GENE-N", "O", "B-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O" ]
Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1. The small GTPase Rac1 has been widely implicated in mammary tumorigenesis and metastasis. Previous studies established that stimulation of ErbB receptors in breast cancer cells activates Rac1 and enhances motility via the Rac-guanine nucleotide exchange factor P-Rex1. As the Janus tyrosine kinase 2 (Jak2)/signal transducer and activator of transcription 3 (Stat3) pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate P-Rex1/Rac1 activation in response to ErbB ligands. Here we found that the anticancer agent cucurbitacin I, a Jak2 inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells. However, Rac1 activation was not affected by Jak2 or Stat3 RNA interference, suggesting that the effect of cucurbitacin I occurs through a Jak2-independent mechanism. Cucurbitacin I also failed to affect the activation of P-Rex1 by heregulin. Subsequent analysis revealed that cucurbitacin I strongly activates RhoA and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers. Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of cucurbitacin I on Rac1 activation by heregulin. Lastly, we found that RhoA activation by cucurbitacin I is mediated by reactive oxygen species (ROS). The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on Rac1 activation. In conclusion, these results indicate that ErbB-driven Rac1 activation in breast cancer cells proceeds independently of the Jak2 pathway. Moreover, they established that the inhibitory effect of cucurbitacin I on Rac1 activity involves the alteration of the balance between Rho and Rac.
[ "Cucurbitacin", "I", "inhibits", "rac1", "activation", "in", "breast", "cancer", "cells", "by", "a", "reactive", "oxygen", "species", "-", "mediated", "mechanism", "and", "independently", "of", "janus", "tyrosine", "kinase", "2", "and", "p", "-", "rex1", ".", "\n", "The", "small", "GTPase", "Rac1", "has", "been", "widely", "implicated", "in", "mammary", "tumorigenesis", "and", "metastasis", ".", "Previous", "studies", "established", "that", "stimulation", "of", "ErbB", "receptors", "in", "breast", "cancer", "cells", "activates", "Rac1", "and", "enhances", "motility", "via", "the", "Rac", "-", "guanine", "nucleotide", "exchange", "factor", "P", "-", "Rex1", ".", "As", "the", "Janus", "tyrosine", "kinase", "2", "(", "Jak2)/signal", "transducer", "and", "activator", "of", "transcription", "3", "(", "Stat3", ")", "pathway", "has", "been", "shown", "to", "be", "functionally", "associated", "with", "ErbB", "receptors", ",", "we", "asked", "if", "this", "pathway", "could", "mediate", "P", "-", "Rex1", "/", "Rac1", "activation", "in", "response", "to", "ErbB", "ligands", ".", "Here", "we", "found", "that", "the", "anticancer", "agent", "cucurbitacin", "I", ",", "a", "Jak2", "inhibitor", ",", "reduced", "the", "activation", "of", "Rac1", "and", "motility", "in", "response", "to", "the", "ErbB3", "ligand", "heregulin", "in", "breast", "cancer", "cells", ".", "However", ",", "Rac1", "activation", "was", "not", "affected", "by", "Jak2", "or", "Stat3", "RNA", "interference", ",", "suggesting", "that", "the", "effect", "of", "cucurbitacin", "I", "occurs", "through", "a", "Jak2-independent", "mechanism", ".", "Cucurbitacin", "I", "also", "failed", "to", "affect", "the", "activation", "of", "P", "-", "Rex1", "by", "heregulin", ".", "Subsequent", "analysis", "revealed", "that", "cucurbitacin", "I", "strongly", "activates", "RhoA", "and", "the", "Rho", "effector", "Rho", "kinase", "(", "ROCK", ")", "in", "breast", "cancer", "cells", "and", "induces", "the", "formation", "of", "stress", "fibers", ".", "Interestingly", ",", "disruption", "of", "the", "RhoA", "-", "ROCK", "pathway", "prevented", "the", "inhibitory", "effect", "of", "cucurbitacin", "I", "on", "Rac1", "activation", "by", "heregulin", ".", "Lastly", ",", "we", "found", "that", "RhoA", "activation", "by", "cucurbitacin", "I", "is", "mediated", "by", "reactive", "oxygen", "species", "(", "ROS", ")", ".", "The", "ROS", "scavenger", "N", "-", "acetyl", "l", "-", "cysteine", "and", "the", "mitochondrial", "antioxidant", "Mito", "-", "TEMPO", "rescued", "the", "inhibitory", "effect", "of", "cucurbitacin", "I", "on", "Rac1", "activation", ".", "In", "conclusion", ",", "these", "results", "indicate", "that", "ErbB", "-", "driven", "Rac1", "activation", "in", "breast", "cancer", "cells", "proceeds", "independently", "of", "the", "Jak2", "pathway", ".", "Moreover", ",", "they", "established", "that", "the", "inhibitory", "effect", "of", "cucurbitacin", "I", "on", "Rac1", "activity", "involves", "the", "alteration", "of", "the", "balance", "between", "Rho", "and", "Rac", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Cucurbitacin I is a CHEMICAL, rac1 is a GENE-Y, oxygen is a CHEMICAL, janus tyrosine kinase 2 is a GENE-Y, p - rex1 is a GENE-Y, GTPase is a GENE-N, Rac1 is a GENE-Y, ErbB is a GENE-Y, Rac1 is a GENE-Y, Rac - guanine nucleotide exchange factor is a GENE-N, P - Rex1 is a GENE-Y, Janus tyrosine kinase 2 is a GENE-Y, Stat3 is a GENE-Y, ErbB is a GENE-Y, P - Rex1 is a GENE-Y, Rac1 is a GENE-Y, ErbB is a GENE-Y, cucurbitacin I is a CHEMICAL, Jak2 is a GENE-N, Rac1 is a GENE-Y, ErbB3 is a GENE-Y, heregulin is a GENE-Y, Rac1 is a GENE-Y, Jak2 is a GENE-Y, Stat3 is a GENE-Y, cucurbitacin I is a CHEMICAL, Cucurbitacin I is a CHEMICAL, P - Rex1 is a GENE-Y, heregulin is a GENE-Y, cucurbitacin I is a CHEMICAL, RhoA is a GENE-N, Rho is a GENE-N, Rho kinase is a GENE-N, ROCK is a GENE-N, RhoA is a GENE-N, ROCK is a GENE-N, cucurbitacin I is a CHEMICAL, Rac1 is a GENE-Y, heregulin is a GENE-Y, RhoA is a GENE-N, cucurbitacin I is a CHEMICAL, oxygen is a CHEMICAL, N - acetyl l - cysteine is a CHEMICAL, cucurbitacin I is a CHEMICAL, Rac1 is a GENE-Y, ErbB is a GENE-Y, Rac1 is a GENE-Y, Jak2 is a GENE-N, cucurbitacin I is a CHEMICAL, Rac1 is a GENE-Y, Rho is a GENE-N, Rac is a GENE-N
24521_task1
Sentence: Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1. The small GTPase Rac1 has been widely implicated in mammary tumorigenesis and metastasis. Previous studies established that stimulation of ErbB receptors in breast cancer cells activates Rac1 and enhances motility via the Rac-guanine nucleotide exchange factor P-Rex1. As the Janus tyrosine kinase 2 (Jak2)/signal transducer and activator of transcription 3 (Stat3) pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate P-Rex1/Rac1 activation in response to ErbB ligands. Here we found that the anticancer agent cucurbitacin I, a Jak2 inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells. However, Rac1 activation was not affected by Jak2 or Stat3 RNA interference, suggesting that the effect of cucurbitacin I occurs through a Jak2-independent mechanism. Cucurbitacin I also failed to affect the activation of P-Rex1 by heregulin. Subsequent analysis revealed that cucurbitacin I strongly activates RhoA and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers. Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of cucurbitacin I on Rac1 activation by heregulin. Lastly, we found that RhoA activation by cucurbitacin I is mediated by reactive oxygen species (ROS). The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on Rac1 activation. In conclusion, these results indicate that ErbB-driven Rac1 activation in breast cancer cells proceeds independently of the Jak2 pathway. Moreover, they established that the inhibitory effect of cucurbitacin I on Rac1 activity involves the alteration of the balance between Rho and Rac. Instructions: please typing these entity words according to sentence: Cucurbitacin I, rac1, oxygen, janus tyrosine kinase 2, p - rex1, GTPase, Rac1, ErbB, Rac1, Rac - guanine nucleotide exchange factor, P - Rex1, Janus tyrosine kinase 2, Stat3, ErbB, P - Rex1, Rac1, ErbB, cucurbitacin I, Jak2, Rac1, ErbB3, heregulin, Rac1, Jak2, Stat3, cucurbitacin I, Cucurbitacin I, P - Rex1, heregulin, cucurbitacin I, RhoA, Rho, Rho kinase, ROCK, RhoA, ROCK, cucurbitacin I, Rac1, heregulin, RhoA, cucurbitacin I, oxygen, N - acetyl l - cysteine, cucurbitacin I, Rac1, ErbB, Rac1, Jak2, cucurbitacin I, Rac1, Rho, Rac Options: GENE-N, GENE-Y, CHEMICAL
[ "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-N", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "B-GENE-N", "O", "B-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O" ]
Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1. The small GTPase Rac1 has been widely implicated in mammary tumorigenesis and metastasis. Previous studies established that stimulation of ErbB receptors in breast cancer cells activates Rac1 and enhances motility via the Rac-guanine nucleotide exchange factor P-Rex1. As the Janus tyrosine kinase 2 (Jak2)/signal transducer and activator of transcription 3 (Stat3) pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate P-Rex1/Rac1 activation in response to ErbB ligands. Here we found that the anticancer agent cucurbitacin I, a Jak2 inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells. However, Rac1 activation was not affected by Jak2 or Stat3 RNA interference, suggesting that the effect of cucurbitacin I occurs through a Jak2-independent mechanism. Cucurbitacin I also failed to affect the activation of P-Rex1 by heregulin. Subsequent analysis revealed that cucurbitacin I strongly activates RhoA and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers. Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of cucurbitacin I on Rac1 activation by heregulin. Lastly, we found that RhoA activation by cucurbitacin I is mediated by reactive oxygen species (ROS). The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on Rac1 activation. In conclusion, these results indicate that ErbB-driven Rac1 activation in breast cancer cells proceeds independently of the Jak2 pathway. Moreover, they established that the inhibitory effect of cucurbitacin I on Rac1 activity involves the alteration of the balance between Rho and Rac.
[ "Cucurbitacin", "I", "inhibits", "rac1", "activation", "in", "breast", "cancer", "cells", "by", "a", "reactive", "oxygen", "species", "-", "mediated", "mechanism", "and", "independently", "of", "janus", "tyrosine", "kinase", "2", "and", "p", "-", "rex1", ".", "\n", "The", "small", "GTPase", "Rac1", "has", "been", "widely", "implicated", "in", "mammary", "tumorigenesis", "and", "metastasis", ".", "Previous", "studies", "established", "that", "stimulation", "of", "ErbB", "receptors", "in", "breast", "cancer", "cells", "activates", "Rac1", "and", "enhances", "motility", "via", "the", "Rac", "-", "guanine", "nucleotide", "exchange", "factor", "P", "-", "Rex1", ".", "As", "the", "Janus", "tyrosine", "kinase", "2", "(", "Jak2)/signal", "transducer", "and", "activator", "of", "transcription", "3", "(", "Stat3", ")", "pathway", "has", "been", "shown", "to", "be", "functionally", "associated", "with", "ErbB", "receptors", ",", "we", "asked", "if", "this", "pathway", "could", "mediate", "P", "-", "Rex1", "/", "Rac1", "activation", "in", "response", "to", "ErbB", "ligands", ".", "Here", "we", "found", "that", "the", "anticancer", "agent", "cucurbitacin", "I", ",", "a", "Jak2", "inhibitor", ",", "reduced", "the", "activation", "of", "Rac1", "and", "motility", "in", "response", "to", "the", "ErbB3", "ligand", "heregulin", "in", "breast", "cancer", "cells", ".", "However", ",", "Rac1", "activation", "was", "not", "affected", "by", "Jak2", "or", "Stat3", "RNA", "interference", ",", "suggesting", "that", "the", "effect", "of", "cucurbitacin", "I", "occurs", "through", "a", "Jak2-independent", "mechanism", ".", "Cucurbitacin", "I", "also", "failed", "to", "affect", "the", "activation", "of", "P", "-", "Rex1", "by", "heregulin", ".", "Subsequent", "analysis", "revealed", "that", "cucurbitacin", "I", "strongly", "activates", "RhoA", "and", "the", "Rho", "effector", "Rho", "kinase", "(", "ROCK", ")", "in", "breast", "cancer", "cells", "and", "induces", "the", "formation", "of", "stress", "fibers", ".", "Interestingly", ",", "disruption", "of", "the", "RhoA", "-", "ROCK", "pathway", "prevented", "the", "inhibitory", "effect", "of", "cucurbitacin", "I", "on", "Rac1", "activation", "by", "heregulin", ".", "Lastly", ",", "we", "found", "that", "RhoA", "activation", "by", "cucurbitacin", "I", "is", "mediated", "by", "reactive", "oxygen", "species", "(", "ROS", ")", ".", "The", "ROS", "scavenger", "N", "-", "acetyl", "l", "-", "cysteine", "and", "the", "mitochondrial", "antioxidant", "Mito", "-", "TEMPO", "rescued", "the", "inhibitory", "effect", "of", "cucurbitacin", "I", "on", "Rac1", "activation", ".", "In", "conclusion", ",", "these", "results", "indicate", "that", "ErbB", "-", "driven", "Rac1", "activation", "in", "breast", "cancer", "cells", "proceeds", "independently", "of", "the", "Jak2", "pathway", ".", "Moreover", ",", "they", "established", "that", "the", "inhibitory", "effect", "of", "cucurbitacin", "I", "on", "Rac1", "activity", "involves", "the", "alteration", "of", "the", "balance", "between", "Rho", "and", "Rac", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Cucurbitacin I, rac1, oxygen, janus tyrosine kinase 2, p - rex1, GTPase, Rac1, ErbB, Rac1, Rac - guanine nucleotide exchange factor, P - Rex1, Janus tyrosine kinase 2, Stat3, ErbB, P - Rex1, Rac1, ErbB, cucurbitacin I, Jak2, Rac1, ErbB3, heregulin, Rac1, Jak2, Stat3, cucurbitacin I, Cucurbitacin I, P - Rex1, heregulin, cucurbitacin I, RhoA, Rho, Rho kinase, ROCK, RhoA, ROCK, cucurbitacin I, Rac1, heregulin, RhoA, cucurbitacin I, oxygen, N - acetyl l - cysteine, cucurbitacin I, Rac1, ErbB, Rac1, Jak2, cucurbitacin I, Rac1, Rho, Rac
24521_task2
Sentence: Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1. The small GTPase Rac1 has been widely implicated in mammary tumorigenesis and metastasis. Previous studies established that stimulation of ErbB receptors in breast cancer cells activates Rac1 and enhances motility via the Rac-guanine nucleotide exchange factor P-Rex1. As the Janus tyrosine kinase 2 (Jak2)/signal transducer and activator of transcription 3 (Stat3) pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate P-Rex1/Rac1 activation in response to ErbB ligands. Here we found that the anticancer agent cucurbitacin I, a Jak2 inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells. However, Rac1 activation was not affected by Jak2 or Stat3 RNA interference, suggesting that the effect of cucurbitacin I occurs through a Jak2-independent mechanism. Cucurbitacin I also failed to affect the activation of P-Rex1 by heregulin. Subsequent analysis revealed that cucurbitacin I strongly activates RhoA and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers. Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of cucurbitacin I on Rac1 activation by heregulin. Lastly, we found that RhoA activation by cucurbitacin I is mediated by reactive oxygen species (ROS). The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on Rac1 activation. In conclusion, these results indicate that ErbB-driven Rac1 activation in breast cancer cells proceeds independently of the Jak2 pathway. Moreover, they established that the inhibitory effect of cucurbitacin I on Rac1 activity involves the alteration of the balance between Rho and Rac. Instructions: please extract entity words from the input sentence
[ "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-N", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "B-GENE-N", "O", "B-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O" ]
Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1. The small GTPase Rac1 has been widely implicated in mammary tumorigenesis and metastasis. Previous studies established that stimulation of ErbB receptors in breast cancer cells activates Rac1 and enhances motility via the Rac-guanine nucleotide exchange factor P-Rex1. As the Janus tyrosine kinase 2 (Jak2)/signal transducer and activator of transcription 3 (Stat3) pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate P-Rex1/Rac1 activation in response to ErbB ligands. Here we found that the anticancer agent cucurbitacin I, a Jak2 inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells. However, Rac1 activation was not affected by Jak2 or Stat3 RNA interference, suggesting that the effect of cucurbitacin I occurs through a Jak2-independent mechanism. Cucurbitacin I also failed to affect the activation of P-Rex1 by heregulin. Subsequent analysis revealed that cucurbitacin I strongly activates RhoA and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers. Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of cucurbitacin I on Rac1 activation by heregulin. Lastly, we found that RhoA activation by cucurbitacin I is mediated by reactive oxygen species (ROS). The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on Rac1 activation. In conclusion, these results indicate that ErbB-driven Rac1 activation in breast cancer cells proceeds independently of the Jak2 pathway. Moreover, they established that the inhibitory effect of cucurbitacin I on Rac1 activity involves the alteration of the balance between Rho and Rac.
[ "Cucurbitacin", "I", "inhibits", "rac1", "activation", "in", "breast", "cancer", "cells", "by", "a", "reactive", "oxygen", "species", "-", "mediated", "mechanism", "and", "independently", "of", "janus", "tyrosine", "kinase", "2", "and", "p", "-", "rex1", ".", "\n", "The", "small", "GTPase", "Rac1", "has", "been", "widely", "implicated", "in", "mammary", "tumorigenesis", "and", "metastasis", ".", "Previous", "studies", "established", "that", "stimulation", "of", "ErbB", "receptors", "in", "breast", "cancer", "cells", "activates", "Rac1", "and", "enhances", "motility", "via", "the", "Rac", "-", "guanine", "nucleotide", "exchange", "factor", "P", "-", "Rex1", ".", "As", "the", "Janus", "tyrosine", "kinase", "2", "(", "Jak2)/signal", "transducer", "and", "activator", "of", "transcription", "3", "(", "Stat3", ")", "pathway", "has", "been", "shown", "to", "be", "functionally", "associated", "with", "ErbB", "receptors", ",", "we", "asked", "if", "this", "pathway", "could", "mediate", "P", "-", "Rex1", "/", "Rac1", "activation", "in", "response", "to", "ErbB", "ligands", ".", "Here", "we", "found", "that", "the", "anticancer", "agent", "cucurbitacin", "I", ",", "a", "Jak2", "inhibitor", ",", "reduced", "the", "activation", "of", "Rac1", "and", "motility", "in", "response", "to", "the", "ErbB3", "ligand", "heregulin", "in", "breast", "cancer", "cells", ".", "However", ",", "Rac1", "activation", "was", "not", "affected", "by", "Jak2", "or", "Stat3", "RNA", "interference", ",", "suggesting", "that", "the", "effect", "of", "cucurbitacin", "I", "occurs", "through", "a", "Jak2-independent", "mechanism", ".", "Cucurbitacin", "I", "also", "failed", "to", "affect", "the", "activation", "of", "P", "-", "Rex1", "by", "heregulin", ".", "Subsequent", "analysis", "revealed", "that", "cucurbitacin", "I", "strongly", "activates", "RhoA", "and", "the", "Rho", "effector", "Rho", "kinase", "(", "ROCK", ")", "in", "breast", "cancer", "cells", "and", "induces", "the", "formation", "of", "stress", "fibers", ".", "Interestingly", ",", "disruption", "of", "the", "RhoA", "-", "ROCK", "pathway", "prevented", "the", "inhibitory", "effect", "of", "cucurbitacin", "I", "on", "Rac1", "activation", "by", "heregulin", ".", "Lastly", ",", "we", "found", "that", "RhoA", "activation", "by", "cucurbitacin", "I", "is", "mediated", "by", "reactive", "oxygen", "species", "(", "ROS", ")", ".", "The", "ROS", "scavenger", "N", "-", "acetyl", "l", "-", "cysteine", "and", "the", "mitochondrial", "antioxidant", "Mito", "-", "TEMPO", "rescued", "the", "inhibitory", "effect", "of", "cucurbitacin", "I", "on", "Rac1", "activation", ".", "In", "conclusion", ",", "these", "results", "indicate", "that", "ErbB", "-", "driven", "Rac1", "activation", "in", "breast", "cancer", "cells", "proceeds", "independently", "of", "the", "Jak2", "pathway", ".", "Moreover", ",", "they", "established", "that", "the", "inhibitory", "effect", "of", "cucurbitacin", "I", "on", "Rac1", "activity", "involves", "the", "alteration", "of", "the", "balance", "between", "Rho", "and", "Rac", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Behandlung is an umlsterm, Klumpfussrezidives is an umlsterm, Kinderorthopaedie is an umlsterm, Literatur is an umlsterm, Fussdeformitaet is an umlsterm, Osteotomien is an umlsterm, Osteotomien is an umlsterm, Rezidivformen is an umlsterm, Kuneiformeosteotomie is an umlsterm, Mittelfussosteotomie is an umlsterm, Osteotomie is an umlsterm, Supination is an umlsterm, Fussdeformitaeten is an umlsterm, Osteotomie is an umlsterm, Osteotomie is an umlsterm, Patientengutes is an umlsterm, Patienten is an umlsterm, Klumpfuss is an umlsterm, Reoperation is an umlsterm, Literatur is an umlsterm, Osteotomien is an umlsterm, Kalkaneus is an umlsterm, Osteotomie is an umlsterm, Osteotomie is an umlsterm, Kalkaneus is an umlsterm, Mittelfussosteotomie is an umlsterm
DerOrthopaede.90280117.ger.abstr_task0
Sentence: Bezueglich der Behandlung des Klumpfussrezidives , ein relativ haeufiges und schwieriges Problem in der Kinderorthopaedie , fehlen klare therapeutische Richtlinien . In der Literatur sind zahlreiche operative Eingriffe erwaehnt , welche zur Korrektur einer residuellen Fussdeformitaet dienen koennen . Es finden sich zahlreiche Weichteileingriffe ( Releaseoperationen Sehnenverlaengerungen , Sehnenverlagerungen und Redressierung , mittels Fixateur externe ) und ossaere Eingriffe ( Osteotomien Arthrodesen ) , , welche alleine oder in Kombination miteinander durchgefuehrt werden koennen . Im vorliegenden Artikel sind zwei Osteotomien beschrieben , welche die Korrektur der haeufigsten Rezidivformen des Klumpfusses ermoeglichen : die kombinierte zuklappende Kuboid- und aufklappende Kuneiformeosteotomie zur Behebung des Vorfussadduktus und -supinatus , die Kalkaneusosteotomie nach Dwyer zur Behebung des Rueckfussvarus . Die kombinierte Mittelfussosteotomie laesst ueber eine Verkuerzung des lateralen Strahles bei gleichzeitiger Verlaengerung des medialen Strahles - der aus dem Kuboid entnommene Keil wird in das Kuneiforme mediale eingesetzt - hauptsaechlich eine Korrektur des Adduktus zu , ermoeglicht jedoch bei durch saemtliche Kuneiformia fuehrender Osteotomie auch eine partielle Behebung der Supination . Bei rigiden Fussdeformitaeten empfiehlt sich vor der Osteotomie die Vordehnung mittels eines Fixateur externe , beim Bild des Bohnenfusses die Kombination der Osteotomie mit einem medialen und lateralen Release . Resultate einer Nachuntersuchung des eigenen Patientengutes mit dieser Operation haben ergeben , dass bei saemtlichen Patienten mit idiopathischem Klumpfuss keine Reoperation mehr notwendig wurde . Es werden zusaetzlich andere in der Literatur beschriebene Osteotomien zwecks Korrektur des residuellen Vorfussadduktus und -supinatus vergleichend erwaehnt . Die Kalkaneusosteotomie nach Dwyer , welche immer durch einen lateralen Zugang ausgefuehrt wird , fuehrt zu einer in der Regel befriedigenden Korrektur des Rueckfussvarus . Zeigt der Kalkaneus einen kurzen posterioren Teil , so wird diese Osteotomie nicht lateral zuklappend unter Entnahme eines Keiles durchgefuehrt , sondern der Osteotomie schliesst sich eine Lateralverschiebung an . So kann verhindert werden , dass der posterior bereits kurze Kalkaneus noch kuerzer wird . Sowohl die kombinierte Mittelfussosteotomie als auch die Kalkaneusosteotomie nach Dwyer koennen alleine oder in Kombination miteinander bzw. anderen operativen Eingriffen durchgefuehrt werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Bezueglich der Behandlung des Klumpfussrezidives , ein relativ haeufiges und schwieriges Problem in der Kinderorthopaedie , fehlen klare therapeutische Richtlinien . In der Literatur sind zahlreiche operative Eingriffe erwaehnt , welche zur Korrektur einer residuellen Fussdeformitaet dienen koennen . Es finden sich zahlreiche Weichteileingriffe ( Releaseoperationen Sehnenverlaengerungen , Sehnenverlagerungen und Redressierung , mittels Fixateur externe ) und ossaere Eingriffe ( Osteotomien Arthrodesen ) , , welche alleine oder in Kombination miteinander durchgefuehrt werden koennen . Im vorliegenden Artikel sind zwei Osteotomien beschrieben , welche die Korrektur der haeufigsten Rezidivformen des Klumpfusses ermoeglichen : die kombinierte zuklappende Kuboid- und aufklappende Kuneiformeosteotomie zur Behebung des Vorfussadduktus und -supinatus , die Kalkaneusosteotomie nach Dwyer zur Behebung des Rueckfussvarus . Die kombinierte Mittelfussosteotomie laesst ueber eine Verkuerzung des lateralen Strahles bei gleichzeitiger Verlaengerung des medialen Strahles - der aus dem Kuboid entnommene Keil wird in das Kuneiforme mediale eingesetzt - hauptsaechlich eine Korrektur des Adduktus zu , ermoeglicht jedoch bei durch saemtliche Kuneiformia fuehrender Osteotomie auch eine partielle Behebung der Supination . Bei rigiden Fussdeformitaeten empfiehlt sich vor der Osteotomie die Vordehnung mittels eines Fixateur externe , beim Bild des Bohnenfusses die Kombination der Osteotomie mit einem medialen und lateralen Release . Resultate einer Nachuntersuchung des eigenen Patientengutes mit dieser Operation haben ergeben , dass bei saemtlichen Patienten mit idiopathischem Klumpfuss keine Reoperation mehr notwendig wurde . Es werden zusaetzlich andere in der Literatur beschriebene Osteotomien zwecks Korrektur des residuellen Vorfussadduktus und -supinatus vergleichend erwaehnt . Die Kalkaneusosteotomie nach Dwyer , welche immer durch einen lateralen Zugang ausgefuehrt wird , fuehrt zu einer in der Regel befriedigenden Korrektur des Rueckfussvarus . Zeigt der Kalkaneus einen kurzen posterioren Teil , so wird diese Osteotomie nicht lateral zuklappend unter Entnahme eines Keiles durchgefuehrt , sondern der Osteotomie schliesst sich eine Lateralverschiebung an . So kann verhindert werden , dass der posterior bereits kurze Kalkaneus noch kuerzer wird . Sowohl die kombinierte Mittelfussosteotomie als auch die Kalkaneusosteotomie nach Dwyer koennen alleine oder in Kombination miteinander bzw. anderen operativen Eingriffen durchgefuehrt werden .
[ "Bezueglich", "der", "Behandlung", "des", "Klumpfussrezidives", ",", "ein", "relativ", "haeufiges", "und", "schwieriges", "Problem", "in", "der", "Kinderorthopaedie", ",", "fehlen", "klare", "therapeutische", "Richtlinien", ".", "In", "der", "Literatur", "sind", "zahlreiche", "operative", "Eingriffe", "erwaehnt", ",", "welche", "zur", "Korrektur", "einer", "residuellen", "Fussdeformitaet", "dienen", "koennen", ".", "Es", "finden", "sich", "zahlreiche", "Weichteileingriffe", "(", "Releaseoperationen", "Sehnenverlaengerungen", ",", "Sehnenverlagerungen", "und", "Redressierung", ",", "mittels", "Fixateur", "externe", ")", "und", "ossaere", "Eingriffe", "(", "Osteotomien", "Arthrodesen", ")", ",", ",", "welche", "alleine", "oder", "in", "Kombination", "miteinander", "durchgefuehrt", "werden", "koennen", ".", "Im", "vorliegenden", "Artikel", "sind", "zwei", "Osteotomien", "beschrieben", ",", "welche", "die", "Korrektur", "der", "haeufigsten", "Rezidivformen", "des", "Klumpfusses", "ermoeglichen", ":", "die", "kombinierte", "zuklappende", "Kuboid-", "und", "aufklappende", "Kuneiformeosteotomie", "zur", "Behebung", "des", "Vorfussadduktus", "und", "-supinatus", ",", "die", "Kalkaneusosteotomie", "nach", "Dwyer", "zur", "Behebung", "des", "Rueckfussvarus", ".", "Die", "kombinierte", "Mittelfussosteotomie", "laesst", "ueber", "eine", "Verkuerzung", "des", "lateralen", "Strahles", "bei", "gleichzeitiger", "Verlaengerung", "des", "medialen", "Strahles", "-", "der", "aus", "dem", "Kuboid", "entnommene", "Keil", "wird", "in", "das", "Kuneiforme", "mediale", "eingesetzt", "-", "hauptsaechlich", "eine", "Korrektur", "des", "Adduktus", "zu", ",", "ermoeglicht", "jedoch", "bei", "durch", "saemtliche", "Kuneiformia", "fuehrender", "Osteotomie", "auch", "eine", "partielle", "Behebung", "der", "Supination", ".", "Bei", "rigiden", "Fussdeformitaeten", "empfiehlt", "sich", "vor", "der", "Osteotomie", "die", "Vordehnung", "mittels", "eines", "Fixateur", "externe", ",", "beim", "Bild", "des", "Bohnenfusses", "die", "Kombination", "der", "Osteotomie", "mit", "einem", "medialen", "und", "lateralen", "Release", ".", "Resultate", "einer", "Nachuntersuchung", "des", "eigenen", "Patientengutes", "mit", "dieser", "Operation", "haben", "ergeben", ",", "dass", "bei", "saemtlichen", "Patienten", "mit", "idiopathischem", "Klumpfuss", "keine", "Reoperation", "mehr", "notwendig", "wurde", ".", "Es", "werden", "zusaetzlich", "andere", "in", "der", "Literatur", "beschriebene", "Osteotomien", "zwecks", "Korrektur", "des", "residuellen", "Vorfussadduktus", "und", "-supinatus", "vergleichend", "erwaehnt", ".", "Die", "Kalkaneusosteotomie", "nach", "Dwyer", ",", "welche", "immer", "durch", "einen", "lateralen", "Zugang", "ausgefuehrt", "wird", ",", "fuehrt", "zu", "einer", "in", "der", "Regel", "befriedigenden", "Korrektur", "des", "Rueckfussvarus", ".", "Zeigt", "der", "Kalkaneus", "einen", "kurzen", "posterioren", "Teil", ",", "so", "wird", "diese", "Osteotomie", "nicht", "lateral", "zuklappend", "unter", "Entnahme", "eines", "Keiles", "durchgefuehrt", ",", "sondern", "der", "Osteotomie", "schliesst", "sich", "eine", "Lateralverschiebung", "an", ".", "So", "kann", "verhindert", "werden", ",", "dass", "der", "posterior", "bereits", "kurze", "Kalkaneus", "noch", "kuerzer", "wird", ".", "Sowohl", "die", "kombinierte", "Mittelfussosteotomie", "als", "auch", "die", "Kalkaneusosteotomie", "nach", "Dwyer", "koennen", "alleine", "oder", "in", "Kombination", "miteinander", "bzw", ".", "anderen", "operativen", "Eingriffen", "durchgefuehrt", "werden", "." ]
[ "umlsterm" ]
Behandlung is an umlsterm, Klumpfussrezidives is an umlsterm, Kinderorthopaedie is an umlsterm, Literatur is an umlsterm, Fussdeformitaet is an umlsterm, Osteotomien is an umlsterm, Osteotomien is an umlsterm, Rezidivformen is an umlsterm, Kuneiformeosteotomie is an umlsterm, Mittelfussosteotomie is an umlsterm, Osteotomie is an umlsterm, Supination is an umlsterm, Fussdeformitaeten is an umlsterm, Osteotomie is an umlsterm, Osteotomie is an umlsterm, Patientengutes is an umlsterm, Patienten is an umlsterm, Klumpfuss is an umlsterm, Reoperation is an umlsterm, Literatur is an umlsterm, Osteotomien is an umlsterm, Kalkaneus is an umlsterm, Osteotomie is an umlsterm, Osteotomie is an umlsterm, Kalkaneus is an umlsterm, Mittelfussosteotomie is an umlsterm
DerOrthopaede.90280117.ger.abstr_task1
Sentence: Bezueglich der Behandlung des Klumpfussrezidives , ein relativ haeufiges und schwieriges Problem in der Kinderorthopaedie , fehlen klare therapeutische Richtlinien . In der Literatur sind zahlreiche operative Eingriffe erwaehnt , welche zur Korrektur einer residuellen Fussdeformitaet dienen koennen . Es finden sich zahlreiche Weichteileingriffe ( Releaseoperationen Sehnenverlaengerungen , Sehnenverlagerungen und Redressierung , mittels Fixateur externe ) und ossaere Eingriffe ( Osteotomien Arthrodesen ) , , welche alleine oder in Kombination miteinander durchgefuehrt werden koennen . Im vorliegenden Artikel sind zwei Osteotomien beschrieben , welche die Korrektur der haeufigsten Rezidivformen des Klumpfusses ermoeglichen : die kombinierte zuklappende Kuboid- und aufklappende Kuneiformeosteotomie zur Behebung des Vorfussadduktus und -supinatus , die Kalkaneusosteotomie nach Dwyer zur Behebung des Rueckfussvarus . Die kombinierte Mittelfussosteotomie laesst ueber eine Verkuerzung des lateralen Strahles bei gleichzeitiger Verlaengerung des medialen Strahles - der aus dem Kuboid entnommene Keil wird in das Kuneiforme mediale eingesetzt - hauptsaechlich eine Korrektur des Adduktus zu , ermoeglicht jedoch bei durch saemtliche Kuneiformia fuehrender Osteotomie auch eine partielle Behebung der Supination . Bei rigiden Fussdeformitaeten empfiehlt sich vor der Osteotomie die Vordehnung mittels eines Fixateur externe , beim Bild des Bohnenfusses die Kombination der Osteotomie mit einem medialen und lateralen Release . Resultate einer Nachuntersuchung des eigenen Patientengutes mit dieser Operation haben ergeben , dass bei saemtlichen Patienten mit idiopathischem Klumpfuss keine Reoperation mehr notwendig wurde . Es werden zusaetzlich andere in der Literatur beschriebene Osteotomien zwecks Korrektur des residuellen Vorfussadduktus und -supinatus vergleichend erwaehnt . Die Kalkaneusosteotomie nach Dwyer , welche immer durch einen lateralen Zugang ausgefuehrt wird , fuehrt zu einer in der Regel befriedigenden Korrektur des Rueckfussvarus . Zeigt der Kalkaneus einen kurzen posterioren Teil , so wird diese Osteotomie nicht lateral zuklappend unter Entnahme eines Keiles durchgefuehrt , sondern der Osteotomie schliesst sich eine Lateralverschiebung an . So kann verhindert werden , dass der posterior bereits kurze Kalkaneus noch kuerzer wird . Sowohl die kombinierte Mittelfussosteotomie als auch die Kalkaneusosteotomie nach Dwyer koennen alleine oder in Kombination miteinander bzw. anderen operativen Eingriffen durchgefuehrt werden . Instructions: please typing these entity words according to sentence: Behandlung, Klumpfussrezidives, Kinderorthopaedie, Literatur, Fussdeformitaet, Osteotomien, Osteotomien, Rezidivformen, Kuneiformeosteotomie, Mittelfussosteotomie, Osteotomie, Supination, Fussdeformitaeten, Osteotomie, Osteotomie, Patientengutes, Patienten, Klumpfuss, Reoperation, Literatur, Osteotomien, Kalkaneus, Osteotomie, Osteotomie, Kalkaneus, Mittelfussosteotomie Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Bezueglich der Behandlung des Klumpfussrezidives , ein relativ haeufiges und schwieriges Problem in der Kinderorthopaedie , fehlen klare therapeutische Richtlinien . In der Literatur sind zahlreiche operative Eingriffe erwaehnt , welche zur Korrektur einer residuellen Fussdeformitaet dienen koennen . Es finden sich zahlreiche Weichteileingriffe ( Releaseoperationen Sehnenverlaengerungen , Sehnenverlagerungen und Redressierung , mittels Fixateur externe ) und ossaere Eingriffe ( Osteotomien Arthrodesen ) , , welche alleine oder in Kombination miteinander durchgefuehrt werden koennen . Im vorliegenden Artikel sind zwei Osteotomien beschrieben , welche die Korrektur der haeufigsten Rezidivformen des Klumpfusses ermoeglichen : die kombinierte zuklappende Kuboid- und aufklappende Kuneiformeosteotomie zur Behebung des Vorfussadduktus und -supinatus , die Kalkaneusosteotomie nach Dwyer zur Behebung des Rueckfussvarus . Die kombinierte Mittelfussosteotomie laesst ueber eine Verkuerzung des lateralen Strahles bei gleichzeitiger Verlaengerung des medialen Strahles - der aus dem Kuboid entnommene Keil wird in das Kuneiforme mediale eingesetzt - hauptsaechlich eine Korrektur des Adduktus zu , ermoeglicht jedoch bei durch saemtliche Kuneiformia fuehrender Osteotomie auch eine partielle Behebung der Supination . Bei rigiden Fussdeformitaeten empfiehlt sich vor der Osteotomie die Vordehnung mittels eines Fixateur externe , beim Bild des Bohnenfusses die Kombination der Osteotomie mit einem medialen und lateralen Release . Resultate einer Nachuntersuchung des eigenen Patientengutes mit dieser Operation haben ergeben , dass bei saemtlichen Patienten mit idiopathischem Klumpfuss keine Reoperation mehr notwendig wurde . Es werden zusaetzlich andere in der Literatur beschriebene Osteotomien zwecks Korrektur des residuellen Vorfussadduktus und -supinatus vergleichend erwaehnt . Die Kalkaneusosteotomie nach Dwyer , welche immer durch einen lateralen Zugang ausgefuehrt wird , fuehrt zu einer in der Regel befriedigenden Korrektur des Rueckfussvarus . Zeigt der Kalkaneus einen kurzen posterioren Teil , so wird diese Osteotomie nicht lateral zuklappend unter Entnahme eines Keiles durchgefuehrt , sondern der Osteotomie schliesst sich eine Lateralverschiebung an . So kann verhindert werden , dass der posterior bereits kurze Kalkaneus noch kuerzer wird . Sowohl die kombinierte Mittelfussosteotomie als auch die Kalkaneusosteotomie nach Dwyer koennen alleine oder in Kombination miteinander bzw. anderen operativen Eingriffen durchgefuehrt werden .
[ "Bezueglich", "der", "Behandlung", "des", "Klumpfussrezidives", ",", "ein", "relativ", "haeufiges", "und", "schwieriges", "Problem", "in", "der", "Kinderorthopaedie", ",", "fehlen", "klare", "therapeutische", "Richtlinien", ".", "In", "der", "Literatur", "sind", "zahlreiche", "operative", "Eingriffe", "erwaehnt", ",", "welche", "zur", "Korrektur", "einer", "residuellen", "Fussdeformitaet", "dienen", "koennen", ".", "Es", "finden", "sich", "zahlreiche", "Weichteileingriffe", "(", "Releaseoperationen", "Sehnenverlaengerungen", ",", "Sehnenverlagerungen", "und", "Redressierung", ",", "mittels", "Fixateur", "externe", ")", "und", "ossaere", "Eingriffe", "(", "Osteotomien", "Arthrodesen", ")", ",", ",", "welche", "alleine", "oder", "in", "Kombination", "miteinander", "durchgefuehrt", "werden", "koennen", ".", "Im", "vorliegenden", "Artikel", "sind", "zwei", "Osteotomien", "beschrieben", ",", "welche", "die", "Korrektur", "der", "haeufigsten", "Rezidivformen", "des", "Klumpfusses", "ermoeglichen", ":", "die", "kombinierte", "zuklappende", "Kuboid-", "und", "aufklappende", "Kuneiformeosteotomie", "zur", "Behebung", "des", "Vorfussadduktus", "und", "-supinatus", ",", "die", "Kalkaneusosteotomie", "nach", "Dwyer", "zur", "Behebung", "des", "Rueckfussvarus", ".", "Die", "kombinierte", "Mittelfussosteotomie", "laesst", "ueber", "eine", "Verkuerzung", "des", "lateralen", "Strahles", "bei", "gleichzeitiger", "Verlaengerung", "des", "medialen", "Strahles", "-", "der", "aus", "dem", "Kuboid", "entnommene", "Keil", "wird", "in", "das", "Kuneiforme", "mediale", "eingesetzt", "-", "hauptsaechlich", "eine", "Korrektur", "des", "Adduktus", "zu", ",", "ermoeglicht", "jedoch", "bei", "durch", "saemtliche", "Kuneiformia", "fuehrender", "Osteotomie", "auch", "eine", "partielle", "Behebung", "der", "Supination", ".", "Bei", "rigiden", "Fussdeformitaeten", "empfiehlt", "sich", "vor", "der", "Osteotomie", "die", "Vordehnung", "mittels", "eines", "Fixateur", "externe", ",", "beim", "Bild", "des", "Bohnenfusses", "die", "Kombination", "der", "Osteotomie", "mit", "einem", "medialen", "und", "lateralen", "Release", ".", "Resultate", "einer", "Nachuntersuchung", "des", "eigenen", "Patientengutes", "mit", "dieser", "Operation", "haben", "ergeben", ",", "dass", "bei", "saemtlichen", "Patienten", "mit", "idiopathischem", "Klumpfuss", "keine", "Reoperation", "mehr", "notwendig", "wurde", ".", "Es", "werden", "zusaetzlich", "andere", "in", "der", "Literatur", "beschriebene", "Osteotomien", "zwecks", "Korrektur", "des", "residuellen", "Vorfussadduktus", "und", "-supinatus", "vergleichend", "erwaehnt", ".", "Die", "Kalkaneusosteotomie", "nach", "Dwyer", ",", "welche", "immer", "durch", "einen", "lateralen", "Zugang", "ausgefuehrt", "wird", ",", "fuehrt", "zu", "einer", "in", "der", "Regel", "befriedigenden", "Korrektur", "des", "Rueckfussvarus", ".", "Zeigt", "der", "Kalkaneus", "einen", "kurzen", "posterioren", "Teil", ",", "so", "wird", "diese", "Osteotomie", "nicht", "lateral", "zuklappend", "unter", "Entnahme", "eines", "Keiles", "durchgefuehrt", ",", "sondern", "der", "Osteotomie", "schliesst", "sich", "eine", "Lateralverschiebung", "an", ".", "So", "kann", "verhindert", "werden", ",", "dass", "der", "posterior", "bereits", "kurze", "Kalkaneus", "noch", "kuerzer", "wird", ".", "Sowohl", "die", "kombinierte", "Mittelfussosteotomie", "als", "auch", "die", "Kalkaneusosteotomie", "nach", "Dwyer", "koennen", "alleine", "oder", "in", "Kombination", "miteinander", "bzw", ".", "anderen", "operativen", "Eingriffen", "durchgefuehrt", "werden", "." ]
[ "umlsterm" ]
Behandlung, Klumpfussrezidives, Kinderorthopaedie, Literatur, Fussdeformitaet, Osteotomien, Osteotomien, Rezidivformen, Kuneiformeosteotomie, Mittelfussosteotomie, Osteotomie, Supination, Fussdeformitaeten, Osteotomie, Osteotomie, Patientengutes, Patienten, Klumpfuss, Reoperation, Literatur, Osteotomien, Kalkaneus, Osteotomie, Osteotomie, Kalkaneus, Mittelfussosteotomie
DerOrthopaede.90280117.ger.abstr_task2
Sentence: Bezueglich der Behandlung des Klumpfussrezidives , ein relativ haeufiges und schwieriges Problem in der Kinderorthopaedie , fehlen klare therapeutische Richtlinien . In der Literatur sind zahlreiche operative Eingriffe erwaehnt , welche zur Korrektur einer residuellen Fussdeformitaet dienen koennen . Es finden sich zahlreiche Weichteileingriffe ( Releaseoperationen Sehnenverlaengerungen , Sehnenverlagerungen und Redressierung , mittels Fixateur externe ) und ossaere Eingriffe ( Osteotomien Arthrodesen ) , , welche alleine oder in Kombination miteinander durchgefuehrt werden koennen . Im vorliegenden Artikel sind zwei Osteotomien beschrieben , welche die Korrektur der haeufigsten Rezidivformen des Klumpfusses ermoeglichen : die kombinierte zuklappende Kuboid- und aufklappende Kuneiformeosteotomie zur Behebung des Vorfussadduktus und -supinatus , die Kalkaneusosteotomie nach Dwyer zur Behebung des Rueckfussvarus . Die kombinierte Mittelfussosteotomie laesst ueber eine Verkuerzung des lateralen Strahles bei gleichzeitiger Verlaengerung des medialen Strahles - der aus dem Kuboid entnommene Keil wird in das Kuneiforme mediale eingesetzt - hauptsaechlich eine Korrektur des Adduktus zu , ermoeglicht jedoch bei durch saemtliche Kuneiformia fuehrender Osteotomie auch eine partielle Behebung der Supination . Bei rigiden Fussdeformitaeten empfiehlt sich vor der Osteotomie die Vordehnung mittels eines Fixateur externe , beim Bild des Bohnenfusses die Kombination der Osteotomie mit einem medialen und lateralen Release . Resultate einer Nachuntersuchung des eigenen Patientengutes mit dieser Operation haben ergeben , dass bei saemtlichen Patienten mit idiopathischem Klumpfuss keine Reoperation mehr notwendig wurde . Es werden zusaetzlich andere in der Literatur beschriebene Osteotomien zwecks Korrektur des residuellen Vorfussadduktus und -supinatus vergleichend erwaehnt . Die Kalkaneusosteotomie nach Dwyer , welche immer durch einen lateralen Zugang ausgefuehrt wird , fuehrt zu einer in der Regel befriedigenden Korrektur des Rueckfussvarus . Zeigt der Kalkaneus einen kurzen posterioren Teil , so wird diese Osteotomie nicht lateral zuklappend unter Entnahme eines Keiles durchgefuehrt , sondern der Osteotomie schliesst sich eine Lateralverschiebung an . So kann verhindert werden , dass der posterior bereits kurze Kalkaneus noch kuerzer wird . Sowohl die kombinierte Mittelfussosteotomie als auch die Kalkaneusosteotomie nach Dwyer koennen alleine oder in Kombination miteinander bzw. anderen operativen Eingriffen durchgefuehrt werden . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Bezueglich der Behandlung des Klumpfussrezidives , ein relativ haeufiges und schwieriges Problem in der Kinderorthopaedie , fehlen klare therapeutische Richtlinien . In der Literatur sind zahlreiche operative Eingriffe erwaehnt , welche zur Korrektur einer residuellen Fussdeformitaet dienen koennen . Es finden sich zahlreiche Weichteileingriffe ( Releaseoperationen Sehnenverlaengerungen , Sehnenverlagerungen und Redressierung , mittels Fixateur externe ) und ossaere Eingriffe ( Osteotomien Arthrodesen ) , , welche alleine oder in Kombination miteinander durchgefuehrt werden koennen . Im vorliegenden Artikel sind zwei Osteotomien beschrieben , welche die Korrektur der haeufigsten Rezidivformen des Klumpfusses ermoeglichen : die kombinierte zuklappende Kuboid- und aufklappende Kuneiformeosteotomie zur Behebung des Vorfussadduktus und -supinatus , die Kalkaneusosteotomie nach Dwyer zur Behebung des Rueckfussvarus . Die kombinierte Mittelfussosteotomie laesst ueber eine Verkuerzung des lateralen Strahles bei gleichzeitiger Verlaengerung des medialen Strahles - der aus dem Kuboid entnommene Keil wird in das Kuneiforme mediale eingesetzt - hauptsaechlich eine Korrektur des Adduktus zu , ermoeglicht jedoch bei durch saemtliche Kuneiformia fuehrender Osteotomie auch eine partielle Behebung der Supination . Bei rigiden Fussdeformitaeten empfiehlt sich vor der Osteotomie die Vordehnung mittels eines Fixateur externe , beim Bild des Bohnenfusses die Kombination der Osteotomie mit einem medialen und lateralen Release . Resultate einer Nachuntersuchung des eigenen Patientengutes mit dieser Operation haben ergeben , dass bei saemtlichen Patienten mit idiopathischem Klumpfuss keine Reoperation mehr notwendig wurde . Es werden zusaetzlich andere in der Literatur beschriebene Osteotomien zwecks Korrektur des residuellen Vorfussadduktus und -supinatus vergleichend erwaehnt . Die Kalkaneusosteotomie nach Dwyer , welche immer durch einen lateralen Zugang ausgefuehrt wird , fuehrt zu einer in der Regel befriedigenden Korrektur des Rueckfussvarus . Zeigt der Kalkaneus einen kurzen posterioren Teil , so wird diese Osteotomie nicht lateral zuklappend unter Entnahme eines Keiles durchgefuehrt , sondern der Osteotomie schliesst sich eine Lateralverschiebung an . So kann verhindert werden , dass der posterior bereits kurze Kalkaneus noch kuerzer wird . Sowohl die kombinierte Mittelfussosteotomie als auch die Kalkaneusosteotomie nach Dwyer koennen alleine oder in Kombination miteinander bzw. anderen operativen Eingriffen durchgefuehrt werden .
[ "Bezueglich", "der", "Behandlung", "des", "Klumpfussrezidives", ",", "ein", "relativ", "haeufiges", "und", "schwieriges", "Problem", "in", "der", "Kinderorthopaedie", ",", "fehlen", "klare", "therapeutische", "Richtlinien", ".", "In", "der", "Literatur", "sind", "zahlreiche", "operative", "Eingriffe", "erwaehnt", ",", "welche", "zur", "Korrektur", "einer", "residuellen", "Fussdeformitaet", "dienen", "koennen", ".", "Es", "finden", "sich", "zahlreiche", "Weichteileingriffe", "(", "Releaseoperationen", "Sehnenverlaengerungen", ",", "Sehnenverlagerungen", "und", "Redressierung", ",", "mittels", "Fixateur", "externe", ")", "und", "ossaere", "Eingriffe", "(", "Osteotomien", "Arthrodesen", ")", ",", ",", "welche", "alleine", "oder", "in", "Kombination", "miteinander", "durchgefuehrt", "werden", "koennen", ".", "Im", "vorliegenden", "Artikel", "sind", "zwei", "Osteotomien", "beschrieben", ",", "welche", "die", "Korrektur", "der", "haeufigsten", "Rezidivformen", "des", "Klumpfusses", "ermoeglichen", ":", "die", "kombinierte", "zuklappende", "Kuboid-", "und", "aufklappende", "Kuneiformeosteotomie", "zur", "Behebung", "des", "Vorfussadduktus", "und", "-supinatus", ",", "die", "Kalkaneusosteotomie", "nach", "Dwyer", "zur", "Behebung", "des", "Rueckfussvarus", ".", "Die", "kombinierte", "Mittelfussosteotomie", "laesst", "ueber", "eine", "Verkuerzung", "des", "lateralen", "Strahles", "bei", "gleichzeitiger", "Verlaengerung", "des", "medialen", "Strahles", "-", "der", "aus", "dem", "Kuboid", "entnommene", "Keil", "wird", "in", "das", "Kuneiforme", "mediale", "eingesetzt", "-", "hauptsaechlich", "eine", "Korrektur", "des", "Adduktus", "zu", ",", "ermoeglicht", "jedoch", "bei", "durch", "saemtliche", "Kuneiformia", "fuehrender", "Osteotomie", "auch", "eine", "partielle", "Behebung", "der", "Supination", ".", "Bei", "rigiden", "Fussdeformitaeten", "empfiehlt", "sich", "vor", "der", "Osteotomie", "die", "Vordehnung", "mittels", "eines", "Fixateur", "externe", ",", "beim", "Bild", "des", "Bohnenfusses", "die", "Kombination", "der", "Osteotomie", "mit", "einem", "medialen", "und", "lateralen", "Release", ".", "Resultate", "einer", "Nachuntersuchung", "des", "eigenen", "Patientengutes", "mit", "dieser", "Operation", "haben", "ergeben", ",", "dass", "bei", "saemtlichen", "Patienten", "mit", "idiopathischem", "Klumpfuss", "keine", "Reoperation", "mehr", "notwendig", "wurde", ".", "Es", "werden", "zusaetzlich", "andere", "in", "der", "Literatur", "beschriebene", "Osteotomien", "zwecks", "Korrektur", "des", "residuellen", "Vorfussadduktus", "und", "-supinatus", "vergleichend", "erwaehnt", ".", "Die", "Kalkaneusosteotomie", "nach", "Dwyer", ",", "welche", "immer", "durch", "einen", "lateralen", "Zugang", "ausgefuehrt", "wird", ",", "fuehrt", "zu", "einer", "in", "der", "Regel", "befriedigenden", "Korrektur", "des", "Rueckfussvarus", ".", "Zeigt", "der", "Kalkaneus", "einen", "kurzen", "posterioren", "Teil", ",", "so", "wird", "diese", "Osteotomie", "nicht", "lateral", "zuklappend", "unter", "Entnahme", "eines", "Keiles", "durchgefuehrt", ",", "sondern", "der", "Osteotomie", "schliesst", "sich", "eine", "Lateralverschiebung", "an", ".", "So", "kann", "verhindert", "werden", ",", "dass", "der", "posterior", "bereits", "kurze", "Kalkaneus", "noch", "kuerzer", "wird", ".", "Sowohl", "die", "kombinierte", "Mittelfussosteotomie", "als", "auch", "die", "Kalkaneusosteotomie", "nach", "Dwyer", "koennen", "alleine", "oder", "in", "Kombination", "miteinander", "bzw", ".", "anderen", "operativen", "Eingriffen", "durchgefuehrt", "werden", "." ]
[ "umlsterm" ]
interleukin-2 is a Protein, interleukin(IL)-2 is a Protein, IL-2 is a Protein, tumor necrosis factor - alpha is a Protein, p65 is a Protein, GAL4 is a Protein, IL-8 is a Protein, IL-8 is a Protein
158_task0
Sentence: Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. PG490 (triptolide) is a diterpene triepoxide with potent immunosuppressive and antiinflammatory properties. PG490 inhibits interleukin(IL)-2 expression by normal human peripheral blood lymphocytes stimulated with phorbol 12-myristate 13-acetate (PMA) and antibody to CD3 (IC50 of 10 ng/ml), and with PMA and ionomycin (Iono, IC50 of 40 ng/ml). In Jurkat T-cells, PG490 inhibits PMA/Iono-stimulated IL-2 transcription. PG490 inhibits the induction of DNA binding activity at the purine-box/antigen receptor response element (ARRE)/nuclear factor of activated T-cells (NF-AT) target sequence but not at the NF-kappaB site. PG490 can completely inhibit transcriptional activation at the purine-box/ARRE/NF-AT and NF-kappaB target DNA sequences triggered by all stimuli examined (PMA, PMA/Iono, tumor necrosis factor-alpha). PG490 also inhibits PMA-stimulated activation of a chimeric transcription factor in which the C-terminal TA1 transactivation domain of NF-kappaB p65 is fused to the DNA binding domain of GAL4. In 16HBE human bronchial epithelial cells, IL-8 expression is regulated predominantly by NF-kappaB, and PG490 but not cyclosporin A can completely inhibit expression of IL-8. The mechanism of PG490 inhibition of cytokine gene expression differs from cyclosporin A and involves nuclear inhibition of transcriptional activation of NF-kappaB and the purine-box regulator operating at the ARRE/NF-AT site at a step after specific DNA binding. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. PG490 (triptolide) is a diterpene triepoxide with potent immunosuppressive and antiinflammatory properties. PG490 inhibits interleukin(IL)-2 expression by normal human peripheral blood lymphocytes stimulated with phorbol 12-myristate 13-acetate (PMA) and antibody to CD3 (IC50 of 10 ng/ml), and with PMA and ionomycin (Iono, IC50 of 40 ng/ml). In Jurkat T-cells, PG490 inhibits PMA/Iono-stimulated IL-2 transcription. PG490 inhibits the induction of DNA binding activity at the purine-box/antigen receptor response element (ARRE)/nuclear factor of activated T-cells (NF-AT) target sequence but not at the NF-kappaB site. PG490 can completely inhibit transcriptional activation at the purine-box/ARRE/NF-AT and NF-kappaB target DNA sequences triggered by all stimuli examined (PMA, PMA/Iono, tumor necrosis factor-alpha). PG490 also inhibits PMA-stimulated activation of a chimeric transcription factor in which the C-terminal TA1 transactivation domain of NF-kappaB p65 is fused to the DNA binding domain of GAL4. In 16HBE human bronchial epithelial cells, IL-8 expression is regulated predominantly by NF-kappaB, and PG490 but not cyclosporin A can completely inhibit expression of IL-8. The mechanism of PG490 inhibition of cytokine gene expression differs from cyclosporin A and involves nuclear inhibition of transcriptional activation of NF-kappaB and the purine-box regulator operating at the ARRE/NF-AT site at a step after specific DNA binding.
[ "Immunosuppressant", "PG490", "(", "triptolide", ")", "inhibits", "T", "-", "cell", "interleukin-2", "expression", "at", "the", "level", "of", "purine", "-", "box", "/", "nuclear", "factor", "of", "activated", "T", "-", "cells", "and", "NF", "-", "kappaB", "transcriptional", "activation", ".", "\n", "PG490", "(", "triptolide", ")", "is", "a", "diterpene", "triepoxide", "with", "potent", "immunosuppressive", "and", "antiinflammatory", "properties", ".", "PG490", "inhibits", "interleukin(IL)-2", "expression", "by", "normal", "human", "peripheral", "blood", "lymphocytes", "stimulated", "with", "phorbol", "12-myristate", "13-acetate", "(", "PMA", ")", "and", "antibody", "to", "CD3", "(", "IC50", "of", "10", "ng", "/", "ml", ")", ",", "and", "with", "PMA", "and", "ionomycin", "(", "Iono", ",", "IC50", "of", "40", "ng", "/", "ml", ")", ".", "In", "Jurkat", "T", "-", "cells", ",", "PG490", "inhibits", "PMA", "/", "Iono", "-", "stimulated", "IL-2", "transcription", ".", "PG490", "inhibits", "the", "induction", "of", "DNA", "binding", "activity", "at", "the", "purine", "-", "box", "/", "antigen", "receptor", "response", "element", "(", "ARRE)/nuclear", "factor", "of", "activated", "T", "-", "cells", "(", "NF", "-", "AT", ")", "target", "sequence", "but", "not", "at", "the", "NF", "-", "kappaB", "site", ".", "PG490", "can", "completely", "inhibit", "transcriptional", "activation", "at", "the", "purine", "-", "box", "/", "ARRE", "/", "NF", "-", "AT", "and", "NF", "-", "kappaB", "target", "DNA", "sequences", "triggered", "by", "all", "stimuli", "examined", "(", "PMA", ",", "PMA", "/", "Iono", ",", "tumor", "necrosis", "factor", "-", "alpha", ")", ".", "PG490", "also", "inhibits", "PMA", "-", "stimulated", "activation", "of", "a", "chimeric", "transcription", "factor", "in", "which", "the", "C", "-", "terminal", "TA1", "transactivation", "domain", "of", "NF", "-", "kappaB", "p65", "is", "fused", "to", "the", "DNA", "binding", "domain", "of", "GAL4", ".", "In", "16HBE", "human", "bronchial", "epithelial", "cells", ",", "IL-8", "expression", "is", "regulated", "predominantly", "by", "NF", "-", "kappaB", ",", "and", "PG490", "but", "not", "cyclosporin", "A", "can", "completely", "inhibit", "expression", "of", "IL-8", ".", "The", "mechanism", "of", "PG490", "inhibition", "of", "cytokine", "gene", "expression", "differs", "from", "cyclosporin", "A", "and", "involves", "nuclear", "inhibition", "of", "transcriptional", "activation", "of", "NF", "-", "kappaB", "and", "the", "purine", "-", "box", "regulator", "operating", "at", "the", "ARRE", "/", "NF", "-", "AT", "site", "at", "a", "step", "after", "specific", "DNA", "binding", "." ]
[ "Protein" ]
interleukin-2 is a Protein, interleukin(IL)-2 is a Protein, IL-2 is a Protein, tumor necrosis factor - alpha is a Protein, p65 is a Protein, GAL4 is a Protein, IL-8 is a Protein, IL-8 is a Protein
158_task1
Sentence: Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. PG490 (triptolide) is a diterpene triepoxide with potent immunosuppressive and antiinflammatory properties. PG490 inhibits interleukin(IL)-2 expression by normal human peripheral blood lymphocytes stimulated with phorbol 12-myristate 13-acetate (PMA) and antibody to CD3 (IC50 of 10 ng/ml), and with PMA and ionomycin (Iono, IC50 of 40 ng/ml). In Jurkat T-cells, PG490 inhibits PMA/Iono-stimulated IL-2 transcription. PG490 inhibits the induction of DNA binding activity at the purine-box/antigen receptor response element (ARRE)/nuclear factor of activated T-cells (NF-AT) target sequence but not at the NF-kappaB site. PG490 can completely inhibit transcriptional activation at the purine-box/ARRE/NF-AT and NF-kappaB target DNA sequences triggered by all stimuli examined (PMA, PMA/Iono, tumor necrosis factor-alpha). PG490 also inhibits PMA-stimulated activation of a chimeric transcription factor in which the C-terminal TA1 transactivation domain of NF-kappaB p65 is fused to the DNA binding domain of GAL4. In 16HBE human bronchial epithelial cells, IL-8 expression is regulated predominantly by NF-kappaB, and PG490 but not cyclosporin A can completely inhibit expression of IL-8. The mechanism of PG490 inhibition of cytokine gene expression differs from cyclosporin A and involves nuclear inhibition of transcriptional activation of NF-kappaB and the purine-box regulator operating at the ARRE/NF-AT site at a step after specific DNA binding. Instructions: please typing these entity words according to sentence: interleukin-2, interleukin(IL)-2, IL-2, tumor necrosis factor - alpha, p65, GAL4, IL-8, IL-8 Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. PG490 (triptolide) is a diterpene triepoxide with potent immunosuppressive and antiinflammatory properties. PG490 inhibits interleukin(IL)-2 expression by normal human peripheral blood lymphocytes stimulated with phorbol 12-myristate 13-acetate (PMA) and antibody to CD3 (IC50 of 10 ng/ml), and with PMA and ionomycin (Iono, IC50 of 40 ng/ml). In Jurkat T-cells, PG490 inhibits PMA/Iono-stimulated IL-2 transcription. PG490 inhibits the induction of DNA binding activity at the purine-box/antigen receptor response element (ARRE)/nuclear factor of activated T-cells (NF-AT) target sequence but not at the NF-kappaB site. PG490 can completely inhibit transcriptional activation at the purine-box/ARRE/NF-AT and NF-kappaB target DNA sequences triggered by all stimuli examined (PMA, PMA/Iono, tumor necrosis factor-alpha). PG490 also inhibits PMA-stimulated activation of a chimeric transcription factor in which the C-terminal TA1 transactivation domain of NF-kappaB p65 is fused to the DNA binding domain of GAL4. In 16HBE human bronchial epithelial cells, IL-8 expression is regulated predominantly by NF-kappaB, and PG490 but not cyclosporin A can completely inhibit expression of IL-8. The mechanism of PG490 inhibition of cytokine gene expression differs from cyclosporin A and involves nuclear inhibition of transcriptional activation of NF-kappaB and the purine-box regulator operating at the ARRE/NF-AT site at a step after specific DNA binding.
[ "Immunosuppressant", "PG490", "(", "triptolide", ")", "inhibits", "T", "-", "cell", "interleukin-2", "expression", "at", "the", "level", "of", "purine", "-", "box", "/", "nuclear", "factor", "of", "activated", "T", "-", "cells", "and", "NF", "-", "kappaB", "transcriptional", "activation", ".", "\n", "PG490", "(", "triptolide", ")", "is", "a", "diterpene", "triepoxide", "with", "potent", "immunosuppressive", "and", "antiinflammatory", "properties", ".", "PG490", "inhibits", "interleukin(IL)-2", "expression", "by", "normal", "human", "peripheral", "blood", "lymphocytes", "stimulated", "with", "phorbol", "12-myristate", "13-acetate", "(", "PMA", ")", "and", "antibody", "to", "CD3", "(", "IC50", "of", "10", "ng", "/", "ml", ")", ",", "and", "with", "PMA", "and", "ionomycin", "(", "Iono", ",", "IC50", "of", "40", "ng", "/", "ml", ")", ".", "In", "Jurkat", "T", "-", "cells", ",", "PG490", "inhibits", "PMA", "/", "Iono", "-", "stimulated", "IL-2", "transcription", ".", "PG490", "inhibits", "the", "induction", "of", "DNA", "binding", "activity", "at", "the", "purine", "-", "box", "/", "antigen", "receptor", "response", "element", "(", "ARRE)/nuclear", "factor", "of", "activated", "T", "-", "cells", "(", "NF", "-", "AT", ")", "target", "sequence", "but", "not", "at", "the", "NF", "-", "kappaB", "site", ".", "PG490", "can", "completely", "inhibit", "transcriptional", "activation", "at", "the", "purine", "-", "box", "/", "ARRE", "/", "NF", "-", "AT", "and", "NF", "-", "kappaB", "target", "DNA", "sequences", "triggered", "by", "all", "stimuli", "examined", "(", "PMA", ",", "PMA", "/", "Iono", ",", "tumor", "necrosis", "factor", "-", "alpha", ")", ".", "PG490", "also", "inhibits", "PMA", "-", "stimulated", "activation", "of", "a", "chimeric", "transcription", "factor", "in", "which", "the", "C", "-", "terminal", "TA1", "transactivation", "domain", "of", "NF", "-", "kappaB", "p65", "is", "fused", "to", "the", "DNA", "binding", "domain", "of", "GAL4", ".", "In", "16HBE", "human", "bronchial", "epithelial", "cells", ",", "IL-8", "expression", "is", "regulated", "predominantly", "by", "NF", "-", "kappaB", ",", "and", "PG490", "but", "not", "cyclosporin", "A", "can", "completely", "inhibit", "expression", "of", "IL-8", ".", "The", "mechanism", "of", "PG490", "inhibition", "of", "cytokine", "gene", "expression", "differs", "from", "cyclosporin", "A", "and", "involves", "nuclear", "inhibition", "of", "transcriptional", "activation", "of", "NF", "-", "kappaB", "and", "the", "purine", "-", "box", "regulator", "operating", "at", "the", "ARRE", "/", "NF", "-", "AT", "site", "at", "a", "step", "after", "specific", "DNA", "binding", "." ]
[ "Protein" ]
interleukin-2, interleukin(IL)-2, IL-2, tumor necrosis factor - alpha, p65, GAL4, IL-8, IL-8
158_task2
Sentence: Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. PG490 (triptolide) is a diterpene triepoxide with potent immunosuppressive and antiinflammatory properties. PG490 inhibits interleukin(IL)-2 expression by normal human peripheral blood lymphocytes stimulated with phorbol 12-myristate 13-acetate (PMA) and antibody to CD3 (IC50 of 10 ng/ml), and with PMA and ionomycin (Iono, IC50 of 40 ng/ml). In Jurkat T-cells, PG490 inhibits PMA/Iono-stimulated IL-2 transcription. PG490 inhibits the induction of DNA binding activity at the purine-box/antigen receptor response element (ARRE)/nuclear factor of activated T-cells (NF-AT) target sequence but not at the NF-kappaB site. PG490 can completely inhibit transcriptional activation at the purine-box/ARRE/NF-AT and NF-kappaB target DNA sequences triggered by all stimuli examined (PMA, PMA/Iono, tumor necrosis factor-alpha). PG490 also inhibits PMA-stimulated activation of a chimeric transcription factor in which the C-terminal TA1 transactivation domain of NF-kappaB p65 is fused to the DNA binding domain of GAL4. In 16HBE human bronchial epithelial cells, IL-8 expression is regulated predominantly by NF-kappaB, and PG490 but not cyclosporin A can completely inhibit expression of IL-8. The mechanism of PG490 inhibition of cytokine gene expression differs from cyclosporin A and involves nuclear inhibition of transcriptional activation of NF-kappaB and the purine-box regulator operating at the ARRE/NF-AT site at a step after specific DNA binding. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. PG490 (triptolide) is a diterpene triepoxide with potent immunosuppressive and antiinflammatory properties. PG490 inhibits interleukin(IL)-2 expression by normal human peripheral blood lymphocytes stimulated with phorbol 12-myristate 13-acetate (PMA) and antibody to CD3 (IC50 of 10 ng/ml), and with PMA and ionomycin (Iono, IC50 of 40 ng/ml). In Jurkat T-cells, PG490 inhibits PMA/Iono-stimulated IL-2 transcription. PG490 inhibits the induction of DNA binding activity at the purine-box/antigen receptor response element (ARRE)/nuclear factor of activated T-cells (NF-AT) target sequence but not at the NF-kappaB site. PG490 can completely inhibit transcriptional activation at the purine-box/ARRE/NF-AT and NF-kappaB target DNA sequences triggered by all stimuli examined (PMA, PMA/Iono, tumor necrosis factor-alpha). PG490 also inhibits PMA-stimulated activation of a chimeric transcription factor in which the C-terminal TA1 transactivation domain of NF-kappaB p65 is fused to the DNA binding domain of GAL4. In 16HBE human bronchial epithelial cells, IL-8 expression is regulated predominantly by NF-kappaB, and PG490 but not cyclosporin A can completely inhibit expression of IL-8. The mechanism of PG490 inhibition of cytokine gene expression differs from cyclosporin A and involves nuclear inhibition of transcriptional activation of NF-kappaB and the purine-box regulator operating at the ARRE/NF-AT site at a step after specific DNA binding.
[ "Immunosuppressant", "PG490", "(", "triptolide", ")", "inhibits", "T", "-", "cell", "interleukin-2", "expression", "at", "the", "level", "of", "purine", "-", "box", "/", "nuclear", "factor", "of", "activated", "T", "-", "cells", "and", "NF", "-", "kappaB", "transcriptional", "activation", ".", "\n", "PG490", "(", "triptolide", ")", "is", "a", "diterpene", "triepoxide", "with", "potent", "immunosuppressive", "and", "antiinflammatory", "properties", ".", "PG490", "inhibits", "interleukin(IL)-2", "expression", "by", "normal", "human", "peripheral", "blood", "lymphocytes", "stimulated", "with", "phorbol", "12-myristate", "13-acetate", "(", "PMA", ")", "and", "antibody", "to", "CD3", "(", "IC50", "of", "10", "ng", "/", "ml", ")", ",", "and", "with", "PMA", "and", "ionomycin", "(", "Iono", ",", "IC50", "of", "40", "ng", "/", "ml", ")", ".", "In", "Jurkat", "T", "-", "cells", ",", "PG490", "inhibits", "PMA", "/", "Iono", "-", "stimulated", "IL-2", "transcription", ".", "PG490", "inhibits", "the", "induction", "of", "DNA", "binding", "activity", "at", "the", "purine", "-", "box", "/", "antigen", "receptor", "response", "element", "(", "ARRE)/nuclear", "factor", "of", "activated", "T", "-", "cells", "(", "NF", "-", "AT", ")", "target", "sequence", "but", "not", "at", "the", "NF", "-", "kappaB", "site", ".", "PG490", "can", "completely", "inhibit", "transcriptional", "activation", "at", "the", "purine", "-", "box", "/", "ARRE", "/", "NF", "-", "AT", "and", "NF", "-", "kappaB", "target", "DNA", "sequences", "triggered", "by", "all", "stimuli", "examined", "(", "PMA", ",", "PMA", "/", "Iono", ",", "tumor", "necrosis", "factor", "-", "alpha", ")", ".", "PG490", "also", "inhibits", "PMA", "-", "stimulated", "activation", "of", "a", "chimeric", "transcription", "factor", "in", "which", "the", "C", "-", "terminal", "TA1", "transactivation", "domain", "of", "NF", "-", "kappaB", "p65", "is", "fused", "to", "the", "DNA", "binding", "domain", "of", "GAL4", ".", "In", "16HBE", "human", "bronchial", "epithelial", "cells", ",", "IL-8", "expression", "is", "regulated", "predominantly", "by", "NF", "-", "kappaB", ",", "and", "PG490", "but", "not", "cyclosporin", "A", "can", "completely", "inhibit", "expression", "of", "IL-8", ".", "The", "mechanism", "of", "PG490", "inhibition", "of", "cytokine", "gene", "expression", "differs", "from", "cyclosporin", "A", "and", "involves", "nuclear", "inhibition", "of", "transcriptional", "activation", "of", "NF", "-", "kappaB", "and", "the", "purine", "-", "box", "regulator", "operating", "at", "the", "ARRE", "/", "NF", "-", "AT", "site", "at", "a", "step", "after", "specific", "DNA", "binding", "." ]
[ "Protein" ]
absorbable clips is a Intervention_Surgical, laparoscopic cholecystectomy is a Intervention_Surgical, metal clips is a Intervention_Physical, efficacy of absorbable clips is a Outcome_Other, elective laparoscopic cholecystectomy is a Intervention_Surgical, One hundred is a Participant_Sample-size, symptomatic gallstones is a Participant_Condition, two metal clips ( titan clip ETHICONR ) is a Intervention_Surgical, laproclipR Davis and Geck ) is a Intervention_Surgical, one absorbable clip applied on the cystic duct and cystic artery is a Intervention_Surgical, operative time , hospital stay is a Outcome_Other, postoperative complications is a Outcome_Other, absorbable clips seem to be as effective as metal clips is a Outcome_Physical, hemostasis is a Outcome_Physical
91401_task0
Sentence: [ Value of absorbable clips in laparoscopic cholecystectomy . A randomized prospective study ] . Most surgeons use metal clips in laparoscopic cholecystectomy . The aim of this prospective randomized controlled study was to evaluate the efficacy of absorbable clips in elective laparoscopic cholecystectomy . One hundred consecutive patients with symptomatic gallstones without complications were randomized into groups ; group T had two metal clips ( titan clip ETHICONR ) , group R ( laproclipR Davis and Geck ) had one absorbable clip applied on the cystic duct and cystic artery . The patients were followed for one year . There was no difference between the two groups concerning operative time , hospital stay and postoperative complications . The absorbable clips seem to be as effective as metal clips in providing hemostasis in cystic artery and in cystic duct ligation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other, Intervention_Surgical
[ "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
[ Value of absorbable clips in laparoscopic cholecystectomy . A randomized prospective study ] . Most surgeons use metal clips in laparoscopic cholecystectomy . The aim of this prospective randomized controlled study was to evaluate the efficacy of absorbable clips in elective laparoscopic cholecystectomy . One hundred consecutive patients with symptomatic gallstones without complications were randomized into groups ; group T had two metal clips ( titan clip ETHICONR ) , group R ( laproclipR Davis and Geck ) had one absorbable clip applied on the cystic duct and cystic artery . The patients were followed for one year . There was no difference between the two groups concerning operative time , hospital stay and postoperative complications . The absorbable clips seem to be as effective as metal clips in providing hemostasis in cystic artery and in cystic duct ligation .
[ "[", "Value", "of", "absorbable", "clips", "in", "laparoscopic", "cholecystectomy", ".", "A", "randomized", "prospective", "study", "]", ".", "Most", "surgeons", "use", "metal", "clips", "in", "laparoscopic", "cholecystectomy", ".", "The", "aim", "of", "this", "prospective", "randomized", "controlled", "study", "was", "to", "evaluate", "the", "efficacy", "of", "absorbable", "clips", "in", "elective", "laparoscopic", "cholecystectomy", ".", "One", "hundred", "consecutive", "patients", "with", "symptomatic", "gallstones", "without", "complications", "were", "randomized", "into", "groups", ";", "group", "T", "had", "two", "metal", "clips", "(", "titan", "clip", "ETHICONR", ")", ",", "group", "R", "(", "laproclipR", "Davis", "and", "Geck", ")", "had", "one", "absorbable", "clip", "applied", "on", "the", "cystic", "duct", "and", "cystic", "artery", ".", "The", "patients", "were", "followed", "for", "one", "year", ".", "There", "was", "no", "difference", "between", "the", "two", "groups", "concerning", "operative", "time", ",", "hospital", "stay", "and", "postoperative", "complications", ".", "The", "absorbable", "clips", "seem", "to", "be", "as", "effective", "as", "metal", "clips", "in", "providing", "hemostasis", "in", "cystic", "artery", "and", "in", "cystic", "duct", "ligation", "." ]
[ "Intervention_Surgical", "Outcome_Physical", "Outcome_Other", "Participant_Condition", "Intervention_Physical", "Participant_Sample-size" ]
absorbable clips is a Intervention_Surgical, laparoscopic cholecystectomy is a Intervention_Surgical, metal clips is a Intervention_Physical, efficacy of absorbable clips is a Outcome_Other, elective laparoscopic cholecystectomy is a Intervention_Surgical, One hundred is a Participant_Sample-size, symptomatic gallstones is a Participant_Condition, two metal clips ( titan clip ETHICONR ) is a Intervention_Surgical, laproclipR Davis and Geck ) is a Intervention_Surgical, one absorbable clip applied on the cystic duct and cystic artery is a Intervention_Surgical, operative time , hospital stay is a Outcome_Other, postoperative complications is a Outcome_Other, absorbable clips seem to be as effective as metal clips is a Outcome_Physical, hemostasis is a Outcome_Physical
91401_task1
Sentence: [ Value of absorbable clips in laparoscopic cholecystectomy . A randomized prospective study ] . Most surgeons use metal clips in laparoscopic cholecystectomy . The aim of this prospective randomized controlled study was to evaluate the efficacy of absorbable clips in elective laparoscopic cholecystectomy . One hundred consecutive patients with symptomatic gallstones without complications were randomized into groups ; group T had two metal clips ( titan clip ETHICONR ) , group R ( laproclipR Davis and Geck ) had one absorbable clip applied on the cystic duct and cystic artery . The patients were followed for one year . There was no difference between the two groups concerning operative time , hospital stay and postoperative complications . The absorbable clips seem to be as effective as metal clips in providing hemostasis in cystic artery and in cystic duct ligation . Instructions: please typing these entity words according to sentence: absorbable clips, laparoscopic cholecystectomy, metal clips, efficacy of absorbable clips, elective laparoscopic cholecystectomy, One hundred, symptomatic gallstones, two metal clips ( titan clip ETHICONR ), laproclipR Davis and Geck ), one absorbable clip applied on the cystic duct and cystic artery, operative time , hospital stay, postoperative complications, absorbable clips seem to be as effective as metal clips, hemostasis Options: Intervention_Physical, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other, Intervention_Surgical
[ "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
[ Value of absorbable clips in laparoscopic cholecystectomy . A randomized prospective study ] . Most surgeons use metal clips in laparoscopic cholecystectomy . The aim of this prospective randomized controlled study was to evaluate the efficacy of absorbable clips in elective laparoscopic cholecystectomy . One hundred consecutive patients with symptomatic gallstones without complications were randomized into groups ; group T had two metal clips ( titan clip ETHICONR ) , group R ( laproclipR Davis and Geck ) had one absorbable clip applied on the cystic duct and cystic artery . The patients were followed for one year . There was no difference between the two groups concerning operative time , hospital stay and postoperative complications . The absorbable clips seem to be as effective as metal clips in providing hemostasis in cystic artery and in cystic duct ligation .
[ "[", "Value", "of", "absorbable", "clips", "in", "laparoscopic", "cholecystectomy", ".", "A", "randomized", "prospective", "study", "]", ".", "Most", "surgeons", "use", "metal", "clips", "in", "laparoscopic", "cholecystectomy", ".", "The", "aim", "of", "this", "prospective", "randomized", "controlled", "study", "was", "to", "evaluate", "the", "efficacy", "of", "absorbable", "clips", "in", "elective", "laparoscopic", "cholecystectomy", ".", "One", "hundred", "consecutive", "patients", "with", "symptomatic", "gallstones", "without", "complications", "were", "randomized", "into", "groups", ";", "group", "T", "had", "two", "metal", "clips", "(", "titan", "clip", "ETHICONR", ")", ",", "group", "R", "(", "laproclipR", "Davis", "and", "Geck", ")", "had", "one", "absorbable", "clip", "applied", "on", "the", "cystic", "duct", "and", "cystic", "artery", ".", "The", "patients", "were", "followed", "for", "one", "year", ".", "There", "was", "no", "difference", "between", "the", "two", "groups", "concerning", "operative", "time", ",", "hospital", "stay", "and", "postoperative", "complications", ".", "The", "absorbable", "clips", "seem", "to", "be", "as", "effective", "as", "metal", "clips", "in", "providing", "hemostasis", "in", "cystic", "artery", "and", "in", "cystic", "duct", "ligation", "." ]
[ "Intervention_Surgical", "Outcome_Physical", "Outcome_Other", "Participant_Condition", "Intervention_Physical", "Participant_Sample-size" ]
absorbable clips, laparoscopic cholecystectomy, metal clips, efficacy of absorbable clips, elective laparoscopic cholecystectomy, One hundred, symptomatic gallstones, two metal clips ( titan clip ETHICONR ), laproclipR Davis and Geck ), one absorbable clip applied on the cystic duct and cystic artery, operative time , hospital stay, postoperative complications, absorbable clips seem to be as effective as metal clips, hemostasis
91401_task2
Sentence: [ Value of absorbable clips in laparoscopic cholecystectomy . A randomized prospective study ] . Most surgeons use metal clips in laparoscopic cholecystectomy . The aim of this prospective randomized controlled study was to evaluate the efficacy of absorbable clips in elective laparoscopic cholecystectomy . One hundred consecutive patients with symptomatic gallstones without complications were randomized into groups ; group T had two metal clips ( titan clip ETHICONR ) , group R ( laproclipR Davis and Geck ) had one absorbable clip applied on the cystic duct and cystic artery . The patients were followed for one year . There was no difference between the two groups concerning operative time , hospital stay and postoperative complications . The absorbable clips seem to be as effective as metal clips in providing hemostasis in cystic artery and in cystic duct ligation . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
[ Value of absorbable clips in laparoscopic cholecystectomy . A randomized prospective study ] . Most surgeons use metal clips in laparoscopic cholecystectomy . The aim of this prospective randomized controlled study was to evaluate the efficacy of absorbable clips in elective laparoscopic cholecystectomy . One hundred consecutive patients with symptomatic gallstones without complications were randomized into groups ; group T had two metal clips ( titan clip ETHICONR ) , group R ( laproclipR Davis and Geck ) had one absorbable clip applied on the cystic duct and cystic artery . The patients were followed for one year . There was no difference between the two groups concerning operative time , hospital stay and postoperative complications . The absorbable clips seem to be as effective as metal clips in providing hemostasis in cystic artery and in cystic duct ligation .
[ "[", "Value", "of", "absorbable", "clips", "in", "laparoscopic", "cholecystectomy", ".", "A", "randomized", "prospective", "study", "]", ".", "Most", "surgeons", "use", "metal", "clips", "in", "laparoscopic", "cholecystectomy", ".", "The", "aim", "of", "this", "prospective", "randomized", "controlled", "study", "was", "to", "evaluate", "the", "efficacy", "of", "absorbable", "clips", "in", "elective", "laparoscopic", "cholecystectomy", ".", "One", "hundred", "consecutive", "patients", "with", "symptomatic", "gallstones", "without", "complications", "were", "randomized", "into", "groups", ";", "group", "T", "had", "two", "metal", "clips", "(", "titan", "clip", "ETHICONR", ")", ",", "group", "R", "(", "laproclipR", "Davis", "and", "Geck", ")", "had", "one", "absorbable", "clip", "applied", "on", "the", "cystic", "duct", "and", "cystic", "artery", ".", "The", "patients", "were", "followed", "for", "one", "year", ".", "There", "was", "no", "difference", "between", "the", "two", "groups", "concerning", "operative", "time", ",", "hospital", "stay", "and", "postoperative", "complications", ".", "The", "absorbable", "clips", "seem", "to", "be", "as", "effective", "as", "metal", "clips", "in", "providing", "hemostasis", "in", "cystic", "artery", "and", "in", "cystic", "duct", "ligation", "." ]
[ "Intervention_Surgical", "Outcome_Physical", "Outcome_Other", "Participant_Condition", "Intervention_Physical", "Participant_Sample-size" ]
talin is a Gene/protein/RNA, actin is a Gene/protein/RNA
592_task0
Sentence: Polyacrylamide gels of platelets heated at 45 degrees C for 90 minutes showed an increase in talin incorporation into heated platelet cytoskeletons but no increase in filamentous actin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O" ]
Polyacrylamide gels of platelets heated at 45 degrees C for 90 minutes showed an increase in talin incorporation into heated platelet cytoskeletons but no increase in filamentous actin.
[ "Polyacrylamide", "gels", "of", "platelets", "heated", "at", "45", "degrees", "C", "for", "90", "minutes", "showed", "an", "increase", "in", "talin", "incorporation", "into", "heated", "platelet", "cytoskeletons", "but", "no", "increase", "in", "filamentous", "actin", "." ]
[ "Gene/protein/RNA" ]
talin is a Gene/protein/RNA, actin is a Gene/protein/RNA
592_task1
Sentence: Polyacrylamide gels of platelets heated at 45 degrees C for 90 minutes showed an increase in talin incorporation into heated platelet cytoskeletons but no increase in filamentous actin. Instructions: please typing these entity words according to sentence: talin, actin Options: Gene/protein/RNA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O" ]
Polyacrylamide gels of platelets heated at 45 degrees C for 90 minutes showed an increase in talin incorporation into heated platelet cytoskeletons but no increase in filamentous actin.
[ "Polyacrylamide", "gels", "of", "platelets", "heated", "at", "45", "degrees", "C", "for", "90", "minutes", "showed", "an", "increase", "in", "talin", "incorporation", "into", "heated", "platelet", "cytoskeletons", "but", "no", "increase", "in", "filamentous", "actin", "." ]
[ "Gene/protein/RNA" ]
talin, actin
592_task2
Sentence: Polyacrylamide gels of platelets heated at 45 degrees C for 90 minutes showed an increase in talin incorporation into heated platelet cytoskeletons but no increase in filamentous actin. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O" ]
Polyacrylamide gels of platelets heated at 45 degrees C for 90 minutes showed an increase in talin incorporation into heated platelet cytoskeletons but no increase in filamentous actin.
[ "Polyacrylamide", "gels", "of", "platelets", "heated", "at", "45", "degrees", "C", "for", "90", "minutes", "showed", "an", "increase", "in", "talin", "incorporation", "into", "heated", "platelet", "cytoskeletons", "but", "no", "increase", "in", "filamentous", "actin", "." ]
[ "Gene/protein/RNA" ]
linfoma Burkitt like IIB is a MORFOLOGIA_NEOPLASIA, enfermedad de Paget extramamaria is a MORFOLOGIA_NEOPLASIA, afectación a distancia is a MORFOLOGIA_NEOPLASIA
931_task0
Sentence: Anamnesis Mujer de 81 años con antecedentes de un linfoma Burkitt like IIB en respuesta completa tras seis ciclos de R-CHOP (2010), un ictus lacunar vs. ACM derecha con paresia izquierda residual (2010, 2012 y 2013) y demencia vascular secundaria. Es valorada por Dermatología en julio de 2010 por presentar lesiones cutáneas pruriginosas y dolorosas, de crecimiento lento, en las regiones inguinal, perianal y vulva de dos años de evolución. Exploración física En la exploración se objetiva una gran placa eritematosa erosionada en las zonas descritas. Sin otros hallazgos de interés. Pruebas complementarias Se realiza una biopsia donde se visualizan a nivel intraepidérmico numerosas células de citoplasma amplio, claro, con nucléolo prominente con el siguiente inmunofenotipo: Cam 5,2 +, citoqueratina 7+, CEA+ y citoqueratina 20, S100 y Melan A negativas. Diagnóstico Se trata, por tanto, de una enfermedad de Paget extramamaria. Tratamiento Dada la comorbilidad y extensión de la enfermedad, se desestiman tratamiento quirúrgico y radioterápico. Recibe tratamiento tópico con imiquimod 50 mg/g 1 aplicación diaria 5 o 3 días a la semana (varios ciclos de diferente dosis) desde septiembre de 2010 hasta junio de 2012 con respuesta completa, teniendo que suspenderlo por ulceración de la piel refractaria a reducción de dosis. En junio de 2012 inicia terapia fotodinámica sin obtener ninguna respuesta tras dos sesiones. En noviembre de 2012, inicia 5-fluorouracilo tópico al 5 %, administrado diariamente y combinado con imiquimod 2 días a la semana con respuesta parcial hasta junio de 2015. Durante este tiempo, es valorada por la Unidad del Dolor en repetidas ocasiones por dolor intenso en las zonas afectadas, precisando ajuste de tratamiento analgésico, e incluso llegando a asociar radiofrecuencia de nervios pudendos en marzo de 2013. Evolución La paciente fue remitida a nuestra consulta en octubre de 2015 por progresión local a pesar de los tratamientos tópicos administrados. Tras descartar afectación a distancia con una TC, remitimos a la paciente a Oncología Radioterápica. Recibe 30 sesiones de 2 Gy/fracción hasta alcanzar una dosis de 60 Gy (22 de octubre-2 de diciembre de 2015) con respuesta rápida inicial pero nueva progresión un mes después de finalizar el tratamiento. Es derivada de nuevo a Cirugía Plástica, volviéndose a desestimar tratamiento quirúrgico por la extensión de la enfermedad. Las lesiones siguen ocasionando cada vez más dolor, precisando nueva radiofrecuencia de nervios pudendos en septiembre de 2016. Acude de nuevo a nuestra consulta para valorar la administración de tratamiento sistémico, que se desestima por comorbilidad y edad, así como escasa evidencia científica. Mantenemos tratamiento sintomático y solicitamos seguimiento por Unidad de Cuidados Paliativos. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Mujer de 81 años con antecedentes de un linfoma Burkitt like IIB en respuesta completa tras seis ciclos de R-CHOP (2010), un ictus lacunar vs. ACM derecha con paresia izquierda residual (2010, 2012 y 2013) y demencia vascular secundaria. Es valorada por Dermatología en julio de 2010 por presentar lesiones cutáneas pruriginosas y dolorosas, de crecimiento lento, en las regiones inguinal, perianal y vulva de dos años de evolución. Exploración física En la exploración se objetiva una gran placa eritematosa erosionada en las zonas descritas. Sin otros hallazgos de interés. Pruebas complementarias Se realiza una biopsia donde se visualizan a nivel intraepidérmico numerosas células de citoplasma amplio, claro, con nucléolo prominente con el siguiente inmunofenotipo: Cam 5,2 +, citoqueratina 7+, CEA+ y citoqueratina 20, S100 y Melan A negativas. Diagnóstico Se trata, por tanto, de una enfermedad de Paget extramamaria. Tratamiento Dada la comorbilidad y extensión de la enfermedad, se desestiman tratamiento quirúrgico y radioterápico. Recibe tratamiento tópico con imiquimod 50 mg/g 1 aplicación diaria 5 o 3 días a la semana (varios ciclos de diferente dosis) desde septiembre de 2010 hasta junio de 2012 con respuesta completa, teniendo que suspenderlo por ulceración de la piel refractaria a reducción de dosis. En junio de 2012 inicia terapia fotodinámica sin obtener ninguna respuesta tras dos sesiones. En noviembre de 2012, inicia 5-fluorouracilo tópico al 5 %, administrado diariamente y combinado con imiquimod 2 días a la semana con respuesta parcial hasta junio de 2015. Durante este tiempo, es valorada por la Unidad del Dolor en repetidas ocasiones por dolor intenso en las zonas afectadas, precisando ajuste de tratamiento analgésico, e incluso llegando a asociar radiofrecuencia de nervios pudendos en marzo de 2013. Evolución La paciente fue remitida a nuestra consulta en octubre de 2015 por progresión local a pesar de los tratamientos tópicos administrados. Tras descartar afectación a distancia con una TC, remitimos a la paciente a Oncología Radioterápica. Recibe 30 sesiones de 2 Gy/fracción hasta alcanzar una dosis de 60 Gy (22 de octubre-2 de diciembre de 2015) con respuesta rápida inicial pero nueva progresión un mes después de finalizar el tratamiento. Es derivada de nuevo a Cirugía Plástica, volviéndose a desestimar tratamiento quirúrgico por la extensión de la enfermedad. Las lesiones siguen ocasionando cada vez más dolor, precisando nueva radiofrecuencia de nervios pudendos en septiembre de 2016. Acude de nuevo a nuestra consulta para valorar la administración de tratamiento sistémico, que se desestima por comorbilidad y edad, así como escasa evidencia científica. Mantenemos tratamiento sintomático y solicitamos seguimiento por Unidad de Cuidados Paliativos.
[ "Anamnesis", "\n", "Mujer", "de", "81", "años", "con", "antecedentes", "de", "un", "linfoma", "Burkitt", "like", "IIB", "en", "respuesta", "completa", "tras", "seis", "ciclos", "de", "R", "-", "CHOP", "(", "2010", ")", ",", "un", "ictus", "lacunar", "vs", ".", "ACM", "derecha", "con", "paresia", "izquierda", "residual", "(", "2010", ",", "2012", "y", "2013", ")", "y", "demencia", "vascular", "secundaria", ".", "Es", "valorada", "por", "Dermatología", "en", "julio", "de", "2010", "por", "presentar", "lesiones", "cutáneas", "pruriginosas", "y", "dolorosas", ",", "de", "crecimiento", "lento", ",", "en", "las", "regiones", "inguinal", ",", "perianal", "y", "vulva", "de", "dos", "años", "de", "evolución", ".", "\n\n", "Exploración", "física", "\n", "En", "la", "exploración", "se", "objetiva", "una", "gran", "placa", "eritematosa", "erosionada", "en", "las", "zonas", "descritas", ".", "Sin", "otros", "hallazgos", "de", "interés", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "biopsia", "donde", "se", "visualizan", "a", "nivel", "intraepidérmico", "numerosas", "células", "de", "citoplasma", "amplio", ",", "claro", ",", "con", "nucléolo", "prominente", "con", "el", "siguiente", "inmunofenotipo", ":", "Cam", "5,2", "+", ",", "citoqueratina", "7", "+", ",", "CEA+", "y", "citoqueratina", "20", ",", "S100", "y", "Melan", "A", "negativas", ".", "\n\n", "Diagnóstico", "\n", "Se", "trata", ",", "por", "tanto", ",", "de", "una", "enfermedad", "de", "Paget", "extramamaria", ".", "\n\n", "Tratamiento", "\n", "Dada", "la", "comorbilidad", "y", "extensión", "de", "la", "enfermedad", ",", "se", "desestiman", "tratamiento", "quirúrgico", "y", "radioterápico", ".", "Recibe", "tratamiento", "tópico", "con", "imiquimod", "50", "mg", "/", "g", "1", "aplicación", "diaria", "5", "o", "3", "días", "a", "la", "semana", "(", "varios", "ciclos", "de", "diferente", "dosis", ")", "desde", "septiembre", "de", "2010", "hasta", "junio", "de", "2012", "con", "respuesta", "completa", ",", "teniendo", "que", "suspenderlo", "por", "ulceración", "de", "la", "piel", "refractaria", "a", "reducción", "de", "dosis", ".", "\n", "En", "junio", "de", "2012", "inicia", "terapia", "fotodinámica", "sin", "obtener", "ninguna", "respuesta", "tras", "dos", "sesiones", ".", "En", "noviembre", "de", "2012", ",", "inicia", "5-fluorouracilo", "tópico", "al", "5", "%", ",", "administrado", "diariamente", "y", "combinado", "con", "imiquimod", "2", "días", "a", "la", "semana", "con", "respuesta", "parcial", "hasta", "junio", "de", "2015", ".", "Durante", "este", "tiempo", ",", "es", "valorada", "por", "la", "Unidad", "del", "Dolor", "en", "repetidas", "ocasiones", "por", "dolor", "intenso", "en", "las", "zonas", "afectadas", ",", "precisando", "ajuste", "de", "tratamiento", "analgésico", ",", "e", "incluso", "llegando", "a", "asociar", "radiofrecuencia", "de", "nervios", "pudendos", "en", "marzo", "de", "2013", ".", "\n\n", "Evolución", "\n", "La", "paciente", "fue", "remitida", "a", "nuestra", "consulta", "en", "octubre", "de", "2015", "por", "progresión", "local", "a", "pesar", "de", "los", "tratamientos", "tópicos", "administrados", ".", "Tras", "descartar", "afectación", "a", "distancia", "con", "una", "TC", ",", "remitimos", "a", "la", "paciente", "a", "Oncología", "Radioterápica", ".", "Recibe", "30", "sesiones", "de", "2", "Gy", "/", "fracción", "hasta", "alcanzar", "una", "dosis", "de", "60", "Gy", "(", "22", "de", "octubre-2", "de", "diciembre", "de", "2015", ")", "con", "respuesta", "rápida", "inicial", "pero", "nueva", "progresión", "un", "mes", "después", "de", "finalizar", "el", "tratamiento", ".", "\n", "Es", "derivada", "de", "nuevo", "a", "Cirugía", "Plástica", ",", "volviéndose", "a", "desestimar", "tratamiento", "quirúrgico", "por", "la", "extensión", "de", "la", "enfermedad", ".", "Las", "lesiones", "siguen", "ocasionando", "cada", "vez", "más", "dolor", ",", "precisando", "nueva", "radiofrecuencia", "de", "nervios", "pudendos", "en", "septiembre", "de", "2016", ".", "Acude", "de", "nuevo", "a", "nuestra", "consulta", "para", "valorar", "la", "administración", "de", "tratamiento", "sistémico", ",", "que", "se", "desestima", "por", "comorbilidad", "y", "edad", ",", "así", "como", "escasa", "evidencia", "científica", ".", "Mantenemos", "tratamiento", "sintomático", "y", "solicitamos", "seguimiento", "por", "Unidad", "de", "Cuidados", "Paliativos", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
linfoma Burkitt like IIB is a MORFOLOGIA_NEOPLASIA, enfermedad de Paget extramamaria is a MORFOLOGIA_NEOPLASIA, afectación a distancia is a MORFOLOGIA_NEOPLASIA
931_task1
Sentence: Anamnesis Mujer de 81 años con antecedentes de un linfoma Burkitt like IIB en respuesta completa tras seis ciclos de R-CHOP (2010), un ictus lacunar vs. ACM derecha con paresia izquierda residual (2010, 2012 y 2013) y demencia vascular secundaria. Es valorada por Dermatología en julio de 2010 por presentar lesiones cutáneas pruriginosas y dolorosas, de crecimiento lento, en las regiones inguinal, perianal y vulva de dos años de evolución. Exploración física En la exploración se objetiva una gran placa eritematosa erosionada en las zonas descritas. Sin otros hallazgos de interés. Pruebas complementarias Se realiza una biopsia donde se visualizan a nivel intraepidérmico numerosas células de citoplasma amplio, claro, con nucléolo prominente con el siguiente inmunofenotipo: Cam 5,2 +, citoqueratina 7+, CEA+ y citoqueratina 20, S100 y Melan A negativas. Diagnóstico Se trata, por tanto, de una enfermedad de Paget extramamaria. Tratamiento Dada la comorbilidad y extensión de la enfermedad, se desestiman tratamiento quirúrgico y radioterápico. Recibe tratamiento tópico con imiquimod 50 mg/g 1 aplicación diaria 5 o 3 días a la semana (varios ciclos de diferente dosis) desde septiembre de 2010 hasta junio de 2012 con respuesta completa, teniendo que suspenderlo por ulceración de la piel refractaria a reducción de dosis. En junio de 2012 inicia terapia fotodinámica sin obtener ninguna respuesta tras dos sesiones. En noviembre de 2012, inicia 5-fluorouracilo tópico al 5 %, administrado diariamente y combinado con imiquimod 2 días a la semana con respuesta parcial hasta junio de 2015. Durante este tiempo, es valorada por la Unidad del Dolor en repetidas ocasiones por dolor intenso en las zonas afectadas, precisando ajuste de tratamiento analgésico, e incluso llegando a asociar radiofrecuencia de nervios pudendos en marzo de 2013. Evolución La paciente fue remitida a nuestra consulta en octubre de 2015 por progresión local a pesar de los tratamientos tópicos administrados. Tras descartar afectación a distancia con una TC, remitimos a la paciente a Oncología Radioterápica. Recibe 30 sesiones de 2 Gy/fracción hasta alcanzar una dosis de 60 Gy (22 de octubre-2 de diciembre de 2015) con respuesta rápida inicial pero nueva progresión un mes después de finalizar el tratamiento. Es derivada de nuevo a Cirugía Plástica, volviéndose a desestimar tratamiento quirúrgico por la extensión de la enfermedad. Las lesiones siguen ocasionando cada vez más dolor, precisando nueva radiofrecuencia de nervios pudendos en septiembre de 2016. Acude de nuevo a nuestra consulta para valorar la administración de tratamiento sistémico, que se desestima por comorbilidad y edad, así como escasa evidencia científica. Mantenemos tratamiento sintomático y solicitamos seguimiento por Unidad de Cuidados Paliativos. Instructions: please typing these entity words according to sentence: linfoma Burkitt like IIB, enfermedad de Paget extramamaria, afectación a distancia Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Mujer de 81 años con antecedentes de un linfoma Burkitt like IIB en respuesta completa tras seis ciclos de R-CHOP (2010), un ictus lacunar vs. ACM derecha con paresia izquierda residual (2010, 2012 y 2013) y demencia vascular secundaria. Es valorada por Dermatología en julio de 2010 por presentar lesiones cutáneas pruriginosas y dolorosas, de crecimiento lento, en las regiones inguinal, perianal y vulva de dos años de evolución. Exploración física En la exploración se objetiva una gran placa eritematosa erosionada en las zonas descritas. Sin otros hallazgos de interés. Pruebas complementarias Se realiza una biopsia donde se visualizan a nivel intraepidérmico numerosas células de citoplasma amplio, claro, con nucléolo prominente con el siguiente inmunofenotipo: Cam 5,2 +, citoqueratina 7+, CEA+ y citoqueratina 20, S100 y Melan A negativas. Diagnóstico Se trata, por tanto, de una enfermedad de Paget extramamaria. Tratamiento Dada la comorbilidad y extensión de la enfermedad, se desestiman tratamiento quirúrgico y radioterápico. Recibe tratamiento tópico con imiquimod 50 mg/g 1 aplicación diaria 5 o 3 días a la semana (varios ciclos de diferente dosis) desde septiembre de 2010 hasta junio de 2012 con respuesta completa, teniendo que suspenderlo por ulceración de la piel refractaria a reducción de dosis. En junio de 2012 inicia terapia fotodinámica sin obtener ninguna respuesta tras dos sesiones. En noviembre de 2012, inicia 5-fluorouracilo tópico al 5 %, administrado diariamente y combinado con imiquimod 2 días a la semana con respuesta parcial hasta junio de 2015. Durante este tiempo, es valorada por la Unidad del Dolor en repetidas ocasiones por dolor intenso en las zonas afectadas, precisando ajuste de tratamiento analgésico, e incluso llegando a asociar radiofrecuencia de nervios pudendos en marzo de 2013. Evolución La paciente fue remitida a nuestra consulta en octubre de 2015 por progresión local a pesar de los tratamientos tópicos administrados. Tras descartar afectación a distancia con una TC, remitimos a la paciente a Oncología Radioterápica. Recibe 30 sesiones de 2 Gy/fracción hasta alcanzar una dosis de 60 Gy (22 de octubre-2 de diciembre de 2015) con respuesta rápida inicial pero nueva progresión un mes después de finalizar el tratamiento. Es derivada de nuevo a Cirugía Plástica, volviéndose a desestimar tratamiento quirúrgico por la extensión de la enfermedad. Las lesiones siguen ocasionando cada vez más dolor, precisando nueva radiofrecuencia de nervios pudendos en septiembre de 2016. Acude de nuevo a nuestra consulta para valorar la administración de tratamiento sistémico, que se desestima por comorbilidad y edad, así como escasa evidencia científica. Mantenemos tratamiento sintomático y solicitamos seguimiento por Unidad de Cuidados Paliativos.
[ "Anamnesis", "\n", "Mujer", "de", "81", "años", "con", "antecedentes", "de", "un", "linfoma", "Burkitt", "like", "IIB", "en", "respuesta", "completa", "tras", "seis", "ciclos", "de", "R", "-", "CHOP", "(", "2010", ")", ",", "un", "ictus", "lacunar", "vs", ".", "ACM", "derecha", "con", "paresia", "izquierda", "residual", "(", "2010", ",", "2012", "y", "2013", ")", "y", "demencia", "vascular", "secundaria", ".", "Es", "valorada", "por", "Dermatología", "en", "julio", "de", "2010", "por", "presentar", "lesiones", "cutáneas", "pruriginosas", "y", "dolorosas", ",", "de", "crecimiento", "lento", ",", "en", "las", "regiones", "inguinal", ",", "perianal", "y", "vulva", "de", "dos", "años", "de", "evolución", ".", "\n\n", "Exploración", "física", "\n", "En", "la", "exploración", "se", "objetiva", "una", "gran", "placa", "eritematosa", "erosionada", "en", "las", "zonas", "descritas", ".", "Sin", "otros", "hallazgos", "de", "interés", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "biopsia", "donde", "se", "visualizan", "a", "nivel", "intraepidérmico", "numerosas", "células", "de", "citoplasma", "amplio", ",", "claro", ",", "con", "nucléolo", "prominente", "con", "el", "siguiente", "inmunofenotipo", ":", "Cam", "5,2", "+", ",", "citoqueratina", "7", "+", ",", "CEA+", "y", "citoqueratina", "20", ",", "S100", "y", "Melan", "A", "negativas", ".", "\n\n", "Diagnóstico", "\n", "Se", "trata", ",", "por", "tanto", ",", "de", "una", "enfermedad", "de", "Paget", "extramamaria", ".", "\n\n", "Tratamiento", "\n", "Dada", "la", "comorbilidad", "y", "extensión", "de", "la", "enfermedad", ",", "se", "desestiman", "tratamiento", "quirúrgico", "y", "radioterápico", ".", "Recibe", "tratamiento", "tópico", "con", "imiquimod", "50", "mg", "/", "g", "1", "aplicación", "diaria", "5", "o", "3", "días", "a", "la", "semana", "(", "varios", "ciclos", "de", "diferente", "dosis", ")", "desde", "septiembre", "de", "2010", "hasta", "junio", "de", "2012", "con", "respuesta", "completa", ",", "teniendo", "que", "suspenderlo", "por", "ulceración", "de", "la", "piel", "refractaria", "a", "reducción", "de", "dosis", ".", "\n", "En", "junio", "de", "2012", "inicia", "terapia", "fotodinámica", "sin", "obtener", "ninguna", "respuesta", "tras", "dos", "sesiones", ".", "En", "noviembre", "de", "2012", ",", "inicia", "5-fluorouracilo", "tópico", "al", "5", "%", ",", "administrado", "diariamente", "y", "combinado", "con", "imiquimod", "2", "días", "a", "la", "semana", "con", "respuesta", "parcial", "hasta", "junio", "de", "2015", ".", "Durante", "este", "tiempo", ",", "es", "valorada", "por", "la", "Unidad", "del", "Dolor", "en", "repetidas", "ocasiones", "por", "dolor", "intenso", "en", "las", "zonas", "afectadas", ",", "precisando", "ajuste", "de", "tratamiento", "analgésico", ",", "e", "incluso", "llegando", "a", "asociar", "radiofrecuencia", "de", "nervios", "pudendos", "en", "marzo", "de", "2013", ".", "\n\n", "Evolución", "\n", "La", "paciente", "fue", "remitida", "a", "nuestra", "consulta", "en", "octubre", "de", "2015", "por", "progresión", "local", "a", "pesar", "de", "los", "tratamientos", "tópicos", "administrados", ".", "Tras", "descartar", "afectación", "a", "distancia", "con", "una", "TC", ",", "remitimos", "a", "la", "paciente", "a", "Oncología", "Radioterápica", ".", "Recibe", "30", "sesiones", "de", "2", "Gy", "/", "fracción", "hasta", "alcanzar", "una", "dosis", "de", "60", "Gy", "(", "22", "de", "octubre-2", "de", "diciembre", "de", "2015", ")", "con", "respuesta", "rápida", "inicial", "pero", "nueva", "progresión", "un", "mes", "después", "de", "finalizar", "el", "tratamiento", ".", "\n", "Es", "derivada", "de", "nuevo", "a", "Cirugía", "Plástica", ",", "volviéndose", "a", "desestimar", "tratamiento", "quirúrgico", "por", "la", "extensión", "de", "la", "enfermedad", ".", "Las", "lesiones", "siguen", "ocasionando", "cada", "vez", "más", "dolor", ",", "precisando", "nueva", "radiofrecuencia", "de", "nervios", "pudendos", "en", "septiembre", "de", "2016", ".", "Acude", "de", "nuevo", "a", "nuestra", "consulta", "para", "valorar", "la", "administración", "de", "tratamiento", "sistémico", ",", "que", "se", "desestima", "por", "comorbilidad", "y", "edad", ",", "así", "como", "escasa", "evidencia", "científica", ".", "Mantenemos", "tratamiento", "sintomático", "y", "solicitamos", "seguimiento", "por", "Unidad", "de", "Cuidados", "Paliativos", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
linfoma Burkitt like IIB, enfermedad de Paget extramamaria, afectación a distancia
931_task2
Sentence: Anamnesis Mujer de 81 años con antecedentes de un linfoma Burkitt like IIB en respuesta completa tras seis ciclos de R-CHOP (2010), un ictus lacunar vs. ACM derecha con paresia izquierda residual (2010, 2012 y 2013) y demencia vascular secundaria. Es valorada por Dermatología en julio de 2010 por presentar lesiones cutáneas pruriginosas y dolorosas, de crecimiento lento, en las regiones inguinal, perianal y vulva de dos años de evolución. Exploración física En la exploración se objetiva una gran placa eritematosa erosionada en las zonas descritas. Sin otros hallazgos de interés. Pruebas complementarias Se realiza una biopsia donde se visualizan a nivel intraepidérmico numerosas células de citoplasma amplio, claro, con nucléolo prominente con el siguiente inmunofenotipo: Cam 5,2 +, citoqueratina 7+, CEA+ y citoqueratina 20, S100 y Melan A negativas. Diagnóstico Se trata, por tanto, de una enfermedad de Paget extramamaria. Tratamiento Dada la comorbilidad y extensión de la enfermedad, se desestiman tratamiento quirúrgico y radioterápico. Recibe tratamiento tópico con imiquimod 50 mg/g 1 aplicación diaria 5 o 3 días a la semana (varios ciclos de diferente dosis) desde septiembre de 2010 hasta junio de 2012 con respuesta completa, teniendo que suspenderlo por ulceración de la piel refractaria a reducción de dosis. En junio de 2012 inicia terapia fotodinámica sin obtener ninguna respuesta tras dos sesiones. En noviembre de 2012, inicia 5-fluorouracilo tópico al 5 %, administrado diariamente y combinado con imiquimod 2 días a la semana con respuesta parcial hasta junio de 2015. Durante este tiempo, es valorada por la Unidad del Dolor en repetidas ocasiones por dolor intenso en las zonas afectadas, precisando ajuste de tratamiento analgésico, e incluso llegando a asociar radiofrecuencia de nervios pudendos en marzo de 2013. Evolución La paciente fue remitida a nuestra consulta en octubre de 2015 por progresión local a pesar de los tratamientos tópicos administrados. Tras descartar afectación a distancia con una TC, remitimos a la paciente a Oncología Radioterápica. Recibe 30 sesiones de 2 Gy/fracción hasta alcanzar una dosis de 60 Gy (22 de octubre-2 de diciembre de 2015) con respuesta rápida inicial pero nueva progresión un mes después de finalizar el tratamiento. Es derivada de nuevo a Cirugía Plástica, volviéndose a desestimar tratamiento quirúrgico por la extensión de la enfermedad. Las lesiones siguen ocasionando cada vez más dolor, precisando nueva radiofrecuencia de nervios pudendos en septiembre de 2016. Acude de nuevo a nuestra consulta para valorar la administración de tratamiento sistémico, que se desestima por comorbilidad y edad, así como escasa evidencia científica. Mantenemos tratamiento sintomático y solicitamos seguimiento por Unidad de Cuidados Paliativos. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Mujer de 81 años con antecedentes de un linfoma Burkitt like IIB en respuesta completa tras seis ciclos de R-CHOP (2010), un ictus lacunar vs. ACM derecha con paresia izquierda residual (2010, 2012 y 2013) y demencia vascular secundaria. Es valorada por Dermatología en julio de 2010 por presentar lesiones cutáneas pruriginosas y dolorosas, de crecimiento lento, en las regiones inguinal, perianal y vulva de dos años de evolución. Exploración física En la exploración se objetiva una gran placa eritematosa erosionada en las zonas descritas. Sin otros hallazgos de interés. Pruebas complementarias Se realiza una biopsia donde se visualizan a nivel intraepidérmico numerosas células de citoplasma amplio, claro, con nucléolo prominente con el siguiente inmunofenotipo: Cam 5,2 +, citoqueratina 7+, CEA+ y citoqueratina 20, S100 y Melan A negativas. Diagnóstico Se trata, por tanto, de una enfermedad de Paget extramamaria. Tratamiento Dada la comorbilidad y extensión de la enfermedad, se desestiman tratamiento quirúrgico y radioterápico. Recibe tratamiento tópico con imiquimod 50 mg/g 1 aplicación diaria 5 o 3 días a la semana (varios ciclos de diferente dosis) desde septiembre de 2010 hasta junio de 2012 con respuesta completa, teniendo que suspenderlo por ulceración de la piel refractaria a reducción de dosis. En junio de 2012 inicia terapia fotodinámica sin obtener ninguna respuesta tras dos sesiones. En noviembre de 2012, inicia 5-fluorouracilo tópico al 5 %, administrado diariamente y combinado con imiquimod 2 días a la semana con respuesta parcial hasta junio de 2015. Durante este tiempo, es valorada por la Unidad del Dolor en repetidas ocasiones por dolor intenso en las zonas afectadas, precisando ajuste de tratamiento analgésico, e incluso llegando a asociar radiofrecuencia de nervios pudendos en marzo de 2013. Evolución La paciente fue remitida a nuestra consulta en octubre de 2015 por progresión local a pesar de los tratamientos tópicos administrados. Tras descartar afectación a distancia con una TC, remitimos a la paciente a Oncología Radioterápica. Recibe 30 sesiones de 2 Gy/fracción hasta alcanzar una dosis de 60 Gy (22 de octubre-2 de diciembre de 2015) con respuesta rápida inicial pero nueva progresión un mes después de finalizar el tratamiento. Es derivada de nuevo a Cirugía Plástica, volviéndose a desestimar tratamiento quirúrgico por la extensión de la enfermedad. Las lesiones siguen ocasionando cada vez más dolor, precisando nueva radiofrecuencia de nervios pudendos en septiembre de 2016. Acude de nuevo a nuestra consulta para valorar la administración de tratamiento sistémico, que se desestima por comorbilidad y edad, así como escasa evidencia científica. Mantenemos tratamiento sintomático y solicitamos seguimiento por Unidad de Cuidados Paliativos.
[ "Anamnesis", "\n", "Mujer", "de", "81", "años", "con", "antecedentes", "de", "un", "linfoma", "Burkitt", "like", "IIB", "en", "respuesta", "completa", "tras", "seis", "ciclos", "de", "R", "-", "CHOP", "(", "2010", ")", ",", "un", "ictus", "lacunar", "vs", ".", "ACM", "derecha", "con", "paresia", "izquierda", "residual", "(", "2010", ",", "2012", "y", "2013", ")", "y", "demencia", "vascular", "secundaria", ".", "Es", "valorada", "por", "Dermatología", "en", "julio", "de", "2010", "por", "presentar", "lesiones", "cutáneas", "pruriginosas", "y", "dolorosas", ",", "de", "crecimiento", "lento", ",", "en", "las", "regiones", "inguinal", ",", "perianal", "y", "vulva", "de", "dos", "años", "de", "evolución", ".", "\n\n", "Exploración", "física", "\n", "En", "la", "exploración", "se", "objetiva", "una", "gran", "placa", "eritematosa", "erosionada", "en", "las", "zonas", "descritas", ".", "Sin", "otros", "hallazgos", "de", "interés", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "biopsia", "donde", "se", "visualizan", "a", "nivel", "intraepidérmico", "numerosas", "células", "de", "citoplasma", "amplio", ",", "claro", ",", "con", "nucléolo", "prominente", "con", "el", "siguiente", "inmunofenotipo", ":", "Cam", "5,2", "+", ",", "citoqueratina", "7", "+", ",", "CEA+", "y", "citoqueratina", "20", ",", "S100", "y", "Melan", "A", "negativas", ".", "\n\n", "Diagnóstico", "\n", "Se", "trata", ",", "por", "tanto", ",", "de", "una", "enfermedad", "de", "Paget", "extramamaria", ".", "\n\n", "Tratamiento", "\n", "Dada", "la", "comorbilidad", "y", "extensión", "de", "la", "enfermedad", ",", "se", "desestiman", "tratamiento", "quirúrgico", "y", "radioterápico", ".", "Recibe", "tratamiento", "tópico", "con", "imiquimod", "50", "mg", "/", "g", "1", "aplicación", "diaria", "5", "o", "3", "días", "a", "la", "semana", "(", "varios", "ciclos", "de", "diferente", "dosis", ")", "desde", "septiembre", "de", "2010", "hasta", "junio", "de", "2012", "con", "respuesta", "completa", ",", "teniendo", "que", "suspenderlo", "por", "ulceración", "de", "la", "piel", "refractaria", "a", "reducción", "de", "dosis", ".", "\n", "En", "junio", "de", "2012", "inicia", "terapia", "fotodinámica", "sin", "obtener", "ninguna", "respuesta", "tras", "dos", "sesiones", ".", "En", "noviembre", "de", "2012", ",", "inicia", "5-fluorouracilo", "tópico", "al", "5", "%", ",", "administrado", "diariamente", "y", "combinado", "con", "imiquimod", "2", "días", "a", "la", "semana", "con", "respuesta", "parcial", "hasta", "junio", "de", "2015", ".", "Durante", "este", "tiempo", ",", "es", "valorada", "por", "la", "Unidad", "del", "Dolor", "en", "repetidas", "ocasiones", "por", "dolor", "intenso", "en", "las", "zonas", "afectadas", ",", "precisando", "ajuste", "de", "tratamiento", "analgésico", ",", "e", "incluso", "llegando", "a", "asociar", "radiofrecuencia", "de", "nervios", "pudendos", "en", "marzo", "de", "2013", ".", "\n\n", "Evolución", "\n", "La", "paciente", "fue", "remitida", "a", "nuestra", "consulta", "en", "octubre", "de", "2015", "por", "progresión", "local", "a", "pesar", "de", "los", "tratamientos", "tópicos", "administrados", ".", "Tras", "descartar", "afectación", "a", "distancia", "con", "una", "TC", ",", "remitimos", "a", "la", "paciente", "a", "Oncología", "Radioterápica", ".", "Recibe", "30", "sesiones", "de", "2", "Gy", "/", "fracción", "hasta", "alcanzar", "una", "dosis", "de", "60", "Gy", "(", "22", "de", "octubre-2", "de", "diciembre", "de", "2015", ")", "con", "respuesta", "rápida", "inicial", "pero", "nueva", "progresión", "un", "mes", "después", "de", "finalizar", "el", "tratamiento", ".", "\n", "Es", "derivada", "de", "nuevo", "a", "Cirugía", "Plástica", ",", "volviéndose", "a", "desestimar", "tratamiento", "quirúrgico", "por", "la", "extensión", "de", "la", "enfermedad", ".", "Las", "lesiones", "siguen", "ocasionando", "cada", "vez", "más", "dolor", ",", "precisando", "nueva", "radiofrecuencia", "de", "nervios", "pudendos", "en", "septiembre", "de", "2016", ".", "Acude", "de", "nuevo", "a", "nuestra", "consulta", "para", "valorar", "la", "administración", "de", "tratamiento", "sistémico", ",", "que", "se", "desestima", "por", "comorbilidad", "y", "edad", ",", "así", "como", "escasa", "evidencia", "científica", ".", "Mantenemos", "tratamiento", "sintomático", "y", "solicitamos", "seguimiento", "por", "Unidad", "de", "Cuidados", "Paliativos", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
human is a Eukaryote, POP2 gene is a Gene
17_task0
Sentence: The human POP2 gene: identification, sequencing, and mapping to the critical region of the 5q- syndrome. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Eukaryote, Gene
[ "O", "B-Eukaryote", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The human POP2 gene: identification, sequencing, and mapping to the critical region of the 5q- syndrome.
[ "The", "human", "POP2", "gene", ":", "identification", ",", "sequencing", ",", "and", "mapping", "to", "the", "critical", "region", "of", "the", "5q-", "syndrome", ".", "\n" ]
[ "Gene", "Eukaryote" ]
human is a Eukaryote, POP2 gene is a Gene
17_task1
Sentence: The human POP2 gene: identification, sequencing, and mapping to the critical region of the 5q- syndrome. Instructions: please typing these entity words according to sentence: human, POP2 gene Options: Eukaryote, Gene
[ "O", "B-Eukaryote", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The human POP2 gene: identification, sequencing, and mapping to the critical region of the 5q- syndrome.
[ "The", "human", "POP2", "gene", ":", "identification", ",", "sequencing", ",", "and", "mapping", "to", "the", "critical", "region", "of", "the", "5q-", "syndrome", ".", "\n" ]
[ "Gene", "Eukaryote" ]
human, POP2 gene
17_task2
Sentence: The human POP2 gene: identification, sequencing, and mapping to the critical region of the 5q- syndrome. Instructions: please extract entity words from the input sentence
[ "O", "B-Eukaryote", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The human POP2 gene: identification, sequencing, and mapping to the critical region of the 5q- syndrome.
[ "The", "human", "POP2", "gene", ":", "identification", ",", "sequencing", ",", "and", "mapping", "to", "the", "critical", "region", "of", "the", "5q-", "syndrome", ".", "\n" ]
[ "Gene", "Eukaryote" ]
PLA is a CHEMICAL, PCL is a CHEMICAL, PEG is a CHEMICAL, PCL is a CHEMICAL, PLA is a CHEMICAL
23626400_task0
Sentence: Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA) based nanoparticles for controlled drug delivery: Effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL
[ "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA) based nanoparticles for controlled drug delivery: Effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles.
[ "Novel", "pentablock", "copolymer", "(", "PLA", "-", "PCL", "-", "PEG", "-", "PCL", "-", "PLA", ")", "based", "nanoparticles", "for", "controlled", "drug", "delivery", ":", "Effect", "of", "copolymer", "compositions", "on", "the", "crystallinity", "of", "copolymers", "and", "in", "vitro", "drug", "release", "profile", "from", "nanoparticles", "." ]
[ "CHEMICAL" ]
PLA is a CHEMICAL, PCL is a CHEMICAL, PEG is a CHEMICAL, PCL is a CHEMICAL, PLA is a CHEMICAL
23626400_task1
Sentence: Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA) based nanoparticles for controlled drug delivery: Effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles. Instructions: please typing these entity words according to sentence: PLA, PCL, PEG, PCL, PLA Options: CHEMICAL
[ "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA) based nanoparticles for controlled drug delivery: Effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles.
[ "Novel", "pentablock", "copolymer", "(", "PLA", "-", "PCL", "-", "PEG", "-", "PCL", "-", "PLA", ")", "based", "nanoparticles", "for", "controlled", "drug", "delivery", ":", "Effect", "of", "copolymer", "compositions", "on", "the", "crystallinity", "of", "copolymers", "and", "in", "vitro", "drug", "release", "profile", "from", "nanoparticles", "." ]
[ "CHEMICAL" ]
PLA, PCL, PEG, PCL, PLA
23626400_task2
Sentence: Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA) based nanoparticles for controlled drug delivery: Effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA) based nanoparticles for controlled drug delivery: Effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles.
[ "Novel", "pentablock", "copolymer", "(", "PLA", "-", "PCL", "-", "PEG", "-", "PCL", "-", "PLA", ")", "based", "nanoparticles", "for", "controlled", "drug", "delivery", ":", "Effect", "of", "copolymer", "compositions", "on", "the", "crystallinity", "of", "copolymers", "and", "in", "vitro", "drug", "release", "profile", "from", "nanoparticles", "." ]
[ "CHEMICAL" ]
STAT3 is a protein_molecule, interferon - gamma is a protein_molecule, human neutrophils is a cell_type
42688_task0
Sentence: Lineage-specific activation of STAT3 by interferon-gamma in human neutrophils. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, protein_molecule
[ "O", "O", "O", "O", "O", "B-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O" ]
Lineage-specific activation of STAT3 by interferon-gamma in human neutrophils.
[ "Lineage", "-", "specific", "activation", "of", "STAT3", "by", "interferon", "-", "gamma", "in", "human", "neutrophils", "." ]
[ "cell_type", "other_name", "protein_subunit", "protein_substructure", "protein_family_or_group", "protein_molecule", "cell_line", "protein_domain_or_region", "amino_acid_monomer" ]
STAT3 is a protein_molecule, interferon - gamma is a protein_molecule, human neutrophils is a cell_type
42688_task1
Sentence: Lineage-specific activation of STAT3 by interferon-gamma in human neutrophils. Instructions: please typing these entity words according to sentence: STAT3, interferon - gamma, human neutrophils Options: cell_type, protein_molecule
[ "O", "O", "O", "O", "O", "B-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O" ]
Lineage-specific activation of STAT3 by interferon-gamma in human neutrophils.
[ "Lineage", "-", "specific", "activation", "of", "STAT3", "by", "interferon", "-", "gamma", "in", "human", "neutrophils", "." ]
[ "cell_type", "other_name", "protein_subunit", "protein_substructure", "protein_family_or_group", "protein_molecule", "cell_line", "protein_domain_or_region", "amino_acid_monomer" ]
STAT3, interferon - gamma, human neutrophils
42688_task2
Sentence: Lineage-specific activation of STAT3 by interferon-gamma in human neutrophils. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O" ]
Lineage-specific activation of STAT3 by interferon-gamma in human neutrophils.
[ "Lineage", "-", "specific", "activation", "of", "STAT3", "by", "interferon", "-", "gamma", "in", "human", "neutrophils", "." ]
[ "cell_type", "other_name", "protein_subunit", "protein_substructure", "protein_family_or_group", "protein_molecule", "cell_line", "protein_domain_or_region", "amino_acid_monomer" ]
Thrombozyten is an umlsterm, Thrombozytenaggregation is an umlsterm, Thrombozytenaggregation is an umlsterm, Blutproben is an umlsterm, in vitro is an umlsterm, Clonidin is an umlsterm, Dexmedetomidin is an umlsterm, Kollagen - induzierte is an umlsterm, Thrombozytenaggregation is an umlsterm, Konzentrationen is an umlsterm, Clonidin is an umlsterm, Dexmedetomidin is an umlsterm, Thrombozytenaggregation is an umlsterm, Dexmedetomidin is an umlsterm, Thrombozytenaggregation is an umlsterm, Thrombozytenaggregation is an umlsterm
DerAnaesthesist.60450255.ger.abstr_task0
Sentence: Thrombozyten tragen 2-Rezeptoren auf der Zelloberflaeche , deren Stimulation die Thrombozytenaggregation ausloest . Die vorliegende Untersuchung ging der Frage nach , ob 2-Agonisten die Dichte thrombozytaerer 2-Rezeptoren vermindern und hierueber die Thrombozytenaggregation beeintraechtigen . Venoese Blutproben von 20 gesunden Probanden wurden ueber 24 h in vitro mit Clonidin und Dexmedetomidin inkubiert . Die Epinephrin- und Kollagen-induzierte Thrombozytenaggregation wurde mit Hilfe der Turbidometrie und die Dichte der thrombozytaeren 2-Rezeptoren in Radioliganden-Bindungsstudien mit3H-Yohimbin gemessen . Die klinisch relevanten Konzentrationen von 1 ng/ml Clonidin bzw. Dexmedetomidin fuehrten zu keinen signifikanten Veraenderungen der Thrombozytenaggregation oder der 2-Rezeptoren-Dichte. 10 ng/ml Dexmedetomidin verursachten eine signifikante ( p 0,05 ) Abnahme der Epinephrin-induzierten Thrombozytenaggregation ( 16,0 +/- 5,4% , n=20, Mittelwert +/- SEM ) verglichen mit der Kontrollprobe ( 46,0 +/- 1,3% , n=20). Fuer die 2-Rezeptorendichte ergaben sich keine signifikanten Unterschiede zur Kontrollprobe . Dieses Ergebnis zeigte , dass eine Desensitivierung der Epinephrin-induzierten Thrombozytenaggregation ohne quantitative Veraenderung der 2-Rezeptoren auftreten kann . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
Thrombozyten tragen 2-Rezeptoren auf der Zelloberflaeche , deren Stimulation die Thrombozytenaggregation ausloest . Die vorliegende Untersuchung ging der Frage nach , ob 2-Agonisten die Dichte thrombozytaerer 2-Rezeptoren vermindern und hierueber die Thrombozytenaggregation beeintraechtigen . Venoese Blutproben von 20 gesunden Probanden wurden ueber 24 h in vitro mit Clonidin und Dexmedetomidin inkubiert . Die Epinephrin- und Kollagen-induzierte Thrombozytenaggregation wurde mit Hilfe der Turbidometrie und die Dichte der thrombozytaeren 2-Rezeptoren in Radioliganden-Bindungsstudien mit3H-Yohimbin gemessen . Die klinisch relevanten Konzentrationen von 1 ng/ml Clonidin bzw. Dexmedetomidin fuehrten zu keinen signifikanten Veraenderungen der Thrombozytenaggregation oder der 2-Rezeptoren-Dichte. 10 ng/ml Dexmedetomidin verursachten eine signifikante ( p 0,05 ) Abnahme der Epinephrin-induzierten Thrombozytenaggregation ( 16,0 +/- 5,4% , n=20, Mittelwert +/- SEM ) verglichen mit der Kontrollprobe ( 46,0 +/- 1,3% , n=20). Fuer die 2-Rezeptorendichte ergaben sich keine signifikanten Unterschiede zur Kontrollprobe . Dieses Ergebnis zeigte , dass eine Desensitivierung der Epinephrin-induzierten Thrombozytenaggregation ohne quantitative Veraenderung der 2-Rezeptoren auftreten kann .
[ "Thrombozyten", "tragen", "2-Rezeptoren", "auf", "der", "Zelloberflaeche", ",", "deren", "Stimulation", "die", "Thrombozytenaggregation", "ausloest", ".", "Die", "vorliegende", "Untersuchung", "ging", "der", "Frage", "nach", ",", "ob", "2-Agonisten", "die", "Dichte", "thrombozytaerer", "2-Rezeptoren", "vermindern", "und", "hierueber", "die", "Thrombozytenaggregation", "beeintraechtigen", ".", "Venoese", "Blutproben", "von", "20", "gesunden", "Probanden", "wurden", "ueber", "24", "h", "in", "vitro", "mit", "Clonidin", "und", "Dexmedetomidin", "inkubiert", ".", "Die", "Epinephrin-", "und", "Kollagen", "-", "induzierte", "Thrombozytenaggregation", "wurde", "mit", "Hilfe", "der", "Turbidometrie", "und", "die", "Dichte", "der", "thrombozytaeren", "2-Rezeptoren", "in", "Radioliganden", "-", "Bindungsstudien", "mit3H", "-", "Yohimbin", "gemessen", ".", "Die", "klinisch", "relevanten", "Konzentrationen", "von", "1", "ng", "/", "ml", "Clonidin", "bzw", ".", "Dexmedetomidin", "fuehrten", "zu", "keinen", "signifikanten", "Veraenderungen", "der", "Thrombozytenaggregation", "oder", "der", "2-Rezeptoren", "-", "Dichte", ".", "10", "ng", "/", "ml", "Dexmedetomidin", "verursachten", "eine", "signifikante", "(", "p", "0,05", ")", "Abnahme", "der", "Epinephrin", "-", "induzierten", "Thrombozytenaggregation", "(", "16,0", "+", "/-", "5,4", "%", ",", "n=20", ",", "Mittelwert", "+", "/-", "SEM", ")", "verglichen", "mit", "der", "Kontrollprobe", "(", "46,0", "+", "/-", "1,3", "%", ",", "n=20", ")", ".", "Fuer", "die", "2-Rezeptorendichte", "ergaben", "sich", "keine", "signifikanten", "Unterschiede", "zur", "Kontrollprobe", ".", "Dieses", "Ergebnis", "zeigte", ",", "dass", "eine", "Desensitivierung", "der", "Epinephrin", "-", "induzierten", "Thrombozytenaggregation", "ohne", "quantitative", "Veraenderung", "der", "2-Rezeptoren", "auftreten", "kann", "." ]
[ "umlsterm" ]
Thrombozyten is an umlsterm, Thrombozytenaggregation is an umlsterm, Thrombozytenaggregation is an umlsterm, Blutproben is an umlsterm, in vitro is an umlsterm, Clonidin is an umlsterm, Dexmedetomidin is an umlsterm, Kollagen - induzierte is an umlsterm, Thrombozytenaggregation is an umlsterm, Konzentrationen is an umlsterm, Clonidin is an umlsterm, Dexmedetomidin is an umlsterm, Thrombozytenaggregation is an umlsterm, Dexmedetomidin is an umlsterm, Thrombozytenaggregation is an umlsterm, Thrombozytenaggregation is an umlsterm
DerAnaesthesist.60450255.ger.abstr_task1
Sentence: Thrombozyten tragen 2-Rezeptoren auf der Zelloberflaeche , deren Stimulation die Thrombozytenaggregation ausloest . Die vorliegende Untersuchung ging der Frage nach , ob 2-Agonisten die Dichte thrombozytaerer 2-Rezeptoren vermindern und hierueber die Thrombozytenaggregation beeintraechtigen . Venoese Blutproben von 20 gesunden Probanden wurden ueber 24 h in vitro mit Clonidin und Dexmedetomidin inkubiert . Die Epinephrin- und Kollagen-induzierte Thrombozytenaggregation wurde mit Hilfe der Turbidometrie und die Dichte der thrombozytaeren 2-Rezeptoren in Radioliganden-Bindungsstudien mit3H-Yohimbin gemessen . Die klinisch relevanten Konzentrationen von 1 ng/ml Clonidin bzw. Dexmedetomidin fuehrten zu keinen signifikanten Veraenderungen der Thrombozytenaggregation oder der 2-Rezeptoren-Dichte. 10 ng/ml Dexmedetomidin verursachten eine signifikante ( p 0,05 ) Abnahme der Epinephrin-induzierten Thrombozytenaggregation ( 16,0 +/- 5,4% , n=20, Mittelwert +/- SEM ) verglichen mit der Kontrollprobe ( 46,0 +/- 1,3% , n=20). Fuer die 2-Rezeptorendichte ergaben sich keine signifikanten Unterschiede zur Kontrollprobe . Dieses Ergebnis zeigte , dass eine Desensitivierung der Epinephrin-induzierten Thrombozytenaggregation ohne quantitative Veraenderung der 2-Rezeptoren auftreten kann . Instructions: please typing these entity words according to sentence: Thrombozyten, Thrombozytenaggregation, Thrombozytenaggregation, Blutproben, in vitro, Clonidin, Dexmedetomidin, Kollagen - induzierte, Thrombozytenaggregation, Konzentrationen, Clonidin, Dexmedetomidin, Thrombozytenaggregation, Dexmedetomidin, Thrombozytenaggregation, Thrombozytenaggregation Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
Thrombozyten tragen 2-Rezeptoren auf der Zelloberflaeche , deren Stimulation die Thrombozytenaggregation ausloest . Die vorliegende Untersuchung ging der Frage nach , ob 2-Agonisten die Dichte thrombozytaerer 2-Rezeptoren vermindern und hierueber die Thrombozytenaggregation beeintraechtigen . Venoese Blutproben von 20 gesunden Probanden wurden ueber 24 h in vitro mit Clonidin und Dexmedetomidin inkubiert . Die Epinephrin- und Kollagen-induzierte Thrombozytenaggregation wurde mit Hilfe der Turbidometrie und die Dichte der thrombozytaeren 2-Rezeptoren in Radioliganden-Bindungsstudien mit3H-Yohimbin gemessen . Die klinisch relevanten Konzentrationen von 1 ng/ml Clonidin bzw. Dexmedetomidin fuehrten zu keinen signifikanten Veraenderungen der Thrombozytenaggregation oder der 2-Rezeptoren-Dichte. 10 ng/ml Dexmedetomidin verursachten eine signifikante ( p 0,05 ) Abnahme der Epinephrin-induzierten Thrombozytenaggregation ( 16,0 +/- 5,4% , n=20, Mittelwert +/- SEM ) verglichen mit der Kontrollprobe ( 46,0 +/- 1,3% , n=20). Fuer die 2-Rezeptorendichte ergaben sich keine signifikanten Unterschiede zur Kontrollprobe . Dieses Ergebnis zeigte , dass eine Desensitivierung der Epinephrin-induzierten Thrombozytenaggregation ohne quantitative Veraenderung der 2-Rezeptoren auftreten kann .
[ "Thrombozyten", "tragen", "2-Rezeptoren", "auf", "der", "Zelloberflaeche", ",", "deren", "Stimulation", "die", "Thrombozytenaggregation", "ausloest", ".", "Die", "vorliegende", "Untersuchung", "ging", "der", "Frage", "nach", ",", "ob", "2-Agonisten", "die", "Dichte", "thrombozytaerer", "2-Rezeptoren", "vermindern", "und", "hierueber", "die", "Thrombozytenaggregation", "beeintraechtigen", ".", "Venoese", "Blutproben", "von", "20", "gesunden", "Probanden", "wurden", "ueber", "24", "h", "in", "vitro", "mit", "Clonidin", "und", "Dexmedetomidin", "inkubiert", ".", "Die", "Epinephrin-", "und", "Kollagen", "-", "induzierte", "Thrombozytenaggregation", "wurde", "mit", "Hilfe", "der", "Turbidometrie", "und", "die", "Dichte", "der", "thrombozytaeren", "2-Rezeptoren", "in", "Radioliganden", "-", "Bindungsstudien", "mit3H", "-", "Yohimbin", "gemessen", ".", "Die", "klinisch", "relevanten", "Konzentrationen", "von", "1", "ng", "/", "ml", "Clonidin", "bzw", ".", "Dexmedetomidin", "fuehrten", "zu", "keinen", "signifikanten", "Veraenderungen", "der", "Thrombozytenaggregation", "oder", "der", "2-Rezeptoren", "-", "Dichte", ".", "10", "ng", "/", "ml", "Dexmedetomidin", "verursachten", "eine", "signifikante", "(", "p", "0,05", ")", "Abnahme", "der", "Epinephrin", "-", "induzierten", "Thrombozytenaggregation", "(", "16,0", "+", "/-", "5,4", "%", ",", "n=20", ",", "Mittelwert", "+", "/-", "SEM", ")", "verglichen", "mit", "der", "Kontrollprobe", "(", "46,0", "+", "/-", "1,3", "%", ",", "n=20", ")", ".", "Fuer", "die", "2-Rezeptorendichte", "ergaben", "sich", "keine", "signifikanten", "Unterschiede", "zur", "Kontrollprobe", ".", "Dieses", "Ergebnis", "zeigte", ",", "dass", "eine", "Desensitivierung", "der", "Epinephrin", "-", "induzierten", "Thrombozytenaggregation", "ohne", "quantitative", "Veraenderung", "der", "2-Rezeptoren", "auftreten", "kann", "." ]
[ "umlsterm" ]
Thrombozyten, Thrombozytenaggregation, Thrombozytenaggregation, Blutproben, in vitro, Clonidin, Dexmedetomidin, Kollagen - induzierte, Thrombozytenaggregation, Konzentrationen, Clonidin, Dexmedetomidin, Thrombozytenaggregation, Dexmedetomidin, Thrombozytenaggregation, Thrombozytenaggregation
DerAnaesthesist.60450255.ger.abstr_task2
Sentence: Thrombozyten tragen 2-Rezeptoren auf der Zelloberflaeche , deren Stimulation die Thrombozytenaggregation ausloest . Die vorliegende Untersuchung ging der Frage nach , ob 2-Agonisten die Dichte thrombozytaerer 2-Rezeptoren vermindern und hierueber die Thrombozytenaggregation beeintraechtigen . Venoese Blutproben von 20 gesunden Probanden wurden ueber 24 h in vitro mit Clonidin und Dexmedetomidin inkubiert . Die Epinephrin- und Kollagen-induzierte Thrombozytenaggregation wurde mit Hilfe der Turbidometrie und die Dichte der thrombozytaeren 2-Rezeptoren in Radioliganden-Bindungsstudien mit3H-Yohimbin gemessen . Die klinisch relevanten Konzentrationen von 1 ng/ml Clonidin bzw. Dexmedetomidin fuehrten zu keinen signifikanten Veraenderungen der Thrombozytenaggregation oder der 2-Rezeptoren-Dichte. 10 ng/ml Dexmedetomidin verursachten eine signifikante ( p 0,05 ) Abnahme der Epinephrin-induzierten Thrombozytenaggregation ( 16,0 +/- 5,4% , n=20, Mittelwert +/- SEM ) verglichen mit der Kontrollprobe ( 46,0 +/- 1,3% , n=20). Fuer die 2-Rezeptorendichte ergaben sich keine signifikanten Unterschiede zur Kontrollprobe . Dieses Ergebnis zeigte , dass eine Desensitivierung der Epinephrin-induzierten Thrombozytenaggregation ohne quantitative Veraenderung der 2-Rezeptoren auftreten kann . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
Thrombozyten tragen 2-Rezeptoren auf der Zelloberflaeche , deren Stimulation die Thrombozytenaggregation ausloest . Die vorliegende Untersuchung ging der Frage nach , ob 2-Agonisten die Dichte thrombozytaerer 2-Rezeptoren vermindern und hierueber die Thrombozytenaggregation beeintraechtigen . Venoese Blutproben von 20 gesunden Probanden wurden ueber 24 h in vitro mit Clonidin und Dexmedetomidin inkubiert . Die Epinephrin- und Kollagen-induzierte Thrombozytenaggregation wurde mit Hilfe der Turbidometrie und die Dichte der thrombozytaeren 2-Rezeptoren in Radioliganden-Bindungsstudien mit3H-Yohimbin gemessen . Die klinisch relevanten Konzentrationen von 1 ng/ml Clonidin bzw. Dexmedetomidin fuehrten zu keinen signifikanten Veraenderungen der Thrombozytenaggregation oder der 2-Rezeptoren-Dichte. 10 ng/ml Dexmedetomidin verursachten eine signifikante ( p 0,05 ) Abnahme der Epinephrin-induzierten Thrombozytenaggregation ( 16,0 +/- 5,4% , n=20, Mittelwert +/- SEM ) verglichen mit der Kontrollprobe ( 46,0 +/- 1,3% , n=20). Fuer die 2-Rezeptorendichte ergaben sich keine signifikanten Unterschiede zur Kontrollprobe . Dieses Ergebnis zeigte , dass eine Desensitivierung der Epinephrin-induzierten Thrombozytenaggregation ohne quantitative Veraenderung der 2-Rezeptoren auftreten kann .
[ "Thrombozyten", "tragen", "2-Rezeptoren", "auf", "der", "Zelloberflaeche", ",", "deren", "Stimulation", "die", "Thrombozytenaggregation", "ausloest", ".", "Die", "vorliegende", "Untersuchung", "ging", "der", "Frage", "nach", ",", "ob", "2-Agonisten", "die", "Dichte", "thrombozytaerer", "2-Rezeptoren", "vermindern", "und", "hierueber", "die", "Thrombozytenaggregation", "beeintraechtigen", ".", "Venoese", "Blutproben", "von", "20", "gesunden", "Probanden", "wurden", "ueber", "24", "h", "in", "vitro", "mit", "Clonidin", "und", "Dexmedetomidin", "inkubiert", ".", "Die", "Epinephrin-", "und", "Kollagen", "-", "induzierte", "Thrombozytenaggregation", "wurde", "mit", "Hilfe", "der", "Turbidometrie", "und", "die", "Dichte", "der", "thrombozytaeren", "2-Rezeptoren", "in", "Radioliganden", "-", "Bindungsstudien", "mit3H", "-", "Yohimbin", "gemessen", ".", "Die", "klinisch", "relevanten", "Konzentrationen", "von", "1", "ng", "/", "ml", "Clonidin", "bzw", ".", "Dexmedetomidin", "fuehrten", "zu", "keinen", "signifikanten", "Veraenderungen", "der", "Thrombozytenaggregation", "oder", "der", "2-Rezeptoren", "-", "Dichte", ".", "10", "ng", "/", "ml", "Dexmedetomidin", "verursachten", "eine", "signifikante", "(", "p", "0,05", ")", "Abnahme", "der", "Epinephrin", "-", "induzierten", "Thrombozytenaggregation", "(", "16,0", "+", "/-", "5,4", "%", ",", "n=20", ",", "Mittelwert", "+", "/-", "SEM", ")", "verglichen", "mit", "der", "Kontrollprobe", "(", "46,0", "+", "/-", "1,3", "%", ",", "n=20", ")", ".", "Fuer", "die", "2-Rezeptorendichte", "ergaben", "sich", "keine", "signifikanten", "Unterschiede", "zur", "Kontrollprobe", ".", "Dieses", "Ergebnis", "zeigte", ",", "dass", "eine", "Desensitivierung", "der", "Epinephrin", "-", "induzierten", "Thrombozytenaggregation", "ohne", "quantitative", "Veraenderung", "der", "2-Rezeptoren", "auftreten", "kann", "." ]
[ "umlsterm" ]
ET-1 is a protein, bosentan is a compound
DS.d479_task0
Sentence: Like PSC, DSL6A cells secrete less ET-1 when cultured with bosentan. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein
[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-compound", "O" ]
Like PSC, DSL6A cells secrete less ET-1 when cultured with bosentan.
[ "Like", "PSC", ",", "DSL6A", "cells", "secrete", "less", "ET-1", "when", "cultured", "with", "bosentan", "." ]
[ "compound", "protein" ]
ET-1 is a protein, bosentan is a compound
DS.d479_task1
Sentence: Like PSC, DSL6A cells secrete less ET-1 when cultured with bosentan. Instructions: please typing these entity words according to sentence: ET-1, bosentan Options: compound, protein
[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-compound", "O" ]
Like PSC, DSL6A cells secrete less ET-1 when cultured with bosentan.
[ "Like", "PSC", ",", "DSL6A", "cells", "secrete", "less", "ET-1", "when", "cultured", "with", "bosentan", "." ]
[ "compound", "protein" ]
ET-1, bosentan
DS.d479_task2
Sentence: Like PSC, DSL6A cells secrete less ET-1 when cultured with bosentan. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-compound", "O" ]
Like PSC, DSL6A cells secrete less ET-1 when cultured with bosentan.
[ "Like", "PSC", ",", "DSL6A", "cells", "secrete", "less", "ET-1", "when", "cultured", "with", "bosentan", "." ]
[ "compound", "protein" ]
Patienten is an umlsterm, Prostatakarzinom is an umlsterm, Androgendeprivation is an umlsterm, Therapie is an umlsterm, Leben is an umlsterm, Patienten is an umlsterm, Lebensqualitaet is an umlsterm, Behandlung is an umlsterm, Kombinationstherapie is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Chemotherapie is an umlsterm, Schmerztherapie is an umlsterm, TURP is an umlsterm, Dekompression is an umlsterm
DerUrologeA.80370159.ger.abstr_task0
Sentence: Patienten mit einem hormonrefraktaeren Prostatakarzinom sind durch ein Versagen der primaeren Androgendeprivation gekennzeichnet . Der Zeitpunkt fuer eine sekundaere Therapie richtet sich nach der klinischen Symptomatik , da bei eingetretener Progression das Leben der Patienten nicht verlaengert werden kann und somit die Verbesserung der Lebensqualitaet im Vordergrund steht . Umstellung der Hormontherapie und Antiandrogenentzug koennen zu einer voruebergehenden Besserung der subjektiven Befindlichkeit fuehren . Chemotherapeutisch sollte einer Behandlung mit gut vertraeglichen Einzelsubstanzen gegenueber einer Kombinationstherapie der Vorzug gegeben werden , da mit einer zytostatischen Therapie Remissionsraten 30 % nicht uebersteigen . Zwar profitieren 2/3 der Patienten subjektiv von einer Chemotherapie , dennoch ist nicht gesichert , dass sie einer symptomorientierten Schmerztherapie ueberlegen ist . Operative Eingriffe wie TURP und spinale Dekompression und Stabilisierung orientieren sich an der Klinik bedingt durch lokalen Progress und Fernmetastasierung . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Patienten mit einem hormonrefraktaeren Prostatakarzinom sind durch ein Versagen der primaeren Androgendeprivation gekennzeichnet . Der Zeitpunkt fuer eine sekundaere Therapie richtet sich nach der klinischen Symptomatik , da bei eingetretener Progression das Leben der Patienten nicht verlaengert werden kann und somit die Verbesserung der Lebensqualitaet im Vordergrund steht . Umstellung der Hormontherapie und Antiandrogenentzug koennen zu einer voruebergehenden Besserung der subjektiven Befindlichkeit fuehren . Chemotherapeutisch sollte einer Behandlung mit gut vertraeglichen Einzelsubstanzen gegenueber einer Kombinationstherapie der Vorzug gegeben werden , da mit einer zytostatischen Therapie Remissionsraten 30 % nicht uebersteigen . Zwar profitieren 2/3 der Patienten subjektiv von einer Chemotherapie , dennoch ist nicht gesichert , dass sie einer symptomorientierten Schmerztherapie ueberlegen ist . Operative Eingriffe wie TURP und spinale Dekompression und Stabilisierung orientieren sich an der Klinik bedingt durch lokalen Progress und Fernmetastasierung .
[ "Patienten", "mit", "einem", "hormonrefraktaeren", "Prostatakarzinom", "sind", "durch", "ein", "Versagen", "der", "primaeren", "Androgendeprivation", "gekennzeichnet", ".", "Der", "Zeitpunkt", "fuer", "eine", "sekundaere", "Therapie", "richtet", "sich", "nach", "der", "klinischen", "Symptomatik", ",", "da", "bei", "eingetretener", "Progression", "das", "Leben", "der", "Patienten", "nicht", "verlaengert", "werden", "kann", "und", "somit", "die", "Verbesserung", "der", "Lebensqualitaet", "im", "Vordergrund", "steht", ".", "Umstellung", "der", "Hormontherapie", "und", "Antiandrogenentzug", "koennen", "zu", "einer", "voruebergehenden", "Besserung", "der", "subjektiven", "Befindlichkeit", "fuehren", ".", "Chemotherapeutisch", "sollte", "einer", "Behandlung", "mit", "gut", "vertraeglichen", "Einzelsubstanzen", "gegenueber", "einer", "Kombinationstherapie", "der", "Vorzug", "gegeben", "werden", ",", "da", "mit", "einer", "zytostatischen", "Therapie", "Remissionsraten", "30", "%", "nicht", "uebersteigen", ".", "Zwar", "profitieren", "2/3", "der", "Patienten", "subjektiv", "von", "einer", "Chemotherapie", ",", "dennoch", "ist", "nicht", "gesichert", ",", "dass", "sie", "einer", "symptomorientierten", "Schmerztherapie", "ueberlegen", "ist", ".", "Operative", "Eingriffe", "wie", "TURP", "und", "spinale", "Dekompression", "und", "Stabilisierung", "orientieren", "sich", "an", "der", "Klinik", "bedingt", "durch", "lokalen", "Progress", "und", "Fernmetastasierung", "." ]
[ "umlsterm" ]
Patienten is an umlsterm, Prostatakarzinom is an umlsterm, Androgendeprivation is an umlsterm, Therapie is an umlsterm, Leben is an umlsterm, Patienten is an umlsterm, Lebensqualitaet is an umlsterm, Behandlung is an umlsterm, Kombinationstherapie is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Chemotherapie is an umlsterm, Schmerztherapie is an umlsterm, TURP is an umlsterm, Dekompression is an umlsterm
DerUrologeA.80370159.ger.abstr_task1
Sentence: Patienten mit einem hormonrefraktaeren Prostatakarzinom sind durch ein Versagen der primaeren Androgendeprivation gekennzeichnet . Der Zeitpunkt fuer eine sekundaere Therapie richtet sich nach der klinischen Symptomatik , da bei eingetretener Progression das Leben der Patienten nicht verlaengert werden kann und somit die Verbesserung der Lebensqualitaet im Vordergrund steht . Umstellung der Hormontherapie und Antiandrogenentzug koennen zu einer voruebergehenden Besserung der subjektiven Befindlichkeit fuehren . Chemotherapeutisch sollte einer Behandlung mit gut vertraeglichen Einzelsubstanzen gegenueber einer Kombinationstherapie der Vorzug gegeben werden , da mit einer zytostatischen Therapie Remissionsraten 30 % nicht uebersteigen . Zwar profitieren 2/3 der Patienten subjektiv von einer Chemotherapie , dennoch ist nicht gesichert , dass sie einer symptomorientierten Schmerztherapie ueberlegen ist . Operative Eingriffe wie TURP und spinale Dekompression und Stabilisierung orientieren sich an der Klinik bedingt durch lokalen Progress und Fernmetastasierung . Instructions: please typing these entity words according to sentence: Patienten, Prostatakarzinom, Androgendeprivation, Therapie, Leben, Patienten, Lebensqualitaet, Behandlung, Kombinationstherapie, Therapie, Patienten, Chemotherapie, Schmerztherapie, TURP, Dekompression Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Patienten mit einem hormonrefraktaeren Prostatakarzinom sind durch ein Versagen der primaeren Androgendeprivation gekennzeichnet . Der Zeitpunkt fuer eine sekundaere Therapie richtet sich nach der klinischen Symptomatik , da bei eingetretener Progression das Leben der Patienten nicht verlaengert werden kann und somit die Verbesserung der Lebensqualitaet im Vordergrund steht . Umstellung der Hormontherapie und Antiandrogenentzug koennen zu einer voruebergehenden Besserung der subjektiven Befindlichkeit fuehren . Chemotherapeutisch sollte einer Behandlung mit gut vertraeglichen Einzelsubstanzen gegenueber einer Kombinationstherapie der Vorzug gegeben werden , da mit einer zytostatischen Therapie Remissionsraten 30 % nicht uebersteigen . Zwar profitieren 2/3 der Patienten subjektiv von einer Chemotherapie , dennoch ist nicht gesichert , dass sie einer symptomorientierten Schmerztherapie ueberlegen ist . Operative Eingriffe wie TURP und spinale Dekompression und Stabilisierung orientieren sich an der Klinik bedingt durch lokalen Progress und Fernmetastasierung .
[ "Patienten", "mit", "einem", "hormonrefraktaeren", "Prostatakarzinom", "sind", "durch", "ein", "Versagen", "der", "primaeren", "Androgendeprivation", "gekennzeichnet", ".", "Der", "Zeitpunkt", "fuer", "eine", "sekundaere", "Therapie", "richtet", "sich", "nach", "der", "klinischen", "Symptomatik", ",", "da", "bei", "eingetretener", "Progression", "das", "Leben", "der", "Patienten", "nicht", "verlaengert", "werden", "kann", "und", "somit", "die", "Verbesserung", "der", "Lebensqualitaet", "im", "Vordergrund", "steht", ".", "Umstellung", "der", "Hormontherapie", "und", "Antiandrogenentzug", "koennen", "zu", "einer", "voruebergehenden", "Besserung", "der", "subjektiven", "Befindlichkeit", "fuehren", ".", "Chemotherapeutisch", "sollte", "einer", "Behandlung", "mit", "gut", "vertraeglichen", "Einzelsubstanzen", "gegenueber", "einer", "Kombinationstherapie", "der", "Vorzug", "gegeben", "werden", ",", "da", "mit", "einer", "zytostatischen", "Therapie", "Remissionsraten", "30", "%", "nicht", "uebersteigen", ".", "Zwar", "profitieren", "2/3", "der", "Patienten", "subjektiv", "von", "einer", "Chemotherapie", ",", "dennoch", "ist", "nicht", "gesichert", ",", "dass", "sie", "einer", "symptomorientierten", "Schmerztherapie", "ueberlegen", "ist", ".", "Operative", "Eingriffe", "wie", "TURP", "und", "spinale", "Dekompression", "und", "Stabilisierung", "orientieren", "sich", "an", "der", "Klinik", "bedingt", "durch", "lokalen", "Progress", "und", "Fernmetastasierung", "." ]
[ "umlsterm" ]
Patienten, Prostatakarzinom, Androgendeprivation, Therapie, Leben, Patienten, Lebensqualitaet, Behandlung, Kombinationstherapie, Therapie, Patienten, Chemotherapie, Schmerztherapie, TURP, Dekompression
DerUrologeA.80370159.ger.abstr_task2
Sentence: Patienten mit einem hormonrefraktaeren Prostatakarzinom sind durch ein Versagen der primaeren Androgendeprivation gekennzeichnet . Der Zeitpunkt fuer eine sekundaere Therapie richtet sich nach der klinischen Symptomatik , da bei eingetretener Progression das Leben der Patienten nicht verlaengert werden kann und somit die Verbesserung der Lebensqualitaet im Vordergrund steht . Umstellung der Hormontherapie und Antiandrogenentzug koennen zu einer voruebergehenden Besserung der subjektiven Befindlichkeit fuehren . Chemotherapeutisch sollte einer Behandlung mit gut vertraeglichen Einzelsubstanzen gegenueber einer Kombinationstherapie der Vorzug gegeben werden , da mit einer zytostatischen Therapie Remissionsraten 30 % nicht uebersteigen . Zwar profitieren 2/3 der Patienten subjektiv von einer Chemotherapie , dennoch ist nicht gesichert , dass sie einer symptomorientierten Schmerztherapie ueberlegen ist . Operative Eingriffe wie TURP und spinale Dekompression und Stabilisierung orientieren sich an der Klinik bedingt durch lokalen Progress und Fernmetastasierung . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Patienten mit einem hormonrefraktaeren Prostatakarzinom sind durch ein Versagen der primaeren Androgendeprivation gekennzeichnet . Der Zeitpunkt fuer eine sekundaere Therapie richtet sich nach der klinischen Symptomatik , da bei eingetretener Progression das Leben der Patienten nicht verlaengert werden kann und somit die Verbesserung der Lebensqualitaet im Vordergrund steht . Umstellung der Hormontherapie und Antiandrogenentzug koennen zu einer voruebergehenden Besserung der subjektiven Befindlichkeit fuehren . Chemotherapeutisch sollte einer Behandlung mit gut vertraeglichen Einzelsubstanzen gegenueber einer Kombinationstherapie der Vorzug gegeben werden , da mit einer zytostatischen Therapie Remissionsraten 30 % nicht uebersteigen . Zwar profitieren 2/3 der Patienten subjektiv von einer Chemotherapie , dennoch ist nicht gesichert , dass sie einer symptomorientierten Schmerztherapie ueberlegen ist . Operative Eingriffe wie TURP und spinale Dekompression und Stabilisierung orientieren sich an der Klinik bedingt durch lokalen Progress und Fernmetastasierung .
[ "Patienten", "mit", "einem", "hormonrefraktaeren", "Prostatakarzinom", "sind", "durch", "ein", "Versagen", "der", "primaeren", "Androgendeprivation", "gekennzeichnet", ".", "Der", "Zeitpunkt", "fuer", "eine", "sekundaere", "Therapie", "richtet", "sich", "nach", "der", "klinischen", "Symptomatik", ",", "da", "bei", "eingetretener", "Progression", "das", "Leben", "der", "Patienten", "nicht", "verlaengert", "werden", "kann", "und", "somit", "die", "Verbesserung", "der", "Lebensqualitaet", "im", "Vordergrund", "steht", ".", "Umstellung", "der", "Hormontherapie", "und", "Antiandrogenentzug", "koennen", "zu", "einer", "voruebergehenden", "Besserung", "der", "subjektiven", "Befindlichkeit", "fuehren", ".", "Chemotherapeutisch", "sollte", "einer", "Behandlung", "mit", "gut", "vertraeglichen", "Einzelsubstanzen", "gegenueber", "einer", "Kombinationstherapie", "der", "Vorzug", "gegeben", "werden", ",", "da", "mit", "einer", "zytostatischen", "Therapie", "Remissionsraten", "30", "%", "nicht", "uebersteigen", ".", "Zwar", "profitieren", "2/3", "der", "Patienten", "subjektiv", "von", "einer", "Chemotherapie", ",", "dennoch", "ist", "nicht", "gesichert", ",", "dass", "sie", "einer", "symptomorientierten", "Schmerztherapie", "ueberlegen", "ist", ".", "Operative", "Eingriffe", "wie", "TURP", "und", "spinale", "Dekompression", "und", "Stabilisierung", "orientieren", "sich", "an", "der", "Klinik", "bedingt", "durch", "lokalen", "Progress", "und", "Fernmetastasierung", "." ]
[ "umlsterm" ]
Gehirn is an umlsterm, Gonadenhormone is an umlsterm, Oestrogene is an umlsterm, Neurotransmittersysteme is an umlsterm, Oestrogene is an umlsterm, Postmenopause is an umlsterm, Oestrogene is an umlsterm, Faehigkeiten is an umlsterm, Gedaechtnis is an umlsterm, Stimmung is an umlsterm, Therapieempfehlungen is an umlsterm, Demenzprophylaxe is an umlsterm, Demenztherapie is an umlsterm, Depression is an umlsterm
DerGynaekologe.00330385.ger.abstr_task0
Sentence: Das Gehirn ist ein wichtiges Zielorgan fuer Gonadenhormone . Oestrogene haben neuroprotektive und neurotrophe Effekte und beeinflussen die Aktivitaet verschiedener Neurotransmittersysteme . Erste Studien unterstuetzen teilweise die Hypothese , dass Oestrogene in der Postmenopause eine Prophylaxe dementieller Erkrankungen insbesondere der Alzheimer Erkrankung , darstellen koennen . Oestrogene verbessern unter bestimmten Bedingungen verbale Faehigkeiten und Gedaechtnis im Alter und heben Stimmung und Befinden an . Fuer allgemeine Therapieempfehlungen hinsichtlich der Indikationen Demenzprophylaxe , Demenztherapie und Depression sind die vorliegenden Evidenzen aber noch nicht ausreichend . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Das Gehirn ist ein wichtiges Zielorgan fuer Gonadenhormone . Oestrogene haben neuroprotektive und neurotrophe Effekte und beeinflussen die Aktivitaet verschiedener Neurotransmittersysteme . Erste Studien unterstuetzen teilweise die Hypothese , dass Oestrogene in der Postmenopause eine Prophylaxe dementieller Erkrankungen insbesondere der Alzheimer Erkrankung , darstellen koennen . Oestrogene verbessern unter bestimmten Bedingungen verbale Faehigkeiten und Gedaechtnis im Alter und heben Stimmung und Befinden an . Fuer allgemeine Therapieempfehlungen hinsichtlich der Indikationen Demenzprophylaxe , Demenztherapie und Depression sind die vorliegenden Evidenzen aber noch nicht ausreichend .
[ "Das", "Gehirn", "ist", "ein", "wichtiges", "Zielorgan", "fuer", "Gonadenhormone", ".", "Oestrogene", "haben", "neuroprotektive", "und", "neurotrophe", "Effekte", "und", "beeinflussen", "die", "Aktivitaet", "verschiedener", "Neurotransmittersysteme", ".", "Erste", "Studien", "unterstuetzen", "teilweise", "die", "Hypothese", ",", "dass", "Oestrogene", "in", "der", "Postmenopause", "eine", "Prophylaxe", "dementieller", "Erkrankungen", "insbesondere", "der", "Alzheimer", "Erkrankung", ",", "darstellen", "koennen", ".", "Oestrogene", "verbessern", "unter", "bestimmten", "Bedingungen", "verbale", "Faehigkeiten", "und", "Gedaechtnis", "im", "Alter", "und", "heben", "Stimmung", "und", "Befinden", "an", ".", "Fuer", "allgemeine", "Therapieempfehlungen", "hinsichtlich", "der", "Indikationen", "Demenzprophylaxe", ",", "Demenztherapie", "und", "Depression", "sind", "die", "vorliegenden", "Evidenzen", "aber", "noch", "nicht", "ausreichend", "." ]
[ "umlsterm" ]
Gehirn is an umlsterm, Gonadenhormone is an umlsterm, Oestrogene is an umlsterm, Neurotransmittersysteme is an umlsterm, Oestrogene is an umlsterm, Postmenopause is an umlsterm, Oestrogene is an umlsterm, Faehigkeiten is an umlsterm, Gedaechtnis is an umlsterm, Stimmung is an umlsterm, Therapieempfehlungen is an umlsterm, Demenzprophylaxe is an umlsterm, Demenztherapie is an umlsterm, Depression is an umlsterm
DerGynaekologe.00330385.ger.abstr_task1
Sentence: Das Gehirn ist ein wichtiges Zielorgan fuer Gonadenhormone . Oestrogene haben neuroprotektive und neurotrophe Effekte und beeinflussen die Aktivitaet verschiedener Neurotransmittersysteme . Erste Studien unterstuetzen teilweise die Hypothese , dass Oestrogene in der Postmenopause eine Prophylaxe dementieller Erkrankungen insbesondere der Alzheimer Erkrankung , darstellen koennen . Oestrogene verbessern unter bestimmten Bedingungen verbale Faehigkeiten und Gedaechtnis im Alter und heben Stimmung und Befinden an . Fuer allgemeine Therapieempfehlungen hinsichtlich der Indikationen Demenzprophylaxe , Demenztherapie und Depression sind die vorliegenden Evidenzen aber noch nicht ausreichend . Instructions: please typing these entity words according to sentence: Gehirn, Gonadenhormone, Oestrogene, Neurotransmittersysteme, Oestrogene, Postmenopause, Oestrogene, Faehigkeiten, Gedaechtnis, Stimmung, Therapieempfehlungen, Demenzprophylaxe, Demenztherapie, Depression Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Das Gehirn ist ein wichtiges Zielorgan fuer Gonadenhormone . Oestrogene haben neuroprotektive und neurotrophe Effekte und beeinflussen die Aktivitaet verschiedener Neurotransmittersysteme . Erste Studien unterstuetzen teilweise die Hypothese , dass Oestrogene in der Postmenopause eine Prophylaxe dementieller Erkrankungen insbesondere der Alzheimer Erkrankung , darstellen koennen . Oestrogene verbessern unter bestimmten Bedingungen verbale Faehigkeiten und Gedaechtnis im Alter und heben Stimmung und Befinden an . Fuer allgemeine Therapieempfehlungen hinsichtlich der Indikationen Demenzprophylaxe , Demenztherapie und Depression sind die vorliegenden Evidenzen aber noch nicht ausreichend .
[ "Das", "Gehirn", "ist", "ein", "wichtiges", "Zielorgan", "fuer", "Gonadenhormone", ".", "Oestrogene", "haben", "neuroprotektive", "und", "neurotrophe", "Effekte", "und", "beeinflussen", "die", "Aktivitaet", "verschiedener", "Neurotransmittersysteme", ".", "Erste", "Studien", "unterstuetzen", "teilweise", "die", "Hypothese", ",", "dass", "Oestrogene", "in", "der", "Postmenopause", "eine", "Prophylaxe", "dementieller", "Erkrankungen", "insbesondere", "der", "Alzheimer", "Erkrankung", ",", "darstellen", "koennen", ".", "Oestrogene", "verbessern", "unter", "bestimmten", "Bedingungen", "verbale", "Faehigkeiten", "und", "Gedaechtnis", "im", "Alter", "und", "heben", "Stimmung", "und", "Befinden", "an", ".", "Fuer", "allgemeine", "Therapieempfehlungen", "hinsichtlich", "der", "Indikationen", "Demenzprophylaxe", ",", "Demenztherapie", "und", "Depression", "sind", "die", "vorliegenden", "Evidenzen", "aber", "noch", "nicht", "ausreichend", "." ]
[ "umlsterm" ]
Gehirn, Gonadenhormone, Oestrogene, Neurotransmittersysteme, Oestrogene, Postmenopause, Oestrogene, Faehigkeiten, Gedaechtnis, Stimmung, Therapieempfehlungen, Demenzprophylaxe, Demenztherapie, Depression
DerGynaekologe.00330385.ger.abstr_task2
Sentence: Das Gehirn ist ein wichtiges Zielorgan fuer Gonadenhormone . Oestrogene haben neuroprotektive und neurotrophe Effekte und beeinflussen die Aktivitaet verschiedener Neurotransmittersysteme . Erste Studien unterstuetzen teilweise die Hypothese , dass Oestrogene in der Postmenopause eine Prophylaxe dementieller Erkrankungen insbesondere der Alzheimer Erkrankung , darstellen koennen . Oestrogene verbessern unter bestimmten Bedingungen verbale Faehigkeiten und Gedaechtnis im Alter und heben Stimmung und Befinden an . Fuer allgemeine Therapieempfehlungen hinsichtlich der Indikationen Demenzprophylaxe , Demenztherapie und Depression sind die vorliegenden Evidenzen aber noch nicht ausreichend . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Das Gehirn ist ein wichtiges Zielorgan fuer Gonadenhormone . Oestrogene haben neuroprotektive und neurotrophe Effekte und beeinflussen die Aktivitaet verschiedener Neurotransmittersysteme . Erste Studien unterstuetzen teilweise die Hypothese , dass Oestrogene in der Postmenopause eine Prophylaxe dementieller Erkrankungen insbesondere der Alzheimer Erkrankung , darstellen koennen . Oestrogene verbessern unter bestimmten Bedingungen verbale Faehigkeiten und Gedaechtnis im Alter und heben Stimmung und Befinden an . Fuer allgemeine Therapieempfehlungen hinsichtlich der Indikationen Demenzprophylaxe , Demenztherapie und Depression sind die vorliegenden Evidenzen aber noch nicht ausreichend .
[ "Das", "Gehirn", "ist", "ein", "wichtiges", "Zielorgan", "fuer", "Gonadenhormone", ".", "Oestrogene", "haben", "neuroprotektive", "und", "neurotrophe", "Effekte", "und", "beeinflussen", "die", "Aktivitaet", "verschiedener", "Neurotransmittersysteme", ".", "Erste", "Studien", "unterstuetzen", "teilweise", "die", "Hypothese", ",", "dass", "Oestrogene", "in", "der", "Postmenopause", "eine", "Prophylaxe", "dementieller", "Erkrankungen", "insbesondere", "der", "Alzheimer", "Erkrankung", ",", "darstellen", "koennen", ".", "Oestrogene", "verbessern", "unter", "bestimmten", "Bedingungen", "verbale", "Faehigkeiten", "und", "Gedaechtnis", "im", "Alter", "und", "heben", "Stimmung", "und", "Befinden", "an", ".", "Fuer", "allgemeine", "Therapieempfehlungen", "hinsichtlich", "der", "Indikationen", "Demenzprophylaxe", ",", "Demenztherapie", "und", "Depression", "sind", "die", "vorliegenden", "Evidenzen", "aber", "noch", "nicht", "ausreichend", "." ]
[ "umlsterm" ]
body mass index ( BMI ) is a Measurement, between 19 to 30 kg / m2 is a Value, body weight is a Measurement, 50 to 100 kg inclusive is a Value
NCT00812344_inc_task0
Sentence: body mass index (BMI) between 19 to 30 kg/m2 and body weight between 50 to 100 kg inclusive Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Measurement, Value
[ "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O" ]
body mass index (BMI) between 19 to 30 kg/m2 and body weight between 50 to 100 kg inclusive
[ "body", "mass", "index", "(", "BMI", ")", "between", "19", "to", "30", "kg", "/", "m2", "and", "body", "weight", "between", "50", "to", "100", "kg", "inclusive", "\n" ]
[ "Value", "Measurement" ]
body mass index ( BMI ) is a Measurement, between 19 to 30 kg / m2 is a Value, body weight is a Measurement, 50 to 100 kg inclusive is a Value
NCT00812344_inc_task1
Sentence: body mass index (BMI) between 19 to 30 kg/m2 and body weight between 50 to 100 kg inclusive Instructions: please typing these entity words according to sentence: body mass index ( BMI ), between 19 to 30 kg / m2, body weight, 50 to 100 kg inclusive Options: Measurement, Value
[ "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O" ]
body mass index (BMI) between 19 to 30 kg/m2 and body weight between 50 to 100 kg inclusive
[ "body", "mass", "index", "(", "BMI", ")", "between", "19", "to", "30", "kg", "/", "m2", "and", "body", "weight", "between", "50", "to", "100", "kg", "inclusive", "\n" ]
[ "Value", "Measurement" ]
body mass index ( BMI ), between 19 to 30 kg / m2, body weight, 50 to 100 kg inclusive
NCT00812344_inc_task2
Sentence: body mass index (BMI) between 19 to 30 kg/m2 and body weight between 50 to 100 kg inclusive Instructions: please extract entity words from the input sentence
[ "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O" ]
body mass index (BMI) between 19 to 30 kg/m2 and body weight between 50 to 100 kg inclusive
[ "body", "mass", "index", "(", "BMI", ")", "between", "19", "to", "30", "kg", "/", "m2", "and", "body", "weight", "between", "50", "to", "100", "kg", "inclusive", "\n" ]
[ "Value", "Measurement" ]
helicase - primase is a Protein_complex, UL5 is a Gene, UL52 is a Gene, UL8 is a Gene
339_task0
Sentence: Herpes simplex virus type 1 encodes a heterotrimeric helicase-primase complex that is composed of the products of the UL5, UL52, and UL8 genes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein_complex, Gene
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein_complex", "I-Protein_complex", "I-Protein_complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "B-Gene", "O", "O" ]
Herpes simplex virus type 1 encodes a heterotrimeric helicase-primase complex that is composed of the products of the UL5, UL52, and UL8 genes.
[ "Herpes", "simplex", "virus", "type", "1", "encodes", "a", "heterotrimeric", "helicase", "-", "primase", "complex", "that", "is", "composed", "of", "the", "products", "of", "the", "UL5", ",", "UL52", ",", "and", "UL8", "genes", "." ]
[ "Protein_complex", "Gene" ]
helicase - primase is a Protein_complex, UL5 is a Gene, UL52 is a Gene, UL8 is a Gene
339_task1
Sentence: Herpes simplex virus type 1 encodes a heterotrimeric helicase-primase complex that is composed of the products of the UL5, UL52, and UL8 genes. Instructions: please typing these entity words according to sentence: helicase - primase, UL5, UL52, UL8 Options: Protein_complex, Gene
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein_complex", "I-Protein_complex", "I-Protein_complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "B-Gene", "O", "O" ]
Herpes simplex virus type 1 encodes a heterotrimeric helicase-primase complex that is composed of the products of the UL5, UL52, and UL8 genes.
[ "Herpes", "simplex", "virus", "type", "1", "encodes", "a", "heterotrimeric", "helicase", "-", "primase", "complex", "that", "is", "composed", "of", "the", "products", "of", "the", "UL5", ",", "UL52", ",", "and", "UL8", "genes", "." ]
[ "Protein_complex", "Gene" ]
helicase - primase, UL5, UL52, UL8
339_task2
Sentence: Herpes simplex virus type 1 encodes a heterotrimeric helicase-primase complex that is composed of the products of the UL5, UL52, and UL8 genes. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein_complex", "I-Protein_complex", "I-Protein_complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "B-Gene", "O", "O" ]
Herpes simplex virus type 1 encodes a heterotrimeric helicase-primase complex that is composed of the products of the UL5, UL52, and UL8 genes.
[ "Herpes", "simplex", "virus", "type", "1", "encodes", "a", "heterotrimeric", "helicase", "-", "primase", "complex", "that", "is", "composed", "of", "the", "products", "of", "the", "UL5", ",", "UL52", ",", "and", "UL8", "genes", "." ]
[ "Protein_complex", "Gene" ]
Pyrin - only protein 2 is a Gene_or_gene_product, NF - kappaB is a Complex, NF - kappaB is a Complex, caspase-1 is a Gene_or_gene_product, IL-1beta is a Gene_or_gene_product, Pyrin - only proteins is a Gene_or_gene_product, POPs is a Gene_or_gene_product, NF - kappaB is a Complex, p65 is a Gene_or_gene_product, POP2 is a Gene_or_gene_product, POP2 is a Gene_or_gene_product, TNFalpha is a Gene_or_gene_product, IL-1beta is a Gene_or_gene_product, POP2 is a Gene_or_gene_product, NF - kappaB is a Complex, Glu(6 ) is a Simple_chemical, Asp(8 ) is a Simple_chemical, Glu(16 ) is a Simple_chemical, Pyrin is a Gene_or_gene_product, Pyrin is a Gene_or_gene_product, POP2 is a Gene_or_gene_product, NF - kappaB is a Complex, NF - kappaB is a Complex, POP2 is a Gene_or_gene_product, POP2 is a Gene_or_gene_product
222_task0
Sentence: Uncoupling of Pyrin-only protein 2 (POP2)-mediated dual regulation of NF-kappaB and the inflammasome. Activation of transcription factor NF-kappaB and inflammasome-directed caspase-1 cleavage of IL-1beta are key processes in the inflammatory response to pathogen or host-derived signals. Pyrin-only proteins (POPs) are restricted to Old World monkeys, apes, and humans and have previously been shown to impair inflammasome assembly and/or NF-kappaB p65 transcriptional activity in transfected epithelial cells. However, the biological role of POP2 and the molecular basis for its observed functions are not well understood. In this report we demonstrate that POP2 regulates TNFalpha and IL-1beta responses in human monocytic THP-1 cells and in stable transfectants of mouse J774A.1 macrophages. Deletion analysis of POP2 revealed that the first alpha-helix (residues 1-19) is necessary and sufficient for both inflammasome and NF-kappaB inhibitory functions. Further, key acidic residues Glu(6), Asp(8), and Glu(16), believed critical for Pyrin/Pyrin domain interaction, are important for inflammasome inhibition. Moreover, these mutations did not reduce the effect of POP2 upon NF-kappaB, indicating that the inflammasome and NF-kappaB inhibitory properties of POP2 can be uncoupled mechanistically. Collectively, these data demonstrate that POP2 acts as a regulator of inflammatory signals and exerts its two known functions through distinct modalities employed by its first alpha-helix. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Simple_chemical, Complex, Gene_or_gene_product
[ "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Uncoupling of Pyrin-only protein 2 (POP2)-mediated dual regulation of NF-kappaB and the inflammasome. Activation of transcription factor NF-kappaB and inflammasome-directed caspase-1 cleavage of IL-1beta are key processes in the inflammatory response to pathogen or host-derived signals. Pyrin-only proteins (POPs) are restricted to Old World monkeys, apes, and humans and have previously been shown to impair inflammasome assembly and/or NF-kappaB p65 transcriptional activity in transfected epithelial cells. However, the biological role of POP2 and the molecular basis for its observed functions are not well understood. In this report we demonstrate that POP2 regulates TNFalpha and IL-1beta responses in human monocytic THP-1 cells and in stable transfectants of mouse J774A.1 macrophages. Deletion analysis of POP2 revealed that the first alpha-helix (residues 1-19) is necessary and sufficient for both inflammasome and NF-kappaB inhibitory functions. Further, key acidic residues Glu(6), Asp(8), and Glu(16), believed critical for Pyrin/Pyrin domain interaction, are important for inflammasome inhibition. Moreover, these mutations did not reduce the effect of POP2 upon NF-kappaB, indicating that the inflammasome and NF-kappaB inhibitory properties of POP2 can be uncoupled mechanistically. Collectively, these data demonstrate that POP2 acts as a regulator of inflammatory signals and exerts its two known functions through distinct modalities employed by its first alpha-helix.
[ "Uncoupling", "of", "Pyrin", "-", "only", "protein", "2", "(", "POP2)-mediated", "dual", "regulation", "of", "NF", "-", "kappaB", "and", "the", "inflammasome", ".", "\n", "Activation", "of", "transcription", "factor", "NF", "-", "kappaB", "and", "inflammasome", "-", "directed", "caspase-1", "cleavage", "of", "IL-1beta", "are", "key", "processes", "in", "the", "inflammatory", "response", "to", "pathogen", "or", "host", "-", "derived", "signals", ".", "Pyrin", "-", "only", "proteins", "(", "POPs", ")", "are", "restricted", "to", "Old", "World", "monkeys", ",", "apes", ",", "and", "humans", "and", "have", "previously", "been", "shown", "to", "impair", "inflammasome", "assembly", "and", "/", "or", "NF", "-", "kappaB", "p65", "transcriptional", "activity", "in", "transfected", "epithelial", "cells", ".", "However", ",", "the", "biological", "role", "of", "POP2", "and", "the", "molecular", "basis", "for", "its", "observed", "functions", "are", "not", "well", "understood", ".", "In", "this", "report", "we", "demonstrate", "that", "POP2", "regulates", "TNFalpha", "and", "IL-1beta", "responses", "in", "human", "monocytic", "THP-1", "cells", "and", "in", "stable", "transfectants", "of", "mouse", "J774A.1", "macrophages", ".", "Deletion", "analysis", "of", "POP2", "revealed", "that", "the", "first", "alpha", "-", "helix", "(", "residues", "1", "-", "19", ")", "is", "necessary", "and", "sufficient", "for", "both", "inflammasome", "and", "NF", "-", "kappaB", "inhibitory", "functions", ".", "Further", ",", "key", "acidic", "residues", "Glu(6", ")", ",", "Asp(8", ")", ",", "and", "Glu(16", ")", ",", "believed", "critical", "for", "Pyrin", "/", "Pyrin", "domain", "interaction", ",", "are", "important", "for", "inflammasome", "inhibition", ".", "Moreover", ",", "these", "mutations", "did", "not", "reduce", "the", "effect", "of", "POP2", "upon", "NF", "-", "kappaB", ",", "indicating", "that", "the", "inflammasome", "and", "NF", "-", "kappaB", "inhibitory", "properties", "of", "POP2", "can", "be", "uncoupled", "mechanistically", ".", "Collectively", ",", "these", "data", "demonstrate", "that", "POP2", "acts", "as", "a", "regulator", "of", "inflammatory", "signals", "and", "exerts", "its", "two", "known", "functions", "through", "distinct", "modalities", "employed", "by", "its", "first", "alpha", "-", "helix", ".", "\n" ]
[ "Gene_or_gene_product", "Complex", "Simple_chemical" ]
Pyrin - only protein 2 is a Gene_or_gene_product, NF - kappaB is a Complex, NF - kappaB is a Complex, caspase-1 is a Gene_or_gene_product, IL-1beta is a Gene_or_gene_product, Pyrin - only proteins is a Gene_or_gene_product, POPs is a Gene_or_gene_product, NF - kappaB is a Complex, p65 is a Gene_or_gene_product, POP2 is a Gene_or_gene_product, POP2 is a Gene_or_gene_product, TNFalpha is a Gene_or_gene_product, IL-1beta is a Gene_or_gene_product, POP2 is a Gene_or_gene_product, NF - kappaB is a Complex, Glu(6 ) is a Simple_chemical, Asp(8 ) is a Simple_chemical, Glu(16 ) is a Simple_chemical, Pyrin is a Gene_or_gene_product, Pyrin is a Gene_or_gene_product, POP2 is a Gene_or_gene_product, NF - kappaB is a Complex, NF - kappaB is a Complex, POP2 is a Gene_or_gene_product, POP2 is a Gene_or_gene_product
222_task1
Sentence: Uncoupling of Pyrin-only protein 2 (POP2)-mediated dual regulation of NF-kappaB and the inflammasome. Activation of transcription factor NF-kappaB and inflammasome-directed caspase-1 cleavage of IL-1beta are key processes in the inflammatory response to pathogen or host-derived signals. Pyrin-only proteins (POPs) are restricted to Old World monkeys, apes, and humans and have previously been shown to impair inflammasome assembly and/or NF-kappaB p65 transcriptional activity in transfected epithelial cells. However, the biological role of POP2 and the molecular basis for its observed functions are not well understood. In this report we demonstrate that POP2 regulates TNFalpha and IL-1beta responses in human monocytic THP-1 cells and in stable transfectants of mouse J774A.1 macrophages. Deletion analysis of POP2 revealed that the first alpha-helix (residues 1-19) is necessary and sufficient for both inflammasome and NF-kappaB inhibitory functions. Further, key acidic residues Glu(6), Asp(8), and Glu(16), believed critical for Pyrin/Pyrin domain interaction, are important for inflammasome inhibition. Moreover, these mutations did not reduce the effect of POP2 upon NF-kappaB, indicating that the inflammasome and NF-kappaB inhibitory properties of POP2 can be uncoupled mechanistically. Collectively, these data demonstrate that POP2 acts as a regulator of inflammatory signals and exerts its two known functions through distinct modalities employed by its first alpha-helix. Instructions: please typing these entity words according to sentence: Pyrin - only protein 2, NF - kappaB, NF - kappaB, caspase-1, IL-1beta, Pyrin - only proteins, POPs, NF - kappaB, p65, POP2, POP2, TNFalpha, IL-1beta, POP2, NF - kappaB, Glu(6 ), Asp(8 ), Glu(16 ), Pyrin, Pyrin, POP2, NF - kappaB, NF - kappaB, POP2, POP2 Options: Simple_chemical, Complex, Gene_or_gene_product
[ "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Uncoupling of Pyrin-only protein 2 (POP2)-mediated dual regulation of NF-kappaB and the inflammasome. Activation of transcription factor NF-kappaB and inflammasome-directed caspase-1 cleavage of IL-1beta are key processes in the inflammatory response to pathogen or host-derived signals. Pyrin-only proteins (POPs) are restricted to Old World monkeys, apes, and humans and have previously been shown to impair inflammasome assembly and/or NF-kappaB p65 transcriptional activity in transfected epithelial cells. However, the biological role of POP2 and the molecular basis for its observed functions are not well understood. In this report we demonstrate that POP2 regulates TNFalpha and IL-1beta responses in human monocytic THP-1 cells and in stable transfectants of mouse J774A.1 macrophages. Deletion analysis of POP2 revealed that the first alpha-helix (residues 1-19) is necessary and sufficient for both inflammasome and NF-kappaB inhibitory functions. Further, key acidic residues Glu(6), Asp(8), and Glu(16), believed critical for Pyrin/Pyrin domain interaction, are important for inflammasome inhibition. Moreover, these mutations did not reduce the effect of POP2 upon NF-kappaB, indicating that the inflammasome and NF-kappaB inhibitory properties of POP2 can be uncoupled mechanistically. Collectively, these data demonstrate that POP2 acts as a regulator of inflammatory signals and exerts its two known functions through distinct modalities employed by its first alpha-helix.
[ "Uncoupling", "of", "Pyrin", "-", "only", "protein", "2", "(", "POP2)-mediated", "dual", "regulation", "of", "NF", "-", "kappaB", "and", "the", "inflammasome", ".", "\n", "Activation", "of", "transcription", "factor", "NF", "-", "kappaB", "and", "inflammasome", "-", "directed", "caspase-1", "cleavage", "of", "IL-1beta", "are", "key", "processes", "in", "the", "inflammatory", "response", "to", "pathogen", "or", "host", "-", "derived", "signals", ".", "Pyrin", "-", "only", "proteins", "(", "POPs", ")", "are", "restricted", "to", "Old", "World", "monkeys", ",", "apes", ",", "and", "humans", "and", "have", "previously", "been", "shown", "to", "impair", "inflammasome", "assembly", "and", "/", "or", "NF", "-", "kappaB", "p65", "transcriptional", "activity", "in", "transfected", "epithelial", "cells", ".", "However", ",", "the", "biological", "role", "of", "POP2", "and", "the", "molecular", "basis", "for", "its", "observed", "functions", "are", "not", "well", "understood", ".", "In", "this", "report", "we", "demonstrate", "that", "POP2", "regulates", "TNFalpha", "and", "IL-1beta", "responses", "in", "human", "monocytic", "THP-1", "cells", "and", "in", "stable", "transfectants", "of", "mouse", "J774A.1", "macrophages", ".", "Deletion", "analysis", "of", "POP2", "revealed", "that", "the", "first", "alpha", "-", "helix", "(", "residues", "1", "-", "19", ")", "is", "necessary", "and", "sufficient", "for", "both", "inflammasome", "and", "NF", "-", "kappaB", "inhibitory", "functions", ".", "Further", ",", "key", "acidic", "residues", "Glu(6", ")", ",", "Asp(8", ")", ",", "and", "Glu(16", ")", ",", "believed", "critical", "for", "Pyrin", "/", "Pyrin", "domain", "interaction", ",", "are", "important", "for", "inflammasome", "inhibition", ".", "Moreover", ",", "these", "mutations", "did", "not", "reduce", "the", "effect", "of", "POP2", "upon", "NF", "-", "kappaB", ",", "indicating", "that", "the", "inflammasome", "and", "NF", "-", "kappaB", "inhibitory", "properties", "of", "POP2", "can", "be", "uncoupled", "mechanistically", ".", "Collectively", ",", "these", "data", "demonstrate", "that", "POP2", "acts", "as", "a", "regulator", "of", "inflammatory", "signals", "and", "exerts", "its", "two", "known", "functions", "through", "distinct", "modalities", "employed", "by", "its", "first", "alpha", "-", "helix", ".", "\n" ]
[ "Gene_or_gene_product", "Complex", "Simple_chemical" ]
Pyrin - only protein 2, NF - kappaB, NF - kappaB, caspase-1, IL-1beta, Pyrin - only proteins, POPs, NF - kappaB, p65, POP2, POP2, TNFalpha, IL-1beta, POP2, NF - kappaB, Glu(6 ), Asp(8 ), Glu(16 ), Pyrin, Pyrin, POP2, NF - kappaB, NF - kappaB, POP2, POP2
222_task2
Sentence: Uncoupling of Pyrin-only protein 2 (POP2)-mediated dual regulation of NF-kappaB and the inflammasome. Activation of transcription factor NF-kappaB and inflammasome-directed caspase-1 cleavage of IL-1beta are key processes in the inflammatory response to pathogen or host-derived signals. Pyrin-only proteins (POPs) are restricted to Old World monkeys, apes, and humans and have previously been shown to impair inflammasome assembly and/or NF-kappaB p65 transcriptional activity in transfected epithelial cells. However, the biological role of POP2 and the molecular basis for its observed functions are not well understood. In this report we demonstrate that POP2 regulates TNFalpha and IL-1beta responses in human monocytic THP-1 cells and in stable transfectants of mouse J774A.1 macrophages. Deletion analysis of POP2 revealed that the first alpha-helix (residues 1-19) is necessary and sufficient for both inflammasome and NF-kappaB inhibitory functions. Further, key acidic residues Glu(6), Asp(8), and Glu(16), believed critical for Pyrin/Pyrin domain interaction, are important for inflammasome inhibition. Moreover, these mutations did not reduce the effect of POP2 upon NF-kappaB, indicating that the inflammasome and NF-kappaB inhibitory properties of POP2 can be uncoupled mechanistically. Collectively, these data demonstrate that POP2 acts as a regulator of inflammatory signals and exerts its two known functions through distinct modalities employed by its first alpha-helix. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Uncoupling of Pyrin-only protein 2 (POP2)-mediated dual regulation of NF-kappaB and the inflammasome. Activation of transcription factor NF-kappaB and inflammasome-directed caspase-1 cleavage of IL-1beta are key processes in the inflammatory response to pathogen or host-derived signals. Pyrin-only proteins (POPs) are restricted to Old World monkeys, apes, and humans and have previously been shown to impair inflammasome assembly and/or NF-kappaB p65 transcriptional activity in transfected epithelial cells. However, the biological role of POP2 and the molecular basis for its observed functions are not well understood. In this report we demonstrate that POP2 regulates TNFalpha and IL-1beta responses in human monocytic THP-1 cells and in stable transfectants of mouse J774A.1 macrophages. Deletion analysis of POP2 revealed that the first alpha-helix (residues 1-19) is necessary and sufficient for both inflammasome and NF-kappaB inhibitory functions. Further, key acidic residues Glu(6), Asp(8), and Glu(16), believed critical for Pyrin/Pyrin domain interaction, are important for inflammasome inhibition. Moreover, these mutations did not reduce the effect of POP2 upon NF-kappaB, indicating that the inflammasome and NF-kappaB inhibitory properties of POP2 can be uncoupled mechanistically. Collectively, these data demonstrate that POP2 acts as a regulator of inflammatory signals and exerts its two known functions through distinct modalities employed by its first alpha-helix.
[ "Uncoupling", "of", "Pyrin", "-", "only", "protein", "2", "(", "POP2)-mediated", "dual", "regulation", "of", "NF", "-", "kappaB", "and", "the", "inflammasome", ".", "\n", "Activation", "of", "transcription", "factor", "NF", "-", "kappaB", "and", "inflammasome", "-", "directed", "caspase-1", "cleavage", "of", "IL-1beta", "are", "key", "processes", "in", "the", "inflammatory", "response", "to", "pathogen", "or", "host", "-", "derived", "signals", ".", "Pyrin", "-", "only", "proteins", "(", "POPs", ")", "are", "restricted", "to", "Old", "World", "monkeys", ",", "apes", ",", "and", "humans", "and", "have", "previously", "been", "shown", "to", "impair", "inflammasome", "assembly", "and", "/", "or", "NF", "-", "kappaB", "p65", "transcriptional", "activity", "in", "transfected", "epithelial", "cells", ".", "However", ",", "the", "biological", "role", "of", "POP2", "and", "the", "molecular", "basis", "for", "its", "observed", "functions", "are", "not", "well", "understood", ".", "In", "this", "report", "we", "demonstrate", "that", "POP2", "regulates", "TNFalpha", "and", "IL-1beta", "responses", "in", "human", "monocytic", "THP-1", "cells", "and", "in", "stable", "transfectants", "of", "mouse", "J774A.1", "macrophages", ".", "Deletion", "analysis", "of", "POP2", "revealed", "that", "the", "first", "alpha", "-", "helix", "(", "residues", "1", "-", "19", ")", "is", "necessary", "and", "sufficient", "for", "both", "inflammasome", "and", "NF", "-", "kappaB", "inhibitory", "functions", ".", "Further", ",", "key", "acidic", "residues", "Glu(6", ")", ",", "Asp(8", ")", ",", "and", "Glu(16", ")", ",", "believed", "critical", "for", "Pyrin", "/", "Pyrin", "domain", "interaction", ",", "are", "important", "for", "inflammasome", "inhibition", ".", "Moreover", ",", "these", "mutations", "did", "not", "reduce", "the", "effect", "of", "POP2", "upon", "NF", "-", "kappaB", ",", "indicating", "that", "the", "inflammasome", "and", "NF", "-", "kappaB", "inhibitory", "properties", "of", "POP2", "can", "be", "uncoupled", "mechanistically", ".", "Collectively", ",", "these", "data", "demonstrate", "that", "POP2", "acts", "as", "a", "regulator", "of", "inflammatory", "signals", "and", "exerts", "its", "two", "known", "functions", "through", "distinct", "modalities", "employed", "by", "its", "first", "alpha", "-", "helix", ".", "\n" ]
[ "Gene_or_gene_product", "Complex", "Simple_chemical" ]
Trecator is a BRAND, isoniazid is a DRUG, Trecator is a BRAND, antituberculous drugs is a GROUP, ethionamide is a DRUG, cycloserine is a DRUG, ethanol is a DRUG
Ethionamide_ddi_task0
Sentence: Trecator has been found to temporarily raise serum concentrations of isoniazid. Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly. In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs. Excessive ethanol ingestion should be avoided because a psychotic reaction has been reported. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG, BRAND
[ "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Trecator has been found to temporarily raise serum concentrations of isoniazid. Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly. In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs. Excessive ethanol ingestion should be avoided because a psychotic reaction has been reported.
[ "Trecator", "has", "been", "found", "to", "temporarily", "raise", "serum", "concentrations", "of", "isoniazid", ".", "Trecator", "may", "potentiate", "the", "adverse", "effects", "of", "other", "antituberculous", "drugs", "administered", "concomitantly", ".", "In", "particular", ",", "convulsions", "have", "been", "reported", "when", "ethionamide", "is", "administered", "with", "cycloserine", "and", "special", "care", "should", "be", "taken", "when", "the", "treatment", "regimen", "includes", "both", "of", "these", "drugs", ".", "Excessive", "ethanol", "ingestion", "should", "be", "avoided", "because", "a", "psychotic", "reaction", "has", "been", "reported", "." ]
[ "GROUP", "DRUG", "BRAND" ]
Trecator is a BRAND, isoniazid is a DRUG, Trecator is a BRAND, antituberculous drugs is a GROUP, ethionamide is a DRUG, cycloserine is a DRUG, ethanol is a DRUG
Ethionamide_ddi_task1
Sentence: Trecator has been found to temporarily raise serum concentrations of isoniazid. Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly. In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs. Excessive ethanol ingestion should be avoided because a psychotic reaction has been reported. Instructions: please typing these entity words according to sentence: Trecator, isoniazid, Trecator, antituberculous drugs, ethionamide, cycloserine, ethanol Options: GROUP, DRUG, BRAND
[ "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Trecator has been found to temporarily raise serum concentrations of isoniazid. Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly. In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs. Excessive ethanol ingestion should be avoided because a psychotic reaction has been reported.
[ "Trecator", "has", "been", "found", "to", "temporarily", "raise", "serum", "concentrations", "of", "isoniazid", ".", "Trecator", "may", "potentiate", "the", "adverse", "effects", "of", "other", "antituberculous", "drugs", "administered", "concomitantly", ".", "In", "particular", ",", "convulsions", "have", "been", "reported", "when", "ethionamide", "is", "administered", "with", "cycloserine", "and", "special", "care", "should", "be", "taken", "when", "the", "treatment", "regimen", "includes", "both", "of", "these", "drugs", ".", "Excessive", "ethanol", "ingestion", "should", "be", "avoided", "because", "a", "psychotic", "reaction", "has", "been", "reported", "." ]
[ "GROUP", "DRUG", "BRAND" ]
Trecator, isoniazid, Trecator, antituberculous drugs, ethionamide, cycloserine, ethanol
Ethionamide_ddi_task2
Sentence: Trecator has been found to temporarily raise serum concentrations of isoniazid. Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly. In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs. Excessive ethanol ingestion should be avoided because a psychotic reaction has been reported. Instructions: please extract entity words from the input sentence
[ "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Trecator has been found to temporarily raise serum concentrations of isoniazid. Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly. In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs. Excessive ethanol ingestion should be avoided because a psychotic reaction has been reported.
[ "Trecator", "has", "been", "found", "to", "temporarily", "raise", "serum", "concentrations", "of", "isoniazid", ".", "Trecator", "may", "potentiate", "the", "adverse", "effects", "of", "other", "antituberculous", "drugs", "administered", "concomitantly", ".", "In", "particular", ",", "convulsions", "have", "been", "reported", "when", "ethionamide", "is", "administered", "with", "cycloserine", "and", "special", "care", "should", "be", "taken", "when", "the", "treatment", "regimen", "includes", "both", "of", "these", "drugs", ".", "Excessive", "ethanol", "ingestion", "should", "be", "avoided", "because", "a", "psychotic", "reaction", "has", "been", "reported", "." ]
[ "GROUP", "DRUG", "BRAND" ]
genistein is a CHEMICAL
23645249_task0
Sentence: Repression of mammary adipogenesis by genistein limits mammosphere formationof human MCF-7 cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL
[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]
Repression of mammary adipogenesis by genistein limits mammosphere formationof human MCF-7 cells.
[ "Repression", "of", "mammary", "adipogenesis", "by", "genistein", "limits", "mammosphere", "formationof", "human", "MCF-7", "cells", "." ]
[ "CHEMICAL", "GENE-Y" ]
genistein is a CHEMICAL
23645249_task1
Sentence: Repression of mammary adipogenesis by genistein limits mammosphere formationof human MCF-7 cells. Instructions: please typing these entity words according to sentence: genistein Options: CHEMICAL
[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]
Repression of mammary adipogenesis by genistein limits mammosphere formationof human MCF-7 cells.
[ "Repression", "of", "mammary", "adipogenesis", "by", "genistein", "limits", "mammosphere", "formationof", "human", "MCF-7", "cells", "." ]
[ "CHEMICAL", "GENE-Y" ]
genistein
23645249_task2
Sentence: Repression of mammary adipogenesis by genistein limits mammosphere formationof human MCF-7 cells. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]
Repression of mammary adipogenesis by genistein limits mammosphere formationof human MCF-7 cells.
[ "Repression", "of", "mammary", "adipogenesis", "by", "genistein", "limits", "mammosphere", "formationof", "human", "MCF-7", "cells", "." ]
[ "CHEMICAL", "GENE-Y" ]
CD4 is a Protein, IL-4 is a Protein, IL-5 is a Protein, IL-4 is a Protein, IL-5 is a Protein, IL-4 is a Protein, IL-5 is a Protein, p50 is a Protein, p50 is a Protein, p50 is a Protein, p65 is a Protein, p50 is a Protein, p65 is a Protein
8018594_task0
Sentence: Effects of prostaglandin E2 on Th0-type human T cell clones: modulation of functions of nuclear proteins involved in cytokine production. The effects of prostaglandin E2 (PGE2) on cytokine production and proliferation of the CD4+ human helper T cell clone SP-B21 were investigated. In cells stimulated with anti-CD3 mAb, PGE2 inhibited cell proliferation and the production of all the cytokines examined. Addition of rIL-2 fully restored the proliferative response and partially restored the production of IL-4 and IL-5, but not that of other cytokines. In contrast, in cells stimulated with phorbol myristate acetate (PMA)/A23187, PGE2 enhanced the production of IL-4 and IL-5, and only partially inhibited the production of other cytokines. Therefore, the effects of PGE2 vary depending on the mode of T cell activation, and the IL-4 and IL-5 are regulated differently from other cytokines. In a mobility shift assay, only the NF-kappa B (p50/p50) homodimer was observed in a complex formed with the kappa B sequence in unstimulated SP-B21 cells. When cells were stimulated with anti-CD3 mAb or PMA/A23187, a complex formation of NF-kappa B (p50/p65) heterodimer with the kappa B sequence was induced. Interestingly, PGE2 or di-butyryl (Bt2)cAMP abolished the binding of NF-kappa B (p50/p65) heterodimer to the kappa B sequence in cells stimulated with anti-CD3 mAb but not with PMA/A23187. Our results suggest that the target of PGE2 action is a component in the signal transduction pathway leading to the activation of protein kinase C. However, the inhibition of the T cell activation signals by PGE2 is selective. PGE2 enhanced the complex formation with NF-AT, AP-1 and CLE0 sequences when the cells were activated by either anti-CD3 mAb or PMA/A23187 stimulation. It seems therefore that PGE2, by elevating cAMP levels, interferes with the activation pathway for NF-kappa B but not for NF-AT, AP-1 or CLE0 binding protein. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Effects of prostaglandin E2 on Th0-type human T cell clones: modulation of functions of nuclear proteins involved in cytokine production. The effects of prostaglandin E2 (PGE2) on cytokine production and proliferation of the CD4+ human helper T cell clone SP-B21 were investigated. In cells stimulated with anti-CD3 mAb, PGE2 inhibited cell proliferation and the production of all the cytokines examined. Addition of rIL-2 fully restored the proliferative response and partially restored the production of IL-4 and IL-5, but not that of other cytokines. In contrast, in cells stimulated with phorbol myristate acetate (PMA)/A23187, PGE2 enhanced the production of IL-4 and IL-5, and only partially inhibited the production of other cytokines. Therefore, the effects of PGE2 vary depending on the mode of T cell activation, and the IL-4 and IL-5 are regulated differently from other cytokines. In a mobility shift assay, only the NF-kappa B (p50/p50) homodimer was observed in a complex formed with the kappa B sequence in unstimulated SP-B21 cells. When cells were stimulated with anti-CD3 mAb or PMA/A23187, a complex formation of NF-kappa B (p50/p65) heterodimer with the kappa B sequence was induced. Interestingly, PGE2 or di-butyryl (Bt2)cAMP abolished the binding of NF-kappa B (p50/p65) heterodimer to the kappa B sequence in cells stimulated with anti-CD3 mAb but not with PMA/A23187. Our results suggest that the target of PGE2 action is a component in the signal transduction pathway leading to the activation of protein kinase C. However, the inhibition of the T cell activation signals by PGE2 is selective. PGE2 enhanced the complex formation with NF-AT, AP-1 and CLE0 sequences when the cells were activated by either anti-CD3 mAb or PMA/A23187 stimulation. It seems therefore that PGE2, by elevating cAMP levels, interferes with the activation pathway for NF-kappa B but not for NF-AT, AP-1 or CLE0 binding protein.
[ "Effects", "of", "prostaglandin", "E2", "on", "Th0-type", "human", "T", "cell", "clones", ":", "modulation", "of", "functions", "of", "nuclear", "proteins", "involved", "in", "cytokine", "production", ".", "\n", "The", "effects", "of", "prostaglandin", "E2", "(", "PGE2", ")", "on", "cytokine", "production", "and", "proliferation", "of", "the", "CD4", "+", "human", "helper", "T", "cell", "clone", "SP", "-", "B21", "were", "investigated", ".", "In", "cells", "stimulated", "with", "anti", "-", "CD3", "mAb", ",", "PGE2", "inhibited", "cell", "proliferation", "and", "the", "production", "of", "all", "the", "cytokines", "examined", ".", "Addition", "of", "rIL-2", "fully", "restored", "the", "proliferative", "response", "and", "partially", "restored", "the", "production", "of", "IL-4", "and", "IL-5", ",", "but", "not", "that", "of", "other", "cytokines", ".", "In", "contrast", ",", "in", "cells", "stimulated", "with", "phorbol", "myristate", "acetate", "(", "PMA)/A23187", ",", "PGE2", "enhanced", "the", "production", "of", "IL-4", "and", "IL-5", ",", "and", "only", "partially", "inhibited", "the", "production", "of", "other", "cytokines", ".", "Therefore", ",", "the", "effects", "of", "PGE2", "vary", "depending", "on", "the", "mode", "of", "T", "cell", "activation", ",", "and", "the", "IL-4", "and", "IL-5", "are", "regulated", "differently", "from", "other", "cytokines", ".", "In", "a", "mobility", "shift", "assay", ",", "only", "the", "NF", "-", "kappa", "B", "(", "p50", "/", "p50", ")", "homodimer", "was", "observed", "in", "a", "complex", "formed", "with", "the", "kappa", "B", "sequence", "in", "unstimulated", "SP", "-", "B21", "cells", ".", "When", "cells", "were", "stimulated", "with", "anti", "-", "CD3", "mAb", "or", "PMA", "/", "A23187", ",", "a", "complex", "formation", "of", "NF", "-", "kappa", "B", "(", "p50", "/", "p65", ")", "heterodimer", "with", "the", "kappa", "B", "sequence", "was", "induced", ".", "Interestingly", ",", "PGE2", "or", "di", "-", "butyryl", "(", "Bt2)cAMP", "abolished", "the", "binding", "of", "NF", "-", "kappa", "B", "(", "p50", "/", "p65", ")", "heterodimer", "to", "the", "kappa", "B", "sequence", "in", "cells", "stimulated", "with", "anti", "-", "CD3", "mAb", "but", "not", "with", "PMA", "/", "A23187", ".", "Our", "results", "suggest", "that", "the", "target", "of", "PGE2", "action", "is", "a", "component", "in", "the", "signal", "transduction", "pathway", "leading", "to", "the", "activation", "of", "protein", "kinase", "C.", "However", ",", "the", "inhibition", "of", "the", "T", "cell", "activation", "signals", "by", "PGE2", "is", "selective", ".", "PGE2", "enhanced", "the", "complex", "formation", "with", "NF", "-", "AT", ",", "AP-1", "and", "CLE0", "sequences", "when", "the", "cells", "were", "activated", "by", "either", "anti", "-", "CD3", "mAb", "or", "PMA", "/", "A23187", "stimulation", ".", "It", "seems", "therefore", "that", "PGE2", ",", "by", "elevating", "cAMP", "levels", ",", "interferes", "with", "the", "activation", "pathway", "for", "NF", "-", "kappa", "B", "but", "not", "for", "NF", "-", "AT", ",", "AP-1", "or", "CLE0", "binding", "protein", "." ]
[ "Protein" ]
CD4 is a Protein, IL-4 is a Protein, IL-5 is a Protein, IL-4 is a Protein, IL-5 is a Protein, IL-4 is a Protein, IL-5 is a Protein, p50 is a Protein, p50 is a Protein, p50 is a Protein, p65 is a Protein, p50 is a Protein, p65 is a Protein
8018594_task1
Sentence: Effects of prostaglandin E2 on Th0-type human T cell clones: modulation of functions of nuclear proteins involved in cytokine production. The effects of prostaglandin E2 (PGE2) on cytokine production and proliferation of the CD4+ human helper T cell clone SP-B21 were investigated. In cells stimulated with anti-CD3 mAb, PGE2 inhibited cell proliferation and the production of all the cytokines examined. Addition of rIL-2 fully restored the proliferative response and partially restored the production of IL-4 and IL-5, but not that of other cytokines. In contrast, in cells stimulated with phorbol myristate acetate (PMA)/A23187, PGE2 enhanced the production of IL-4 and IL-5, and only partially inhibited the production of other cytokines. Therefore, the effects of PGE2 vary depending on the mode of T cell activation, and the IL-4 and IL-5 are regulated differently from other cytokines. In a mobility shift assay, only the NF-kappa B (p50/p50) homodimer was observed in a complex formed with the kappa B sequence in unstimulated SP-B21 cells. When cells were stimulated with anti-CD3 mAb or PMA/A23187, a complex formation of NF-kappa B (p50/p65) heterodimer with the kappa B sequence was induced. Interestingly, PGE2 or di-butyryl (Bt2)cAMP abolished the binding of NF-kappa B (p50/p65) heterodimer to the kappa B sequence in cells stimulated with anti-CD3 mAb but not with PMA/A23187. Our results suggest that the target of PGE2 action is a component in the signal transduction pathway leading to the activation of protein kinase C. However, the inhibition of the T cell activation signals by PGE2 is selective. PGE2 enhanced the complex formation with NF-AT, AP-1 and CLE0 sequences when the cells were activated by either anti-CD3 mAb or PMA/A23187 stimulation. It seems therefore that PGE2, by elevating cAMP levels, interferes with the activation pathway for NF-kappa B but not for NF-AT, AP-1 or CLE0 binding protein. Instructions: please typing these entity words according to sentence: CD4, IL-4, IL-5, IL-4, IL-5, IL-4, IL-5, p50, p50, p50, p65, p50, p65 Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Effects of prostaglandin E2 on Th0-type human T cell clones: modulation of functions of nuclear proteins involved in cytokine production. The effects of prostaglandin E2 (PGE2) on cytokine production and proliferation of the CD4+ human helper T cell clone SP-B21 were investigated. In cells stimulated with anti-CD3 mAb, PGE2 inhibited cell proliferation and the production of all the cytokines examined. Addition of rIL-2 fully restored the proliferative response and partially restored the production of IL-4 and IL-5, but not that of other cytokines. In contrast, in cells stimulated with phorbol myristate acetate (PMA)/A23187, PGE2 enhanced the production of IL-4 and IL-5, and only partially inhibited the production of other cytokines. Therefore, the effects of PGE2 vary depending on the mode of T cell activation, and the IL-4 and IL-5 are regulated differently from other cytokines. In a mobility shift assay, only the NF-kappa B (p50/p50) homodimer was observed in a complex formed with the kappa B sequence in unstimulated SP-B21 cells. When cells were stimulated with anti-CD3 mAb or PMA/A23187, a complex formation of NF-kappa B (p50/p65) heterodimer with the kappa B sequence was induced. Interestingly, PGE2 or di-butyryl (Bt2)cAMP abolished the binding of NF-kappa B (p50/p65) heterodimer to the kappa B sequence in cells stimulated with anti-CD3 mAb but not with PMA/A23187. Our results suggest that the target of PGE2 action is a component in the signal transduction pathway leading to the activation of protein kinase C. However, the inhibition of the T cell activation signals by PGE2 is selective. PGE2 enhanced the complex formation with NF-AT, AP-1 and CLE0 sequences when the cells were activated by either anti-CD3 mAb or PMA/A23187 stimulation. It seems therefore that PGE2, by elevating cAMP levels, interferes with the activation pathway for NF-kappa B but not for NF-AT, AP-1 or CLE0 binding protein.
[ "Effects", "of", "prostaglandin", "E2", "on", "Th0-type", "human", "T", "cell", "clones", ":", "modulation", "of", "functions", "of", "nuclear", "proteins", "involved", "in", "cytokine", "production", ".", "\n", "The", "effects", "of", "prostaglandin", "E2", "(", "PGE2", ")", "on", "cytokine", "production", "and", "proliferation", "of", "the", "CD4", "+", "human", "helper", "T", "cell", "clone", "SP", "-", "B21", "were", "investigated", ".", "In", "cells", "stimulated", "with", "anti", "-", "CD3", "mAb", ",", "PGE2", "inhibited", "cell", "proliferation", "and", "the", "production", "of", "all", "the", "cytokines", "examined", ".", "Addition", "of", "rIL-2", "fully", "restored", "the", "proliferative", "response", "and", "partially", "restored", "the", "production", "of", "IL-4", "and", "IL-5", ",", "but", "not", "that", "of", "other", "cytokines", ".", "In", "contrast", ",", "in", "cells", "stimulated", "with", "phorbol", "myristate", "acetate", "(", "PMA)/A23187", ",", "PGE2", "enhanced", "the", "production", "of", "IL-4", "and", "IL-5", ",", "and", "only", "partially", "inhibited", "the", "production", "of", "other", "cytokines", ".", "Therefore", ",", "the", "effects", "of", "PGE2", "vary", "depending", "on", "the", "mode", "of", "T", "cell", "activation", ",", "and", "the", "IL-4", "and", "IL-5", "are", "regulated", "differently", "from", "other", "cytokines", ".", "In", "a", "mobility", "shift", "assay", ",", "only", "the", "NF", "-", "kappa", "B", "(", "p50", "/", "p50", ")", "homodimer", "was", "observed", "in", "a", "complex", "formed", "with", "the", "kappa", "B", "sequence", "in", "unstimulated", "SP", "-", "B21", "cells", ".", "When", "cells", "were", "stimulated", "with", "anti", "-", "CD3", "mAb", "or", "PMA", "/", "A23187", ",", "a", "complex", "formation", "of", "NF", "-", "kappa", "B", "(", "p50", "/", "p65", ")", "heterodimer", "with", "the", "kappa", "B", "sequence", "was", "induced", ".", "Interestingly", ",", "PGE2", "or", "di", "-", "butyryl", "(", "Bt2)cAMP", "abolished", "the", "binding", "of", "NF", "-", "kappa", "B", "(", "p50", "/", "p65", ")", "heterodimer", "to", "the", "kappa", "B", "sequence", "in", "cells", "stimulated", "with", "anti", "-", "CD3", "mAb", "but", "not", "with", "PMA", "/", "A23187", ".", "Our", "results", "suggest", "that", "the", "target", "of", "PGE2", "action", "is", "a", "component", "in", "the", "signal", "transduction", "pathway", "leading", "to", "the", "activation", "of", "protein", "kinase", "C.", "However", ",", "the", "inhibition", "of", "the", "T", "cell", "activation", "signals", "by", "PGE2", "is", "selective", ".", "PGE2", "enhanced", "the", "complex", "formation", "with", "NF", "-", "AT", ",", "AP-1", "and", "CLE0", "sequences", "when", "the", "cells", "were", "activated", "by", "either", "anti", "-", "CD3", "mAb", "or", "PMA", "/", "A23187", "stimulation", ".", "It", "seems", "therefore", "that", "PGE2", ",", "by", "elevating", "cAMP", "levels", ",", "interferes", "with", "the", "activation", "pathway", "for", "NF", "-", "kappa", "B", "but", "not", "for", "NF", "-", "AT", ",", "AP-1", "or", "CLE0", "binding", "protein", "." ]
[ "Protein" ]
CD4, IL-4, IL-5, IL-4, IL-5, IL-4, IL-5, p50, p50, p50, p65, p50, p65
8018594_task2
Sentence: Effects of prostaglandin E2 on Th0-type human T cell clones: modulation of functions of nuclear proteins involved in cytokine production. The effects of prostaglandin E2 (PGE2) on cytokine production and proliferation of the CD4+ human helper T cell clone SP-B21 were investigated. In cells stimulated with anti-CD3 mAb, PGE2 inhibited cell proliferation and the production of all the cytokines examined. Addition of rIL-2 fully restored the proliferative response and partially restored the production of IL-4 and IL-5, but not that of other cytokines. In contrast, in cells stimulated with phorbol myristate acetate (PMA)/A23187, PGE2 enhanced the production of IL-4 and IL-5, and only partially inhibited the production of other cytokines. Therefore, the effects of PGE2 vary depending on the mode of T cell activation, and the IL-4 and IL-5 are regulated differently from other cytokines. In a mobility shift assay, only the NF-kappa B (p50/p50) homodimer was observed in a complex formed with the kappa B sequence in unstimulated SP-B21 cells. When cells were stimulated with anti-CD3 mAb or PMA/A23187, a complex formation of NF-kappa B (p50/p65) heterodimer with the kappa B sequence was induced. Interestingly, PGE2 or di-butyryl (Bt2)cAMP abolished the binding of NF-kappa B (p50/p65) heterodimer to the kappa B sequence in cells stimulated with anti-CD3 mAb but not with PMA/A23187. Our results suggest that the target of PGE2 action is a component in the signal transduction pathway leading to the activation of protein kinase C. However, the inhibition of the T cell activation signals by PGE2 is selective. PGE2 enhanced the complex formation with NF-AT, AP-1 and CLE0 sequences when the cells were activated by either anti-CD3 mAb or PMA/A23187 stimulation. It seems therefore that PGE2, by elevating cAMP levels, interferes with the activation pathway for NF-kappa B but not for NF-AT, AP-1 or CLE0 binding protein. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Effects of prostaglandin E2 on Th0-type human T cell clones: modulation of functions of nuclear proteins involved in cytokine production. The effects of prostaglandin E2 (PGE2) on cytokine production and proliferation of the CD4+ human helper T cell clone SP-B21 were investigated. In cells stimulated with anti-CD3 mAb, PGE2 inhibited cell proliferation and the production of all the cytokines examined. Addition of rIL-2 fully restored the proliferative response and partially restored the production of IL-4 and IL-5, but not that of other cytokines. In contrast, in cells stimulated with phorbol myristate acetate (PMA)/A23187, PGE2 enhanced the production of IL-4 and IL-5, and only partially inhibited the production of other cytokines. Therefore, the effects of PGE2 vary depending on the mode of T cell activation, and the IL-4 and IL-5 are regulated differently from other cytokines. In a mobility shift assay, only the NF-kappa B (p50/p50) homodimer was observed in a complex formed with the kappa B sequence in unstimulated SP-B21 cells. When cells were stimulated with anti-CD3 mAb or PMA/A23187, a complex formation of NF-kappa B (p50/p65) heterodimer with the kappa B sequence was induced. Interestingly, PGE2 or di-butyryl (Bt2)cAMP abolished the binding of NF-kappa B (p50/p65) heterodimer to the kappa B sequence in cells stimulated with anti-CD3 mAb but not with PMA/A23187. Our results suggest that the target of PGE2 action is a component in the signal transduction pathway leading to the activation of protein kinase C. However, the inhibition of the T cell activation signals by PGE2 is selective. PGE2 enhanced the complex formation with NF-AT, AP-1 and CLE0 sequences when the cells were activated by either anti-CD3 mAb or PMA/A23187 stimulation. It seems therefore that PGE2, by elevating cAMP levels, interferes with the activation pathway for NF-kappa B but not for NF-AT, AP-1 or CLE0 binding protein.
[ "Effects", "of", "prostaglandin", "E2", "on", "Th0-type", "human", "T", "cell", "clones", ":", "modulation", "of", "functions", "of", "nuclear", "proteins", "involved", "in", "cytokine", "production", ".", "\n", "The", "effects", "of", "prostaglandin", "E2", "(", "PGE2", ")", "on", "cytokine", "production", "and", "proliferation", "of", "the", "CD4", "+", "human", "helper", "T", "cell", "clone", "SP", "-", "B21", "were", "investigated", ".", "In", "cells", "stimulated", "with", "anti", "-", "CD3", "mAb", ",", "PGE2", "inhibited", "cell", "proliferation", "and", "the", "production", "of", "all", "the", "cytokines", "examined", ".", "Addition", "of", "rIL-2", "fully", "restored", "the", "proliferative", "response", "and", "partially", "restored", "the", "production", "of", "IL-4", "and", "IL-5", ",", "but", "not", "that", "of", "other", "cytokines", ".", "In", "contrast", ",", "in", "cells", "stimulated", "with", "phorbol", "myristate", "acetate", "(", "PMA)/A23187", ",", "PGE2", "enhanced", "the", "production", "of", "IL-4", "and", "IL-5", ",", "and", "only", "partially", "inhibited", "the", "production", "of", "other", "cytokines", ".", "Therefore", ",", "the", "effects", "of", "PGE2", "vary", "depending", "on", "the", "mode", "of", "T", "cell", "activation", ",", "and", "the", "IL-4", "and", "IL-5", "are", "regulated", "differently", "from", "other", "cytokines", ".", "In", "a", "mobility", "shift", "assay", ",", "only", "the", "NF", "-", "kappa", "B", "(", "p50", "/", "p50", ")", "homodimer", "was", "observed", "in", "a", "complex", "formed", "with", "the", "kappa", "B", "sequence", "in", "unstimulated", "SP", "-", "B21", "cells", ".", "When", "cells", "were", "stimulated", "with", "anti", "-", "CD3", "mAb", "or", "PMA", "/", "A23187", ",", "a", "complex", "formation", "of", "NF", "-", "kappa", "B", "(", "p50", "/", "p65", ")", "heterodimer", "with", "the", "kappa", "B", "sequence", "was", "induced", ".", "Interestingly", ",", "PGE2", "or", "di", "-", "butyryl", "(", "Bt2)cAMP", "abolished", "the", "binding", "of", "NF", "-", "kappa", "B", "(", "p50", "/", "p65", ")", "heterodimer", "to", "the", "kappa", "B", "sequence", "in", "cells", "stimulated", "with", "anti", "-", "CD3", "mAb", "but", "not", "with", "PMA", "/", "A23187", ".", "Our", "results", "suggest", "that", "the", "target", "of", "PGE2", "action", "is", "a", "component", "in", "the", "signal", "transduction", "pathway", "leading", "to", "the", "activation", "of", "protein", "kinase", "C.", "However", ",", "the", "inhibition", "of", "the", "T", "cell", "activation", "signals", "by", "PGE2", "is", "selective", ".", "PGE2", "enhanced", "the", "complex", "formation", "with", "NF", "-", "AT", ",", "AP-1", "and", "CLE0", "sequences", "when", "the", "cells", "were", "activated", "by", "either", "anti", "-", "CD3", "mAb", "or", "PMA", "/", "A23187", "stimulation", ".", "It", "seems", "therefore", "that", "PGE2", ",", "by", "elevating", "cAMP", "levels", ",", "interferes", "with", "the", "activation", "pathway", "for", "NF", "-", "kappa", "B", "but", "not", "for", "NF", "-", "AT", ",", "AP-1", "or", "CLE0", "binding", "protein", "." ]
[ "Protein" ]
postoperative pain is a Participant_Condition, total knee arthroplasty is a Participant_Condition, Transcutaneous electrical nerve stimulation ( TENS ) is a Intervention_Control, cumulative dose of morphine is a Outcome_Physical, requirement for patient - controlled analgesia is a Outcome_Pain
15873_task0
Sentence: Transcutaneous electrical nerve stimulation for postoperative pain relief after total knee arthroplasty . Transcutaneous electrical nerve stimulation ( TENS ) has been used to treat chronic pain syndromes and has been reported to be of some utility in the treatment of postsurgical pain . A randomized , blinded , placebo-controlled trial was designed to evaluate the utility of TENS after total knee arthroplasty . Patients were randomly enrolled into patient-controlled anesthesia ( PCA ) alone , PCA plus TENS , or PCA plus sham TENS . The cumulative dose of morphine by PCA for each group was used as the end-point of the study . There was no significant reduction in the requirement for patient-controlled analgesia with or without TENS . We conclude that there is no utility for TENS in the postoperative management of pain after knee arthroplasty . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Pain, Intervention_Control, Outcome_Physical, Participant_Condition
[ "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Transcutaneous electrical nerve stimulation for postoperative pain relief after total knee arthroplasty . Transcutaneous electrical nerve stimulation ( TENS ) has been used to treat chronic pain syndromes and has been reported to be of some utility in the treatment of postsurgical pain . A randomized , blinded , placebo-controlled trial was designed to evaluate the utility of TENS after total knee arthroplasty . Patients were randomly enrolled into patient-controlled anesthesia ( PCA ) alone , PCA plus TENS , or PCA plus sham TENS . The cumulative dose of morphine by PCA for each group was used as the end-point of the study . There was no significant reduction in the requirement for patient-controlled analgesia with or without TENS . We conclude that there is no utility for TENS in the postoperative management of pain after knee arthroplasty .
[ "Transcutaneous", "electrical", "nerve", "stimulation", "for", "postoperative", "pain", "relief", "after", "total", "knee", "arthroplasty", ".", "Transcutaneous", "electrical", "nerve", "stimulation", "(", "TENS", ")", "has", "been", "used", "to", "treat", "chronic", "pain", "syndromes", "and", "has", "been", "reported", "to", "be", "of", "some", "utility", "in", "the", "treatment", "of", "postsurgical", "pain", ".", "A", "randomized", ",", "blinded", ",", "placebo", "-", "controlled", "trial", "was", "designed", "to", "evaluate", "the", "utility", "of", "TENS", "after", "total", "knee", "arthroplasty", ".", "Patients", "were", "randomly", "enrolled", "into", "patient", "-", "controlled", "anesthesia", "(", "PCA", ")", "alone", ",", "PCA", "plus", "TENS", ",", "or", "PCA", "plus", "sham", "TENS", ".", "The", "cumulative", "dose", "of", "morphine", "by", "PCA", "for", "each", "group", "was", "used", "as", "the", "end", "-", "point", "of", "the", "study", ".", "There", "was", "no", "significant", "reduction", "in", "the", "requirement", "for", "patient", "-", "controlled", "analgesia", "with", "or", "without", "TENS", ".", "We", "conclude", "that", "there", "is", "no", "utility", "for", "TENS", "in", "the", "postoperative", "management", "of", "pain", "after", "knee", "arthroplasty", "." ]
[ "Intervention_Control", "Outcome_Pain", "Outcome_Physical", "Participant_Condition" ]
postoperative pain is a Participant_Condition, total knee arthroplasty is a Participant_Condition, Transcutaneous electrical nerve stimulation ( TENS ) is a Intervention_Control, cumulative dose of morphine is a Outcome_Physical, requirement for patient - controlled analgesia is a Outcome_Pain
15873_task1
Sentence: Transcutaneous electrical nerve stimulation for postoperative pain relief after total knee arthroplasty . Transcutaneous electrical nerve stimulation ( TENS ) has been used to treat chronic pain syndromes and has been reported to be of some utility in the treatment of postsurgical pain . A randomized , blinded , placebo-controlled trial was designed to evaluate the utility of TENS after total knee arthroplasty . Patients were randomly enrolled into patient-controlled anesthesia ( PCA ) alone , PCA plus TENS , or PCA plus sham TENS . The cumulative dose of morphine by PCA for each group was used as the end-point of the study . There was no significant reduction in the requirement for patient-controlled analgesia with or without TENS . We conclude that there is no utility for TENS in the postoperative management of pain after knee arthroplasty . Instructions: please typing these entity words according to sentence: postoperative pain, total knee arthroplasty, Transcutaneous electrical nerve stimulation ( TENS ), cumulative dose of morphine, requirement for patient - controlled analgesia Options: Outcome_Pain, Intervention_Control, Outcome_Physical, Participant_Condition
[ "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Transcutaneous electrical nerve stimulation for postoperative pain relief after total knee arthroplasty . Transcutaneous electrical nerve stimulation ( TENS ) has been used to treat chronic pain syndromes and has been reported to be of some utility in the treatment of postsurgical pain . A randomized , blinded , placebo-controlled trial was designed to evaluate the utility of TENS after total knee arthroplasty . Patients were randomly enrolled into patient-controlled anesthesia ( PCA ) alone , PCA plus TENS , or PCA plus sham TENS . The cumulative dose of morphine by PCA for each group was used as the end-point of the study . There was no significant reduction in the requirement for patient-controlled analgesia with or without TENS . We conclude that there is no utility for TENS in the postoperative management of pain after knee arthroplasty .
[ "Transcutaneous", "electrical", "nerve", "stimulation", "for", "postoperative", "pain", "relief", "after", "total", "knee", "arthroplasty", ".", "Transcutaneous", "electrical", "nerve", "stimulation", "(", "TENS", ")", "has", "been", "used", "to", "treat", "chronic", "pain", "syndromes", "and", "has", "been", "reported", "to", "be", "of", "some", "utility", "in", "the", "treatment", "of", "postsurgical", "pain", ".", "A", "randomized", ",", "blinded", ",", "placebo", "-", "controlled", "trial", "was", "designed", "to", "evaluate", "the", "utility", "of", "TENS", "after", "total", "knee", "arthroplasty", ".", "Patients", "were", "randomly", "enrolled", "into", "patient", "-", "controlled", "anesthesia", "(", "PCA", ")", "alone", ",", "PCA", "plus", "TENS", ",", "or", "PCA", "plus", "sham", "TENS", ".", "The", "cumulative", "dose", "of", "morphine", "by", "PCA", "for", "each", "group", "was", "used", "as", "the", "end", "-", "point", "of", "the", "study", ".", "There", "was", "no", "significant", "reduction", "in", "the", "requirement", "for", "patient", "-", "controlled", "analgesia", "with", "or", "without", "TENS", ".", "We", "conclude", "that", "there", "is", "no", "utility", "for", "TENS", "in", "the", "postoperative", "management", "of", "pain", "after", "knee", "arthroplasty", "." ]
[ "Intervention_Control", "Outcome_Pain", "Outcome_Physical", "Participant_Condition" ]
postoperative pain, total knee arthroplasty, Transcutaneous electrical nerve stimulation ( TENS ), cumulative dose of morphine, requirement for patient - controlled analgesia
15873_task2
Sentence: Transcutaneous electrical nerve stimulation for postoperative pain relief after total knee arthroplasty . Transcutaneous electrical nerve stimulation ( TENS ) has been used to treat chronic pain syndromes and has been reported to be of some utility in the treatment of postsurgical pain . A randomized , blinded , placebo-controlled trial was designed to evaluate the utility of TENS after total knee arthroplasty . Patients were randomly enrolled into patient-controlled anesthesia ( PCA ) alone , PCA plus TENS , or PCA plus sham TENS . The cumulative dose of morphine by PCA for each group was used as the end-point of the study . There was no significant reduction in the requirement for patient-controlled analgesia with or without TENS . We conclude that there is no utility for TENS in the postoperative management of pain after knee arthroplasty . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Transcutaneous electrical nerve stimulation for postoperative pain relief after total knee arthroplasty . Transcutaneous electrical nerve stimulation ( TENS ) has been used to treat chronic pain syndromes and has been reported to be of some utility in the treatment of postsurgical pain . A randomized , blinded , placebo-controlled trial was designed to evaluate the utility of TENS after total knee arthroplasty . Patients were randomly enrolled into patient-controlled anesthesia ( PCA ) alone , PCA plus TENS , or PCA plus sham TENS . The cumulative dose of morphine by PCA for each group was used as the end-point of the study . There was no significant reduction in the requirement for patient-controlled analgesia with or without TENS . We conclude that there is no utility for TENS in the postoperative management of pain after knee arthroplasty .
[ "Transcutaneous", "electrical", "nerve", "stimulation", "for", "postoperative", "pain", "relief", "after", "total", "knee", "arthroplasty", ".", "Transcutaneous", "electrical", "nerve", "stimulation", "(", "TENS", ")", "has", "been", "used", "to", "treat", "chronic", "pain", "syndromes", "and", "has", "been", "reported", "to", "be", "of", "some", "utility", "in", "the", "treatment", "of", "postsurgical", "pain", ".", "A", "randomized", ",", "blinded", ",", "placebo", "-", "controlled", "trial", "was", "designed", "to", "evaluate", "the", "utility", "of", "TENS", "after", "total", "knee", "arthroplasty", ".", "Patients", "were", "randomly", "enrolled", "into", "patient", "-", "controlled", "anesthesia", "(", "PCA", ")", "alone", ",", "PCA", "plus", "TENS", ",", "or", "PCA", "plus", "sham", "TENS", ".", "The", "cumulative", "dose", "of", "morphine", "by", "PCA", "for", "each", "group", "was", "used", "as", "the", "end", "-", "point", "of", "the", "study", ".", "There", "was", "no", "significant", "reduction", "in", "the", "requirement", "for", "patient", "-", "controlled", "analgesia", "with", "or", "without", "TENS", ".", "We", "conclude", "that", "there", "is", "no", "utility", "for", "TENS", "in", "the", "postoperative", "management", "of", "pain", "after", "knee", "arthroplasty", "." ]
[ "Intervention_Control", "Outcome_Pain", "Outcome_Physical", "Participant_Condition" ]
Age is a Person, ≥ 18 years is a Value, breast cancer is a Condition, histologically proven , metastatic or locally advanced is a Scope, Eribulin is a Drug, between January and October 2014 ( for the retrospective part ) or between November 2014 and September 2015 ( for the prospective part ) is a Scope, assessment of the response is a Procedure, Eribulin is a Drug
NCT02393287_inc_task0
Sentence: 1. Age ≥ 18 years 2. Patient with breast cancer, histologically proven, metastatic or locally advanced 3. Patient treated by Eribulin between January and October 2014 (for the retrospective part) or between November 2014 and September 2015 (for the prospective part). 4. Patient with at least an assessment of the response to Eribulin Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Value, Person, Procedure, Scope, Drug
[ "O", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Drug", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "B-Drug", "O" ]
1. Age ≥ 18 years 2. Patient with breast cancer, histologically proven, metastatic or locally advanced 3. Patient treated by Eribulin between January and October 2014 (for the retrospective part) or between November 2014 and September 2015 (for the prospective part). 4. Patient with at least an assessment of the response to Eribulin
[ "1", ".", "Age", "≥", "18", "years", "\n", "2", ".", "Patient", "with", "breast", "cancer", ",", "histologically", "proven", ",", "metastatic", "or", "locally", "advanced", "\n", "3", ".", "Patient", "treated", "by", "Eribulin", "between", "January", "and", "October", "2014", "(", "for", "the", "retrospective", "part", ")", "or", "between", "November", "2014", "and", "September", "2015", "(", "for", "the", "prospective", "part", ")", ".", "\n", "4", ".", "Patient", "with", "at", "least", "an", "assessment", "of", "the", "response", "to", "Eribulin", "\n" ]
[ "Scope", "Temporal", "Procedure", "Qualifier", "Condition", "Value", "Drug", "Person" ]
Age is a Person, ≥ 18 years is a Value, breast cancer is a Condition, histologically proven , metastatic or locally advanced is a Scope, Eribulin is a Drug, between January and October 2014 ( for the retrospective part ) or between November 2014 and September 2015 ( for the prospective part ) is a Scope, assessment of the response is a Procedure, Eribulin is a Drug
NCT02393287_inc_task1
Sentence: 1. Age ≥ 18 years 2. Patient with breast cancer, histologically proven, metastatic or locally advanced 3. Patient treated by Eribulin between January and October 2014 (for the retrospective part) or between November 2014 and September 2015 (for the prospective part). 4. Patient with at least an assessment of the response to Eribulin Instructions: please typing these entity words according to sentence: Age, ≥ 18 years, breast cancer, histologically proven , metastatic or locally advanced, Eribulin, between January and October 2014 ( for the retrospective part ) or between November 2014 and September 2015 ( for the prospective part ), assessment of the response, Eribulin Options: Condition, Value, Person, Procedure, Scope, Drug
[ "O", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Drug", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "B-Drug", "O" ]
1. Age ≥ 18 years 2. Patient with breast cancer, histologically proven, metastatic or locally advanced 3. Patient treated by Eribulin between January and October 2014 (for the retrospective part) or between November 2014 and September 2015 (for the prospective part). 4. Patient with at least an assessment of the response to Eribulin
[ "1", ".", "Age", "≥", "18", "years", "\n", "2", ".", "Patient", "with", "breast", "cancer", ",", "histologically", "proven", ",", "metastatic", "or", "locally", "advanced", "\n", "3", ".", "Patient", "treated", "by", "Eribulin", "between", "January", "and", "October", "2014", "(", "for", "the", "retrospective", "part", ")", "or", "between", "November", "2014", "and", "September", "2015", "(", "for", "the", "prospective", "part", ")", ".", "\n", "4", ".", "Patient", "with", "at", "least", "an", "assessment", "of", "the", "response", "to", "Eribulin", "\n" ]
[ "Scope", "Temporal", "Procedure", "Qualifier", "Condition", "Value", "Drug", "Person" ]
Age, ≥ 18 years, breast cancer, histologically proven , metastatic or locally advanced, Eribulin, between January and October 2014 ( for the retrospective part ) or between November 2014 and September 2015 ( for the prospective part ), assessment of the response, Eribulin
NCT02393287_inc_task2
Sentence: 1. Age ≥ 18 years 2. Patient with breast cancer, histologically proven, metastatic or locally advanced 3. Patient treated by Eribulin between January and October 2014 (for the retrospective part) or between November 2014 and September 2015 (for the prospective part). 4. Patient with at least an assessment of the response to Eribulin Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Drug", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "B-Drug", "O" ]
1. Age ≥ 18 years 2. Patient with breast cancer, histologically proven, metastatic or locally advanced 3. Patient treated by Eribulin between January and October 2014 (for the retrospective part) or between November 2014 and September 2015 (for the prospective part). 4. Patient with at least an assessment of the response to Eribulin
[ "1", ".", "Age", "≥", "18", "years", "\n", "2", ".", "Patient", "with", "breast", "cancer", ",", "histologically", "proven", ",", "metastatic", "or", "locally", "advanced", "\n", "3", ".", "Patient", "treated", "by", "Eribulin", "between", "January", "and", "October", "2014", "(", "for", "the", "retrospective", "part", ")", "or", "between", "November", "2014", "and", "September", "2015", "(", "for", "the", "prospective", "part", ")", ".", "\n", "4", ".", "Patient", "with", "at", "least", "an", "assessment", "of", "the", "response", "to", "Eribulin", "\n" ]
[ "Scope", "Temporal", "Procedure", "Qualifier", "Condition", "Value", "Drug", "Person" ]
vaccine is a Intervention_Pharmacological, heifers is a Participant_Sex, aureus is a Outcome_Physical, placebo is a Intervention_Control, frequencies of intramammary infections caused by Staph is a Outcome_Physical, protective effect is a Outcome_Other, relative risk of mastitis caused by Staph is a Outcome_Physical, results of the trial indicated the effectiveness of the vaccine is a Outcome_Other, fat production is a Outcome_Physical
89865_task0
Sentence: Field trials of a vaccine against bovine mastitis . 1 . Evaluation in heifers . A vaccine was developed against bovine mastitis based on inactivated , highly encapsulated Staphylococcus aureus cells ; a crude extract of Staph . aureus exopolysaccharides ; and inactivated , unencapsulated Staph , aureus and Streptococcus spp . cells . This vaccine was tested on 30 heifers during a 7-mo period . The 30 heifers were randomly assigned to three groups of 10 heifers each . The prepartum group received two injections of the vaccine at 8 and 4 wk before calving , and the postpartum group received two injections at 1 and 5 wk after calving . The control group received two injections of a placebo at 8 and 4 wk before calving . The vaccine or the placebo was administered subcutaneously in the brachiocephalicus muscle of the neck . The frequencies of intramammary infections caused by Staph . aureus were reduced from 18.8 % for heifers in the control group to 6.7 and 6.0 % for heifers in the prepartum and postpartum groups , respectively . This protective effect was maintained for at least 6 mo . The relative risk of mastitis caused by Staph . aureus was 0.31 and 0.28 for heifers in the prepartum and postpartum groups , respectively , compared with that for heifers in the control group . The results of the trial indicated the effectiveness of the vaccine in decreasing the incidence of intrammammary infections caused by Staph . aureus . A slight but nonsignificant increase occurred in fat production in the milk of vaccinated cows . The vaccine had no observable effect on somatic cell count or streptococcal infections . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Sex, Outcome_Physical, Outcome_Other
[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Field trials of a vaccine against bovine mastitis . 1 . Evaluation in heifers . A vaccine was developed against bovine mastitis based on inactivated , highly encapsulated Staphylococcus aureus cells ; a crude extract of Staph . aureus exopolysaccharides ; and inactivated , unencapsulated Staph , aureus and Streptococcus spp . cells . This vaccine was tested on 30 heifers during a 7-mo period . The 30 heifers were randomly assigned to three groups of 10 heifers each . The prepartum group received two injections of the vaccine at 8 and 4 wk before calving , and the postpartum group received two injections at 1 and 5 wk after calving . The control group received two injections of a placebo at 8 and 4 wk before calving . The vaccine or the placebo was administered subcutaneously in the brachiocephalicus muscle of the neck . The frequencies of intramammary infections caused by Staph . aureus were reduced from 18.8 % for heifers in the control group to 6.7 and 6.0 % for heifers in the prepartum and postpartum groups , respectively . This protective effect was maintained for at least 6 mo . The relative risk of mastitis caused by Staph . aureus was 0.31 and 0.28 for heifers in the prepartum and postpartum groups , respectively , compared with that for heifers in the control group . The results of the trial indicated the effectiveness of the vaccine in decreasing the incidence of intrammammary infections caused by Staph . aureus . A slight but nonsignificant increase occurred in fat production in the milk of vaccinated cows . The vaccine had no observable effect on somatic cell count or streptococcal infections .
[ "Field", "trials", "of", "a", "vaccine", "against", "bovine", "mastitis", ".", "1", ".", "Evaluation", "in", "heifers", ".", "A", "vaccine", "was", "developed", "against", "bovine", "mastitis", "based", "on", "inactivated", ",", "highly", "encapsulated", "Staphylococcus", "aureus", "cells", ";", "a", "crude", "extract", "of", "Staph", ".", "aureus", "exopolysaccharides", ";", "and", "inactivated", ",", "unencapsulated", "Staph", ",", "aureus", "and", "Streptococcus", "spp", ".", "cells", ".", "This", "vaccine", "was", "tested", "on", "30", "heifers", "during", "a", "7-mo", "period", ".", "The", "30", "heifers", "were", "randomly", "assigned", "to", "three", "groups", "of", "10", "heifers", "each", ".", "The", "prepartum", "group", "received", "two", "injections", "of", "the", "vaccine", "at", "8", "and", "4", "wk", "before", "calving", ",", "and", "the", "postpartum", "group", "received", "two", "injections", "at", "1", "and", "5", "wk", "after", "calving", ".", "The", "control", "group", "received", "two", "injections", "of", "a", "placebo", "at", "8", "and", "4", "wk", "before", "calving", ".", "The", "vaccine", "or", "the", "placebo", "was", "administered", "subcutaneously", "in", "the", "brachiocephalicus", "muscle", "of", "the", "neck", ".", "The", "frequencies", "of", "intramammary", "infections", "caused", "by", "Staph", ".", "aureus", "were", "reduced", "from", "18.8", "%", "for", "heifers", "in", "the", "control", "group", "to", "6.7", "and", "6.0", "%", "for", "heifers", "in", "the", "prepartum", "and", "postpartum", "groups", ",", "respectively", ".", "This", "protective", "effect", "was", "maintained", "for", "at", "least", "6", "mo", ".", "The", "relative", "risk", "of", "mastitis", "caused", "by", "Staph", ".", "aureus", "was", "0.31", "and", "0.28", "for", "heifers", "in", "the", "prepartum", "and", "postpartum", "groups", ",", "respectively", ",", "compared", "with", "that", "for", "heifers", "in", "the", "control", "group", ".", "The", "results", "of", "the", "trial", "indicated", "the", "effectiveness", "of", "the", "vaccine", "in", "decreasing", "the", "incidence", "of", "intrammammary", "infections", "caused", "by", "Staph", ".", "aureus", ".", "A", "slight", "but", "nonsignificant", "increase", "occurred", "in", "fat", "production", "in", "the", "milk", "of", "vaccinated", "cows", ".", "The", "vaccine", "had", "no", "observable", "effect", "on", "somatic", "cell", "count", "or", "streptococcal", "infections", "." ]
[ "Outcome_Other", "Outcome_Physical", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sex" ]
vaccine is a Intervention_Pharmacological, heifers is a Participant_Sex, aureus is a Outcome_Physical, placebo is a Intervention_Control, frequencies of intramammary infections caused by Staph is a Outcome_Physical, protective effect is a Outcome_Other, relative risk of mastitis caused by Staph is a Outcome_Physical, results of the trial indicated the effectiveness of the vaccine is a Outcome_Other, fat production is a Outcome_Physical
89865_task1
Sentence: Field trials of a vaccine against bovine mastitis . 1 . Evaluation in heifers . A vaccine was developed against bovine mastitis based on inactivated , highly encapsulated Staphylococcus aureus cells ; a crude extract of Staph . aureus exopolysaccharides ; and inactivated , unencapsulated Staph , aureus and Streptococcus spp . cells . This vaccine was tested on 30 heifers during a 7-mo period . The 30 heifers were randomly assigned to three groups of 10 heifers each . The prepartum group received two injections of the vaccine at 8 and 4 wk before calving , and the postpartum group received two injections at 1 and 5 wk after calving . The control group received two injections of a placebo at 8 and 4 wk before calving . The vaccine or the placebo was administered subcutaneously in the brachiocephalicus muscle of the neck . The frequencies of intramammary infections caused by Staph . aureus were reduced from 18.8 % for heifers in the control group to 6.7 and 6.0 % for heifers in the prepartum and postpartum groups , respectively . This protective effect was maintained for at least 6 mo . The relative risk of mastitis caused by Staph . aureus was 0.31 and 0.28 for heifers in the prepartum and postpartum groups , respectively , compared with that for heifers in the control group . The results of the trial indicated the effectiveness of the vaccine in decreasing the incidence of intrammammary infections caused by Staph . aureus . A slight but nonsignificant increase occurred in fat production in the milk of vaccinated cows . The vaccine had no observable effect on somatic cell count or streptococcal infections . Instructions: please typing these entity words according to sentence: vaccine, heifers, aureus, placebo, frequencies of intramammary infections caused by Staph, protective effect, relative risk of mastitis caused by Staph, results of the trial indicated the effectiveness of the vaccine, fat production Options: Intervention_Pharmacological, Intervention_Control, Participant_Sex, Outcome_Physical, Outcome_Other
[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Field trials of a vaccine against bovine mastitis . 1 . Evaluation in heifers . A vaccine was developed against bovine mastitis based on inactivated , highly encapsulated Staphylococcus aureus cells ; a crude extract of Staph . aureus exopolysaccharides ; and inactivated , unencapsulated Staph , aureus and Streptococcus spp . cells . This vaccine was tested on 30 heifers during a 7-mo period . The 30 heifers were randomly assigned to three groups of 10 heifers each . The prepartum group received two injections of the vaccine at 8 and 4 wk before calving , and the postpartum group received two injections at 1 and 5 wk after calving . The control group received two injections of a placebo at 8 and 4 wk before calving . The vaccine or the placebo was administered subcutaneously in the brachiocephalicus muscle of the neck . The frequencies of intramammary infections caused by Staph . aureus were reduced from 18.8 % for heifers in the control group to 6.7 and 6.0 % for heifers in the prepartum and postpartum groups , respectively . This protective effect was maintained for at least 6 mo . The relative risk of mastitis caused by Staph . aureus was 0.31 and 0.28 for heifers in the prepartum and postpartum groups , respectively , compared with that for heifers in the control group . The results of the trial indicated the effectiveness of the vaccine in decreasing the incidence of intrammammary infections caused by Staph . aureus . A slight but nonsignificant increase occurred in fat production in the milk of vaccinated cows . The vaccine had no observable effect on somatic cell count or streptococcal infections .
[ "Field", "trials", "of", "a", "vaccine", "against", "bovine", "mastitis", ".", "1", ".", "Evaluation", "in", "heifers", ".", "A", "vaccine", "was", "developed", "against", "bovine", "mastitis", "based", "on", "inactivated", ",", "highly", "encapsulated", "Staphylococcus", "aureus", "cells", ";", "a", "crude", "extract", "of", "Staph", ".", "aureus", "exopolysaccharides", ";", "and", "inactivated", ",", "unencapsulated", "Staph", ",", "aureus", "and", "Streptococcus", "spp", ".", "cells", ".", "This", "vaccine", "was", "tested", "on", "30", "heifers", "during", "a", "7-mo", "period", ".", "The", "30", "heifers", "were", "randomly", "assigned", "to", "three", "groups", "of", "10", "heifers", "each", ".", "The", "prepartum", "group", "received", "two", "injections", "of", "the", "vaccine", "at", "8", "and", "4", "wk", "before", "calving", ",", "and", "the", "postpartum", "group", "received", "two", "injections", "at", "1", "and", "5", "wk", "after", "calving", ".", "The", "control", "group", "received", "two", "injections", "of", "a", "placebo", "at", "8", "and", "4", "wk", "before", "calving", ".", "The", "vaccine", "or", "the", "placebo", "was", "administered", "subcutaneously", "in", "the", "brachiocephalicus", "muscle", "of", "the", "neck", ".", "The", "frequencies", "of", "intramammary", "infections", "caused", "by", "Staph", ".", "aureus", "were", "reduced", "from", "18.8", "%", "for", "heifers", "in", "the", "control", "group", "to", "6.7", "and", "6.0", "%", "for", "heifers", "in", "the", "prepartum", "and", "postpartum", "groups", ",", "respectively", ".", "This", "protective", "effect", "was", "maintained", "for", "at", "least", "6", "mo", ".", "The", "relative", "risk", "of", "mastitis", "caused", "by", "Staph", ".", "aureus", "was", "0.31", "and", "0.28", "for", "heifers", "in", "the", "prepartum", "and", "postpartum", "groups", ",", "respectively", ",", "compared", "with", "that", "for", "heifers", "in", "the", "control", "group", ".", "The", "results", "of", "the", "trial", "indicated", "the", "effectiveness", "of", "the", "vaccine", "in", "decreasing", "the", "incidence", "of", "intrammammary", "infections", "caused", "by", "Staph", ".", "aureus", ".", "A", "slight", "but", "nonsignificant", "increase", "occurred", "in", "fat", "production", "in", "the", "milk", "of", "vaccinated", "cows", ".", "The", "vaccine", "had", "no", "observable", "effect", "on", "somatic", "cell", "count", "or", "streptococcal", "infections", "." ]
[ "Outcome_Other", "Outcome_Physical", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sex" ]
vaccine, heifers, aureus, placebo, frequencies of intramammary infections caused by Staph, protective effect, relative risk of mastitis caused by Staph, results of the trial indicated the effectiveness of the vaccine, fat production
89865_task2
Sentence: Field trials of a vaccine against bovine mastitis . 1 . Evaluation in heifers . A vaccine was developed against bovine mastitis based on inactivated , highly encapsulated Staphylococcus aureus cells ; a crude extract of Staph . aureus exopolysaccharides ; and inactivated , unencapsulated Staph , aureus and Streptococcus spp . cells . This vaccine was tested on 30 heifers during a 7-mo period . The 30 heifers were randomly assigned to three groups of 10 heifers each . The prepartum group received two injections of the vaccine at 8 and 4 wk before calving , and the postpartum group received two injections at 1 and 5 wk after calving . The control group received two injections of a placebo at 8 and 4 wk before calving . The vaccine or the placebo was administered subcutaneously in the brachiocephalicus muscle of the neck . The frequencies of intramammary infections caused by Staph . aureus were reduced from 18.8 % for heifers in the control group to 6.7 and 6.0 % for heifers in the prepartum and postpartum groups , respectively . This protective effect was maintained for at least 6 mo . The relative risk of mastitis caused by Staph . aureus was 0.31 and 0.28 for heifers in the prepartum and postpartum groups , respectively , compared with that for heifers in the control group . The results of the trial indicated the effectiveness of the vaccine in decreasing the incidence of intrammammary infections caused by Staph . aureus . A slight but nonsignificant increase occurred in fat production in the milk of vaccinated cows . The vaccine had no observable effect on somatic cell count or streptococcal infections . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Field trials of a vaccine against bovine mastitis . 1 . Evaluation in heifers . A vaccine was developed against bovine mastitis based on inactivated , highly encapsulated Staphylococcus aureus cells ; a crude extract of Staph . aureus exopolysaccharides ; and inactivated , unencapsulated Staph , aureus and Streptococcus spp . cells . This vaccine was tested on 30 heifers during a 7-mo period . The 30 heifers were randomly assigned to three groups of 10 heifers each . The prepartum group received two injections of the vaccine at 8 and 4 wk before calving , and the postpartum group received two injections at 1 and 5 wk after calving . The control group received two injections of a placebo at 8 and 4 wk before calving . The vaccine or the placebo was administered subcutaneously in the brachiocephalicus muscle of the neck . The frequencies of intramammary infections caused by Staph . aureus were reduced from 18.8 % for heifers in the control group to 6.7 and 6.0 % for heifers in the prepartum and postpartum groups , respectively . This protective effect was maintained for at least 6 mo . The relative risk of mastitis caused by Staph . aureus was 0.31 and 0.28 for heifers in the prepartum and postpartum groups , respectively , compared with that for heifers in the control group . The results of the trial indicated the effectiveness of the vaccine in decreasing the incidence of intrammammary infections caused by Staph . aureus . A slight but nonsignificant increase occurred in fat production in the milk of vaccinated cows . The vaccine had no observable effect on somatic cell count or streptococcal infections .
[ "Field", "trials", "of", "a", "vaccine", "against", "bovine", "mastitis", ".", "1", ".", "Evaluation", "in", "heifers", ".", "A", "vaccine", "was", "developed", "against", "bovine", "mastitis", "based", "on", "inactivated", ",", "highly", "encapsulated", "Staphylococcus", "aureus", "cells", ";", "a", "crude", "extract", "of", "Staph", ".", "aureus", "exopolysaccharides", ";", "and", "inactivated", ",", "unencapsulated", "Staph", ",", "aureus", "and", "Streptococcus", "spp", ".", "cells", ".", "This", "vaccine", "was", "tested", "on", "30", "heifers", "during", "a", "7-mo", "period", ".", "The", "30", "heifers", "were", "randomly", "assigned", "to", "three", "groups", "of", "10", "heifers", "each", ".", "The", "prepartum", "group", "received", "two", "injections", "of", "the", "vaccine", "at", "8", "and", "4", "wk", "before", "calving", ",", "and", "the", "postpartum", "group", "received", "two", "injections", "at", "1", "and", "5", "wk", "after", "calving", ".", "The", "control", "group", "received", "two", "injections", "of", "a", "placebo", "at", "8", "and", "4", "wk", "before", "calving", ".", "The", "vaccine", "or", "the", "placebo", "was", "administered", "subcutaneously", "in", "the", "brachiocephalicus", "muscle", "of", "the", "neck", ".", "The", "frequencies", "of", "intramammary", "infections", "caused", "by", "Staph", ".", "aureus", "were", "reduced", "from", "18.8", "%", "for", "heifers", "in", "the", "control", "group", "to", "6.7", "and", "6.0", "%", "for", "heifers", "in", "the", "prepartum", "and", "postpartum", "groups", ",", "respectively", ".", "This", "protective", "effect", "was", "maintained", "for", "at", "least", "6", "mo", ".", "The", "relative", "risk", "of", "mastitis", "caused", "by", "Staph", ".", "aureus", "was", "0.31", "and", "0.28", "for", "heifers", "in", "the", "prepartum", "and", "postpartum", "groups", ",", "respectively", ",", "compared", "with", "that", "for", "heifers", "in", "the", "control", "group", ".", "The", "results", "of", "the", "trial", "indicated", "the", "effectiveness", "of", "the", "vaccine", "in", "decreasing", "the", "incidence", "of", "intrammammary", "infections", "caused", "by", "Staph", ".", "aureus", ".", "A", "slight", "but", "nonsignificant", "increase", "occurred", "in", "fat", "production", "in", "the", "milk", "of", "vaccinated", "cows", ".", "The", "vaccine", "had", "no", "observable", "effect", "on", "somatic", "cell", "count", "or", "streptococcal", "infections", "." ]
[ "Outcome_Other", "Outcome_Physical", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sex" ]
microcirculation is an umlsterm, human is an umlsterm, skin tumours is an umlsterm, methods is an umlsterm, microcirculation is an umlsterm, research is an umlsterm, capillaroscopy is an umlsterm, laser is an umlsterm, blood is an umlsterm, tumours is an umlsterm, prospective study is an umlsterm, melanoma - associated is an umlsterm, microcirculation is an umlsterm, skin tumours is an umlsterm, patients is an umlsterm, women is an umlsterm, men is an umlsterm, age is an umlsterm, findings is an umlsterm, naevus is an umlsterm, malignant melanoma is an umlsterm, malignant melanoma is an umlsterm, capillaries is an umlsterm, capillaries is an umlsterm, melanoma is an umlsterm, sodium fluorescein is an umlsterm, Laser is an umlsterm, measure is an umlsterm, circulation is an umlsterm, skin is an umlsterm, melanoma is an umlsterm, naevus is an umlsterm, skin is an umlsterm, future is an umlsterm, antiangiogenetic is an umlsterm, therapy is an umlsterm, role is an umlsterm, treatment is an umlsterm, malignant melanoma is an umlsterm, methods is an umlsterm, antiangiogenetic is an umlsterm, treatments is an umlsterm, cutaneous melanoma is an umlsterm
DerHautarzt.90500848.eng.abstr_task0
Sentence: The microcirculation of human skin tumours can be visualized with noninvasive methods from clinical microcirculation research ( capillaroscopy and laser Doppler fluxmetry ( LDF ) . The latter can also be used to measure the blood flow in such tumours . This prospective study was designed to evaluate melanoma-associated cutaneous neoangiogenesis . We studied the microcirculation of 114 pigmented skin tumours in 103 patients ( 63 women , 40 men ) averaging 38.8 +/- 21.1 years of age . On the basis of histological findings , we diagnosed melanocytic naevus in 86 cases and malignant melanoma in 28. The malignant melanoma was characterized by a chaotic arrangement of the capillaries , which were dilated and formed corkscrew-shaped or glomerular structures . In the transitional area between healthy and cancerous areas there was hypervascularization . The capillaries of the melanoma appeared to be more permeable towards the low-molecular-weight , water-soluble sodium fluorescein . Laser Doppler flux , a measure of cutaneous circulation in the upper 2 mm of the skin , is higher in the centre of the melanoma than in either the middle of a melanocytic naevus ( p 0.0005 ) or in neighbouring healthy skin areas ( p 0.005 ) . In the future , antiangiogenetic therapy strategies could play a significant role in the treatment of malignant melanoma . These methods provide a reliable means of evaluating the specific antiangiogenetic efficacy of treatments for cutaneous melanoma . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]
The microcirculation of human skin tumours can be visualized with noninvasive methods from clinical microcirculation research ( capillaroscopy and laser Doppler fluxmetry ( LDF ) . The latter can also be used to measure the blood flow in such tumours . This prospective study was designed to evaluate melanoma-associated cutaneous neoangiogenesis . We studied the microcirculation of 114 pigmented skin tumours in 103 patients ( 63 women , 40 men ) averaging 38.8 +/- 21.1 years of age . On the basis of histological findings , we diagnosed melanocytic naevus in 86 cases and malignant melanoma in 28. The malignant melanoma was characterized by a chaotic arrangement of the capillaries , which were dilated and formed corkscrew-shaped or glomerular structures . In the transitional area between healthy and cancerous areas there was hypervascularization . The capillaries of the melanoma appeared to be more permeable towards the low-molecular-weight , water-soluble sodium fluorescein . Laser Doppler flux , a measure of cutaneous circulation in the upper 2 mm of the skin , is higher in the centre of the melanoma than in either the middle of a melanocytic naevus ( p 0.0005 ) or in neighbouring healthy skin areas ( p 0.005 ) . In the future , antiangiogenetic therapy strategies could play a significant role in the treatment of malignant melanoma . These methods provide a reliable means of evaluating the specific antiangiogenetic efficacy of treatments for cutaneous melanoma .
[ "The", "microcirculation", "of", "human", "skin", "tumours", "can", "be", "visualized", "with", "noninvasive", "methods", "from", "clinical", "microcirculation", "research", "(", "capillaroscopy", "and", "laser", "Doppler", "fluxmetry", "(", "LDF", ")", ".", "The", "latter", "can", "also", "be", "used", "to", "measure", "the", "blood", "flow", "in", "such", "tumours", ".", "This", "prospective", "study", "was", "designed", "to", "evaluate", "melanoma", "-", "associated", "cutaneous", "neoangiogenesis", ".", "We", "studied", "the", "microcirculation", "of", "114", "pigmented", "skin", "tumours", "in", "103", "patients", "(", "63", "women", ",", "40", "men", ")", "averaging", "38.8", "+", "/-", "21.1", "years", "of", "age", ".", "On", "the", "basis", "of", "histological", "findings", ",", "we", "diagnosed", "melanocytic", "naevus", "in", "86", "cases", "and", "malignant", "melanoma", "in", "28", ".", "The", "malignant", "melanoma", "was", "characterized", "by", "a", "chaotic", "arrangement", "of", "the", "capillaries", ",", "which", "were", "dilated", "and", "formed", "corkscrew", "-", "shaped", "or", "glomerular", "structures", ".", "In", "the", "transitional", "area", "between", "healthy", "and", "cancerous", "areas", "there", "was", "hypervascularization", ".", "The", "capillaries", "of", "the", "melanoma", "appeared", "to", "be", "more", "permeable", "towards", "the", "low", "-", "molecular", "-", "weight", ",", "water", "-", "soluble", "sodium", "fluorescein", ".", "Laser", "Doppler", "flux", ",", "a", "measure", "of", "cutaneous", "circulation", "in", "the", "upper", "2", "mm", "of", "the", "skin", ",", "is", "higher", "in", "the", "centre", "of", "the", "melanoma", "than", "in", "either", "the", "middle", "of", "a", "melanocytic", "naevus", "(", "p", "0.0005", ")", "or", "in", "neighbouring", "healthy", "skin", "areas", "(", "p", "0.005", ")", ".", "In", "the", "future", ",", "antiangiogenetic", "therapy", "strategies", "could", "play", "a", "significant", "role", "in", "the", "treatment", "of", "malignant", "melanoma", ".", "These", "methods", "provide", "a", "reliable", "means", "of", "evaluating", "the", "specific", "antiangiogenetic", "efficacy", "of", "treatments", "for", "cutaneous", "melanoma", "." ]
[ "umlsterm" ]
microcirculation is an umlsterm, human is an umlsterm, skin tumours is an umlsterm, methods is an umlsterm, microcirculation is an umlsterm, research is an umlsterm, capillaroscopy is an umlsterm, laser is an umlsterm, blood is an umlsterm, tumours is an umlsterm, prospective study is an umlsterm, melanoma - associated is an umlsterm, microcirculation is an umlsterm, skin tumours is an umlsterm, patients is an umlsterm, women is an umlsterm, men is an umlsterm, age is an umlsterm, findings is an umlsterm, naevus is an umlsterm, malignant melanoma is an umlsterm, malignant melanoma is an umlsterm, capillaries is an umlsterm, capillaries is an umlsterm, melanoma is an umlsterm, sodium fluorescein is an umlsterm, Laser is an umlsterm, measure is an umlsterm, circulation is an umlsterm, skin is an umlsterm, melanoma is an umlsterm, naevus is an umlsterm, skin is an umlsterm, future is an umlsterm, antiangiogenetic is an umlsterm, therapy is an umlsterm, role is an umlsterm, treatment is an umlsterm, malignant melanoma is an umlsterm, methods is an umlsterm, antiangiogenetic is an umlsterm, treatments is an umlsterm, cutaneous melanoma is an umlsterm
DerHautarzt.90500848.eng.abstr_task1
Sentence: The microcirculation of human skin tumours can be visualized with noninvasive methods from clinical microcirculation research ( capillaroscopy and laser Doppler fluxmetry ( LDF ) . The latter can also be used to measure the blood flow in such tumours . This prospective study was designed to evaluate melanoma-associated cutaneous neoangiogenesis . We studied the microcirculation of 114 pigmented skin tumours in 103 patients ( 63 women , 40 men ) averaging 38.8 +/- 21.1 years of age . On the basis of histological findings , we diagnosed melanocytic naevus in 86 cases and malignant melanoma in 28. The malignant melanoma was characterized by a chaotic arrangement of the capillaries , which were dilated and formed corkscrew-shaped or glomerular structures . In the transitional area between healthy and cancerous areas there was hypervascularization . The capillaries of the melanoma appeared to be more permeable towards the low-molecular-weight , water-soluble sodium fluorescein . Laser Doppler flux , a measure of cutaneous circulation in the upper 2 mm of the skin , is higher in the centre of the melanoma than in either the middle of a melanocytic naevus ( p 0.0005 ) or in neighbouring healthy skin areas ( p 0.005 ) . In the future , antiangiogenetic therapy strategies could play a significant role in the treatment of malignant melanoma . These methods provide a reliable means of evaluating the specific antiangiogenetic efficacy of treatments for cutaneous melanoma . Instructions: please typing these entity words according to sentence: microcirculation, human, skin tumours, methods, microcirculation, research, capillaroscopy, laser, blood, tumours, prospective study, melanoma - associated, microcirculation, skin tumours, patients, women, men, age, findings, naevus, malignant melanoma, malignant melanoma, capillaries, capillaries, melanoma, sodium fluorescein, Laser, measure, circulation, skin, melanoma, naevus, skin, future, antiangiogenetic, therapy, role, treatment, malignant melanoma, methods, antiangiogenetic, treatments, cutaneous melanoma Options: umlsterm
[ "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]
The microcirculation of human skin tumours can be visualized with noninvasive methods from clinical microcirculation research ( capillaroscopy and laser Doppler fluxmetry ( LDF ) . The latter can also be used to measure the blood flow in such tumours . This prospective study was designed to evaluate melanoma-associated cutaneous neoangiogenesis . We studied the microcirculation of 114 pigmented skin tumours in 103 patients ( 63 women , 40 men ) averaging 38.8 +/- 21.1 years of age . On the basis of histological findings , we diagnosed melanocytic naevus in 86 cases and malignant melanoma in 28. The malignant melanoma was characterized by a chaotic arrangement of the capillaries , which were dilated and formed corkscrew-shaped or glomerular structures . In the transitional area between healthy and cancerous areas there was hypervascularization . The capillaries of the melanoma appeared to be more permeable towards the low-molecular-weight , water-soluble sodium fluorescein . Laser Doppler flux , a measure of cutaneous circulation in the upper 2 mm of the skin , is higher in the centre of the melanoma than in either the middle of a melanocytic naevus ( p 0.0005 ) or in neighbouring healthy skin areas ( p 0.005 ) . In the future , antiangiogenetic therapy strategies could play a significant role in the treatment of malignant melanoma . These methods provide a reliable means of evaluating the specific antiangiogenetic efficacy of treatments for cutaneous melanoma .
[ "The", "microcirculation", "of", "human", "skin", "tumours", "can", "be", "visualized", "with", "noninvasive", "methods", "from", "clinical", "microcirculation", "research", "(", "capillaroscopy", "and", "laser", "Doppler", "fluxmetry", "(", "LDF", ")", ".", "The", "latter", "can", "also", "be", "used", "to", "measure", "the", "blood", "flow", "in", "such", "tumours", ".", "This", "prospective", "study", "was", "designed", "to", "evaluate", "melanoma", "-", "associated", "cutaneous", "neoangiogenesis", ".", "We", "studied", "the", "microcirculation", "of", "114", "pigmented", "skin", "tumours", "in", "103", "patients", "(", "63", "women", ",", "40", "men", ")", "averaging", "38.8", "+", "/-", "21.1", "years", "of", "age", ".", "On", "the", "basis", "of", "histological", "findings", ",", "we", "diagnosed", "melanocytic", "naevus", "in", "86", "cases", "and", "malignant", "melanoma", "in", "28", ".", "The", "malignant", "melanoma", "was", "characterized", "by", "a", "chaotic", "arrangement", "of", "the", "capillaries", ",", "which", "were", "dilated", "and", "formed", "corkscrew", "-", "shaped", "or", "glomerular", "structures", ".", "In", "the", "transitional", "area", "between", "healthy", "and", "cancerous", "areas", "there", "was", "hypervascularization", ".", "The", "capillaries", "of", "the", "melanoma", "appeared", "to", "be", "more", "permeable", "towards", "the", "low", "-", "molecular", "-", "weight", ",", "water", "-", "soluble", "sodium", "fluorescein", ".", "Laser", "Doppler", "flux", ",", "a", "measure", "of", "cutaneous", "circulation", "in", "the", "upper", "2", "mm", "of", "the", "skin", ",", "is", "higher", "in", "the", "centre", "of", "the", "melanoma", "than", "in", "either", "the", "middle", "of", "a", "melanocytic", "naevus", "(", "p", "0.0005", ")", "or", "in", "neighbouring", "healthy", "skin", "areas", "(", "p", "0.005", ")", ".", "In", "the", "future", ",", "antiangiogenetic", "therapy", "strategies", "could", "play", "a", "significant", "role", "in", "the", "treatment", "of", "malignant", "melanoma", ".", "These", "methods", "provide", "a", "reliable", "means", "of", "evaluating", "the", "specific", "antiangiogenetic", "efficacy", "of", "treatments", "for", "cutaneous", "melanoma", "." ]
[ "umlsterm" ]
microcirculation, human, skin tumours, methods, microcirculation, research, capillaroscopy, laser, blood, tumours, prospective study, melanoma - associated, microcirculation, skin tumours, patients, women, men, age, findings, naevus, malignant melanoma, malignant melanoma, capillaries, capillaries, melanoma, sodium fluorescein, Laser, measure, circulation, skin, melanoma, naevus, skin, future, antiangiogenetic, therapy, role, treatment, malignant melanoma, methods, antiangiogenetic, treatments, cutaneous melanoma
DerHautarzt.90500848.eng.abstr_task2
Sentence: The microcirculation of human skin tumours can be visualized with noninvasive methods from clinical microcirculation research ( capillaroscopy and laser Doppler fluxmetry ( LDF ) . The latter can also be used to measure the blood flow in such tumours . This prospective study was designed to evaluate melanoma-associated cutaneous neoangiogenesis . We studied the microcirculation of 114 pigmented skin tumours in 103 patients ( 63 women , 40 men ) averaging 38.8 +/- 21.1 years of age . On the basis of histological findings , we diagnosed melanocytic naevus in 86 cases and malignant melanoma in 28. The malignant melanoma was characterized by a chaotic arrangement of the capillaries , which were dilated and formed corkscrew-shaped or glomerular structures . In the transitional area between healthy and cancerous areas there was hypervascularization . The capillaries of the melanoma appeared to be more permeable towards the low-molecular-weight , water-soluble sodium fluorescein . Laser Doppler flux , a measure of cutaneous circulation in the upper 2 mm of the skin , is higher in the centre of the melanoma than in either the middle of a melanocytic naevus ( p 0.0005 ) or in neighbouring healthy skin areas ( p 0.005 ) . In the future , antiangiogenetic therapy strategies could play a significant role in the treatment of malignant melanoma . These methods provide a reliable means of evaluating the specific antiangiogenetic efficacy of treatments for cutaneous melanoma . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]
The microcirculation of human skin tumours can be visualized with noninvasive methods from clinical microcirculation research ( capillaroscopy and laser Doppler fluxmetry ( LDF ) . The latter can also be used to measure the blood flow in such tumours . This prospective study was designed to evaluate melanoma-associated cutaneous neoangiogenesis . We studied the microcirculation of 114 pigmented skin tumours in 103 patients ( 63 women , 40 men ) averaging 38.8 +/- 21.1 years of age . On the basis of histological findings , we diagnosed melanocytic naevus in 86 cases and malignant melanoma in 28. The malignant melanoma was characterized by a chaotic arrangement of the capillaries , which were dilated and formed corkscrew-shaped or glomerular structures . In the transitional area between healthy and cancerous areas there was hypervascularization . The capillaries of the melanoma appeared to be more permeable towards the low-molecular-weight , water-soluble sodium fluorescein . Laser Doppler flux , a measure of cutaneous circulation in the upper 2 mm of the skin , is higher in the centre of the melanoma than in either the middle of a melanocytic naevus ( p 0.0005 ) or in neighbouring healthy skin areas ( p 0.005 ) . In the future , antiangiogenetic therapy strategies could play a significant role in the treatment of malignant melanoma . These methods provide a reliable means of evaluating the specific antiangiogenetic efficacy of treatments for cutaneous melanoma .
[ "The", "microcirculation", "of", "human", "skin", "tumours", "can", "be", "visualized", "with", "noninvasive", "methods", "from", "clinical", "microcirculation", "research", "(", "capillaroscopy", "and", "laser", "Doppler", "fluxmetry", "(", "LDF", ")", ".", "The", "latter", "can", "also", "be", "used", "to", "measure", "the", "blood", "flow", "in", "such", "tumours", ".", "This", "prospective", "study", "was", "designed", "to", "evaluate", "melanoma", "-", "associated", "cutaneous", "neoangiogenesis", ".", "We", "studied", "the", "microcirculation", "of", "114", "pigmented", "skin", "tumours", "in", "103", "patients", "(", "63", "women", ",", "40", "men", ")", "averaging", "38.8", "+", "/-", "21.1", "years", "of", "age", ".", "On", "the", "basis", "of", "histological", "findings", ",", "we", "diagnosed", "melanocytic", "naevus", "in", "86", "cases", "and", "malignant", "melanoma", "in", "28", ".", "The", "malignant", "melanoma", "was", "characterized", "by", "a", "chaotic", "arrangement", "of", "the", "capillaries", ",", "which", "were", "dilated", "and", "formed", "corkscrew", "-", "shaped", "or", "glomerular", "structures", ".", "In", "the", "transitional", "area", "between", "healthy", "and", "cancerous", "areas", "there", "was", "hypervascularization", ".", "The", "capillaries", "of", "the", "melanoma", "appeared", "to", "be", "more", "permeable", "towards", "the", "low", "-", "molecular", "-", "weight", ",", "water", "-", "soluble", "sodium", "fluorescein", ".", "Laser", "Doppler", "flux", ",", "a", "measure", "of", "cutaneous", "circulation", "in", "the", "upper", "2", "mm", "of", "the", "skin", ",", "is", "higher", "in", "the", "centre", "of", "the", "melanoma", "than", "in", "either", "the", "middle", "of", "a", "melanocytic", "naevus", "(", "p", "0.0005", ")", "or", "in", "neighbouring", "healthy", "skin", "areas", "(", "p", "0.005", ")", ".", "In", "the", "future", ",", "antiangiogenetic", "therapy", "strategies", "could", "play", "a", "significant", "role", "in", "the", "treatment", "of", "malignant", "melanoma", ".", "These", "methods", "provide", "a", "reliable", "means", "of", "evaluating", "the", "specific", "antiangiogenetic", "efficacy", "of", "treatments", "for", "cutaneous", "melanoma", "." ]
[ "umlsterm" ]
children is an umlsterm, accidents is an umlsterm, leisure is an umlsterm, sports activities is an umlsterm, knee joint is an umlsterm, trauma is an umlsterm, therapy is an umlsterm, retrospective is an umlsterm, treatment is an umlsterm, knee is an umlsterm, children is an umlsterm, age is an umlsterm, injury is an umlsterm, age is an umlsterm, trauma is an umlsterm, injuries is an umlsterm, anterior cruciate ligament is an umlsterm, cause is an umlsterm, sports activities is an umlsterm, treatment is an umlsterm, treatment is an umlsterm, collateral ligaments is an umlsterm, patellar ligaments is an umlsterm, Secondary is an umlsterm, knee is an umlsterm, children is an umlsterm, Children is an umlsterm, self is an umlsterm, injury is an umlsterm, Trauma is an umlsterm, surgery is an umlsterm, pain is an umlsterm, immobilisation is an umlsterm, physiotherapy is an umlsterm
DerUnfallchirurg.91020619.eng.abstr_task0
Sentence: Although children are injured everyday through accidents , road traffic , leisure or sports activities , internal lesions of the knee joint due to the trauma are rare . Diagnose and therapy follow rather empirical than analytical patterns . A retrospective , controlled study evaluates and recommends ways of treatment . Traumatic internal lesions of the knee where analysed in 76 children up to age 16. The pattern of injury changed with increasing age , the trauma remaining the same . Most common where injuries to the anterior cruciate ligament ( ACL ) . Main cause where sports activities . Operative treatment seems to be the appropriate treatment . Osseous avulsions of the cruciates and collateral ligaments showed good results after transosseous refixation with a suture . Suturing of intraligamentous ACL-ruptures as well as patellar ligaments plasty showed unsatisfactory results . Secondary lesions due to instability of the knee where also observed in children . Children cannot self estimate the severity of the injury so subjective statements are insecure . Trauma , surgery , pain and immobilisation cause a marked malfunction of the senso-motor system which is effectively treated by physiotherapy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Although children are injured everyday through accidents , road traffic , leisure or sports activities , internal lesions of the knee joint due to the trauma are rare . Diagnose and therapy follow rather empirical than analytical patterns . A retrospective , controlled study evaluates and recommends ways of treatment . Traumatic internal lesions of the knee where analysed in 76 children up to age 16. The pattern of injury changed with increasing age , the trauma remaining the same . Most common where injuries to the anterior cruciate ligament ( ACL ) . Main cause where sports activities . Operative treatment seems to be the appropriate treatment . Osseous avulsions of the cruciates and collateral ligaments showed good results after transosseous refixation with a suture . Suturing of intraligamentous ACL-ruptures as well as patellar ligaments plasty showed unsatisfactory results . Secondary lesions due to instability of the knee where also observed in children . Children cannot self estimate the severity of the injury so subjective statements are insecure . Trauma , surgery , pain and immobilisation cause a marked malfunction of the senso-motor system which is effectively treated by physiotherapy .
[ "Although", "children", "are", "injured", "everyday", "through", "accidents", ",", "road", "traffic", ",", "leisure", "or", "sports", "activities", ",", "internal", "lesions", "of", "the", "knee", "joint", "due", "to", "the", "trauma", "are", "rare", ".", "Diagnose", "and", "therapy", "follow", "rather", "empirical", "than", "analytical", "patterns", ".", "A", "retrospective", ",", "controlled", "study", "evaluates", "and", "recommends", "ways", "of", "treatment", ".", "Traumatic", "internal", "lesions", "of", "the", "knee", "where", "analysed", "in", "76", "children", "up", "to", "age", "16", ".", "The", "pattern", "of", "injury", "changed", "with", "increasing", "age", ",", "the", "trauma", "remaining", "the", "same", ".", "Most", "common", "where", "injuries", "to", "the", "anterior", "cruciate", "ligament", "(", "ACL", ")", ".", "Main", "cause", "where", "sports", "activities", ".", "Operative", "treatment", "seems", "to", "be", "the", "appropriate", "treatment", ".", "Osseous", "avulsions", "of", "the", "cruciates", "and", "collateral", "ligaments", "showed", "good", "results", "after", "transosseous", "refixation", "with", "a", "suture", ".", "Suturing", "of", "intraligamentous", "ACL", "-", "ruptures", "as", "well", "as", "patellar", "ligaments", "plasty", "showed", "unsatisfactory", "results", ".", "Secondary", "lesions", "due", "to", "instability", "of", "the", "knee", "where", "also", "observed", "in", "children", ".", "Children", "cannot", "self", "estimate", "the", "severity", "of", "the", "injury", "so", "subjective", "statements", "are", "insecure", ".", "Trauma", ",", "surgery", ",", "pain", "and", "immobilisation", "cause", "a", "marked", "malfunction", "of", "the", "senso", "-", "motor", "system", "which", "is", "effectively", "treated", "by", "physiotherapy", "." ]
[ "umlsterm" ]
children is an umlsterm, accidents is an umlsterm, leisure is an umlsterm, sports activities is an umlsterm, knee joint is an umlsterm, trauma is an umlsterm, therapy is an umlsterm, retrospective is an umlsterm, treatment is an umlsterm, knee is an umlsterm, children is an umlsterm, age is an umlsterm, injury is an umlsterm, age is an umlsterm, trauma is an umlsterm, injuries is an umlsterm, anterior cruciate ligament is an umlsterm, cause is an umlsterm, sports activities is an umlsterm, treatment is an umlsterm, treatment is an umlsterm, collateral ligaments is an umlsterm, patellar ligaments is an umlsterm, Secondary is an umlsterm, knee is an umlsterm, children is an umlsterm, Children is an umlsterm, self is an umlsterm, injury is an umlsterm, Trauma is an umlsterm, surgery is an umlsterm, pain is an umlsterm, immobilisation is an umlsterm, physiotherapy is an umlsterm
DerUnfallchirurg.91020619.eng.abstr_task1
Sentence: Although children are injured everyday through accidents , road traffic , leisure or sports activities , internal lesions of the knee joint due to the trauma are rare . Diagnose and therapy follow rather empirical than analytical patterns . A retrospective , controlled study evaluates and recommends ways of treatment . Traumatic internal lesions of the knee where analysed in 76 children up to age 16. The pattern of injury changed with increasing age , the trauma remaining the same . Most common where injuries to the anterior cruciate ligament ( ACL ) . Main cause where sports activities . Operative treatment seems to be the appropriate treatment . Osseous avulsions of the cruciates and collateral ligaments showed good results after transosseous refixation with a suture . Suturing of intraligamentous ACL-ruptures as well as patellar ligaments plasty showed unsatisfactory results . Secondary lesions due to instability of the knee where also observed in children . Children cannot self estimate the severity of the injury so subjective statements are insecure . Trauma , surgery , pain and immobilisation cause a marked malfunction of the senso-motor system which is effectively treated by physiotherapy . Instructions: please typing these entity words according to sentence: children, accidents, leisure, sports activities, knee joint, trauma, therapy, retrospective, treatment, knee, children, age, injury, age, trauma, injuries, anterior cruciate ligament, cause, sports activities, treatment, treatment, collateral ligaments, patellar ligaments, Secondary, knee, children, Children, self, injury, Trauma, surgery, pain, immobilisation, physiotherapy Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Although children are injured everyday through accidents , road traffic , leisure or sports activities , internal lesions of the knee joint due to the trauma are rare . Diagnose and therapy follow rather empirical than analytical patterns . A retrospective , controlled study evaluates and recommends ways of treatment . Traumatic internal lesions of the knee where analysed in 76 children up to age 16. The pattern of injury changed with increasing age , the trauma remaining the same . Most common where injuries to the anterior cruciate ligament ( ACL ) . Main cause where sports activities . Operative treatment seems to be the appropriate treatment . Osseous avulsions of the cruciates and collateral ligaments showed good results after transosseous refixation with a suture . Suturing of intraligamentous ACL-ruptures as well as patellar ligaments plasty showed unsatisfactory results . Secondary lesions due to instability of the knee where also observed in children . Children cannot self estimate the severity of the injury so subjective statements are insecure . Trauma , surgery , pain and immobilisation cause a marked malfunction of the senso-motor system which is effectively treated by physiotherapy .
[ "Although", "children", "are", "injured", "everyday", "through", "accidents", ",", "road", "traffic", ",", "leisure", "or", "sports", "activities", ",", "internal", "lesions", "of", "the", "knee", "joint", "due", "to", "the", "trauma", "are", "rare", ".", "Diagnose", "and", "therapy", "follow", "rather", "empirical", "than", "analytical", "patterns", ".", "A", "retrospective", ",", "controlled", "study", "evaluates", "and", "recommends", "ways", "of", "treatment", ".", "Traumatic", "internal", "lesions", "of", "the", "knee", "where", "analysed", "in", "76", "children", "up", "to", "age", "16", ".", "The", "pattern", "of", "injury", "changed", "with", "increasing", "age", ",", "the", "trauma", "remaining", "the", "same", ".", "Most", "common", "where", "injuries", "to", "the", "anterior", "cruciate", "ligament", "(", "ACL", ")", ".", "Main", "cause", "where", "sports", "activities", ".", "Operative", "treatment", "seems", "to", "be", "the", "appropriate", "treatment", ".", "Osseous", "avulsions", "of", "the", "cruciates", "and", "collateral", "ligaments", "showed", "good", "results", "after", "transosseous", "refixation", "with", "a", "suture", ".", "Suturing", "of", "intraligamentous", "ACL", "-", "ruptures", "as", "well", "as", "patellar", "ligaments", "plasty", "showed", "unsatisfactory", "results", ".", "Secondary", "lesions", "due", "to", "instability", "of", "the", "knee", "where", "also", "observed", "in", "children", ".", "Children", "cannot", "self", "estimate", "the", "severity", "of", "the", "injury", "so", "subjective", "statements", "are", "insecure", ".", "Trauma", ",", "surgery", ",", "pain", "and", "immobilisation", "cause", "a", "marked", "malfunction", "of", "the", "senso", "-", "motor", "system", "which", "is", "effectively", "treated", "by", "physiotherapy", "." ]
[ "umlsterm" ]
children, accidents, leisure, sports activities, knee joint, trauma, therapy, retrospective, treatment, knee, children, age, injury, age, trauma, injuries, anterior cruciate ligament, cause, sports activities, treatment, treatment, collateral ligaments, patellar ligaments, Secondary, knee, children, Children, self, injury, Trauma, surgery, pain, immobilisation, physiotherapy
DerUnfallchirurg.91020619.eng.abstr_task2
Sentence: Although children are injured everyday through accidents , road traffic , leisure or sports activities , internal lesions of the knee joint due to the trauma are rare . Diagnose and therapy follow rather empirical than analytical patterns . A retrospective , controlled study evaluates and recommends ways of treatment . Traumatic internal lesions of the knee where analysed in 76 children up to age 16. The pattern of injury changed with increasing age , the trauma remaining the same . Most common where injuries to the anterior cruciate ligament ( ACL ) . Main cause where sports activities . Operative treatment seems to be the appropriate treatment . Osseous avulsions of the cruciates and collateral ligaments showed good results after transosseous refixation with a suture . Suturing of intraligamentous ACL-ruptures as well as patellar ligaments plasty showed unsatisfactory results . Secondary lesions due to instability of the knee where also observed in children . Children cannot self estimate the severity of the injury so subjective statements are insecure . Trauma , surgery , pain and immobilisation cause a marked malfunction of the senso-motor system which is effectively treated by physiotherapy . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Although children are injured everyday through accidents , road traffic , leisure or sports activities , internal lesions of the knee joint due to the trauma are rare . Diagnose and therapy follow rather empirical than analytical patterns . A retrospective , controlled study evaluates and recommends ways of treatment . Traumatic internal lesions of the knee where analysed in 76 children up to age 16. The pattern of injury changed with increasing age , the trauma remaining the same . Most common where injuries to the anterior cruciate ligament ( ACL ) . Main cause where sports activities . Operative treatment seems to be the appropriate treatment . Osseous avulsions of the cruciates and collateral ligaments showed good results after transosseous refixation with a suture . Suturing of intraligamentous ACL-ruptures as well as patellar ligaments plasty showed unsatisfactory results . Secondary lesions due to instability of the knee where also observed in children . Children cannot self estimate the severity of the injury so subjective statements are insecure . Trauma , surgery , pain and immobilisation cause a marked malfunction of the senso-motor system which is effectively treated by physiotherapy .
[ "Although", "children", "are", "injured", "everyday", "through", "accidents", ",", "road", "traffic", ",", "leisure", "or", "sports", "activities", ",", "internal", "lesions", "of", "the", "knee", "joint", "due", "to", "the", "trauma", "are", "rare", ".", "Diagnose", "and", "therapy", "follow", "rather", "empirical", "than", "analytical", "patterns", ".", "A", "retrospective", ",", "controlled", "study", "evaluates", "and", "recommends", "ways", "of", "treatment", ".", "Traumatic", "internal", "lesions", "of", "the", "knee", "where", "analysed", "in", "76", "children", "up", "to", "age", "16", ".", "The", "pattern", "of", "injury", "changed", "with", "increasing", "age", ",", "the", "trauma", "remaining", "the", "same", ".", "Most", "common", "where", "injuries", "to", "the", "anterior", "cruciate", "ligament", "(", "ACL", ")", ".", "Main", "cause", "where", "sports", "activities", ".", "Operative", "treatment", "seems", "to", "be", "the", "appropriate", "treatment", ".", "Osseous", "avulsions", "of", "the", "cruciates", "and", "collateral", "ligaments", "showed", "good", "results", "after", "transosseous", "refixation", "with", "a", "suture", ".", "Suturing", "of", "intraligamentous", "ACL", "-", "ruptures", "as", "well", "as", "patellar", "ligaments", "plasty", "showed", "unsatisfactory", "results", ".", "Secondary", "lesions", "due", "to", "instability", "of", "the", "knee", "where", "also", "observed", "in", "children", ".", "Children", "cannot", "self", "estimate", "the", "severity", "of", "the", "injury", "so", "subjective", "statements", "are", "insecure", ".", "Trauma", ",", "surgery", ",", "pain", "and", "immobilisation", "cause", "a", "marked", "malfunction", "of", "the", "senso", "-", "motor", "system", "which", "is", "effectively", "treated", "by", "physiotherapy", "." ]
[ "umlsterm" ]
Gewichtsverlustes is an umlsterm, Abgeschlagenheit is an umlsterm, Hausarzt is an umlsterm, Leukozytose is an umlsterm, Sonographie is an umlsterm, Lymphknotenvergroesserung is an umlsterm, malignen Lymphoms is an umlsterm, Lymphknoten is an umlsterm, Knochenmarkbiopsie is an umlsterm, Lymphknotenpunktion is an umlsterm, Therapie is an umlsterm, Lymphknotenschwellung is an umlsterm, Infektion is an umlsterm, Yersinia enterocolitica is an umlsterm, Literatur is an umlsterm, Diagnostik is an umlsterm, Differentialdiagnose is an umlsterm, Lymphknotenvergroesserungen is an umlsterm
DerRadiologe.80380037.ger.abstr_task0
Sentence: Berichtet wird der Fall einer klinisch inapperenten Yersinia-enterocolitica-Infektion bei einer 46 jaehrigen Patientin , die aufgrund stetigen Gewichtsverlustes und koerperlicher Abgeschlagenheit den Hausarzt konsultierte . Dieser diagnostizierte eine Leukozytose . Die daraufhin durchgefuehrte Sonographie ergab eine massive abdominale Lymphknotenvergroesserung . Unter dem Verdacht eines malignen Lymphoms erfolgte eine computertomographische Ausbreitungsdiagnostik , die die Erkrankung auf mesenteriale und retroperitoneale Lymphknoten beschraenkt zeigte . Knochenmarkbiopsie und CT-gestuetzte Lymphknotenpunktion ergaben keinen Hinweis auf eine lymphatische Systemerkrankung . Ohne Therapie zeigte eine CT-Kontrolle nach 6 Monaten eine deutliche Regredienz der Lymphknotenschwellung . Bei der Erregersuche konnte serologisch eine zurueckliegende Infektion mit Yersinia enterocolitica , Serotyp 03 , nachgewiesen werden . Zu diesem Zeitpunkt war die Patientin beschwerdefrei . Anhand der Literatur werden Diagnostik und Differentialdiagnose benigner abdominaler Lymphknotenvergroesserungen diskutiert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]
Berichtet wird der Fall einer klinisch inapperenten Yersinia-enterocolitica-Infektion bei einer 46 jaehrigen Patientin , die aufgrund stetigen Gewichtsverlustes und koerperlicher Abgeschlagenheit den Hausarzt konsultierte . Dieser diagnostizierte eine Leukozytose . Die daraufhin durchgefuehrte Sonographie ergab eine massive abdominale Lymphknotenvergroesserung . Unter dem Verdacht eines malignen Lymphoms erfolgte eine computertomographische Ausbreitungsdiagnostik , die die Erkrankung auf mesenteriale und retroperitoneale Lymphknoten beschraenkt zeigte . Knochenmarkbiopsie und CT-gestuetzte Lymphknotenpunktion ergaben keinen Hinweis auf eine lymphatische Systemerkrankung . Ohne Therapie zeigte eine CT-Kontrolle nach 6 Monaten eine deutliche Regredienz der Lymphknotenschwellung . Bei der Erregersuche konnte serologisch eine zurueckliegende Infektion mit Yersinia enterocolitica , Serotyp 03 , nachgewiesen werden . Zu diesem Zeitpunkt war die Patientin beschwerdefrei . Anhand der Literatur werden Diagnostik und Differentialdiagnose benigner abdominaler Lymphknotenvergroesserungen diskutiert .
[ "Berichtet", "wird", "der", "Fall", "einer", "klinisch", "inapperenten", "Yersinia", "-", "enterocolitica", "-", "Infektion", "bei", "einer", "46", "jaehrigen", "Patientin", ",", "die", "aufgrund", "stetigen", "Gewichtsverlustes", "und", "koerperlicher", "Abgeschlagenheit", "den", "Hausarzt", "konsultierte", ".", "Dieser", "diagnostizierte", "eine", "Leukozytose", ".", "Die", "daraufhin", "durchgefuehrte", "Sonographie", "ergab", "eine", "massive", "abdominale", "Lymphknotenvergroesserung", ".", "Unter", "dem", "Verdacht", "eines", "malignen", "Lymphoms", "erfolgte", "eine", "computertomographische", "Ausbreitungsdiagnostik", ",", "die", "die", "Erkrankung", "auf", "mesenteriale", "und", "retroperitoneale", "Lymphknoten", "beschraenkt", "zeigte", ".", "Knochenmarkbiopsie", "und", "CT", "-", "gestuetzte", "Lymphknotenpunktion", "ergaben", "keinen", "Hinweis", "auf", "eine", "lymphatische", "Systemerkrankung", ".", "Ohne", "Therapie", "zeigte", "eine", "CT", "-", "Kontrolle", "nach", "6", "Monaten", "eine", "deutliche", "Regredienz", "der", "Lymphknotenschwellung", ".", "Bei", "der", "Erregersuche", "konnte", "serologisch", "eine", "zurueckliegende", "Infektion", "mit", "Yersinia", "enterocolitica", ",", "Serotyp", "03", ",", "nachgewiesen", "werden", ".", "Zu", "diesem", "Zeitpunkt", "war", "die", "Patientin", "beschwerdefrei", ".", "Anhand", "der", "Literatur", "werden", "Diagnostik", "und", "Differentialdiagnose", "benigner", "abdominaler", "Lymphknotenvergroesserungen", "diskutiert", "." ]
[ "umlsterm" ]
Gewichtsverlustes is an umlsterm, Abgeschlagenheit is an umlsterm, Hausarzt is an umlsterm, Leukozytose is an umlsterm, Sonographie is an umlsterm, Lymphknotenvergroesserung is an umlsterm, malignen Lymphoms is an umlsterm, Lymphknoten is an umlsterm, Knochenmarkbiopsie is an umlsterm, Lymphknotenpunktion is an umlsterm, Therapie is an umlsterm, Lymphknotenschwellung is an umlsterm, Infektion is an umlsterm, Yersinia enterocolitica is an umlsterm, Literatur is an umlsterm, Diagnostik is an umlsterm, Differentialdiagnose is an umlsterm, Lymphknotenvergroesserungen is an umlsterm
DerRadiologe.80380037.ger.abstr_task1
Sentence: Berichtet wird der Fall einer klinisch inapperenten Yersinia-enterocolitica-Infektion bei einer 46 jaehrigen Patientin , die aufgrund stetigen Gewichtsverlustes und koerperlicher Abgeschlagenheit den Hausarzt konsultierte . Dieser diagnostizierte eine Leukozytose . Die daraufhin durchgefuehrte Sonographie ergab eine massive abdominale Lymphknotenvergroesserung . Unter dem Verdacht eines malignen Lymphoms erfolgte eine computertomographische Ausbreitungsdiagnostik , die die Erkrankung auf mesenteriale und retroperitoneale Lymphknoten beschraenkt zeigte . Knochenmarkbiopsie und CT-gestuetzte Lymphknotenpunktion ergaben keinen Hinweis auf eine lymphatische Systemerkrankung . Ohne Therapie zeigte eine CT-Kontrolle nach 6 Monaten eine deutliche Regredienz der Lymphknotenschwellung . Bei der Erregersuche konnte serologisch eine zurueckliegende Infektion mit Yersinia enterocolitica , Serotyp 03 , nachgewiesen werden . Zu diesem Zeitpunkt war die Patientin beschwerdefrei . Anhand der Literatur werden Diagnostik und Differentialdiagnose benigner abdominaler Lymphknotenvergroesserungen diskutiert . Instructions: please typing these entity words according to sentence: Gewichtsverlustes, Abgeschlagenheit, Hausarzt, Leukozytose, Sonographie, Lymphknotenvergroesserung, malignen Lymphoms, Lymphknoten, Knochenmarkbiopsie, Lymphknotenpunktion, Therapie, Lymphknotenschwellung, Infektion, Yersinia enterocolitica, Literatur, Diagnostik, Differentialdiagnose, Lymphknotenvergroesserungen Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]
Berichtet wird der Fall einer klinisch inapperenten Yersinia-enterocolitica-Infektion bei einer 46 jaehrigen Patientin , die aufgrund stetigen Gewichtsverlustes und koerperlicher Abgeschlagenheit den Hausarzt konsultierte . Dieser diagnostizierte eine Leukozytose . Die daraufhin durchgefuehrte Sonographie ergab eine massive abdominale Lymphknotenvergroesserung . Unter dem Verdacht eines malignen Lymphoms erfolgte eine computertomographische Ausbreitungsdiagnostik , die die Erkrankung auf mesenteriale und retroperitoneale Lymphknoten beschraenkt zeigte . Knochenmarkbiopsie und CT-gestuetzte Lymphknotenpunktion ergaben keinen Hinweis auf eine lymphatische Systemerkrankung . Ohne Therapie zeigte eine CT-Kontrolle nach 6 Monaten eine deutliche Regredienz der Lymphknotenschwellung . Bei der Erregersuche konnte serologisch eine zurueckliegende Infektion mit Yersinia enterocolitica , Serotyp 03 , nachgewiesen werden . Zu diesem Zeitpunkt war die Patientin beschwerdefrei . Anhand der Literatur werden Diagnostik und Differentialdiagnose benigner abdominaler Lymphknotenvergroesserungen diskutiert .
[ "Berichtet", "wird", "der", "Fall", "einer", "klinisch", "inapperenten", "Yersinia", "-", "enterocolitica", "-", "Infektion", "bei", "einer", "46", "jaehrigen", "Patientin", ",", "die", "aufgrund", "stetigen", "Gewichtsverlustes", "und", "koerperlicher", "Abgeschlagenheit", "den", "Hausarzt", "konsultierte", ".", "Dieser", "diagnostizierte", "eine", "Leukozytose", ".", "Die", "daraufhin", "durchgefuehrte", "Sonographie", "ergab", "eine", "massive", "abdominale", "Lymphknotenvergroesserung", ".", "Unter", "dem", "Verdacht", "eines", "malignen", "Lymphoms", "erfolgte", "eine", "computertomographische", "Ausbreitungsdiagnostik", ",", "die", "die", "Erkrankung", "auf", "mesenteriale", "und", "retroperitoneale", "Lymphknoten", "beschraenkt", "zeigte", ".", "Knochenmarkbiopsie", "und", "CT", "-", "gestuetzte", "Lymphknotenpunktion", "ergaben", "keinen", "Hinweis", "auf", "eine", "lymphatische", "Systemerkrankung", ".", "Ohne", "Therapie", "zeigte", "eine", "CT", "-", "Kontrolle", "nach", "6", "Monaten", "eine", "deutliche", "Regredienz", "der", "Lymphknotenschwellung", ".", "Bei", "der", "Erregersuche", "konnte", "serologisch", "eine", "zurueckliegende", "Infektion", "mit", "Yersinia", "enterocolitica", ",", "Serotyp", "03", ",", "nachgewiesen", "werden", ".", "Zu", "diesem", "Zeitpunkt", "war", "die", "Patientin", "beschwerdefrei", ".", "Anhand", "der", "Literatur", "werden", "Diagnostik", "und", "Differentialdiagnose", "benigner", "abdominaler", "Lymphknotenvergroesserungen", "diskutiert", "." ]
[ "umlsterm" ]
Gewichtsverlustes, Abgeschlagenheit, Hausarzt, Leukozytose, Sonographie, Lymphknotenvergroesserung, malignen Lymphoms, Lymphknoten, Knochenmarkbiopsie, Lymphknotenpunktion, Therapie, Lymphknotenschwellung, Infektion, Yersinia enterocolitica, Literatur, Diagnostik, Differentialdiagnose, Lymphknotenvergroesserungen
DerRadiologe.80380037.ger.abstr_task2
Sentence: Berichtet wird der Fall einer klinisch inapperenten Yersinia-enterocolitica-Infektion bei einer 46 jaehrigen Patientin , die aufgrund stetigen Gewichtsverlustes und koerperlicher Abgeschlagenheit den Hausarzt konsultierte . Dieser diagnostizierte eine Leukozytose . Die daraufhin durchgefuehrte Sonographie ergab eine massive abdominale Lymphknotenvergroesserung . Unter dem Verdacht eines malignen Lymphoms erfolgte eine computertomographische Ausbreitungsdiagnostik , die die Erkrankung auf mesenteriale und retroperitoneale Lymphknoten beschraenkt zeigte . Knochenmarkbiopsie und CT-gestuetzte Lymphknotenpunktion ergaben keinen Hinweis auf eine lymphatische Systemerkrankung . Ohne Therapie zeigte eine CT-Kontrolle nach 6 Monaten eine deutliche Regredienz der Lymphknotenschwellung . Bei der Erregersuche konnte serologisch eine zurueckliegende Infektion mit Yersinia enterocolitica , Serotyp 03 , nachgewiesen werden . Zu diesem Zeitpunkt war die Patientin beschwerdefrei . Anhand der Literatur werden Diagnostik und Differentialdiagnose benigner abdominaler Lymphknotenvergroesserungen diskutiert . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]
Berichtet wird der Fall einer klinisch inapperenten Yersinia-enterocolitica-Infektion bei einer 46 jaehrigen Patientin , die aufgrund stetigen Gewichtsverlustes und koerperlicher Abgeschlagenheit den Hausarzt konsultierte . Dieser diagnostizierte eine Leukozytose . Die daraufhin durchgefuehrte Sonographie ergab eine massive abdominale Lymphknotenvergroesserung . Unter dem Verdacht eines malignen Lymphoms erfolgte eine computertomographische Ausbreitungsdiagnostik , die die Erkrankung auf mesenteriale und retroperitoneale Lymphknoten beschraenkt zeigte . Knochenmarkbiopsie und CT-gestuetzte Lymphknotenpunktion ergaben keinen Hinweis auf eine lymphatische Systemerkrankung . Ohne Therapie zeigte eine CT-Kontrolle nach 6 Monaten eine deutliche Regredienz der Lymphknotenschwellung . Bei der Erregersuche konnte serologisch eine zurueckliegende Infektion mit Yersinia enterocolitica , Serotyp 03 , nachgewiesen werden . Zu diesem Zeitpunkt war die Patientin beschwerdefrei . Anhand der Literatur werden Diagnostik und Differentialdiagnose benigner abdominaler Lymphknotenvergroesserungen diskutiert .
[ "Berichtet", "wird", "der", "Fall", "einer", "klinisch", "inapperenten", "Yersinia", "-", "enterocolitica", "-", "Infektion", "bei", "einer", "46", "jaehrigen", "Patientin", ",", "die", "aufgrund", "stetigen", "Gewichtsverlustes", "und", "koerperlicher", "Abgeschlagenheit", "den", "Hausarzt", "konsultierte", ".", "Dieser", "diagnostizierte", "eine", "Leukozytose", ".", "Die", "daraufhin", "durchgefuehrte", "Sonographie", "ergab", "eine", "massive", "abdominale", "Lymphknotenvergroesserung", ".", "Unter", "dem", "Verdacht", "eines", "malignen", "Lymphoms", "erfolgte", "eine", "computertomographische", "Ausbreitungsdiagnostik", ",", "die", "die", "Erkrankung", "auf", "mesenteriale", "und", "retroperitoneale", "Lymphknoten", "beschraenkt", "zeigte", ".", "Knochenmarkbiopsie", "und", "CT", "-", "gestuetzte", "Lymphknotenpunktion", "ergaben", "keinen", "Hinweis", "auf", "eine", "lymphatische", "Systemerkrankung", ".", "Ohne", "Therapie", "zeigte", "eine", "CT", "-", "Kontrolle", "nach", "6", "Monaten", "eine", "deutliche", "Regredienz", "der", "Lymphknotenschwellung", ".", "Bei", "der", "Erregersuche", "konnte", "serologisch", "eine", "zurueckliegende", "Infektion", "mit", "Yersinia", "enterocolitica", ",", "Serotyp", "03", ",", "nachgewiesen", "werden", ".", "Zu", "diesem", "Zeitpunkt", "war", "die", "Patientin", "beschwerdefrei", ".", "Anhand", "der", "Literatur", "werden", "Diagnostik", "und", "Differentialdiagnose", "benigner", "abdominaler", "Lymphknotenvergroesserungen", "diskutiert", "." ]
[ "umlsterm" ]
secretory phospholipase A2 is a GENE-N, sPLA2 is a GENE-N, sulfasalazine is a CHEMICAL
9256165_task0
Sentence: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL
[ "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity.
[ "Inhibition", "of", "extracellular", "release", "of", "proinflammatory", "secretory", "phospholipase", "A2", "(", "sPLA2", ")", "by", "sulfasalazine", ":", "a", "novel", "mechanism", "of", "anti", "-", "inflammatory", "activity", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
secretory phospholipase A2 is a GENE-N, sPLA2 is a GENE-N, sulfasalazine is a CHEMICAL
9256165_task1
Sentence: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Instructions: please typing these entity words according to sentence: secretory phospholipase A2, sPLA2, sulfasalazine Options: GENE-N, CHEMICAL
[ "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity.
[ "Inhibition", "of", "extracellular", "release", "of", "proinflammatory", "secretory", "phospholipase", "A2", "(", "sPLA2", ")", "by", "sulfasalazine", ":", "a", "novel", "mechanism", "of", "anti", "-", "inflammatory", "activity", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
secretory phospholipase A2, sPLA2, sulfasalazine
9256165_task2
Sentence: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity.
[ "Inhibition", "of", "extracellular", "release", "of", "proinflammatory", "secretory", "phospholipase", "A2", "(", "sPLA2", ")", "by", "sulfasalazine", ":", "a", "novel", "mechanism", "of", "anti", "-", "inflammatory", "activity", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
myosin heavy chain is a Individual_protein, actin is a Individual_protein
498_task0
Sentence: It therefore appears that myosin heavy chain and actin multigene families are both expressed in a species specific fashion but are independently regulated within a species. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein
[ "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
It therefore appears that myosin heavy chain and actin multigene families are both expressed in a species specific fashion but are independently regulated within a species.
[ "It", "therefore", "appears", "that", "myosin", "heavy", "chain", "and", "actin", "multigene", "families", "are", "both", "expressed", "in", "a", "species", "specific", "fashion", "but", "are", "independently", "regulated", "within", "a", "species", "." ]
[ "Individual_protein" ]
myosin heavy chain is a Individual_protein, actin is a Individual_protein
498_task1
Sentence: It therefore appears that myosin heavy chain and actin multigene families are both expressed in a species specific fashion but are independently regulated within a species. Instructions: please typing these entity words according to sentence: myosin heavy chain, actin Options: Individual_protein
[ "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
It therefore appears that myosin heavy chain and actin multigene families are both expressed in a species specific fashion but are independently regulated within a species.
[ "It", "therefore", "appears", "that", "myosin", "heavy", "chain", "and", "actin", "multigene", "families", "are", "both", "expressed", "in", "a", "species", "specific", "fashion", "but", "are", "independently", "regulated", "within", "a", "species", "." ]
[ "Individual_protein" ]
myosin heavy chain, actin
498_task2
Sentence: It therefore appears that myosin heavy chain and actin multigene families are both expressed in a species specific fashion but are independently regulated within a species. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
It therefore appears that myosin heavy chain and actin multigene families are both expressed in a species specific fashion but are independently regulated within a species.
[ "It", "therefore", "appears", "that", "myosin", "heavy", "chain", "and", "actin", "multigene", "families", "are", "both", "expressed", "in", "a", "species", "specific", "fashion", "but", "are", "independently", "regulated", "within", "a", "species", "." ]
[ "Individual_protein" ]
Patienten is an umlsterm, Elektrokrampftherapie is an umlsterm, Genehmigung is an umlsterm, Heilbehandlung is an umlsterm, vormundschaftsgerichtliche is an umlsterm, Risiko is an umlsterm, retrograder Amnesien is an umlsterm, Elektrokrampftherapie is an umlsterm, Kontraindikationen is an umlsterm, Therapiemassnahme is an umlsterm, Behandlung is an umlsterm, Depressionen is an umlsterm, Psychosen is an umlsterm, Kurzpulsstimulation is an umlsterm, retrograde Amnesien is an umlsterm, vormundschaftsgerichtliche is an umlsterm
DerNervenarzt.90700657.ger.abstr_task0
Sentence: Besteht bei einwilligungsunfaehigen Patienten die Indikation zur Durchfuehrung einer Elektrokrampftherapie ( EKT ) , ist die Genehmigung des Betreuers zur Durchfuehrung der Heilbehandlung erforderlich . Unklar ist , ob aufgrund von eventuellen Nebenwirkungen zusaetzlich eine vormundschaftsgerichtliche Genehmigungspflicht im Sinne des § 1904 BGB anzunehmen ist . Das Landgericht Hamburg war unter Verweis auf das Risiko persistierender retrograder Amnesien von der begruendeten Gefahr eines laenger dauernden gesundheitlichen Schadens ausgegangen und hatte die Genehmigungspflicht bejaht . Die Elektrokrampftherapie ist jedoch unter Beachtung der Kontraindikationen eine sichere und effektive Therapiemassnahme zur Behandlung von Depressionen und schizophrenen Psychosen . Die Anwendung der unilateralen Kurzpulsstimulation reduziert die Haeufigkeit und Auspraegung der kognitiven Nebenwirkungen . Insbesondere retrograde Amnesien treten nur sehr selten und in einer Auspraegung auf , die angesichts der Gefaehrdungen durch die Grunderkrankung zu vernachlaessigen ist . Eine vormundschaftsgerichtliche Genehmigungspflicht im Rahmen des Betreuungsgesetzes ist nach Meinung der Autoren zu verneinen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Besteht bei einwilligungsunfaehigen Patienten die Indikation zur Durchfuehrung einer Elektrokrampftherapie ( EKT ) , ist die Genehmigung des Betreuers zur Durchfuehrung der Heilbehandlung erforderlich . Unklar ist , ob aufgrund von eventuellen Nebenwirkungen zusaetzlich eine vormundschaftsgerichtliche Genehmigungspflicht im Sinne des § 1904 BGB anzunehmen ist . Das Landgericht Hamburg war unter Verweis auf das Risiko persistierender retrograder Amnesien von der begruendeten Gefahr eines laenger dauernden gesundheitlichen Schadens ausgegangen und hatte die Genehmigungspflicht bejaht . Die Elektrokrampftherapie ist jedoch unter Beachtung der Kontraindikationen eine sichere und effektive Therapiemassnahme zur Behandlung von Depressionen und schizophrenen Psychosen . Die Anwendung der unilateralen Kurzpulsstimulation reduziert die Haeufigkeit und Auspraegung der kognitiven Nebenwirkungen . Insbesondere retrograde Amnesien treten nur sehr selten und in einer Auspraegung auf , die angesichts der Gefaehrdungen durch die Grunderkrankung zu vernachlaessigen ist . Eine vormundschaftsgerichtliche Genehmigungspflicht im Rahmen des Betreuungsgesetzes ist nach Meinung der Autoren zu verneinen .
[ "Besteht", "bei", "einwilligungsunfaehigen", "Patienten", "die", "Indikation", "zur", "Durchfuehrung", "einer", "Elektrokrampftherapie", "(", "EKT", ")", ",", "ist", "die", "Genehmigung", "des", "Betreuers", "zur", "Durchfuehrung", "der", "Heilbehandlung", "erforderlich", ".", "Unklar", "ist", ",", "ob", "aufgrund", "von", "eventuellen", "Nebenwirkungen", "zusaetzlich", "eine", "vormundschaftsgerichtliche", "Genehmigungspflicht", "im", "Sinne", "des", "§", "1904", "BGB", "anzunehmen", "ist", ".", "Das", "Landgericht", "Hamburg", "war", "unter", "Verweis", "auf", "das", "Risiko", "persistierender", "retrograder", "Amnesien", "von", "der", "begruendeten", "Gefahr", "eines", "laenger", "dauernden", "gesundheitlichen", "Schadens", "ausgegangen", "und", "hatte", "die", "Genehmigungspflicht", "bejaht", ".", "Die", "Elektrokrampftherapie", "ist", "jedoch", "unter", "Beachtung", "der", "Kontraindikationen", "eine", "sichere", "und", "effektive", "Therapiemassnahme", "zur", "Behandlung", "von", "Depressionen", "und", "schizophrenen", "Psychosen", ".", "Die", "Anwendung", "der", "unilateralen", "Kurzpulsstimulation", "reduziert", "die", "Haeufigkeit", "und", "Auspraegung", "der", "kognitiven", "Nebenwirkungen", ".", "Insbesondere", "retrograde", "Amnesien", "treten", "nur", "sehr", "selten", "und", "in", "einer", "Auspraegung", "auf", ",", "die", "angesichts", "der", "Gefaehrdungen", "durch", "die", "Grunderkrankung", "zu", "vernachlaessigen", "ist", ".", "Eine", "vormundschaftsgerichtliche", "Genehmigungspflicht", "im", "Rahmen", "des", "Betreuungsgesetzes", "ist", "nach", "Meinung", "der", "Autoren", "zu", "verneinen", "." ]
[ "umlsterm" ]
Patienten is an umlsterm, Elektrokrampftherapie is an umlsterm, Genehmigung is an umlsterm, Heilbehandlung is an umlsterm, vormundschaftsgerichtliche is an umlsterm, Risiko is an umlsterm, retrograder Amnesien is an umlsterm, Elektrokrampftherapie is an umlsterm, Kontraindikationen is an umlsterm, Therapiemassnahme is an umlsterm, Behandlung is an umlsterm, Depressionen is an umlsterm, Psychosen is an umlsterm, Kurzpulsstimulation is an umlsterm, retrograde Amnesien is an umlsterm, vormundschaftsgerichtliche is an umlsterm
DerNervenarzt.90700657.ger.abstr_task1
Sentence: Besteht bei einwilligungsunfaehigen Patienten die Indikation zur Durchfuehrung einer Elektrokrampftherapie ( EKT ) , ist die Genehmigung des Betreuers zur Durchfuehrung der Heilbehandlung erforderlich . Unklar ist , ob aufgrund von eventuellen Nebenwirkungen zusaetzlich eine vormundschaftsgerichtliche Genehmigungspflicht im Sinne des § 1904 BGB anzunehmen ist . Das Landgericht Hamburg war unter Verweis auf das Risiko persistierender retrograder Amnesien von der begruendeten Gefahr eines laenger dauernden gesundheitlichen Schadens ausgegangen und hatte die Genehmigungspflicht bejaht . Die Elektrokrampftherapie ist jedoch unter Beachtung der Kontraindikationen eine sichere und effektive Therapiemassnahme zur Behandlung von Depressionen und schizophrenen Psychosen . Die Anwendung der unilateralen Kurzpulsstimulation reduziert die Haeufigkeit und Auspraegung der kognitiven Nebenwirkungen . Insbesondere retrograde Amnesien treten nur sehr selten und in einer Auspraegung auf , die angesichts der Gefaehrdungen durch die Grunderkrankung zu vernachlaessigen ist . Eine vormundschaftsgerichtliche Genehmigungspflicht im Rahmen des Betreuungsgesetzes ist nach Meinung der Autoren zu verneinen . Instructions: please typing these entity words according to sentence: Patienten, Elektrokrampftherapie, Genehmigung, Heilbehandlung, vormundschaftsgerichtliche, Risiko, retrograder Amnesien, Elektrokrampftherapie, Kontraindikationen, Therapiemassnahme, Behandlung, Depressionen, Psychosen, Kurzpulsstimulation, retrograde Amnesien, vormundschaftsgerichtliche Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Besteht bei einwilligungsunfaehigen Patienten die Indikation zur Durchfuehrung einer Elektrokrampftherapie ( EKT ) , ist die Genehmigung des Betreuers zur Durchfuehrung der Heilbehandlung erforderlich . Unklar ist , ob aufgrund von eventuellen Nebenwirkungen zusaetzlich eine vormundschaftsgerichtliche Genehmigungspflicht im Sinne des § 1904 BGB anzunehmen ist . Das Landgericht Hamburg war unter Verweis auf das Risiko persistierender retrograder Amnesien von der begruendeten Gefahr eines laenger dauernden gesundheitlichen Schadens ausgegangen und hatte die Genehmigungspflicht bejaht . Die Elektrokrampftherapie ist jedoch unter Beachtung der Kontraindikationen eine sichere und effektive Therapiemassnahme zur Behandlung von Depressionen und schizophrenen Psychosen . Die Anwendung der unilateralen Kurzpulsstimulation reduziert die Haeufigkeit und Auspraegung der kognitiven Nebenwirkungen . Insbesondere retrograde Amnesien treten nur sehr selten und in einer Auspraegung auf , die angesichts der Gefaehrdungen durch die Grunderkrankung zu vernachlaessigen ist . Eine vormundschaftsgerichtliche Genehmigungspflicht im Rahmen des Betreuungsgesetzes ist nach Meinung der Autoren zu verneinen .
[ "Besteht", "bei", "einwilligungsunfaehigen", "Patienten", "die", "Indikation", "zur", "Durchfuehrung", "einer", "Elektrokrampftherapie", "(", "EKT", ")", ",", "ist", "die", "Genehmigung", "des", "Betreuers", "zur", "Durchfuehrung", "der", "Heilbehandlung", "erforderlich", ".", "Unklar", "ist", ",", "ob", "aufgrund", "von", "eventuellen", "Nebenwirkungen", "zusaetzlich", "eine", "vormundschaftsgerichtliche", "Genehmigungspflicht", "im", "Sinne", "des", "§", "1904", "BGB", "anzunehmen", "ist", ".", "Das", "Landgericht", "Hamburg", "war", "unter", "Verweis", "auf", "das", "Risiko", "persistierender", "retrograder", "Amnesien", "von", "der", "begruendeten", "Gefahr", "eines", "laenger", "dauernden", "gesundheitlichen", "Schadens", "ausgegangen", "und", "hatte", "die", "Genehmigungspflicht", "bejaht", ".", "Die", "Elektrokrampftherapie", "ist", "jedoch", "unter", "Beachtung", "der", "Kontraindikationen", "eine", "sichere", "und", "effektive", "Therapiemassnahme", "zur", "Behandlung", "von", "Depressionen", "und", "schizophrenen", "Psychosen", ".", "Die", "Anwendung", "der", "unilateralen", "Kurzpulsstimulation", "reduziert", "die", "Haeufigkeit", "und", "Auspraegung", "der", "kognitiven", "Nebenwirkungen", ".", "Insbesondere", "retrograde", "Amnesien", "treten", "nur", "sehr", "selten", "und", "in", "einer", "Auspraegung", "auf", ",", "die", "angesichts", "der", "Gefaehrdungen", "durch", "die", "Grunderkrankung", "zu", "vernachlaessigen", "ist", ".", "Eine", "vormundschaftsgerichtliche", "Genehmigungspflicht", "im", "Rahmen", "des", "Betreuungsgesetzes", "ist", "nach", "Meinung", "der", "Autoren", "zu", "verneinen", "." ]
[ "umlsterm" ]
Patienten, Elektrokrampftherapie, Genehmigung, Heilbehandlung, vormundschaftsgerichtliche, Risiko, retrograder Amnesien, Elektrokrampftherapie, Kontraindikationen, Therapiemassnahme, Behandlung, Depressionen, Psychosen, Kurzpulsstimulation, retrograde Amnesien, vormundschaftsgerichtliche
DerNervenarzt.90700657.ger.abstr_task2
Sentence: Besteht bei einwilligungsunfaehigen Patienten die Indikation zur Durchfuehrung einer Elektrokrampftherapie ( EKT ) , ist die Genehmigung des Betreuers zur Durchfuehrung der Heilbehandlung erforderlich . Unklar ist , ob aufgrund von eventuellen Nebenwirkungen zusaetzlich eine vormundschaftsgerichtliche Genehmigungspflicht im Sinne des § 1904 BGB anzunehmen ist . Das Landgericht Hamburg war unter Verweis auf das Risiko persistierender retrograder Amnesien von der begruendeten Gefahr eines laenger dauernden gesundheitlichen Schadens ausgegangen und hatte die Genehmigungspflicht bejaht . Die Elektrokrampftherapie ist jedoch unter Beachtung der Kontraindikationen eine sichere und effektive Therapiemassnahme zur Behandlung von Depressionen und schizophrenen Psychosen . Die Anwendung der unilateralen Kurzpulsstimulation reduziert die Haeufigkeit und Auspraegung der kognitiven Nebenwirkungen . Insbesondere retrograde Amnesien treten nur sehr selten und in einer Auspraegung auf , die angesichts der Gefaehrdungen durch die Grunderkrankung zu vernachlaessigen ist . Eine vormundschaftsgerichtliche Genehmigungspflicht im Rahmen des Betreuungsgesetzes ist nach Meinung der Autoren zu verneinen . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Besteht bei einwilligungsunfaehigen Patienten die Indikation zur Durchfuehrung einer Elektrokrampftherapie ( EKT ) , ist die Genehmigung des Betreuers zur Durchfuehrung der Heilbehandlung erforderlich . Unklar ist , ob aufgrund von eventuellen Nebenwirkungen zusaetzlich eine vormundschaftsgerichtliche Genehmigungspflicht im Sinne des § 1904 BGB anzunehmen ist . Das Landgericht Hamburg war unter Verweis auf das Risiko persistierender retrograder Amnesien von der begruendeten Gefahr eines laenger dauernden gesundheitlichen Schadens ausgegangen und hatte die Genehmigungspflicht bejaht . Die Elektrokrampftherapie ist jedoch unter Beachtung der Kontraindikationen eine sichere und effektive Therapiemassnahme zur Behandlung von Depressionen und schizophrenen Psychosen . Die Anwendung der unilateralen Kurzpulsstimulation reduziert die Haeufigkeit und Auspraegung der kognitiven Nebenwirkungen . Insbesondere retrograde Amnesien treten nur sehr selten und in einer Auspraegung auf , die angesichts der Gefaehrdungen durch die Grunderkrankung zu vernachlaessigen ist . Eine vormundschaftsgerichtliche Genehmigungspflicht im Rahmen des Betreuungsgesetzes ist nach Meinung der Autoren zu verneinen .
[ "Besteht", "bei", "einwilligungsunfaehigen", "Patienten", "die", "Indikation", "zur", "Durchfuehrung", "einer", "Elektrokrampftherapie", "(", "EKT", ")", ",", "ist", "die", "Genehmigung", "des", "Betreuers", "zur", "Durchfuehrung", "der", "Heilbehandlung", "erforderlich", ".", "Unklar", "ist", ",", "ob", "aufgrund", "von", "eventuellen", "Nebenwirkungen", "zusaetzlich", "eine", "vormundschaftsgerichtliche", "Genehmigungspflicht", "im", "Sinne", "des", "§", "1904", "BGB", "anzunehmen", "ist", ".", "Das", "Landgericht", "Hamburg", "war", "unter", "Verweis", "auf", "das", "Risiko", "persistierender", "retrograder", "Amnesien", "von", "der", "begruendeten", "Gefahr", "eines", "laenger", "dauernden", "gesundheitlichen", "Schadens", "ausgegangen", "und", "hatte", "die", "Genehmigungspflicht", "bejaht", ".", "Die", "Elektrokrampftherapie", "ist", "jedoch", "unter", "Beachtung", "der", "Kontraindikationen", "eine", "sichere", "und", "effektive", "Therapiemassnahme", "zur", "Behandlung", "von", "Depressionen", "und", "schizophrenen", "Psychosen", ".", "Die", "Anwendung", "der", "unilateralen", "Kurzpulsstimulation", "reduziert", "die", "Haeufigkeit", "und", "Auspraegung", "der", "kognitiven", "Nebenwirkungen", ".", "Insbesondere", "retrograde", "Amnesien", "treten", "nur", "sehr", "selten", "und", "in", "einer", "Auspraegung", "auf", ",", "die", "angesichts", "der", "Gefaehrdungen", "durch", "die", "Grunderkrankung", "zu", "vernachlaessigen", "ist", ".", "Eine", "vormundschaftsgerichtliche", "Genehmigungspflicht", "im", "Rahmen", "des", "Betreuungsgesetzes", "ist", "nach", "Meinung", "der", "Autoren", "zu", "verneinen", "." ]
[ "umlsterm" ]
remote ischemic perconditioning is a Intervention_Surgical, valve replacement surgery . is a Participant_Condition, Remote ischemic perconditioning ( RIPerc is a Intervention_Surgical, Patients with rheumatic heart disease undergoing valve replacement surgery is a Participant_Condition, control is a Intervention_Control, surgery . Clinical data is a Outcome_Physical, the levels of injury biomarkers for the heart , lungs , liver , and kidneys is a Outcome_Physical, the release of serum cardiac troponin is a Outcome_Physical, P = 0.04 ) is a Outcome_Other, the inotropic is a Outcome_Other, that of the control ; postoperative is a Outcome_Other, 545.1 ± 349.0 ml , P = 0.048 ) is a Outcome_Physical, the incidence is a Outcome_Adverse-effects, difference was observed in the levels of biomarkers for renal injury and is a Outcome_Physical, valve replacement surgery induced multiple beneficial effects postoperatively including reduced drainage and myocardial damage , lower incidence of acute lung injury , and is a Outcome_Physical
72170_task0
Sentence: Multiorgan protection of remote ischemic perconditioning in valve replacement surgery . BACKGROUND Remote ischemic perconditioning ( RIPerc ) is a new alternative of remote ischemic conditioning and has not been well studied . RIPerc attenuates myocardial injury when applied during cardiac surgery . However , its protective effects on other organs remain unknown . MATERIALS AND METHODS Patients with rheumatic heart disease undergoing valve replacement surgery were randomized into the RIPerc group ( n = 101 ) or the control group ( n = 100 ) . RIPerc was achieved by three cycles of 5-min ischemia-5-min reperfusion in the right thigh during surgery . Clinical data and the levels of injury biomarkers for the heart , lungs , liver , and kidneys within 48 h after surgery were compared using one-way or repeated measurement analysis of variance . RESULTS In the RIPerc group , the release of serum cardiac troponin I ( 128.68 ± 102.56 versus 172.33 ± 184.38 , P = 0.04 ) and the inotropic score ( 96.4 ± 73.8 versus 121.5 ± 89.6 , P = 0.032 ) decreased compared with that of the control ; postoperative drainage ( 458.2 ± 264.2 versus 545.1 ± 349.0 ml , P = 0.048 ) and the incidence of acute lung injury was reduced ( 36.6 % versus 51 % , P = 0.04 ) , and the extent of hyperbilirubinemia was also attenuated . No significant difference was observed in the levels of biomarkers for renal injury and systemic inflammation response . CONCLUSIONS RIPerc applied during the valve replacement surgery induced multiple beneficial effects postoperatively including reduced drainage and myocardial damage , lower incidence of acute lung injury , and attenuated hyperbilirubinemia . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other, Intervention_Surgical
[ "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O" ]
Multiorgan protection of remote ischemic perconditioning in valve replacement surgery . BACKGROUND Remote ischemic perconditioning ( RIPerc ) is a new alternative of remote ischemic conditioning and has not been well studied . RIPerc attenuates myocardial injury when applied during cardiac surgery . However , its protective effects on other organs remain unknown . MATERIALS AND METHODS Patients with rheumatic heart disease undergoing valve replacement surgery were randomized into the RIPerc group ( n = 101 ) or the control group ( n = 100 ) . RIPerc was achieved by three cycles of 5-min ischemia-5-min reperfusion in the right thigh during surgery . Clinical data and the levels of injury biomarkers for the heart , lungs , liver , and kidneys within 48 h after surgery were compared using one-way or repeated measurement analysis of variance . RESULTS In the RIPerc group , the release of serum cardiac troponin I ( 128.68 ± 102.56 versus 172.33 ± 184.38 , P = 0.04 ) and the inotropic score ( 96.4 ± 73.8 versus 121.5 ± 89.6 , P = 0.032 ) decreased compared with that of the control ; postoperative drainage ( 458.2 ± 264.2 versus 545.1 ± 349.0 ml , P = 0.048 ) and the incidence of acute lung injury was reduced ( 36.6 % versus 51 % , P = 0.04 ) , and the extent of hyperbilirubinemia was also attenuated . No significant difference was observed in the levels of biomarkers for renal injury and systemic inflammation response . CONCLUSIONS RIPerc applied during the valve replacement surgery induced multiple beneficial effects postoperatively including reduced drainage and myocardial damage , lower incidence of acute lung injury , and attenuated hyperbilirubinemia .
[ "Multiorgan", "protection", "of", "remote", "ischemic", "perconditioning", "in", "valve", "replacement", "surgery", ".", "BACKGROUND", "Remote", "ischemic", "perconditioning", "(", "RIPerc", ")", "is", "a", "new", "alternative", "of", "remote", "ischemic", "conditioning", "and", "has", "not", "been", "well", "studied", ".", "RIPerc", "attenuates", "myocardial", "injury", "when", "applied", "during", "cardiac", "surgery", ".", "However", ",", "its", "protective", "effects", "on", "other", "organs", "remain", "unknown", ".", "MATERIALS", "AND", "METHODS", "Patients", "with", "rheumatic", "heart", "disease", "undergoing", "valve", "replacement", "surgery", "were", "randomized", "into", "the", "RIPerc", "group", "(", "n", "=", "101", ")", "or", "the", "control", "group", "(", "n", "=", "100", ")", ".", "RIPerc", "was", "achieved", "by", "three", "cycles", "of", "5-min", "ischemia-5-min", "reperfusion", "in", "the", "right", "thigh", "during", "surgery", ".", "Clinical", "data", "and", "the", "levels", "of", "injury", "biomarkers", "for", "the", "heart", ",", "lungs", ",", "liver", ",", "and", "kidneys", "within", "48", "h", "after", "surgery", "were", "compared", "using", "one", "-", "way", "or", "repeated", "measurement", "analysis", "of", "variance", ".", "RESULTS", "In", "the", "RIPerc", "group", ",", "the", "release", "of", "serum", "cardiac", "troponin", "I", "(", "128.68", "±", "102.56", "versus", "172.33", "±", "184.38", ",", "P", "=", "0.04", ")", "and", "the", "inotropic", "score", "(", "96.4", "±", "73.8", "versus", "121.5", "±", "89.6", ",", "P", "=", "0.032", ")", "decreased", "compared", "with", "that", "of", "the", "control", ";", "postoperative", "drainage", "(", "458.2", "±", "264.2", "versus", "545.1", "±", "349.0", "ml", ",", "P", "=", "0.048", ")", "and", "the", "incidence", "of", "acute", "lung", "injury", "was", "reduced", "(", "36.6", "%", "versus", "51", "%", ",", "P", "=", "0.04", ")", ",", "and", "the", "extent", "of", "hyperbilirubinemia", "was", "also", "attenuated", ".", "No", "significant", "difference", "was", "observed", "in", "the", "levels", "of", "biomarkers", "for", "renal", "injury", "and", "systemic", "inflammation", "response", ".", "CONCLUSIONS", "RIPerc", "applied", "during", "the", "valve", "replacement", "surgery", "induced", "multiple", "beneficial", "effects", "postoperatively", "including", "reduced", "drainage", "and", "myocardial", "damage", ",", "lower", "incidence", "of", "acute", "lung", "injury", ",", "and", "attenuated", "hyperbilirubinemia", "." ]
[ "Outcome_Physical", "Participant_Condition", "Intervention_Surgical", "Outcome_Other", "Outcome_Adverse-effects", "Intervention_Control" ]
remote ischemic perconditioning is a Intervention_Surgical, valve replacement surgery . is a Participant_Condition, Remote ischemic perconditioning ( RIPerc is a Intervention_Surgical, Patients with rheumatic heart disease undergoing valve replacement surgery is a Participant_Condition, control is a Intervention_Control, surgery . Clinical data is a Outcome_Physical, the levels of injury biomarkers for the heart , lungs , liver , and kidneys is a Outcome_Physical, the release of serum cardiac troponin is a Outcome_Physical, P = 0.04 ) is a Outcome_Other, the inotropic is a Outcome_Other, that of the control ; postoperative is a Outcome_Other, 545.1 ± 349.0 ml , P = 0.048 ) is a Outcome_Physical, the incidence is a Outcome_Adverse-effects, difference was observed in the levels of biomarkers for renal injury and is a Outcome_Physical, valve replacement surgery induced multiple beneficial effects postoperatively including reduced drainage and myocardial damage , lower incidence of acute lung injury , and is a Outcome_Physical
72170_task1
Sentence: Multiorgan protection of remote ischemic perconditioning in valve replacement surgery . BACKGROUND Remote ischemic perconditioning ( RIPerc ) is a new alternative of remote ischemic conditioning and has not been well studied . RIPerc attenuates myocardial injury when applied during cardiac surgery . However , its protective effects on other organs remain unknown . MATERIALS AND METHODS Patients with rheumatic heart disease undergoing valve replacement surgery were randomized into the RIPerc group ( n = 101 ) or the control group ( n = 100 ) . RIPerc was achieved by three cycles of 5-min ischemia-5-min reperfusion in the right thigh during surgery . Clinical data and the levels of injury biomarkers for the heart , lungs , liver , and kidneys within 48 h after surgery were compared using one-way or repeated measurement analysis of variance . RESULTS In the RIPerc group , the release of serum cardiac troponin I ( 128.68 ± 102.56 versus 172.33 ± 184.38 , P = 0.04 ) and the inotropic score ( 96.4 ± 73.8 versus 121.5 ± 89.6 , P = 0.032 ) decreased compared with that of the control ; postoperative drainage ( 458.2 ± 264.2 versus 545.1 ± 349.0 ml , P = 0.048 ) and the incidence of acute lung injury was reduced ( 36.6 % versus 51 % , P = 0.04 ) , and the extent of hyperbilirubinemia was also attenuated . No significant difference was observed in the levels of biomarkers for renal injury and systemic inflammation response . CONCLUSIONS RIPerc applied during the valve replacement surgery induced multiple beneficial effects postoperatively including reduced drainage and myocardial damage , lower incidence of acute lung injury , and attenuated hyperbilirubinemia . Instructions: please typing these entity words according to sentence: remote ischemic perconditioning, valve replacement surgery ., Remote ischemic perconditioning ( RIPerc, Patients with rheumatic heart disease undergoing valve replacement surgery, control, surgery . Clinical data, the levels of injury biomarkers for the heart , lungs , liver , and kidneys, the release of serum cardiac troponin, P = 0.04 ), the inotropic, that of the control ; postoperative, 545.1 ± 349.0 ml , P = 0.048 ), the incidence, difference was observed in the levels of biomarkers for renal injury and, valve replacement surgery induced multiple beneficial effects postoperatively including reduced drainage and myocardial damage , lower incidence of acute lung injury , and Options: Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other, Intervention_Surgical
[ "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O" ]
Multiorgan protection of remote ischemic perconditioning in valve replacement surgery . BACKGROUND Remote ischemic perconditioning ( RIPerc ) is a new alternative of remote ischemic conditioning and has not been well studied . RIPerc attenuates myocardial injury when applied during cardiac surgery . However , its protective effects on other organs remain unknown . MATERIALS AND METHODS Patients with rheumatic heart disease undergoing valve replacement surgery were randomized into the RIPerc group ( n = 101 ) or the control group ( n = 100 ) . RIPerc was achieved by three cycles of 5-min ischemia-5-min reperfusion in the right thigh during surgery . Clinical data and the levels of injury biomarkers for the heart , lungs , liver , and kidneys within 48 h after surgery were compared using one-way or repeated measurement analysis of variance . RESULTS In the RIPerc group , the release of serum cardiac troponin I ( 128.68 ± 102.56 versus 172.33 ± 184.38 , P = 0.04 ) and the inotropic score ( 96.4 ± 73.8 versus 121.5 ± 89.6 , P = 0.032 ) decreased compared with that of the control ; postoperative drainage ( 458.2 ± 264.2 versus 545.1 ± 349.0 ml , P = 0.048 ) and the incidence of acute lung injury was reduced ( 36.6 % versus 51 % , P = 0.04 ) , and the extent of hyperbilirubinemia was also attenuated . No significant difference was observed in the levels of biomarkers for renal injury and systemic inflammation response . CONCLUSIONS RIPerc applied during the valve replacement surgery induced multiple beneficial effects postoperatively including reduced drainage and myocardial damage , lower incidence of acute lung injury , and attenuated hyperbilirubinemia .
[ "Multiorgan", "protection", "of", "remote", "ischemic", "perconditioning", "in", "valve", "replacement", "surgery", ".", "BACKGROUND", "Remote", "ischemic", "perconditioning", "(", "RIPerc", ")", "is", "a", "new", "alternative", "of", "remote", "ischemic", "conditioning", "and", "has", "not", "been", "well", "studied", ".", "RIPerc", "attenuates", "myocardial", "injury", "when", "applied", "during", "cardiac", "surgery", ".", "However", ",", "its", "protective", "effects", "on", "other", "organs", "remain", "unknown", ".", "MATERIALS", "AND", "METHODS", "Patients", "with", "rheumatic", "heart", "disease", "undergoing", "valve", "replacement", "surgery", "were", "randomized", "into", "the", "RIPerc", "group", "(", "n", "=", "101", ")", "or", "the", "control", "group", "(", "n", "=", "100", ")", ".", "RIPerc", "was", "achieved", "by", "three", "cycles", "of", "5-min", "ischemia-5-min", "reperfusion", "in", "the", "right", "thigh", "during", "surgery", ".", "Clinical", "data", "and", "the", "levels", "of", "injury", "biomarkers", "for", "the", "heart", ",", "lungs", ",", "liver", ",", "and", "kidneys", "within", "48", "h", "after", "surgery", "were", "compared", "using", "one", "-", "way", "or", "repeated", "measurement", "analysis", "of", "variance", ".", "RESULTS", "In", "the", "RIPerc", "group", ",", "the", "release", "of", "serum", "cardiac", "troponin", "I", "(", "128.68", "±", "102.56", "versus", "172.33", "±", "184.38", ",", "P", "=", "0.04", ")", "and", "the", "inotropic", "score", "(", "96.4", "±", "73.8", "versus", "121.5", "±", "89.6", ",", "P", "=", "0.032", ")", "decreased", "compared", "with", "that", "of", "the", "control", ";", "postoperative", "drainage", "(", "458.2", "±", "264.2", "versus", "545.1", "±", "349.0", "ml", ",", "P", "=", "0.048", ")", "and", "the", "incidence", "of", "acute", "lung", "injury", "was", "reduced", "(", "36.6", "%", "versus", "51", "%", ",", "P", "=", "0.04", ")", ",", "and", "the", "extent", "of", "hyperbilirubinemia", "was", "also", "attenuated", ".", "No", "significant", "difference", "was", "observed", "in", "the", "levels", "of", "biomarkers", "for", "renal", "injury", "and", "systemic", "inflammation", "response", ".", "CONCLUSIONS", "RIPerc", "applied", "during", "the", "valve", "replacement", "surgery", "induced", "multiple", "beneficial", "effects", "postoperatively", "including", "reduced", "drainage", "and", "myocardial", "damage", ",", "lower", "incidence", "of", "acute", "lung", "injury", ",", "and", "attenuated", "hyperbilirubinemia", "." ]
[ "Outcome_Physical", "Participant_Condition", "Intervention_Surgical", "Outcome_Other", "Outcome_Adverse-effects", "Intervention_Control" ]
remote ischemic perconditioning, valve replacement surgery ., Remote ischemic perconditioning ( RIPerc, Patients with rheumatic heart disease undergoing valve replacement surgery, control, surgery . Clinical data, the levels of injury biomarkers for the heart , lungs , liver , and kidneys, the release of serum cardiac troponin, P = 0.04 ), the inotropic, that of the control ; postoperative, 545.1 ± 349.0 ml , P = 0.048 ), the incidence, difference was observed in the levels of biomarkers for renal injury and, valve replacement surgery induced multiple beneficial effects postoperatively including reduced drainage and myocardial damage , lower incidence of acute lung injury , and
72170_task2
Sentence: Multiorgan protection of remote ischemic perconditioning in valve replacement surgery . BACKGROUND Remote ischemic perconditioning ( RIPerc ) is a new alternative of remote ischemic conditioning and has not been well studied . RIPerc attenuates myocardial injury when applied during cardiac surgery . However , its protective effects on other organs remain unknown . MATERIALS AND METHODS Patients with rheumatic heart disease undergoing valve replacement surgery were randomized into the RIPerc group ( n = 101 ) or the control group ( n = 100 ) . RIPerc was achieved by three cycles of 5-min ischemia-5-min reperfusion in the right thigh during surgery . Clinical data and the levels of injury biomarkers for the heart , lungs , liver , and kidneys within 48 h after surgery were compared using one-way or repeated measurement analysis of variance . RESULTS In the RIPerc group , the release of serum cardiac troponin I ( 128.68 ± 102.56 versus 172.33 ± 184.38 , P = 0.04 ) and the inotropic score ( 96.4 ± 73.8 versus 121.5 ± 89.6 , P = 0.032 ) decreased compared with that of the control ; postoperative drainage ( 458.2 ± 264.2 versus 545.1 ± 349.0 ml , P = 0.048 ) and the incidence of acute lung injury was reduced ( 36.6 % versus 51 % , P = 0.04 ) , and the extent of hyperbilirubinemia was also attenuated . No significant difference was observed in the levels of biomarkers for renal injury and systemic inflammation response . CONCLUSIONS RIPerc applied during the valve replacement surgery induced multiple beneficial effects postoperatively including reduced drainage and myocardial damage , lower incidence of acute lung injury , and attenuated hyperbilirubinemia . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O" ]
Multiorgan protection of remote ischemic perconditioning in valve replacement surgery . BACKGROUND Remote ischemic perconditioning ( RIPerc ) is a new alternative of remote ischemic conditioning and has not been well studied . RIPerc attenuates myocardial injury when applied during cardiac surgery . However , its protective effects on other organs remain unknown . MATERIALS AND METHODS Patients with rheumatic heart disease undergoing valve replacement surgery were randomized into the RIPerc group ( n = 101 ) or the control group ( n = 100 ) . RIPerc was achieved by three cycles of 5-min ischemia-5-min reperfusion in the right thigh during surgery . Clinical data and the levels of injury biomarkers for the heart , lungs , liver , and kidneys within 48 h after surgery were compared using one-way or repeated measurement analysis of variance . RESULTS In the RIPerc group , the release of serum cardiac troponin I ( 128.68 ± 102.56 versus 172.33 ± 184.38 , P = 0.04 ) and the inotropic score ( 96.4 ± 73.8 versus 121.5 ± 89.6 , P = 0.032 ) decreased compared with that of the control ; postoperative drainage ( 458.2 ± 264.2 versus 545.1 ± 349.0 ml , P = 0.048 ) and the incidence of acute lung injury was reduced ( 36.6 % versus 51 % , P = 0.04 ) , and the extent of hyperbilirubinemia was also attenuated . No significant difference was observed in the levels of biomarkers for renal injury and systemic inflammation response . CONCLUSIONS RIPerc applied during the valve replacement surgery induced multiple beneficial effects postoperatively including reduced drainage and myocardial damage , lower incidence of acute lung injury , and attenuated hyperbilirubinemia .
[ "Multiorgan", "protection", "of", "remote", "ischemic", "perconditioning", "in", "valve", "replacement", "surgery", ".", "BACKGROUND", "Remote", "ischemic", "perconditioning", "(", "RIPerc", ")", "is", "a", "new", "alternative", "of", "remote", "ischemic", "conditioning", "and", "has", "not", "been", "well", "studied", ".", "RIPerc", "attenuates", "myocardial", "injury", "when", "applied", "during", "cardiac", "surgery", ".", "However", ",", "its", "protective", "effects", "on", "other", "organs", "remain", "unknown", ".", "MATERIALS", "AND", "METHODS", "Patients", "with", "rheumatic", "heart", "disease", "undergoing", "valve", "replacement", "surgery", "were", "randomized", "into", "the", "RIPerc", "group", "(", "n", "=", "101", ")", "or", "the", "control", "group", "(", "n", "=", "100", ")", ".", "RIPerc", "was", "achieved", "by", "three", "cycles", "of", "5-min", "ischemia-5-min", "reperfusion", "in", "the", "right", "thigh", "during", "surgery", ".", "Clinical", "data", "and", "the", "levels", "of", "injury", "biomarkers", "for", "the", "heart", ",", "lungs", ",", "liver", ",", "and", "kidneys", "within", "48", "h", "after", "surgery", "were", "compared", "using", "one", "-", "way", "or", "repeated", "measurement", "analysis", "of", "variance", ".", "RESULTS", "In", "the", "RIPerc", "group", ",", "the", "release", "of", "serum", "cardiac", "troponin", "I", "(", "128.68", "±", "102.56", "versus", "172.33", "±", "184.38", ",", "P", "=", "0.04", ")", "and", "the", "inotropic", "score", "(", "96.4", "±", "73.8", "versus", "121.5", "±", "89.6", ",", "P", "=", "0.032", ")", "decreased", "compared", "with", "that", "of", "the", "control", ";", "postoperative", "drainage", "(", "458.2", "±", "264.2", "versus", "545.1", "±", "349.0", "ml", ",", "P", "=", "0.048", ")", "and", "the", "incidence", "of", "acute", "lung", "injury", "was", "reduced", "(", "36.6", "%", "versus", "51", "%", ",", "P", "=", "0.04", ")", ",", "and", "the", "extent", "of", "hyperbilirubinemia", "was", "also", "attenuated", ".", "No", "significant", "difference", "was", "observed", "in", "the", "levels", "of", "biomarkers", "for", "renal", "injury", "and", "systemic", "inflammation", "response", ".", "CONCLUSIONS", "RIPerc", "applied", "during", "the", "valve", "replacement", "surgery", "induced", "multiple", "beneficial", "effects", "postoperatively", "including", "reduced", "drainage", "and", "myocardial", "damage", ",", "lower", "incidence", "of", "acute", "lung", "injury", ",", "and", "attenuated", "hyperbilirubinemia", "." ]
[ "Outcome_Physical", "Participant_Condition", "Intervention_Surgical", "Outcome_Other", "Outcome_Adverse-effects", "Intervention_Control" ]